1 00:00:06,305 --> 00:00:07,573 >> GOOD MORNING AND GOOD 2 00:00:07,573 --> 00:00:08,974 AFTERNOON EVERY ONE. 3 00:00:08,974 --> 00:00:12,211 MY NAME IS MARY GLENSHAW I'M 4 00:00:12,211 --> 00:00:13,746 THE EXECUTIVE SECRETARY OF THE 5 00:00:13,746 --> 00:00:16,081 OFFICE OF AIDS RESEARCH 6 00:00:16,081 --> 00:00:18,384 ADVISORY COUNCIL, THE OARAC, 7 00:00:18,384 --> 00:00:18,851 WELCOME. 8 00:00:18,851 --> 00:00:21,153 THANK YOU FOR PARTICIPATING 9 00:00:21,153 --> 00:00:21,353 TODAY. 10 00:00:21,353 --> 00:00:25,057 AS A BRIEF REMINDER OUR COUNCIL 11 00:00:25,057 --> 00:00:29,828 IS GOVERNED BY THE ACT WHICH 12 00:00:29,828 --> 00:00:32,264 SETS FORTH THE FORMATION AND 13 00:00:32,264 --> 00:00:32,898 ADVISORY COMMITTEES. 14 00:00:32,898 --> 00:00:35,668 ANY ROLE TO IS PREPARE 15 00:00:35,668 --> 00:00:37,469 MEETINGS, ORGANIZE ATTEND AND 16 00:00:37,469 --> 00:00:39,572 APPROVE ALL COUNCIL ACTIONS, 17 00:00:39,572 --> 00:00:40,706 ADJOURN ANY MEETING WHEN IT'S 18 00:00:40,706 --> 00:00:43,275 DEEMED TO BE IN PUBLIC INTEREST 19 00:00:43,275 --> 00:00:45,544 AND CHAIR MEETINGS WHEN 20 00:00:45,544 --> 00:00:51,183 DIRECTED BY THE NIH OR OAR 21 00:00:51,183 --> 00:00:53,552 DIRECTOR. 22 00:00:53,552 --> 00:00:55,120 SO AS PREVIOUS MEETINGS LET'S 23 00:00:55,120 --> 00:00:56,989 GO OVER SOME GENERAL GUIDELINES. 24 00:00:56,989 --> 00:01:00,392 AS THIS IS A VIRTUAL MEETING, 25 00:01:00,392 --> 00:01:01,760 PLEASE STAY MUTED UNLESS YOU'RE 26 00:01:01,760 --> 00:01:03,095 SPEAKING. 27 00:01:03,095 --> 00:01:04,930 PLEASE KEEP YOUR CAMERA FOR 28 00:01:04,930 --> 00:01:06,865 MOST OF THE MEETING, YOU MAY 29 00:01:06,865 --> 00:01:08,434 HIDE IT WHEN YOU NEED TO BUT 30 00:01:08,434 --> 00:01:10,603 TURN IT BACK ON WHEN YOU CAN. 31 00:01:10,603 --> 00:01:12,404 WHEN YOU WANT TO PARTICIPATE IN 32 00:01:12,404 --> 00:01:15,341 DISCUSSIONS, WE ASK YOU TO USE 33 00:01:15,341 --> 00:01:19,044 THE ZOOM RAISE HAND FEATURE. 34 00:01:19,044 --> 00:01:20,346 SO WE AVOID SPEAKING OVER EACH 35 00:01:20,346 --> 00:01:21,413 OTHER. 36 00:01:21,413 --> 00:01:22,781 PLEASE, BE AWARE THAT YOU'LL 37 00:01:22,781 --> 00:01:25,050 NEED TO LOWER YOUR HAND 38 00:01:25,050 --> 00:01:26,819 VIRTUALLY ONCE YOU'VE MADE YOUR 39 00:01:26,819 --> 00:01:29,154 REMARKS. 40 00:01:29,154 --> 00:01:31,657 WE HAVE THE CHAT FEATURE 41 00:01:31,657 --> 00:01:33,993 DISABLED EXCEPT FOR LOGITIC 42 00:01:33,993 --> 00:01:36,495 MESSAGES, IF YOU NEED ANYTHING, 43 00:01:36,495 --> 00:01:38,631 FEEL FREE TO ACCEPTED ME AN 44 00:01:38,631 --> 00:01:39,498 EMAIL. 45 00:01:39,498 --> 00:01:46,372 YOU CAN ALSO EMAIL OARAC @ 46 00:01:46,372 --> 00:01:47,273 NIH.GOV. 47 00:01:47,273 --> 00:01:49,141 FOR EVERY ONE ON VIDEO CAST IF 48 00:01:49,141 --> 00:01:52,111 YOU WOULD LIKE TO USE THE CLOSE 49 00:01:52,111 --> 00:01:53,078 CAPTION FEATURE, PLEASE CLICK 50 00:01:53,078 --> 00:01:57,383 ON THE CC ICON WHICH IS ON THE 51 00:01:57,383 --> 00:01:58,917 RIGHT HAND BOTTOM CORNER OF THE 52 00:01:58,917 --> 00:01:59,718 SCREEN. 53 00:01:59,718 --> 00:02:01,787 SO FOR MEMBERS, I WOULD LIKE TO 54 00:02:01,787 --> 00:02:05,024 REMIND YOU OF POLICIES 55 00:02:05,024 --> 00:02:06,859 RECORDING CONFLICT OF INTEREST. 56 00:02:06,859 --> 00:02:07,793 COUNCILMEMBERS MAY NOT 57 00:02:07,793 --> 00:02:09,161 PARTICIPATE IN THE SPECIFIC 58 00:02:09,161 --> 00:02:10,562 PROJECT FOR WHICH YOU HAVE A 59 00:02:10,562 --> 00:02:12,131 REAL OR PARENT CONFLICT OF 60 00:02:12,131 --> 00:02:13,098 INTEREST. 61 00:02:13,098 --> 00:02:16,068 IF A PROGRAM OR PROJECT IS 62 00:02:16,068 --> 00:02:19,004 DISCUSSED THAT PRESENTS A 63 00:02:19,004 --> 00:02:20,606 CONFLICT, PLEASE EXCUSE 64 00:02:20,606 --> 00:02:23,175 YOURSELF AND TO DO THIS, PLEASE 65 00:02:23,175 --> 00:02:24,843 SIGNAL ME AND WE'LL MOVE TO YOU 66 00:02:24,843 --> 00:02:26,445 A SEPARATE SPACE. 67 00:02:26,445 --> 00:02:27,179 AFTER THE MEETING, SIGN THE 68 00:02:27,179 --> 00:02:29,181 FORM THAT WE WILL BE SENDING 69 00:02:29,181 --> 00:02:30,582 YOU LATER TODAY. 70 00:02:30,582 --> 00:02:34,486 THIS WILL VERIFY THAT NOTHING 71 00:02:34,486 --> 00:02:37,189 SAID TODAY WILL POSE A CONFLICT 72 00:02:37,189 --> 00:02:37,790 FOR YOU. 73 00:02:37,790 --> 00:02:39,792 ARE THERE ANY QUESTIONS 74 00:02:39,792 --> 00:02:41,393 REGARDING CONFLICT OF INTEREST 75 00:02:41,393 --> 00:02:42,761 REGARDING TODAY'S AGENDA? 76 00:02:42,761 --> 00:02:43,896 OKAY, HEARING NONE. 77 00:02:43,896 --> 00:02:45,064 PLEASE ALSO, REMEMBER THAT 78 00:02:45,064 --> 00:02:46,699 TODAY'S MEETING IS OPEN TO THE 79 00:02:46,699 --> 00:02:50,135 GENERAL PUBLIC AND IS CURRENTLY 80 00:02:50,135 --> 00:02:52,104 BEING RECORD ASKED VIDEO CAST 81 00:02:52,104 --> 00:02:52,304 LIVE. 82 00:02:52,304 --> 00:02:53,372 I'M HAPPY TO TURN OUR MEETING 83 00:02:53,372 --> 00:02:57,943 OVER TO THE OARAC CHAIR TO 84 00:02:57,943 --> 00:03:00,346 BRING THE MEETING TO ORDER, 85 00:03:00,346 --> 00:03:00,946 THANK YOU. 86 00:03:00,946 --> 00:03:04,183 >> THANK YOU, DR. GLENSHAW. 87 00:03:04,183 --> 00:03:08,520 AND GOOD AFTERNOON, THE 67th 88 00:03:08,520 --> 00:03:11,256 MEETING OF THE AIDS ADVISORY 89 00:03:11,256 --> 00:03:12,091 COUNCIL OARAC, IS NOW IN 90 00:03:12,091 --> 00:03:15,794 SESSION. 91 00:03:15,794 --> 00:03:18,063 WELCOME COUNCILMEMBERS, INVITED 92 00:03:18,063 --> 00:03:18,964 SPEAKERS AND GUESTS. 93 00:03:18,964 --> 00:03:20,332 COLLEAGUES WE WILL NOW CONDUCT 94 00:03:20,332 --> 00:03:22,668 A ROLL CALL, I'M TURNING BACK 95 00:03:22,668 --> 00:03:25,037 OVER TO DR. GLENSHAW, WOULD YOU 96 00:03:25,037 --> 00:03:25,838 PLEASE PROCEED WITH THE ROLL 97 00:03:25,838 --> 00:03:27,039 CALL. 98 00:03:27,039 --> 00:03:29,575 >> YES, MA'AM, THANK YOU. 99 00:03:29,575 --> 00:03:30,709 SO FAR STANDING MEMBERS AND 100 00:03:30,709 --> 00:03:32,778 GUESTS, WHEN WE CALL YOUR NAME, 101 00:03:32,778 --> 00:03:34,646 PLEASE STATE YOUR POSITION AND 102 00:03:34,646 --> 00:03:37,416 YOUR INSTITUTIONAL AFFILIATION. 103 00:03:37,416 --> 00:03:38,684 I'M DELIGHTED THAT IN THIS 104 00:03:38,684 --> 00:03:40,452 FIRST PART OF THE ROLL CALL, WE 105 00:03:40,452 --> 00:03:42,721 HAVE FOUR NEW VOTING MEMBERS, 106 00:03:42,721 --> 00:03:45,657 STARTING WITH THE VERY FIRST 107 00:03:45,657 --> 00:03:48,460 TWO IN ALBA BET CAL ORDER, DR. 108 00:03:48,460 --> 00:03:50,696 COURTNEY FLETCHER. 109 00:03:50,696 --> 00:03:51,430 >> PRESENT, PROFESSOR 110 00:03:51,430 --> 00:03:52,631 UNIVERSITY OF NEBRASKA MEDICAL 111 00:03:52,631 --> 00:03:53,499 CENTER. 112 00:03:53,499 --> 00:03:56,702 >> WELCOME. 113 00:03:56,702 --> 00:03:58,537 DR. SONIA FLORES. 114 00:03:58,537 --> 00:03:59,705 >> HI, WELCOME EVERYBODY. 115 00:03:59,705 --> 00:04:01,740 I'M AT THE UNIVERSITY OF 116 00:04:01,740 --> 00:04:03,142 COLORADO AND CAMPUS AND I'M A 117 00:04:03,142 --> 00:04:04,543 PROFESSOR IN THE DEPARTMENT OF 118 00:04:04,543 --> 00:04:05,911 MEDICINE. 119 00:04:05,911 --> 00:04:15,120 >> THANK YOU, WELCOME. 120 00:04:15,120 --> 00:04:17,322 DR. OMAR GALARRAGA. 121 00:04:17,322 --> 00:04:18,357 >> BROWN UNIVERSITY PUBLIC 122 00:04:18,357 --> 00:04:20,125 HEADLIGHT. 123 00:04:20,125 --> 00:04:22,761 >> WELCOME THANK YOU. 124 00:04:22,761 --> 00:04:28,500 >> DR. LOUIS MONTNTANER? 125 00:04:28,500 --> 00:04:30,602 >> I'M PROFESSOR OF WINDSOR 126 00:04:30,602 --> 00:04:33,439 INSTITUTE AND DIRECTOR OF 127 00:04:33,439 --> 00:04:34,072 DISEASE CENTER. 128 00:04:34,072 --> 00:04:37,876 ?FM WELCOME. 129 00:04:37,876 --> 00:04:41,113 >> DR. 130 00:04:41,113 --> 00:04:48,387 >> PROFESSOR AND CHAIR OF 131 00:04:48,387 --> 00:04:50,255 GENEALOGY AT JOHN HOPKINS. 132 00:04:50,255 --> 00:04:53,859 >> HI, I'M A PROFESSOR OF THE 133 00:04:53,859 --> 00:04:56,261 DEPARTMENT OF MINE AT 134 00:04:56,261 --> 00:04:56,795 NORTHWESTERN UNIVERSITY. 135 00:04:56,795 --> 00:04:58,564 >> WELCOME. 136 00:04:58,564 --> 00:05:01,934 >> DR. ANNE MULE 137 00:05:01,934 --> 00:05:04,269 >> I'M A PHYSICIAN AT 138 00:05:04,269 --> 00:05:06,505 MASSACHUSETTS GENERAL HOSPITAL 139 00:05:06,505 --> 00:05:08,373 AND INFECTIOUS DISEASE SXZ 140 00:05:08,373 --> 00:05:11,376 ASSISTANT PROFESSOR AT 141 00:05:11,376 --> 00:05:12,578 PEDIATRICS AT HARVARD MEDICAL 142 00:05:12,578 --> 00:05:13,011 SCHOOL. 143 00:05:13,011 --> 00:05:15,781 >> WELCOME AND OUR LAST TWO 144 00:05:15,781 --> 00:05:22,421 NEWEST VOTING MEMBERS, DR. 145 00:05:22,421 --> 00:05:27,292 DIANE FINZI. 146 00:05:27,292 --> 00:05:28,427 >> UNFORTUNATELY WE CANNOT HEAR 147 00:05:28,427 --> 00:05:29,161 YOU. 148 00:05:29,161 --> 00:05:33,031 WE KNOW THAT YOU'RE HERE. 149 00:05:33,031 --> 00:05:33,765 SO WE'LL CIRCUMSTANCING BACK TO 150 00:05:33,765 --> 00:05:35,534 YOU. 151 00:05:35,534 --> 00:05:37,336 DR. SARAH SAWYER. 152 00:05:37,336 --> 00:05:41,039 >> HEY GOOD I'M SARAH WATER I'M 153 00:05:41,039 --> 00:05:42,875 A PROFESSOR AT THE UNIVERSITY 154 00:05:42,875 --> 00:05:43,542 OF COLORADO BOULDER. 155 00:05:43,542 --> 00:05:45,677 >> THANK YOU. 156 00:05:45,677 --> 00:05:49,882 WE'LL MOVE TO OUR OARAC 157 00:05:49,882 --> 00:05:52,951 OFFICIOS. 158 00:05:52,951 --> 00:05:54,720 DON'T THINK SHE HAS JOINED US 159 00:05:54,720 --> 00:05:56,622 YET. 160 00:05:56,622 --> 00:05:58,123 CARL JULIE ACHE? 161 00:05:58,123 --> 00:05:59,892 >> GOOD MORNING, EVERY ONE. 162 00:05:59,892 --> 00:06:05,063 OR AFTER I'M I'M INFECTIOUS 163 00:06:05,063 --> 00:06:08,267 DISEASE PHYSICIAN AND DIRECTOR 164 00:06:08,267 --> 00:06:09,201 OF THE INSTITUTE RESEARCH. 165 00:06:09,201 --> 00:06:11,270 >> WELCOME. 166 00:06:11,270 --> 00:06:14,439 >> DR. VICKY GAVI. 167 00:06:14,439 --> 00:06:16,575 >> VICKY GAVE' I'M ASSOCIATE 168 00:06:16,575 --> 00:06:19,378 CHIEF RESEARCH FOR VA AND 169 00:06:19,378 --> 00:06:21,446 EX-OFFICIO FROM THE DEPARTMENT 170 00:06:21,446 --> 00:06:22,214 OF VETERANS AFFAIRS. 171 00:06:22,214 --> 00:06:22,848 THANK YOU. 172 00:06:22,848 --> 00:06:25,984 >> THANK YOU, WELCOME. 173 00:06:25,984 --> 00:06:28,687 >> DR. CARL? 174 00:06:28,687 --> 00:06:30,989 >> GOOD AFTERNOON, I'M DIRECTOR 175 00:06:30,989 --> 00:06:33,492 OF DIVISION OF AIDS OF 176 00:06:33,492 --> 00:06:34,192 INSTITUTION OF INFECTIOUS 177 00:06:34,192 --> 00:06:35,360 DISEASES. 178 00:06:35,360 --> 00:06:37,462 >> THANKS, WELCOME. 179 00:06:37,462 --> 00:06:39,731 DR. JONATHAN? 180 00:06:39,731 --> 00:06:43,168 >> GOOD AFTERNOON, I'M JONATHAN 181 00:06:43,168 --> 00:06:45,237 AND I'M DIRECTOR OF THE 182 00:06:45,237 --> 00:06:51,209 NATIONAL CENTER FOR HIV AND S 183 00:06:51,209 --> 00:06:51,810 T.D.s. 184 00:06:51,810 --> 00:06:56,114 >> THANK YOU. 185 00:06:56,114 --> 00:06:58,483 >> GOOD AFTERNOON, GOOD I'M 186 00:06:58,483 --> 00:07:01,787 ROJAN I'M AT THE KENNEDY 187 00:07:01,787 --> 00:07:03,155 NATIONAL INL STAOULT OF CHILD 188 00:07:03,155 --> 00:07:05,891 HEALTH AND DEVELOPMENT. 189 00:07:05,891 --> 00:07:07,259 HERE AT NIH WHERE I'M THE 190 00:07:07,259 --> 00:07:08,160 DIRECTOR OF RESEARCH. 191 00:07:08,160 --> 00:07:09,828 >> WELCOME, THANK YOU. 192 00:07:09,828 --> 00:07:12,130 >> OUR ADVISORY COUNCIL 193 00:07:12,130 --> 00:07:14,666 REPRESENTATIVES I'M NOT SURE 194 00:07:14,666 --> 00:07:15,701 DR. MARGARITA LIGHTFOOT IS ON 195 00:07:15,701 --> 00:07:16,501 YET. 196 00:07:16,501 --> 00:07:17,903 I THINK NOT YET. 197 00:07:17,903 --> 00:07:22,040 BUT I DO SEE DR. MELONY. 198 00:07:22,040 --> 00:07:23,909 >> YES, HELLO EVERY ONE I'M 199 00:07:23,909 --> 00:07:27,346 DIRECTOR OF GLADSTONE OF 200 00:07:27,346 --> 00:07:30,115 VIROLOGY AND PROFESSOR AT UCSF 201 00:07:30,115 --> 00:07:32,884 AND I REPRESENT NAFTA. 202 00:07:32,884 --> 00:07:35,687 >> THANK YOU, I WILL MOVE ON TO 203 00:07:35,687 --> 00:07:38,223 OUR LEADERS AND SPEAKERS. 204 00:07:38,223 --> 00:07:40,525 IT'S OUR MY GREAT PLEASURE TO 205 00:07:40,525 --> 00:07:42,127 WELCOME OUR NEW DIRECTOR. 206 00:07:42,127 --> 00:07:42,861 >> WELCOME EVERYBODY, I'M 207 00:07:42,861 --> 00:07:44,096 EXCITED TO BE HERE AND I'LL 208 00:07:44,096 --> 00:07:45,697 PRESENT A LITTLE BIT MORE ON 209 00:07:45,697 --> 00:07:46,365 MYSELF LATER. 210 00:07:46,365 --> 00:07:48,400 >> THANK YOU. 211 00:07:48,400 --> 00:07:52,270 >> WE ALSO HAVE SOME OTHER 212 00:07:52,270 --> 00:07:58,844 SPEAKERS AND GUESTS FROM OAR. 213 00:07:58,844 --> 00:08:02,748 >> I'M A HEALTH SCIENTIST HERE. 214 00:08:02,748 --> 00:08:04,016 >> WELCOME. 215 00:08:04,016 --> 00:08:06,385 AND I DON'T SHE HAS MADE IT YET 216 00:08:06,385 --> 00:08:10,455 BUT WE'LL BE HEARING FROM MS. 217 00:08:10,455 --> 00:08:11,923 CARETA. 218 00:08:11,923 --> 00:08:14,026 AND LASTLY SOME OF OUR SPECIAL 219 00:08:14,026 --> 00:08:15,861 GUEST FOR TODAY'S MEET ING, 220 00:08:15,861 --> 00:08:21,900 OUR MOST RESENT DIRECTOR, DR. 221 00:08:21,900 --> 00:08:23,001 FINZARAH I. 222 00:08:23,001 --> 00:08:26,271 >> NICE TO SEE YOU, I WAS THE 223 00:08:26,271 --> 00:08:27,873 ACTING DIRECTOR BUT NOW I'M 224 00:08:27,873 --> 00:08:30,809 BACK TO MY PREVIOUS POSITION AS 225 00:08:30,809 --> 00:08:32,644 DIRECTOR OF SCIENCES PROGRAM IN 226 00:08:32,644 --> 00:08:33,478 THE DIVISION OF AIDS. 227 00:08:33,478 --> 00:08:36,581 >> THANK YOU. 228 00:08:36,581 --> 00:08:38,183 DR. WESLEY WSUNDQUIST. 229 00:08:38,183 --> 00:08:42,087 >> HI EVERY ONE I'M CHAIR OF 230 00:08:42,087 --> 00:08:43,221 CHEMISTRY AT THE UNIVERSITY OF 231 00:08:43,221 --> 00:08:45,524 UTAH AND I DIRECT ONE OF THE 232 00:08:45,524 --> 00:08:48,627 HIV CENTERS WITHIN THE DADES 233 00:08:48,627 --> 00:08:49,394 PROGRAM. 234 00:08:49,394 --> 00:08:50,595 >> THANK YOU FOR JOINING US 235 00:08:50,595 --> 00:08:52,164 TODAY. 236 00:08:52,164 --> 00:08:53,799 OUR LAST THREE GUESTS, I DON'T 237 00:08:53,799 --> 00:08:54,966 BELIEVE ARE ON YET. 238 00:08:54,966 --> 00:08:58,837 THEY ARE DR. TRIP COOLIC, DR. 239 00:08:58,837 --> 00:09:01,606 DONNIE READY AND FRANKLIN YATES. 240 00:09:01,606 --> 00:09:03,809 IS THERE ANYONE THAT WE DID NOT 241 00:09:03,809 --> 00:09:07,079 ANNOUNCE? 242 00:09:07,079 --> 00:09:12,818 OKAY, WONDERFUL, WITH YOU, 243 00:09:12,818 --> 00:09:13,485 TURNBULL BACK TO YOU. 244 00:09:13,485 --> 00:09:19,191 >> THANK YOU, AS A REMINDER OUR 245 00:09:19,191 --> 00:09:20,826 CHARTER AND LEGISLATION, DIRECT 246 00:09:20,826 --> 00:09:23,128 ON BOARD MATTERS RELATING TO 247 00:09:23,128 --> 00:09:24,663 H.I.V. POLICIES AND STRATEGIC 248 00:09:24,663 --> 00:09:28,900 PLANNING INCLUDING THE REVIEW 249 00:09:28,900 --> 00:09:29,835 OF NIHHIV PROGRAMS. 250 00:09:29,835 --> 00:09:34,906 I WILL NOW PROVIDE OVERVIEW OF 251 00:09:34,906 --> 00:09:36,475 TODAY'S AGENDA. 252 00:09:36,475 --> 00:09:40,345 WHICH WILL INCLUDE A REPORT 253 00:09:40,345 --> 00:09:42,414 FROM OAR DIRECTOR. 254 00:09:42,414 --> 00:09:45,584 A PRESENTATION FROM DR. WESLEY 255 00:09:45,584 --> 00:09:48,086 WSUNDQUIST, CO-CHAIR OF 256 00:09:48,086 --> 00:09:49,221 BIOCHEMISTRY UNIVERSITY OF UTAH 257 00:09:49,221 --> 00:09:51,490 SCHOOL OF MEDICINE. 258 00:09:51,490 --> 00:09:56,528 PRESENTATION FROM THE OAR TASK 259 00:09:56,528 --> 00:09:57,863 FORCES RECORDING 260 00:09:57,863 --> 00:09:59,965 RECOMMENDATIONS FOR THE 261 00:09:59,965 --> 00:10:01,533 STRATEGIC PLAN FOR H.I.V. 262 00:10:01,533 --> 00:10:02,968 RESEARCH. 263 00:10:02,968 --> 00:10:03,668 FOLLOWING THIS SEGMENT, THERE 264 00:10:03,668 --> 00:10:05,504 WILL BE A SPECIAL PRESENTATION 265 00:10:05,504 --> 00:10:08,440 FROM THE AIDS RESEARCH 266 00:10:08,440 --> 00:10:10,275 ADVISORY'S COMMITTEE FOLLOWED 267 00:10:10,275 --> 00:10:12,644 BY OTHER ADVISORY COUNCIL 268 00:10:12,644 --> 00:10:14,246 UPDATES AND FINAL LEE ANNE 269 00:10:14,246 --> 00:10:19,284 UPDATE FROM THREE OF THE OARAC 270 00:10:19,284 --> 00:10:19,851 CLINICAL GUIDELINES WORKING 271 00:10:19,851 --> 00:10:20,652 GROUPS. 272 00:10:20,652 --> 00:10:23,588 THE AGENDA ALSO INCLUDES TIME 273 00:10:23,588 --> 00:10:26,324 FOR REGISTERED PUBLIC COMMENT. 274 00:10:26,324 --> 00:10:27,926 ANYONE LISTENING TODAY WHO 275 00:10:27,926 --> 00:10:32,764 WISHES TO MAKE A PUBLIC COMMENT 276 00:10:32,764 --> 00:10:39,871 SHOULD EMAIL OARACINFO @ NIH 277 00:10:39,871 --> 00:10:41,940 DOT GOV, WITH YOUR NAME AND O 278 00:10:41,940 --> 00:10:42,674 FILLATION AND QUESTION OR 279 00:10:42,674 --> 00:10:45,610 COMMENT. 280 00:10:45,610 --> 00:10:48,180 PLEASE VISIT NIH WEBSITE FOR 281 00:10:48,180 --> 00:10:50,081 THE FEDERAL REGISTRY NOTICE FOR 282 00:10:50,081 --> 00:10:51,883 MORE DETAIL. 283 00:10:51,883 --> 00:10:54,386 VERY EXCITED TO ANNOUNCE THAT 284 00:10:54,386 --> 00:10:57,789 TODAY, MARKS THE FIRST OARAC 285 00:10:57,789 --> 00:11:04,396 MEETING FOR THE NEW PERMANENT 286 00:11:04,396 --> 00:11:12,938 DIRECTOR, DR. GERI DO NOTENBERG. 287 00:11:12,938 --> 00:11:21,279 TO INTRODUCE HER, PLEASE 288 00:11:21,279 --> 00:11:22,214 WELCOME DR. SCHETZ. 289 00:11:22,214 --> 00:11:24,983 >> NOT SURE IF SHE'S ON YET. 290 00:11:24,983 --> 00:11:29,120 >> CAN I JUST TAKE A QUICK 291 00:11:29,120 --> 00:11:31,890 MOMENT, TO OUR AV COLLEAGUES, 292 00:11:31,890 --> 00:11:34,860 I'M GETTING A LOT OF MESSAGES 293 00:11:34,860 --> 00:11:36,161 THAT THE VIDEO CAST IS NOT 294 00:11:36,161 --> 00:11:37,362 WORKING. 295 00:11:37,362 --> 00:11:38,930 SO IF SOMEBODY COULD ADJUST 296 00:11:38,930 --> 00:11:40,565 THAT, THAT WOULD BE GREAT. 297 00:11:40,565 --> 00:11:43,435 >> THERE WAS, THERE WERE TWO 298 00:11:43,435 --> 00:11:45,270 VIDEO CASTS EMAILS AND ONE WAS 299 00:11:45,270 --> 00:11:47,138 CANCELED AND ONE IS WORKING. 300 00:11:47,138 --> 00:11:53,245 SO I DON'T KNOW, WHAT WHAT 301 00:11:53,245 --> 00:11:54,713 HAPPENED BUT, I TRIED TO LOG ON 302 00:11:54,713 --> 00:11:56,615 TO THE ONE THAT WAS CANCELED 303 00:11:56,615 --> 00:11:58,316 SEVERAL TIMES. 304 00:11:58,316 --> 00:11:59,150 BUT--. 305 00:11:59,150 --> 00:12:02,387 >> WE'LL GET IT STRENGTHENED 306 00:12:02,387 --> 00:12:04,956 OUT AND CIRCULATE IT, THANKS. 307 00:12:04,956 --> 00:12:10,462 IF YOU WANT TO PROCEED WE'LL 308 00:12:10,462 --> 00:12:15,634 CONTINUE WITH DR. SCHETZWHEN 309 00:12:15,634 --> 00:12:16,334 SHE COMES ON. 310 00:12:16,334 --> 00:12:20,438 >> THANK YOU, I'LL BE HAPPY TO. 311 00:12:20,438 --> 00:12:22,274 ARE MY SLIDES AVAILABLE? 312 00:12:22,274 --> 00:12:24,776 OKAY, WELL WELCOME EVERY ONE. 313 00:12:24,776 --> 00:12:25,911 I AM DELIGHTED TO BE HERE. 314 00:12:25,911 --> 00:12:29,648 THIS IS MY FIRST MEETING OF 315 00:12:29,648 --> 00:12:30,949 OARAC BUT ALSO AS THE NEW 316 00:12:30,949 --> 00:12:31,750 DIRECTOR. 317 00:12:31,750 --> 00:12:34,252 BUT IT'S ALSO THE FINAL OARAC 318 00:12:34,252 --> 00:12:36,554 MEETING OF THE CALENDAR YEAR. 319 00:12:36,554 --> 00:12:39,557 AND I'M DEEPLY HONORED TO STEP 320 00:12:39,557 --> 00:12:45,630 IN THE ROLE AS NIH OFFICE OF 321 00:12:45,630 --> 00:12:46,665 AIDS RESEARCH. 322 00:12:46,665 --> 00:12:49,000 I'M EAGER TO BUILD ON WHAT 323 00:12:49,000 --> 00:12:49,668 OTHERS HAVE ALREADY 324 00:12:49,668 --> 00:12:50,835 ACCOMPLISHED AND HOPING THAT 325 00:12:50,835 --> 00:12:52,871 TOGETHER WITH ALL OF YOU, WE 326 00:12:52,871 --> 00:13:01,846 WILL ENSURE THAT THE HIV AGENDA 327 00:13:01,846 --> 00:13:04,983 MEETS THE NEEDS OF THE EPIDEMIC. 328 00:13:04,983 --> 00:13:07,085 I'M A CLINICAL PSYCHOLOGIST BY 329 00:13:07,085 --> 00:13:09,154 TRAINING, I ATTENDED THE 330 00:13:09,154 --> 00:13:11,690 UNIVERSITY IN MICHIGAN AT ANN 331 00:13:11,690 --> 00:13:13,525 ARBOR AS UNDERGRAD AND RECEIVED 332 00:13:13,525 --> 00:13:17,395 MY MASTERS AND Ph.d FROM UCLA. 333 00:13:17,395 --> 00:13:19,998 AND I HAVE SPENT PRETTY MUCH 334 00:13:19,998 --> 00:13:23,435 THE PAST 25 YEARS IN THE 335 00:13:23,435 --> 00:13:25,036 ACADEMIA IN THE UNIVERSITY OF 336 00:13:25,036 --> 00:13:26,204 CHICAGO. 337 00:13:26,204 --> 00:13:30,108 SXL IT SPANS ABOUT THREE 338 00:13:30,108 --> 00:13:33,044 DECADES OF NIH RESEARCH 339 00:13:33,044 --> 00:13:34,713 ADDRESSING EACH STAGE OF THE 340 00:13:34,713 --> 00:13:36,448 CONTINUUM AT SOME POINT OR 341 00:13:36,448 --> 00:13:37,449 ANOTHER. 342 00:13:37,449 --> 00:13:41,786 I FOCUS ON ADOLESCENT AND YOUNG 343 00:13:41,786 --> 00:13:43,655 ADULTS BUT INTEGRATED MENTAL 344 00:13:43,655 --> 00:13:45,090 HEALTH AND SOCIAL DETERMINANTS 345 00:13:45,090 --> 00:13:47,158 OF HEALTH INTO MOST OF MY 346 00:13:47,158 --> 00:13:49,995 STUDIES AND OVER THE COURSE OF 347 00:13:49,995 --> 00:13:52,197 MY CAREER, I HAVE DEVELOPED AND 348 00:13:52,197 --> 00:13:53,832 DEVELOPED AND TESTED 349 00:13:53,832 --> 00:13:55,700 INTERVENTIONS AND CLINICAL 350 00:13:55,700 --> 00:13:58,970 TRIALS EFFECTIVENESS TRIALS, 351 00:13:58,970 --> 00:14:00,572 HYBRID IMPLEMENTATION, MOST 352 00:14:00,572 --> 00:14:02,907 HAVE FOCUSED ON REDUCING 353 00:14:02,907 --> 00:14:06,344 ADOLESCENT RISK THAT IS 354 00:14:06,344 --> 00:14:09,114 ASSOCIATED WITH TRANSMITTING 355 00:14:09,114 --> 00:14:11,683 HIV AND ALSO REDUCING VIRAL 356 00:14:11,683 --> 00:14:12,150 LOAD. 357 00:14:12,150 --> 00:14:14,019 AND I WOULD LIKE TO POINT OUT 358 00:14:14,019 --> 00:14:16,354 THAT MOST OF MY WORK HAS BEEN 359 00:14:16,354 --> 00:14:19,090 CARRIED OUT IN ALMOST 360 00:14:19,090 --> 00:14:21,860 EXCLUSIVELY REAL PRACTICE 361 00:14:21,860 --> 00:14:22,494 RESOURCE CONSTRAINT SETTINGS, 362 00:14:22,494 --> 00:14:26,164 BOTH IN URBAN AREAS IN U.S. BUT 363 00:14:26,164 --> 00:14:27,799 ALSO GLOBALLY PARTICULARLY IN 364 00:14:27,799 --> 00:14:31,669 AFRICA AND IN ALL OF THAT WORK, 365 00:14:31,669 --> 00:14:35,373 WORKING IN CLOSE COLLABORATION 366 00:14:35,373 --> 00:14:38,009 WITH MEMBERS INCLUDING MEMBERS 367 00:14:38,009 --> 00:14:39,277 WITH HIV. 368 00:14:39,277 --> 00:14:40,745 MOST RECENTLY I FOUNDED AND 369 00:14:40,745 --> 00:14:43,381 DIRECTED THE CENTER FOR DID I 370 00:14:43,381 --> 00:14:46,818 SEM NATION AND IMPLEMENTATION 371 00:14:46,818 --> 00:14:48,987 SCIENCE IN AT UNIVERSITY OF 372 00:14:48,987 --> 00:14:50,755 ILLINOIS, CHICAGO. 373 00:14:50,755 --> 00:14:53,291 AND THE MISSION OF OUR CENTER 374 00:14:53,291 --> 00:14:55,660 IS TO ADVANCE IMPLEMENTATION 375 00:14:55,660 --> 00:14:57,195 SCIENCE RESEARCH, PRACTICE AND 376 00:14:57,195 --> 00:14:59,297 EDUCATION AND PARTNERSHIP WITH 377 00:14:59,297 --> 00:15:01,399 COMMUNITIES TO REDUCE HEALTH 378 00:15:01,399 --> 00:15:04,369 DISPARITIES .D AND I MENTION 379 00:15:04,369 --> 00:15:05,370 THAT BECAUSE AS THE DRIVER OF 380 00:15:05,370 --> 00:15:06,471 THE CENTER AND THE MISSION, I 381 00:15:06,471 --> 00:15:08,273 THINK IT'S IMPORTANT THAT I 382 00:15:08,273 --> 00:15:11,876 THAT I SHARE WITH YOU WHERE MY 383 00:15:11,876 --> 00:15:14,179 POSITION WHERE MY POSITION IS 384 00:15:14,179 --> 00:15:17,415 IN THESE ISSUES AND IN THE 385 00:15:17,415 --> 00:15:18,483 EPIDEMIC. 386 00:15:18,483 --> 00:15:21,419 AS MOST OF YOU KNOW, THERE IS A 387 00:15:21,419 --> 00:15:23,521 PRETTY SIGNIFICANT TIME LAPSE 388 00:15:23,521 --> 00:15:25,857 BETWEEN WHEN A SCIENTIFIC 389 00:15:25,857 --> 00:15:27,025 INNOVATION IS DISCOVERED OR 390 00:15:27,025 --> 00:15:28,426 DEVELOPED AND THEN LIKE LET'S 391 00:15:28,426 --> 00:15:31,162 SAY PREP AND BY THE TIME IT 392 00:15:31,162 --> 00:15:32,964 GETS DELIVERED AND PRACTICED. 393 00:15:32,964 --> 00:15:35,266 IF IT EVER GETS DELIVERED AND 394 00:15:35,266 --> 00:15:35,967 PRACTICED. 395 00:15:35,967 --> 00:15:37,368 AND THE CONCERN OF COURSE IS 396 00:15:37,368 --> 00:15:40,638 THAT THIS GAP IS LOSES AN 397 00:15:40,638 --> 00:15:41,539 ENTIRE GENERATION OF 398 00:15:41,539 --> 00:15:42,941 INDIVIDUALS WHO MIGHT HAVE 399 00:15:42,941 --> 00:15:45,210 BENEFITED FROM IT. 400 00:15:45,210 --> 00:15:48,179 BUT IT ALSO ENDS UP BEING LEAST 401 00:15:48,179 --> 00:15:50,515 LIKELY TO REACH AND BENEFIT THE 402 00:15:50,515 --> 00:15:51,349 POPULATIONS THAT NEED IT THE 403 00:15:51,349 --> 00:15:52,150 MOST. 404 00:15:52,150 --> 00:15:55,386 AND SO THE ABSENCE OF EQUITY IN 405 00:15:55,386 --> 00:15:57,055 THIS RESEARCH AND UP TAKE OF 406 00:15:57,055 --> 00:15:58,490 THESE INTERVENTION SOUTH SIDE 407 00:15:58,490 --> 00:15:59,557 GRAVELY CONCERNING. 408 00:15:59,557 --> 00:16:01,392 AND I'M HOPEFUL THAT AS WE MOVE 409 00:16:01,392 --> 00:16:08,066 INTO THIS NEXT PHASE OF THE 410 00:16:08,066 --> 00:16:10,301 H.I.V. RESEARCH WE'RE GOING TO 411 00:16:10,301 --> 00:16:12,570 ADDRESS THIS HEALTH IMPERATIVE. 412 00:16:12,570 --> 00:16:15,173 SO I'M PASSIONATE ABOUT 413 00:16:15,173 --> 00:16:16,107 ADVANCING EVIDENCE BASE 414 00:16:16,107 --> 00:16:18,209 INTERVENTION THAT'S MAKE A 415 00:16:18,209 --> 00:16:19,811 GLOBAL IMPACT, ESPECIALLY IN 416 00:16:19,811 --> 00:16:22,313 LOW RESEARCH SETTINGS AND THAT 417 00:16:22,313 --> 00:16:25,049 BUILD CAPACITY WITHIN THOSE 418 00:16:25,049 --> 00:16:28,686 SETTINGS TO ACTUALLY SUSTAIN 419 00:16:28,686 --> 00:16:30,421 AFFECTIVE TREATMENT AND USING 420 00:16:30,421 --> 00:16:33,791 IMPLEMENTATION SCIENCE WE CAN 421 00:16:33,791 --> 00:16:36,094 DRIVE FORWARD NIH'S EFFORT TO 422 00:16:36,094 --> 00:16:36,794 ACHIEVE HIV CONTROL. 423 00:16:36,794 --> 00:16:38,863 SO THAT'S A BACKGROUND ABOUT ME. 424 00:16:38,863 --> 00:16:44,369 I WANT TO TAKE A MOMENT TO NEXT 425 00:16:44,369 --> 00:16:45,336 SLIDE, PLEASE. 426 00:16:45,336 --> 00:16:49,107 I WANT TO TAKE A MOMENT TO 427 00:16:49,107 --> 00:16:53,511 THANK AND ACKNOWLEDGELE DR. 428 00:16:53,511 --> 00:16:57,815 FINZI'S ROLE AND HARD WORK AS 429 00:16:57,815 --> 00:16:59,884 THE ACTING OAR DIRECTOR, I HAD 430 00:16:59,884 --> 00:17:01,052 THE GREAT FORTUNATE OF MEETING 431 00:17:01,052 --> 00:17:04,022 HER AT THE INTERNATIONAL 432 00:17:04,022 --> 00:17:05,790 SOCIETY MEETING THIS PAST, I 433 00:17:05,790 --> 00:17:09,227 THINK IT WAS JULY. 434 00:17:09,227 --> 00:17:11,563 AND JUST SO IMPRESSED BY HER 435 00:17:11,563 --> 00:17:15,967 DEDICATION AND HER WORK AND THE 436 00:17:15,967 --> 00:17:18,436 COUNTLESS INITIATIVES THAT THEY 437 00:17:18,436 --> 00:17:20,738 REALLY LEAD DURING HER TENURE 438 00:17:20,738 --> 00:17:22,840 AS ACTING DIRECTOR. 439 00:17:22,840 --> 00:17:24,209 SO I'M HOPING WE CONTINUE TO 440 00:17:24,209 --> 00:17:25,577 WORK TOGETHER WHILE YOU 441 00:17:25,577 --> 00:17:27,011 TRANSITION BACK INTO YOUR ROLE 442 00:17:27,011 --> 00:17:29,147 AS DIRECTOR OF THE BASIC 443 00:17:29,147 --> 00:17:31,749 SCIENCES PROGRAM. 444 00:17:31,749 --> 00:17:34,052 AND MANY MANY THANKS TO YOU FOR 445 00:17:34,052 --> 00:17:35,887 YOUR SUPPORT AND YOUR 446 00:17:35,887 --> 00:17:36,554 LEADERSHIP DURING THIS 447 00:17:36,554 --> 00:17:39,090 TRANSITION. 448 00:17:39,090 --> 00:17:44,062 NEXT SLIDE, PLEASE. 449 00:17:44,062 --> 00:17:46,564 I WOULD ALSO LIKE TO FORMALLY 450 00:17:46,564 --> 00:17:50,301 WELCOME AND INTRODUCE OUR FOUR 451 00:17:50,301 --> 00:17:51,202 NEW OARAC MEMBERS. 452 00:17:51,202 --> 00:17:54,606 WE ARE SO FORTUNATE TO HAVE YOU 453 00:17:54,606 --> 00:17:56,007 WORKING WITH US. 454 00:17:56,007 --> 00:17:57,842 I HE YOU PRESENTED A LITTLE BIT 455 00:17:57,842 --> 00:18:00,812 BUT I'LL ADD TO THAT. 456 00:18:00,812 --> 00:18:03,147 DR. COURTNEY FLETCHER IS A 457 00:18:03,147 --> 00:18:04,983 PROFESSOR OF PHARMACY IN THE 458 00:18:04,983 --> 00:18:06,184 COLLING OF PHARMACY AND 459 00:18:06,184 --> 00:18:09,120 MEDICINE AND DIRECTOR OF ANTI 460 00:18:09,120 --> 00:18:09,787 VIRAL PHARMACOLOGY LABORATORY 461 00:18:09,787 --> 00:18:12,523 AT THE UNIVERSITY OF NEBRASKA 462 00:18:12,523 --> 00:18:13,825 MEDICAL CENTER FOR DRUG 463 00:18:13,825 --> 00:18:15,293 DISCOVERY. 464 00:18:15,293 --> 00:18:17,362 HE'S DEVOTED HIS RESEARCH AND 465 00:18:17,362 --> 00:18:20,732 PRACTICE WHERE THE CLINICAL 466 00:18:20,732 --> 00:18:22,100 PHARMACOLOGY OF ANTI VIRAL 467 00:18:22,100 --> 00:18:24,369 AGENTS AND RECEIVED HIS DOCTOR 468 00:18:24,369 --> 00:18:26,671 OF PHARMACY FROM THE UNIVERSITY 469 00:18:26,671 --> 00:18:28,406 OF MINNESOTA IN MINNEAPOLIS. 470 00:18:28,406 --> 00:18:31,376 NEXT WE HAVE SONIA FLORES WHO 471 00:18:31,376 --> 00:18:34,145 IS A PROFESSOR OF MEDICINE AND 472 00:18:34,145 --> 00:18:35,313 MICROBIOLOGY AT THE UNIVERSITY 473 00:18:35,313 --> 00:18:39,217 OF COLORADO IN DENVER. 474 00:18:39,217 --> 00:18:42,687 DR. FLORES WORK HAS FOCUSED ON 475 00:18:42,687 --> 00:18:44,289 EQUITY AND INCLUSION WITHIN THE 476 00:18:44,289 --> 00:18:50,995 BASIC SCIENCES AND H.I.V. 477 00:18:50,995 --> 00:18:52,530 COMORBIDITY ISSUES. 478 00:18:52,530 --> 00:18:56,434 SHE RECEIVED HER DOCTORAL 479 00:18:56,434 --> 00:18:58,069 DEGREE FROM THE UNIVERSITY OF 480 00:18:58,069 --> 00:18:59,904 ALABAMA. 481 00:18:59,904 --> 00:19:06,744 NEXT IS DR. DIANE SANTA MARIA 482 00:19:06,744 --> 00:19:10,581 WHO IS A DEAN AT THE PHYSICS 483 00:19:10,581 --> 00:19:14,018 SCHOOL OF NURSING, HER RESEARCH 484 00:19:14,018 --> 00:19:15,586 INTEREST INCLUDE WORKING IN 485 00:19:15,586 --> 00:19:18,289 UNDER SERVED COMMUNITIES IN THE 486 00:19:18,289 --> 00:19:21,259 U.S. COMMUNITIES CONDUCTING 487 00:19:21,259 --> 00:19:24,028 H.I.V. AND REDUCTION WITH YOUTH 488 00:19:24,028 --> 00:19:25,530 AND YOUNG ADULTS EXPERIENCING 489 00:19:25,530 --> 00:19:27,031 HOMELESSNESS. 490 00:19:27,031 --> 00:19:30,234 SHE BRINGS EXPERTISE IN 491 00:19:30,234 --> 00:19:35,273 ADOLESCENT HEALTH HIV, STI 492 00:19:35,273 --> 00:19:36,107 PREVENTION AND PREDICT I HAVE 493 00:19:36,107 --> 00:19:38,676 MODELING. 494 00:19:38,676 --> 00:19:39,844 RECEIVED HER DRPH IN THE 495 00:19:39,844 --> 00:19:41,412 UNIVERSITY OF TEXAS IN THE 496 00:19:41,412 --> 00:19:42,980 SCHOOL OF PUBLIC HEALTH. 497 00:19:42,980 --> 00:19:45,316 AND THEN LAST BUT OF COURSE NOT 498 00:19:45,316 --> 00:19:48,553 LEAST, WE HAVE SARAH SAWYER WHO 499 00:19:48,553 --> 00:19:50,388 IS A PROFESSOR AT THE 500 00:19:50,388 --> 00:19:52,890 UNIVERSITY OF COLORADO BOULDER. 501 00:19:52,890 --> 00:19:55,193 SHE HAS RECEIVED NATIONAL SXINT 502 00:19:55,193 --> 00:19:58,563 NATIONAL PRIZES IN VIRALOLOGY 503 00:19:58,563 --> 00:20:00,398 INCLUDING THE PRESIDENTIAL 504 00:20:00,398 --> 00:20:01,566 EARLY CAREER AWARD FOR 505 00:20:01,566 --> 00:20:04,969 SCIENTIST AND ENGINEER FROM 506 00:20:04,969 --> 00:20:07,038 PRESIDENT BARACK OBAMA IN 2001, 507 00:20:07,038 --> 00:20:09,407 AND ALSO RECEIVED NIH 508 00:20:09,407 --> 00:20:10,608 DIRECTOR'S PIONEER AWARD IN 509 00:20:10,608 --> 00:20:12,477 2022. 510 00:20:12,477 --> 00:20:15,947 HER RESEARCH FOCUSES ON H.I.V. 511 00:20:15,947 --> 00:20:19,384 1 VACCINE MODELS INCLUDING A 512 00:20:19,384 --> 00:20:22,587 RECENTLY ESTABLISHED ACUTE AND 513 00:20:22,587 --> 00:20:24,889 CHRONIC H.I.V. 1 INFECTION IN 514 00:20:24,889 --> 00:20:29,394 OWL MONKEYS AND HOLDS A Ph.d 515 00:20:29,394 --> 00:20:30,762 FROM CORNELL UNIVERSITY. 516 00:20:30,762 --> 00:20:33,798 SO WELCOME COLLEAGUES AND WE'RE 517 00:20:33,798 --> 00:20:35,933 LOOKING TO ENGAGEMENT AND 518 00:20:35,933 --> 00:20:38,603 PRODUCTIVE COLLABORATIONS. 519 00:20:38,603 --> 00:20:39,971 NEXT SLIDE PLEASE. 520 00:20:39,971 --> 00:20:44,342 SO YOU'LL SEE THAT WE HAVE A 521 00:20:44,342 --> 00:20:45,276 PRETTY PACKED AGENDA. 522 00:20:45,276 --> 00:20:47,378 WE'RE GOING TO START WITH A 523 00:20:47,378 --> 00:20:48,179 DIRECTOR'S REPORT WHICH I WILL 524 00:20:48,179 --> 00:20:49,013 GIVE. 525 00:20:49,013 --> 00:20:52,417 THEN WE'RE GOING TO HEAR A 526 00:20:52,417 --> 00:20:53,584 PRESENTATION ABOUT THE 527 00:20:53,584 --> 00:20:56,954 STRUCTURE FUNCTION AND 528 00:20:56,954 --> 00:21:00,158 INHIBITION OF THE H.I.V. ONE 529 00:21:00,158 --> 00:21:01,759 CAPSID FROM DR. WSUNDQUIST. 530 00:21:01,759 --> 00:21:04,495 NEXT WE'RE GOING TO HEAR FROM 531 00:21:04,495 --> 00:21:05,863 OUR STRATEGIC PLAN TASK FORCE 532 00:21:05,863 --> 00:21:11,135 THAT'S WERE CREATE TODAY 533 00:21:11,135 --> 00:21:12,303 --CREATED TO HELP GUIDE THE 534 00:21:12,303 --> 00:21:13,271 IDEAS BEHIND THE PLAN. 535 00:21:13,271 --> 00:21:16,007 AND LASTLY, WE ARE GOING TO 536 00:21:16,007 --> 00:21:18,309 HEAR SOME UPDATES FROM THE 537 00:21:18,309 --> 00:21:19,710 H.I.V. ADVISORY COUNCIL AND 538 00:21:19,710 --> 00:21:22,513 ALSO THE CLINICAL GUIDELINES. 539 00:21:22,513 --> 00:21:23,181 NEXT SLIDE, PLEASE. 540 00:21:23,181 --> 00:21:24,582 ALL RIGHT. 541 00:21:24,582 --> 00:21:28,219 SO MY REPORT TODAY WILL COVER A 542 00:21:28,219 --> 00:21:29,387 FEW DIFFERENT POINTS, ONE I'M 543 00:21:29,387 --> 00:21:32,123 GOING TO HAVE A NICE 544 00:21:32,123 --> 00:21:33,291 ANNOUNCEMENT TO SHARE AS WELL 545 00:21:33,291 --> 00:21:43,801 AS GO INTO THE MISS CAL YEAR 546 00:21:45,536 --> 00:21:47,738 2026NIH, H.I.V. ELECTIVE. 547 00:21:47,738 --> 00:21:49,874 AND THEN ENGAGEMENT THAT THEY 548 00:21:49,874 --> 00:21:54,979 HAVE HAD IN THE LAST YEAR AND 549 00:21:54,979 --> 00:21:56,380 ALSO ENGAGEMENT TO SHARE OUR 550 00:21:56,380 --> 00:21:58,416 VISION AS WE'RE MOVING FORWARD 551 00:21:58,416 --> 00:22:01,853 WITH THE RESEARCH PORTFOLIO. 552 00:22:01,853 --> 00:22:03,488 AND THEN YOU'RE GOING TO HEAR 553 00:22:03,488 --> 00:22:05,590 ABOUT SOME STRATEGIC PLAN 554 00:22:05,590 --> 00:22:06,958 DEVELOPMENTS AND UPDATE. 555 00:22:06,958 --> 00:22:09,927 NEXT SLIDE, PLEASE. 556 00:22:09,927 --> 00:22:12,897 SO EXCITINGLY, WE ARE ABLE TO 557 00:22:12,897 --> 00:22:15,399 ANNOUNCE THE APPOINTMENT OF DR. 558 00:22:15,399 --> 00:22:17,268 SARAH READ AS PRINCIPAL DEPUTY 559 00:22:17,268 --> 00:22:26,911 DIRECTOR OF THE NATIONAL 560 00:22:26,911 --> 00:22:29,647 DIRECTOR OF INFECTIOUS DISEASES. 561 00:22:29,647 --> 00:22:33,818 SHE WILL BE WORKING ALONGSIDE 562 00:22:33,818 --> 00:22:38,823 DR. MARATSO TO OVER SUE THE 563 00:22:38,823 --> 00:22:41,592 NYADED PROGRAMS AND INITIATIVES. 564 00:22:41,592 --> 00:22:48,799 NEXT SLIDE PLEASE. 565 00:22:48,799 --> 00:22:50,468 SO MOVING ON TO THE 566 00:22:50,468 --> 00:22:51,102 PROFESSIONAL JUDGMENT. 567 00:22:51,102 --> 00:22:54,305 IS IT POSSIBLE TO JUST SEE IF 568 00:22:54,305 --> 00:22:55,439 ANYONE HAS ANY QUESTIONS? 569 00:22:55,439 --> 00:22:57,508 I FEEL LIKE I'M I DON'T KNOW 570 00:22:57,508 --> 00:22:59,577 HOW THIS WORKS EXACTLY BUT IT 571 00:22:59,577 --> 00:23:00,945 SEEMS LIKE A GOOD POINT TO SEE 572 00:23:00,945 --> 00:23:05,516 IF THERE ARE ANY QUESTIONS. 573 00:23:05,516 --> 00:23:06,384 CAN PEOPLE PUT QUESTIONS IN THE 574 00:23:06,384 --> 00:23:08,719 CHAT? 575 00:23:08,719 --> 00:23:10,354 >> THEY ACTUALLY CANNOT. 576 00:23:10,354 --> 00:23:12,857 >> OH OKAY. 577 00:23:12,857 --> 00:23:15,126 >> AND WE DO HAVE TIME AT THE 578 00:23:15,126 --> 00:23:20,398 END FOR Q & A. 579 00:23:20,398 --> 00:23:21,699 >> OKAY, THANK YOU. 580 00:23:21,699 --> 00:23:25,202 EACH YEAR OUR OFFICE PREPARES A 581 00:23:25,202 --> 00:23:25,903 PROFESSIONAL JUDGMENT BUDGET 582 00:23:25,903 --> 00:23:28,673 THAT IS WHERE WE ESTIMATE THE 583 00:23:28,673 --> 00:23:34,412 NEEDS, THE FUND NEEDS TO FULLY 584 00:23:34,412 --> 00:23:36,447 PURSUE THE GOALS OF THE AGENDA. 585 00:23:36,447 --> 00:23:44,155 SO YOU MAZE RECALL THAT DR. 586 00:23:44,155 --> 00:23:47,091 FINZI HAD IN THE JUNE MEETING 587 00:23:47,091 --> 00:23:48,759 AND NOW THE DOCUMENT HAS BEEN 588 00:23:48,759 --> 00:23:49,393 RELEASED AND AVAILABLE ON THE 589 00:23:49,393 --> 00:23:50,161 WEBSITE. 590 00:23:50,161 --> 00:23:53,364 YOU CAN SCAN THE QR CODE IF YOU 591 00:23:53,364 --> 00:23:54,999 WOULD LIKE TO LEARN MORE ABOUT 592 00:23:54,999 --> 00:23:57,535 IT, IT'S ON THE SCREEN. 593 00:23:57,535 --> 00:23:59,770 THE PROFESSIONAL JUDGMENT 594 00:23:59,770 --> 00:24:02,306 BUDGET IS BASED SOLE REON 595 00:24:02,306 --> 00:24:08,079 CURRENT RESEARCH OPPORTUNITIES 596 00:24:08,079 --> 00:24:10,581 AND NIH, H.I.V. PRIORITIES. 597 00:24:10,581 --> 00:24:12,049 IT'S REFERRED TO AS THE 598 00:24:12,049 --> 00:24:14,952 PROFESSIONAL BUDGET BECAUSE IT 599 00:24:14,952 --> 00:24:16,087 REPRESENTATIVES THE 600 00:24:16,087 --> 00:24:19,724 PROFESSIONAL BUDGET OF OAR AND 601 00:24:19,724 --> 00:24:21,959 PRESENTED DIRECTLY TO THE 602 00:24:21,959 --> 00:24:25,596 PRESIDENT WITHOUT MODIFICATION 603 00:24:25,596 --> 00:24:27,665 THROUGH FEDERAL PROCESSES. 604 00:24:27,665 --> 00:24:28,332 THE PROFESSIONAL JUDGMENT 605 00:24:28,332 --> 00:24:31,636 BUDGET IS ONE OF TWO BUDGETS 606 00:24:31,636 --> 00:24:33,704 THAT OUR OFFICE CREATES. 607 00:24:33,704 --> 00:24:37,375 THE SECOND ONE IS CALLED THE 608 00:24:37,375 --> 00:24:38,075 CONGRESSIONAL BUDGET 609 00:24:38,075 --> 00:24:42,380 JUSTIFICATION AND THAT SUPPORTS 610 00:24:42,380 --> 00:24:43,481 THE NIH, H.I.V. BUDGET TO 611 00:24:43,481 --> 00:24:44,949 CONGRESS. 612 00:24:44,949 --> 00:24:47,852 THE 26 PROFESSIONAL BUDGET IS 613 00:24:47,852 --> 00:24:50,287 STRUCTURE TO ALIGN WITH THE 614 00:24:50,287 --> 00:24:52,990 STRATEGIC GOALS IN THE NEXT 615 00:24:52,990 --> 00:25:00,264 ADORATION OF THE STRATEGIC 616 00:25:00,264 --> 00:25:01,332 PLAN WHICH YOU'LL HEAR ABOUT 617 00:25:01,332 --> 00:25:03,334 LATER TODAY. 618 00:25:03,334 --> 00:25:04,735 IT INCLUDES FUNDAMENTAL 619 00:25:04,735 --> 00:25:09,707 RESEARCH TO PROMOTE DISCOVERY 620 00:25:09,707 --> 00:25:12,209 AND H.I.V. SCIENCE AND INCLUDES 621 00:25:12,209 --> 00:25:13,844 PSYCHOSOCIAL I DON'T VARIABLES 622 00:25:13,844 --> 00:25:17,481 AS WELL AND BEHAVIORAL RESEARCH 623 00:25:17,481 --> 00:25:19,283 AS WELL AS, BASIC OTHER BASIC 624 00:25:19,283 --> 00:25:21,852 SCIENCES. 625 00:25:21,852 --> 00:25:24,422 DEVELOPMENT AND ASSESSMENT OF 626 00:25:24,422 --> 00:25:25,322 NOVEL INTERVENTIONS FOR 627 00:25:25,322 --> 00:25:27,391 PREVENTION AND TREATMENT OF 628 00:25:27,391 --> 00:25:30,795 H.I.V. AND COOCCURING 629 00:25:30,795 --> 00:25:32,863 DIVISIONS, AND IMPLEMENTATION 630 00:25:32,863 --> 00:25:34,265 RESEARCH TO OPTIMIZE PUBLIC 631 00:25:34,265 --> 00:25:36,834 HEALTH IMPACT AND THEN 632 00:25:36,834 --> 00:25:38,903 WORKFORCE DEVELOPMENT AND 633 00:25:38,903 --> 00:25:40,538 INFRASTRUCTURE TO ENHANCE 634 00:25:40,538 --> 00:25:42,840 CAPACITY AND INCREASE DIVERSITY. 635 00:25:42,840 --> 00:25:44,008 NEXT SLIDE, PLEASE. 636 00:25:44,008 --> 00:25:46,143 SO AT THIS POINT, I JUST WANT 637 00:25:46,143 --> 00:25:48,512 TO HIGHLIGHT SOME OF THE OUR 638 00:25:48,512 --> 00:25:49,647 ENGAGEMENTS THAT WE'VE BEEN 639 00:25:49,647 --> 00:25:51,415 INVOLVED IN. 640 00:25:51,415 --> 00:25:53,017 WE'VE BEEN PRETTY BUSY. 641 00:25:53,017 --> 00:25:56,487 SO YOU SEE HERE, THESE ARE JUST 642 00:25:56,487 --> 00:25:58,622 A SELECT NUMBER BUT IF YOU WANT 643 00:25:58,622 --> 00:26:00,224 TO LEARN MORE ABOUT THE EVENTS 644 00:26:00,224 --> 00:26:02,059 THAT I'M HIGHLIGHTING HERE, 645 00:26:02,059 --> 00:26:03,494 PLEASE USE THE QR CODE. 646 00:26:03,494 --> 00:26:05,796 THE FIRST THAT YOU SEE HERE IS 647 00:26:05,796 --> 00:26:07,431 THE U.S. CONFERENCE ON H.I.V. 648 00:26:07,431 --> 00:26:09,734 AND AIDS, THAT WAS IN SEPTEMBER 649 00:26:09,734 --> 00:26:11,969 IN NEW ORLEANS AND WE 650 00:26:11,969 --> 00:26:14,038 PARTICIPATED IN A SESSION 651 00:26:14,038 --> 00:26:17,007 TITLED A FEDERAL UPDATE ON 652 00:26:17,007 --> 00:26:18,642 H.I.V. PROGRAMS AND TAKING A 653 00:26:18,642 --> 00:26:22,646 SIN DEMIC APPROACH. 654 00:26:22,646 --> 00:26:24,815 WE ALSO CONDUCTED LISTENING 655 00:26:24,815 --> 00:26:26,450 SESSIONS FOCUSED ON TRIBAL 656 00:26:26,450 --> 00:26:33,491 HEALTH IN PARTNERSHIP WITH NIH 657 00:26:33,491 --> 00:26:34,592 TRIBAL HEALTH AND INDIAN 658 00:26:34,592 --> 00:26:36,427 SERVICE. 659 00:26:36,427 --> 00:26:38,963 WE LISTENED AND HEARD ABOUT 660 00:26:38,963 --> 00:26:41,398 THEIR PREFERENCES AND CONCERNS. 661 00:26:41,398 --> 00:26:44,668 ANOTHER ACTIVITY WE ENGAGED IN, 662 00:26:44,668 --> 00:26:48,539 WE HOSTED A THE INNOVATION AND 663 00:26:48,539 --> 00:26:51,909 H.I.V. RESEARCH IMPOSIUM THAT 664 00:26:51,909 --> 00:26:55,546 WAS HELD IN ROCKFIELD AS PART 665 00:26:55,546 --> 00:26:59,416 OF THE NIH FESTIVAL. 666 00:26:59,416 --> 00:27:01,719 THAT PARTICULAR ACTIVITY 667 00:27:01,719 --> 00:27:03,587 FEATURED INTERIM MURAL 668 00:27:03,587 --> 00:27:04,922 INVESTIGATORS WHO RECEIVED 669 00:27:04,922 --> 00:27:07,024 INNOVATION AWARDS. 670 00:27:07,024 --> 00:27:09,293 ALSO HAD 16 PRESENTATIONS 671 00:27:09,293 --> 00:27:13,931 COVERING VERY DIVERSE TOPICS 672 00:27:13,931 --> 00:27:16,233 FROM VIRALOLOGY, DATA SCIENCE 673 00:27:16,233 --> 00:27:17,601 AND COMOORE BITITY AND 674 00:27:17,601 --> 00:27:19,470 COINFECTIONS. 675 00:27:19,470 --> 00:27:20,871 THE SYMPOSIUM HIGHLIGHTED THE 676 00:27:20,871 --> 00:27:22,740 PROGRAMS IMPACT AND FOSTERING 677 00:27:22,740 --> 00:27:24,608 INNOVATIVE RESEARCH WITH THE 678 00:27:24,608 --> 00:27:27,678 POTENTIAL TO ADVANCE THE H.I.V. 679 00:27:27,678 --> 00:27:31,782 CARE CONTINUUM AND THE 680 00:27:31,782 --> 00:27:35,419 PARTICIPANTS REPORTED REALLY 681 00:27:35,419 --> 00:27:36,754 APPRECIATING FROM THE H.I.V. 682 00:27:36,754 --> 00:27:38,389 COMMUNITY. 683 00:27:38,389 --> 00:27:42,693 AND MULTIPLE OTHER INSTITUTES 684 00:27:42,693 --> 00:27:44,128 ALSO PARTICIPATED. 685 00:27:44,128 --> 00:27:46,730 NEXT SLIDE, PLEASE. 686 00:27:46,730 --> 00:27:50,034 WE ALSO PARTICIPATED IN THE 687 00:27:50,034 --> 00:27:53,037 AIDS 2024 MEETING OF THE 688 00:27:53,037 --> 00:27:53,737 INTERNATIONAL AIDS CONFERENCE 689 00:27:53,737 --> 00:28:02,179 AS WELL AS H.I.V. SORRY, H.I.V. 690 00:28:02,179 --> 00:28:03,347 R4P. 691 00:28:03,347 --> 00:28:06,584 AND TWO VERY IMPORTANT STUDIES 692 00:28:06,584 --> 00:28:07,852 WERE PRESENTED THAT WE WANTED 693 00:28:07,852 --> 00:28:10,754 TO DRAW YOUR ATTENTION TO. 694 00:28:10,754 --> 00:28:14,391 ONE, WAS THE PURPOSE ONE TRIAL 695 00:28:14,391 --> 00:28:16,260 AND IT REALLY WAS A 696 00:28:16,260 --> 00:28:20,130 BREAKTHROUGH STUDY THAT 697 00:28:20,130 --> 00:28:21,065 DEMONSTRATED LENACAPAVIR WHICH 698 00:28:21,065 --> 00:28:27,004 IS A CAPSID INHIBITOR, IS 100 699 00:28:27,004 --> 00:28:31,742 PERCENT AFFECTIVE IN PREVENTING 700 00:28:31,742 --> 00:28:32,910 H.I.V. TRANSMISSION AGAINST 701 00:28:32,910 --> 00:28:35,646 TRANSGENDER WOMEN AND THAT WAS 702 00:28:35,646 --> 00:28:36,747 GROUND BREAKING, IMPORTANT 703 00:28:36,747 --> 00:28:38,916 FINDING THAT SORT OF MADE EVERY 704 00:28:38,916 --> 00:28:41,485 ONE VERY EXCITED AND IT BUILDS 705 00:28:41,485 --> 00:28:44,822 ON DECADES OF NIH SUPPORTED 706 00:28:44,822 --> 00:28:46,390 BASIC SCIENCE. 707 00:28:46,390 --> 00:28:49,226 THE DEVELOPMENT OF LENACAPAVIR 708 00:28:49,226 --> 00:28:51,962 REALLY UNDER SCORES THE ROLE OF 709 00:28:51,962 --> 00:28:54,498 H.I.V. INVESTMENTS IN 710 00:28:54,498 --> 00:28:55,666 FUNDAMENTAL RESEARCH THAT CAN 711 00:28:55,666 --> 00:28:57,968 LEAD TO THERAPIST AND 712 00:28:57,968 --> 00:28:59,470 SIGNIFICANTLY REDUCE GLOBAL 713 00:28:59,470 --> 00:29:01,171 H.I.V. CASES. 714 00:29:01,171 --> 00:29:06,644 AT THE INTERNATIONAL SOCIETY'S 715 00:29:06,644 --> 00:29:10,948 5th PREVENTION CONFERENCE OR 716 00:29:10,948 --> 00:29:13,884 H.I.V. RAP, THE CONFERENCE 717 00:29:13,884 --> 00:29:16,587 HIGHLIGHTED NEW DATA FROM THE 718 00:29:16,587 --> 00:29:17,988 PURPOSE 2 TRIALS. 719 00:29:17,988 --> 00:29:21,458 THE LARGE NATIONAL AIDS 720 00:29:21,458 --> 00:29:23,294 CONFERENCE REPORTED ON PURPOSE 721 00:29:23,294 --> 00:29:25,796 1, THIS ONE REPORTED ON PURPOSE 722 00:29:25,796 --> 00:29:30,834 2, AND THIS HIGHLIGHTED TWICE 723 00:29:30,834 --> 00:29:33,837 YEARLY LENACAPAVIR, TWO 724 00:29:33,837 --> 00:29:35,172 INJECTIONS SIGNIFICANTLY 725 00:29:35,172 --> 00:29:37,708 REDUCES, DEMONSTRATING 96 726 00:29:37,708 --> 00:29:39,343 PERCENT ETHICACY AMONG A NUMBER 727 00:29:39,343 --> 00:29:43,013 OF HIGH-RISK PO POPULATIONS. 728 00:29:43,013 --> 00:29:46,250 SO THE ADVANCEMENT IS PART OF A 729 00:29:46,250 --> 00:29:48,285 BROADER DISCUSSION AT THE EVENT. 730 00:29:48,285 --> 00:29:51,021 AND IT HIGHLIGHTED INNOVATIONS 731 00:29:51,021 --> 00:29:53,824 IN PREP DELIVERY METHODS, 732 00:29:53,824 --> 00:29:57,962 H.I.V. VACCINE RESEARCH, LONG 733 00:29:57,962 --> 00:29:59,596 ACTING ANTI RETRO TECHNOLOGIES 734 00:29:59,596 --> 00:30:00,965 AND TO ME WHAT IS REALLY 735 00:30:00,965 --> 00:30:02,833 IMPORTANT IS THE EMPHASIS ON 736 00:30:02,833 --> 00:30:04,935 THE NEED FOR GLOBAL ACCESS TO 737 00:30:04,935 --> 00:30:07,137 THESE TOOLS. 738 00:30:07,137 --> 00:30:10,841 ESPECIALLY, IN REGIONS WHERE 739 00:30:10,841 --> 00:30:11,976 H.I.V. ARE RISING LIKE LATIN 740 00:30:11,976 --> 00:30:13,644 AMERICAN. 741 00:30:13,644 --> 00:30:14,845 IT ALSO HIGHLIGHTS FOR ME 742 00:30:14,845 --> 00:30:16,213 OPPORTUNITIES FOR 743 00:30:16,213 --> 00:30:17,982 IMPLEMENTATION SCIENCE. 744 00:30:17,982 --> 00:30:21,385 THAT NOW WE HAVE THESE TOOLS 745 00:30:21,385 --> 00:30:22,987 THAT WORK AND WE NOW HAVE A 746 00:30:22,987 --> 00:30:24,188 NUMBER OF TOOLS THAT WORK. 747 00:30:24,188 --> 00:30:27,191 AND WHAT WE NEED TO UNDERSTAND 748 00:30:27,191 --> 00:30:29,059 IS HOW WE'RE GOING TO GET THOSE 749 00:30:29,059 --> 00:30:30,561 TOOLS INTO THE COMMUNITY THAT'S 750 00:30:30,561 --> 00:30:31,362 MOST NEED THEM? 751 00:30:31,362 --> 00:30:34,031 WHAT DO WE NEED TO DO? 752 00:30:34,031 --> 00:30:35,799 CAN WE IMPROVE REACH? 753 00:30:35,799 --> 00:30:37,668 HOW CAN WE IMPROVE UPDATES? 754 00:30:37,668 --> 00:30:39,703 WE KNOW THAT THERE ARE BARRIERS 755 00:30:39,703 --> 00:30:41,338 TO GETTING THESE TECHNOLOGIES 756 00:30:41,338 --> 00:30:42,973 OR INNOVATIONS OUT THERE AND 757 00:30:42,973 --> 00:30:45,309 THAT IS AN EXCITING PART OF 758 00:30:45,309 --> 00:30:49,413 THIS JOB FOR ME SO THAT I CAN, 759 00:30:49,413 --> 00:30:51,882 SO THAT WE AS A TEAM CAN THINK 760 00:30:51,882 --> 00:30:56,053 ABOUT HOW TO DO THAT. 761 00:30:56,053 --> 00:30:57,955 I THINK I'M SUPPOSE TO PIVOT 762 00:30:57,955 --> 00:31:05,596 RIGHT NOW AND ALLOW--. 763 00:31:05,596 --> 00:31:15,939 >> ACTUALLY DR. DO 764 00:31:18,942 --> 00:31:21,845 NOT--DONENBERG, HE HAD TO EXIT 765 00:31:21,845 --> 00:31:23,914 SO FEEL FREE TO CONTINUE. 766 00:31:23,914 --> 00:31:25,849 >> WE HAVE FOLKS WHO ARE 767 00:31:25,849 --> 00:31:27,384 ATTENDING THAT FROM OUR OFFICE. 768 00:31:27,384 --> 00:31:30,154 THE 15th INTERNATIONAL WORKSHOP 769 00:31:30,154 --> 00:31:31,088 ON HIV AND AGING. 770 00:31:31,088 --> 00:31:35,192 AND THIS IS A PLATFORM FOR 771 00:31:35,192 --> 00:31:36,560 INTERNATIONAL CROSS 772 00:31:36,560 --> 00:31:39,396 DISCIPLINARY EXCHANGE ON 773 00:31:39,396 --> 00:31:40,731 INCREASINGLY ENCOUNTER IN THE 774 00:31:40,731 --> 00:31:42,199 CLINICAL CARE AND DESIGN OF 775 00:31:42,199 --> 00:31:46,503 STUDIES TO IMPROVE THE CARE OF 776 00:31:46,503 --> 00:31:49,673 PERSONS AGING WITH H.I.V. 777 00:31:49,673 --> 00:31:51,041 THEY BRING TOGETHER RESEARCHERS 778 00:31:51,041 --> 00:31:54,478 AND COMMUNITY ADVOCATE IN ORDER 779 00:31:54,478 --> 00:31:57,748 TO FOSTER DIALOGUE AND PROMPT 780 00:31:57,748 --> 00:32:00,517 DISILLUSIONS, MAINLY TO BENEFIT 781 00:32:00,517 --> 00:32:02,052 THE AGING POPULATION LIVING 782 00:32:02,052 --> 00:32:03,720 WITH H.I.V. 783 00:32:03,720 --> 00:32:05,722 WE ALSO ORGANIZED A SYMPOSIUM 784 00:32:05,722 --> 00:32:07,858 IN PARTNERSHIP WITH THE 785 00:32:07,858 --> 00:32:10,194 NATIONAL INSTITUTE OF MENTAL 786 00:32:10,194 --> 00:32:12,729 HEALTH FOR TRAINEES AND JUNIOR 787 00:32:12,729 --> 00:32:14,098 SCHOLARS TO PRESENT THEIR 788 00:32:14,098 --> 00:32:15,933 RESEARCH AND NETWORK AND LEARN 789 00:32:15,933 --> 00:32:19,369 FROM OTHER EXPERTS IN THE FIELD. 790 00:32:19,369 --> 00:32:23,941 COMING UP, WE ARE GOING TO BE 791 00:32:23,941 --> 00:32:27,177 ATTENDING THE ANNUAL 28th 792 00:32:27,177 --> 00:32:29,012 ANNUAL NATIONAL CENTERS FOR 793 00:32:29,012 --> 00:32:31,115 AIDS RESEARCH OR THE C-FAR 794 00:32:31,115 --> 00:32:32,116 MEETING AND THAT'S GOING TO BE 795 00:32:32,116 --> 00:32:32,916 IN NEW YORK. 796 00:32:32,916 --> 00:32:34,118 AND I'LL BE SPEAKING AT THE 797 00:32:34,118 --> 00:32:35,886 MEETING AS PART OF THE LARGER 798 00:32:35,886 --> 00:32:39,690 AS PART OF THE PANEL PROVIDING 799 00:32:39,690 --> 00:32:41,525 NIH PERSPECTIVE AND I REALLY 800 00:32:41,525 --> 00:32:45,395 HOPE TO SPEND SOME TIME 801 00:32:45,395 --> 00:32:48,132 EMPHASIZING THE SPORTS OF 802 00:32:48,132 --> 00:32:50,868 TREATMENT ACCESS UP TAKE, 803 00:32:50,868 --> 00:32:53,303 ADOPTION AND SUSTAINABILITY. 804 00:32:53,303 --> 00:32:55,539 AND FINALLY, I'M REALLY LOOKING 805 00:32:55,539 --> 00:33:02,846 FORWARD TO ATTENDING THE 83rd 806 00:33:02,846 --> 00:33:04,915 MEETING OR PATCHA IN DECEMBER 807 00:33:04,915 --> 00:33:05,215 IN ALABAMA. 808 00:33:05,215 --> 00:33:08,619 AND AUZ A REMINDER, PATCHA 809 00:33:08,619 --> 00:33:10,187 PROVIDES ADVISE, INFORMATION 810 00:33:10,187 --> 00:33:11,388 AND RECOMMENDATIONS TO THE 811 00:33:11,388 --> 00:33:14,224 SECRETARY OF HEALTH AND HUMAN 812 00:33:14,224 --> 00:33:16,627 SERVICES REGARDING PROGRAMS AND 813 00:33:16,627 --> 00:33:18,929 RESEARCH TO PROMOTE AFFECTIVE 814 00:33:18,929 --> 00:33:22,366 TREATMENT AND PREVENTION OF 815 00:33:22,366 --> 00:33:27,604 CURE AND H.I.V. INCLUDING 816 00:33:27,604 --> 00:33:30,407 COMORBIDITIES. 817 00:33:30,407 --> 00:33:32,709 NEXT SLIDE, PLEASE. 818 00:33:32,709 --> 00:33:35,479 I DO WANT TO CALL ATTENTION TO 819 00:33:35,479 --> 00:33:37,080 WORLD AIDS DAY WHICH IS 820 00:33:37,080 --> 00:33:41,885 HAPPENING ON DECEMBER 1st IS 821 00:33:41,885 --> 00:33:43,954 THE ANNUAL OBSERVANCE ALTHOUGH 822 00:33:43,954 --> 00:33:45,822 BECAUSE THAT FALLS ON A 823 00:33:45,822 --> 00:33:46,957 WEEKEND, OUR OFFICE IS GOING TO 824 00:33:46,957 --> 00:33:50,661 BE CELEBRATING IT ON DECEMBER 4. 825 00:33:50,661 --> 00:33:53,630 AND NIH IS STEWARD OF THE WORLD 826 00:33:53,630 --> 00:33:56,667 LARGEST SECTOR INVESTMENT IN 827 00:33:56,667 --> 00:33:58,969 HIV RESEARCH, WE'LL CONVENE 828 00:33:58,969 --> 00:34:00,837 ACROSS RESEARCH PARTNERS TO 829 00:34:00,837 --> 00:34:03,340 DISCUSS, RESENT PROGRESS AND 830 00:34:03,340 --> 00:34:04,508 CHALLENGES THAT REMAIN, SHARE 831 00:34:04,508 --> 00:34:08,245 UPDATES ON THE CURRENT STATE OF 832 00:34:08,245 --> 00:34:12,616 HIV AND AND WHAT IS TO COME AND 833 00:34:12,616 --> 00:34:13,784 COLLABORATE EXTENSIVELY WITH 834 00:34:13,784 --> 00:34:14,918 FEDERAL PARTNERS TO COORDINATE 835 00:34:14,918 --> 00:34:16,520 EFFORTS. 836 00:34:16,520 --> 00:34:19,523 SO THIS YEAR'S FEDERAL WORLD 837 00:34:19,523 --> 00:34:22,092 AIDS DAY THEME IS COLLECTIVE 838 00:34:22,092 --> 00:34:24,795 ACTIONS, SUSTAINED AND 839 00:34:24,795 --> 00:34:27,531 ACCELERATE HIV PROGRESS. 840 00:34:27,531 --> 00:34:30,067 THIS THEME REFLECTS THE U.S. 841 00:34:30,067 --> 00:34:30,767 GOVERNMENT'S COMMITMENT TO 842 00:34:30,767 --> 00:34:33,303 BUILD ON THE MAJOR ACHIEVEMENTS 843 00:34:33,303 --> 00:34:36,039 OF GLOBAL AND DOMESTIC HIV 844 00:34:36,039 --> 00:34:37,140 PROGRAMS OVER THE PAST FOUR 845 00:34:37,140 --> 00:34:38,809 YEARS. 846 00:34:38,809 --> 00:34:41,612 SORRY, THE PAST FOUR DECADES. 847 00:34:41,612 --> 00:34:44,348 THIS WAY, I THINK THIS 848 00:34:44,348 --> 00:34:45,182 PARTICULAR CELEBRATION REALLY 849 00:34:45,182 --> 00:34:47,784 WILL STRIFE TO ENSURE THAT ALL 850 00:34:47,784 --> 00:34:50,120 COMMUNITIES ARE INCLUDED IN IN 851 00:34:50,120 --> 00:34:51,888 THE BENEFITS THAT WE HAVE 852 00:34:51,888 --> 00:34:52,656 ACHIEVED. 853 00:34:52,656 --> 00:34:56,326 AT THE SAME TIME, WE HAVE 854 00:34:56,326 --> 00:34:59,730 FOCUSED ON INNOVATIVE AND 855 00:34:59,730 --> 00:35:01,198 ADAPTING STRATEGIES BASED ON 856 00:35:01,198 --> 00:35:02,733 THE BREAKTHROUGHS, 857 00:35:02,733 --> 00:35:03,900 IMPLEMENTATION RESEARCH AND 858 00:35:03,900 --> 00:35:05,269 INSIDE GAIN FROM ON THE GROUND 859 00:35:05,269 --> 00:35:10,540 PROGRAMS. 860 00:35:10,540 --> 00:35:14,211 THE OAR WORLD AIDS DAY EVENT 861 00:35:14,211 --> 00:35:16,780 WILL OCCUR ON DECEMBER 4th, AS 862 00:35:16,780 --> 00:35:17,648 I MENTIONED. 863 00:35:17,648 --> 00:35:19,683 PLEASE VISIT OUR WEBSITE FOR 864 00:35:19,683 --> 00:35:21,018 MORE INFORMATION AS IT BECOMES 865 00:35:21,018 --> 00:35:23,787 AVAILABLE. 866 00:35:23,787 --> 00:35:26,790 NEXT SLIDE, PLEASE. 867 00:35:26,790 --> 00:35:27,457 WONDERFUL. 868 00:35:27,457 --> 00:35:34,298 OKAY. 869 00:35:34,298 --> 00:35:38,435 HHS, OFFICE OF INFECTIOUS 870 00:35:38,435 --> 00:35:40,704 DISEASES IS IN THE PROCESS OF 871 00:35:40,704 --> 00:35:43,774 DEVELOPING THE 2026 TO 2030 872 00:35:43,774 --> 00:35:44,608 NATIONAL STRATEGIC PLANS FOR 873 00:35:44,608 --> 00:35:46,243 EACH OF THESE AREAS YOU SEE IN 874 00:35:46,243 --> 00:35:47,344 THE SLIDE. 875 00:35:47,344 --> 00:35:51,048 SO YOU SEE FOR SEXUALLY 876 00:35:51,048 --> 00:35:54,718 TRANSMITTED INFECTIONS, VACCINE 877 00:35:54,718 --> 00:35:56,620 AND VIRAL HEPATITIS. 878 00:35:56,620 --> 00:35:57,487 THEY'RE COLLABORATED WITH THE 879 00:35:57,487 --> 00:36:00,457 WHITE HOUSE OF AIDS POLICY TO 880 00:36:00,457 --> 00:36:04,127 DEVELOP THE 2026 TO 2030 881 00:36:04,127 --> 00:36:06,697 NATIONAL AIDS HIV-AIDS STRATEGY. 882 00:36:06,697 --> 00:36:09,199 TONE SURE THESE PLANS ARE 883 00:36:09,199 --> 00:36:10,801 RELEVANT AND AFFECTIVE, THEY 884 00:36:10,801 --> 00:36:13,770 HAVE PUT OUT A REQUEST FOR 885 00:36:13,770 --> 00:36:14,905 INFORMATION AND THAT'S FOR ALL 886 00:36:14,905 --> 00:36:17,207 OF YOU ON THIS CALL OR ANYONE 887 00:36:17,207 --> 00:36:19,910 WHO IS INTERESTED TO SUBMIT 888 00:36:19,910 --> 00:36:22,179 INFORMATION THAT YOU WOULD THAT 889 00:36:22,179 --> 00:36:25,415 IN RESPONSE TO THIS CALL. 890 00:36:25,415 --> 00:36:28,418 SO, THEY WOULD LIKE INPUT FROM 891 00:36:28,418 --> 00:36:30,287 INDIVIDUALS ORGANIZATIONS AND 892 00:36:30,287 --> 00:36:32,622 PUBLIC HEALTH PARTNERS ONLINE 893 00:36:32,622 --> 00:36:34,558 WITH SUBMISSIONS ARE OPEN UNTIL 894 00:36:34,558 --> 00:36:35,892 SEPTEMBER 6. 895 00:36:35,892 --> 00:36:37,961 SO PLEASE CONSIDER USING THE QR 896 00:36:37,961 --> 00:36:40,330 CODE ON THE SLIDE TO ACCESS THE 897 00:36:40,330 --> 00:36:43,967 FORM AND SUBMIT FEEDBACK. 898 00:36:43,967 --> 00:36:45,369 VIRTUAL LISTENING SESSIONS WILL 899 00:36:45,369 --> 00:36:48,605 ALSO BE HELD TOGETHER FEEDBACK 900 00:36:48,605 --> 00:36:51,007 AND OAR OFFICE HAS ALREADY 901 00:36:51,007 --> 00:36:58,915 PROVIDED INPUT FOR THE 2024 TO 902 00:36:58,915 --> 00:37:01,518 2030 STRATEGIC--NATIONAL H.I.V. 903 00:37:01,518 --> 00:37:06,690 STRATEGIC STRATEGY. 904 00:37:06,690 --> 00:37:08,525 NEXT SLIDE, PLEASE, OOPS. 905 00:37:08,525 --> 00:37:13,830 SORRY. 906 00:37:13,830 --> 00:37:15,866 ALL RIGHT, NOW I WOULD LIKE TO 907 00:37:15,866 --> 00:37:20,904 DO A BIT OF AN UPDATE ON THE 908 00:37:20,904 --> 00:37:22,305 STRATEGIC PLAN PROCESS BUT I 909 00:37:22,305 --> 00:37:24,408 THINK YOU'RE GOING TO HEAR MORE 910 00:37:24,408 --> 00:37:26,443 ABOUT THIS LATER. 911 00:37:26,443 --> 00:37:27,844 BUT NEXT SLIDE, PLEASE. 912 00:37:27,844 --> 00:37:32,115 WHAT YOU SEE HERE IS THE WHAT 913 00:37:32,115 --> 00:37:33,817 THE PLAN IS AND WHAT THE PLAN 914 00:37:33,817 --> 00:37:35,085 IS NOT. 915 00:37:35,085 --> 00:37:37,587 AND I THINK IT'S IMPORTANT TO 916 00:37:37,587 --> 00:37:41,258 HIGHLIGHT FOR YOU THAT YOU KNOW 917 00:37:41,258 --> 00:37:45,695 THE NIH STRATEGIC PLAN FOR 918 00:37:45,695 --> 00:37:49,099 H.I.V. AND HIV-RELATED RESEARCH 919 00:37:49,099 --> 00:37:51,668 GUIDES THE LARGEST INVESTMENT 920 00:37:51,668 --> 00:37:53,103 IN HIV RESEARCH AND BUILDS ON 921 00:37:53,103 --> 00:37:57,507 SIGN CIENTIFIC PROGRESS AND 922 00:37:57,507 --> 00:38:00,644 OPPORTUNITIES TO ADVANCE TO 923 00:38:00,644 --> 00:38:04,514 REACH 'EM DEM --EPIDEMIC 924 00:38:04,514 --> 00:38:05,282 CONTROL. 925 00:38:05,282 --> 00:38:08,485 AND YOU'LL SEE ON THIS SLIDE 926 00:38:08,485 --> 00:38:09,920 THE PLAN, AND WHAT IT'S NOT. 927 00:38:09,920 --> 00:38:14,024 IT'S NOT A STATIC PLAN, IT'S 928 00:38:14,024 --> 00:38:16,326 NOT GRANULAR OR ALL INCLUSIVE, 929 00:38:16,326 --> 00:38:19,629 IT CAN'T STAND ALONE. 930 00:38:19,629 --> 00:38:25,068 IT'S OVER ARCHING ROAD MAP FOR 931 00:38:25,068 --> 00:38:25,969 THE GUIDING FRAMEWORK THAEN 932 00:38:25,969 --> 00:38:28,305 SHOESER THAT THE FUNDS ARE 933 00:38:28,305 --> 00:38:33,076 ALLOCATED IN ACCORDANCE WITH 934 00:38:33,076 --> 00:38:34,945 THE ESTABLISHED NIH SCIENTIFIC 935 00:38:34,945 --> 00:38:36,046 PRIORITIES. 936 00:38:36,046 --> 00:38:37,914 YOU'LL ALSO NOTICE THAT THE 937 00:38:37,914 --> 00:38:39,916 PLAN IS BROAD ENOUGH TO CAPTURE 938 00:38:39,916 --> 00:38:41,852 EVERYTHING THAT COULD BE FUNDED 939 00:38:41,852 --> 00:38:44,621 WITH H.I.V. DOLLARS WHILE ALSO 940 00:38:44,621 --> 00:38:46,122 TRYING TO HIGHLIGHT SPECIFIC 941 00:38:46,122 --> 00:38:47,724 AREAS THAT SHOULD BE 942 00:38:47,724 --> 00:38:50,093 PRIORITIZED. 943 00:38:50,093 --> 00:38:53,730 AND THEN, FINALLY THE PLAN IS 944 00:38:53,730 --> 00:39:03,106 ALIGNED WITH NATIONAL NIH, HIV 945 00:39:03,106 --> 00:39:08,144 STRATEGY AND PLAN THAT IS 946 00:39:08,144 --> 00:39:11,314 REVIEWED ANNUALLY. 947 00:39:11,314 --> 00:39:15,886 INPUT FROM A BROAD RANGE OF 948 00:39:15,886 --> 00:39:17,721 INTERESTED PARTIES, THIS 949 00:39:17,721 --> 00:39:18,855 INCLUDES RESEARCHERS, 950 00:39:18,855 --> 00:39:20,724 HEALTHCARE PROFESSIONALS, 951 00:39:20,724 --> 00:39:22,359 ADVOCATE, SCIENTIFIC AND 952 00:39:22,359 --> 00:39:23,059 PROFESSIONAL ORGANIZATIONS AS 953 00:39:23,059 --> 00:39:24,961 WELL AS GOVERNMENT AGENCIES AND 954 00:39:24,961 --> 00:39:25,795 COMMUNITY MEMBERS. 955 00:39:25,795 --> 00:39:28,098 AND THE PLAN WILL CONTINUE TO 956 00:39:28,098 --> 00:39:30,634 EVOLVE TO REFLECT RESEARCH 957 00:39:30,634 --> 00:39:31,535 ADVANCES AND CHANGES IN THE 958 00:39:31,535 --> 00:39:33,837 NEEDS OF THOSE AFFECTED BY 959 00:39:33,837 --> 00:39:36,573 H.I.V. 960 00:39:36,573 --> 00:39:38,208 NEXT SLIDE PLEASE. 961 00:39:38,208 --> 00:39:40,310 THIS SLIDE JUST PROVIDES A BIT 962 00:39:40,310 --> 00:39:42,345 OF AN OVERVIEW OF THE PLAN 963 00:39:42,345 --> 00:39:43,747 PROCESS THAT WE WANT TO 964 00:39:43,747 --> 00:39:45,849 HIGHLIGHT FOR YOU. 965 00:39:45,849 --> 00:39:49,019 THE FIRST IS THAT YOU CAN SEE 966 00:39:49,019 --> 00:39:51,588 HERE, THAT LET'S GO TO THE 967 00:39:51,588 --> 00:39:54,090 NEXT, THE NEXT SLIDE, THE FIRST 968 00:39:54,090 --> 00:39:57,961 IS THAT WE RECEIVED IMPACT FROM 969 00:39:57,961 --> 00:40:02,232 MANY INDIVIDUALS AS I NOTED, 970 00:40:02,232 --> 00:40:04,534 PREVIOUSLY. 971 00:40:04,534 --> 00:40:08,238 AND THEN OVER THE LAST YEAR 972 00:40:08,238 --> 00:40:13,243 INTERNAL WORKING GROUP AT OAR 973 00:40:13,243 --> 00:40:14,411 CORRELATED THE FEEDBACK AND THE 974 00:40:14,411 --> 00:40:19,449 INPUT FROM ALL THE VARIOUS 975 00:40:19,449 --> 00:40:19,916 CONSTITUENCIES. 976 00:40:19,916 --> 00:40:21,217 AND IF YOU CAN GO TO THE NEXT 977 00:40:21,217 --> 00:40:22,218 SLIDE. 978 00:40:22,218 --> 00:40:23,587 SO THIS IS JUST TO SHOW YOU 979 00:40:23,587 --> 00:40:25,455 WHERE ALL THE FEEDBACK AND THE 980 00:40:25,455 --> 00:40:27,757 SOURCES OF ALL THE FEEDBACK AND 981 00:40:27,757 --> 00:40:30,961 SOURCES THAT WENT INTO THE 982 00:40:30,961 --> 00:40:32,596 STRATEGIC PLAN THAT YOU'LL HEAR 983 00:40:32,596 --> 00:40:33,463 ABOUT IN A MOMENT. 984 00:40:33,463 --> 00:40:34,698 BUT I THINK IT'S VERY IMPORTANT 985 00:40:34,698 --> 00:40:37,867 TO SEE ALL THE DIFFERENT 986 00:40:37,867 --> 00:40:38,802 MEMBERS WHO ARE REPRESENTED 987 00:40:38,802 --> 00:40:42,405 HERE AS WELL AS THE DATA THAT 988 00:40:42,405 --> 00:40:45,175 WERE USED TO STRENGTHEN AND 989 00:40:45,175 --> 00:40:46,343 OPTIMIZE THE PLAN. 990 00:40:46,343 --> 00:40:47,978 SO THERE WERE INTERNAL 991 00:40:47,978 --> 00:40:49,212 RESOURCES, YOU CAN SEE ON THE 992 00:40:49,212 --> 00:40:55,752 LEFT IN TERMS OF NIH AND OAR 993 00:40:55,752 --> 00:40:59,389 AND NIAD, BUT ALSO WORKSHOPS 994 00:40:59,389 --> 00:41:00,457 AND LISTENING SESSIONS. 995 00:41:00,457 --> 00:41:03,493 AND THOSE ARE REFLECTED IN THE 996 00:41:03,493 --> 00:41:04,861 BLUE WRECK TANGLES TO THE RIGHT 997 00:41:04,861 --> 00:41:07,664 AND OF COURSE OARAC IS CRITICAL 998 00:41:07,664 --> 00:41:11,801 AND YOU'LL SEE, OARAC STANDS AT 999 00:41:11,801 --> 00:41:15,038 THE BOTTOM WITH AN ARROW INTO 1000 00:41:15,038 --> 00:41:16,773 THE STRATEGIC PLAN AND IT'S 1001 00:41:16,773 --> 00:41:17,807 ANOTHER FOUNDATIONAL SOURCE OF 1002 00:41:17,807 --> 00:41:20,143 INPUT AS SEEN ON THIS GRAPHIC. 1003 00:41:20,143 --> 00:41:21,878 NEXT SLIDE, PLEASE. 1004 00:41:21,878 --> 00:41:26,016 AND THEN THE NEXT STEP THAT WE 1005 00:41:26,016 --> 00:41:31,488 DID WAS TO IDENTIFY TASK FORCES. 1006 00:41:31,488 --> 00:41:34,691 AND THOSE THOSE TASK FORCES 1007 00:41:34,691 --> 00:41:37,260 WERE CONVENED TO ANALYZE THE 1008 00:41:37,260 --> 00:41:38,595 INFORMATION GATHERED BY THE 1009 00:41:38,595 --> 00:41:44,501 SOURCES SHOWN ON THE PREVIOUS 1010 00:41:44,501 --> 00:41:47,203 SLIDE TO RESULT IN A REVISED 1011 00:41:47,203 --> 00:41:48,672 FRAMEWORK. 1012 00:41:48,672 --> 00:41:52,108 AND THESE TASK FORCES REVIEWED 1013 00:41:52,108 --> 00:41:54,411 THE INPUT THEY DISCUSSED, THEY 1014 00:41:54,411 --> 00:41:57,981 DELIBERATE D AND THEY REFINED 1015 00:41:57,981 --> 00:41:59,215 THE INPUT. 1016 00:41:59,215 --> 00:42:02,018 AND THESE THREE ASK FORCES, 1017 00:42:02,018 --> 00:42:05,021 FOCUSED ON FUNCTIONAL AREAS OF 1018 00:42:05,021 --> 00:42:07,557 SCIENCE, BASIC BIOMEDICAL 1019 00:42:07,557 --> 00:42:10,060 CLINICAL RESEARCH, AND 1020 00:42:10,060 --> 00:42:11,861 IMPLEMENTATION RESEARCH AND 1021 00:42:11,861 --> 00:42:12,629 CLINICAL AND INTERVENTION 1022 00:42:12,629 --> 00:42:12,896 RESEARCH. 1023 00:42:12,896 --> 00:42:15,699 SO YOU CAN SEE HERE THE THREE 1024 00:42:15,699 --> 00:42:17,567 TASK FORCES. 1025 00:42:17,567 --> 00:42:23,506 TASK FORCE ONE LEAD BY LOUIE 1026 00:42:23,506 --> 00:42:25,141 MONTANER. 1027 00:42:25,141 --> 00:42:31,081 AND TASK FORCE NUMBER 2 LEAD 1028 00:42:31,081 --> 00:42:33,583 BIO MARCH AND AMBER WILSON. 1029 00:42:33,583 --> 00:42:37,420 AND TASK FORCE NUMBER 3. 1030 00:42:37,420 --> 00:42:39,689 AND WE'RE SO GRATEFUL TO THE 1031 00:42:39,689 --> 00:42:41,791 TASK FORCES FOR REALLY PUTTING 1032 00:42:41,791 --> 00:42:46,296 TOGETHER AND WORKING HARD TO 1033 00:42:46,296 --> 00:42:47,597 DEVELOP THE PLAN THAT THEY PUT 1034 00:42:47,597 --> 00:42:48,798 FORWARD. 1035 00:42:48,798 --> 00:42:54,504 THE TASK FORCES ARE SHORT-TERM, 1036 00:42:54,504 --> 00:42:55,638 MULTI DISCIPLINARY WORKING 1037 00:42:55,638 --> 00:42:57,507 GROUPS SO BEYOND THE LEADERS 1038 00:42:57,507 --> 00:43:00,043 THERE WERE OTHERS THAT JOINED 1039 00:43:00,043 --> 00:43:03,980 AND THEY REPRESENT A VERY BROAD 1040 00:43:03,980 --> 00:43:08,818 DIVERSITY OF SUBJECT MATTER 1041 00:43:08,818 --> 00:43:09,986 EXPERTISE AND SCIENCE AND 1042 00:43:09,986 --> 00:43:11,087 POLICY AS WELL AS LIVED 1043 00:43:11,087 --> 00:43:12,055 EXPERIENCE. 1044 00:43:12,055 --> 00:43:14,824 AND THEY TOGETHER, PROVIDED 1045 00:43:14,824 --> 00:43:16,526 RECOMMENDATIONS REGARDING THE 1046 00:43:16,526 --> 00:43:18,561 RESEARCH PRIORITIES FOR THE NEW 1047 00:43:18,561 --> 00:43:20,296 STRATEGIC PLANS. 1048 00:43:20,296 --> 00:43:22,132 AND AGAIN, THEIR DEDICATION AND 1049 00:43:22,132 --> 00:43:23,800 PASSION TO THIS PROCESS IS 1050 00:43:23,800 --> 00:43:24,701 GREATLY APPRECIATED. 1051 00:43:24,701 --> 00:43:26,770 AND WE'LL BE HEARING MORE ABOUT 1052 00:43:26,770 --> 00:43:29,906 THEIR WORK LATER IN OUR AGENDA. 1053 00:43:29,906 --> 00:43:30,473 NEXT SLIDE, PLEASE. 1054 00:43:30,473 --> 00:43:32,509 THANK YOU. 1055 00:43:32,509 --> 00:43:34,511 AND THAT BRINGS US TO WHERE WE 1056 00:43:34,511 --> 00:43:35,712 ARE TODAY WHICH IS WE ARE 1057 00:43:35,712 --> 00:43:39,649 BRINGING IT TO OARAC, YOU, AND 1058 00:43:39,649 --> 00:43:41,017 YOU ARE RECEIVING REPORT OUTS 1059 00:43:41,017 --> 00:43:44,954 FROM EACH OF THE TASK FORCES 1060 00:43:44,954 --> 00:43:46,356 DURING THIS MEETING AND 1061 00:43:46,356 --> 00:43:48,892 HOPEFULLY YOU'LL BE MAKING 1062 00:43:48,892 --> 00:43:49,459 ADDITIONAL RECOMMENDATIONS 1063 00:43:49,459 --> 00:43:52,829 BASED ON WHAT YOU HEAR TODAY. 1064 00:43:52,829 --> 00:43:55,431 THE NIH CENTERS WILL ALSO SEE 1065 00:43:55,431 --> 00:43:56,733 THE RECOMMENDATIONS AFTER 1066 00:43:56,733 --> 00:43:58,835 OARAC'S FEEDBACK AND THEN WE'LL 1067 00:43:58,835 --> 00:43:59,769 ALSO PROVIDE ADDITIONAL 1068 00:43:59,769 --> 00:44:04,641 FEEDBACK ON STRATEGIC PLAN, 1069 00:44:04,641 --> 00:44:06,943 DRAFT STRATEGIC PLAN. 1070 00:44:06,943 --> 00:44:08,578 AND THEN IN FEBRUARY WE'LL BE 1071 00:44:08,578 --> 00:44:09,412 PRESENTING A UPDATE ON THIS 1072 00:44:09,412 --> 00:44:10,680 AGAIN. 1073 00:44:10,680 --> 00:44:12,782 OKAY, SO THAT INCLUDES MY 1074 00:44:12,782 --> 00:44:14,818 DIRECTOR'S REPORT AND I 1075 00:44:14,818 --> 00:44:19,823 APPRECIATE YOUR ATTENTION AND 1076 00:44:19,823 --> 00:44:21,858 DR. TURBULL BACK TO YOU. 1077 00:44:21,858 --> 00:44:32,168 >> THANK YOU, DR. 1078 00:44:34,704 --> 00:44:37,707 DOAN--DONE--DONENBERG. 1079 00:44:37,707 --> 00:44:39,375 DR. WSUNDQUIST SAID HE HAD TO 1080 00:44:39,375 --> 00:44:41,344 LEAVE EARLY? 1081 00:44:41,344 --> 00:44:42,045 SHOULD WE SHIFT? 1082 00:44:42,045 --> 00:44:44,781 >> I THINK IF WE COULD TAKE ONE 1083 00:44:44,781 --> 00:44:48,685 OR TWO QUICK COMMENTS OR 1084 00:44:48,685 --> 00:44:51,454 QUESTIONS, AND THEN LEAVE MORE 1085 00:44:51,454 --> 00:44:53,957 DISCUSSION FOR AFTER DR. 1086 00:44:53,957 --> 00:44:55,325 WSUNDQUIST IS FINISHED SO WE 1087 00:44:55,325 --> 00:44:56,526 CAN KEEP ON TRACK WITH HIS 1088 00:44:56,526 --> 00:44:56,759 AGENDA. 1089 00:44:56,759 --> 00:44:58,328 THANKS. 1090 00:44:58,328 --> 00:45:00,630 >> OKAY, GREAT, ARE THERE ANY 1091 00:45:00,630 --> 00:45:02,966 ONE OR TWO COMMENTS OR 1092 00:45:02,966 --> 00:45:08,471 QUESTIONS FOR DR. DONEBERG. 1093 00:45:08,471 --> 00:45:12,609 THANK YOU FOR SUCH A GREAT 1094 00:45:12,609 --> 00:45:14,577 REPORT. 1095 00:45:14,577 --> 00:45:17,313 >> WE'LL HAVE PLENTY OF TIME 1096 00:45:17,313 --> 00:45:20,717 LATER THIS AFTERNOON WHEN WE'RE 1097 00:45:20,717 --> 00:45:23,920 DISCUSSING THE STRATEGIC TASK 1098 00:45:23,920 --> 00:45:25,755 FORCE RECOMMENDATIONS, SO, WE 1099 00:45:25,755 --> 00:45:36,165 CAN PIVOT TO FINZI NOW. 1100 00:45:40,670 --> 00:45:43,573 >> DR. FINZI, YOU'RE GOING TO 1101 00:45:43,573 --> 00:45:45,875 INTRODUCE YOUR GUEST. 1102 00:45:45,875 --> 00:45:46,809 YOU MAY PROCEED. 1103 00:45:46,809 --> 00:45:50,346 >> OKAY, I HAD JUST A COUPLE OF 1104 00:45:50,346 --> 00:45:56,486 SLIDES. 1105 00:45:56,486 --> 00:45:58,021 I WAS WONDERING IF YOU HAVE 1106 00:45:58,021 --> 00:46:03,259 THEM. 1107 00:46:03,259 --> 00:46:05,328 OKAY, GREAT. 1108 00:46:05,328 --> 00:46:09,666 SO YOU KNOW, IT'S FUNNY, I, I'M 1109 00:46:09,666 --> 00:46:13,303 SO HAPPY TO HAVE WES HERE 1110 00:46:13,303 --> 00:46:17,407 TODAY, BECAUSE I FEEL LIKE THE 1111 00:46:17,407 --> 00:46:19,242 LENACAPAVIR STORY, YOU GO AND 1112 00:46:19,242 --> 00:46:21,744 HEAR ABOUT HOW GREAT THIS DRUG 1113 00:46:21,744 --> 00:46:23,947 IS AND WHAT AMAZING STRIDES 1114 00:46:23,947 --> 00:46:24,981 WE'VE MADE. 1115 00:46:24,981 --> 00:46:28,918 BUT THE STORY, THE LENACAPAVIR 1116 00:46:28,918 --> 00:46:30,520 STORY DOES NOT START WITH A 1117 00:46:30,520 --> 00:46:32,889 PURPOSE TRIAL, IT STARTS MUCH 1118 00:46:32,889 --> 00:46:34,691 BEFORE THEN. 1119 00:46:34,691 --> 00:46:37,327 AND JUST TO HIGHLIGHT A LITTLE 1120 00:46:37,327 --> 00:46:39,195 BIT, THE NIH, I WOULD LIKE TO 1121 00:46:39,195 --> 00:46:42,665 SAY THAT IT BEGINS WITH THE NIH 1122 00:46:42,665 --> 00:46:45,201 COMMITMENT AND INVESTMENT AIMED 1123 00:46:45,201 --> 00:46:48,871 AT UNDERING THE BASIC MECHANISM 1124 00:46:48,871 --> 00:46:52,976 THAT'S HIV USES TO INFECT CELLS. 1125 00:46:52,976 --> 00:46:58,548 SO NIH STUDIES IN THELE 80s AND 1126 00:46:58,548 --> 00:47:01,718 90s EARLY ON AND REVEALED 1127 00:47:01,718 --> 00:47:06,489 TARGETS, LIKE REVERSE 1128 00:47:06,489 --> 00:47:08,358 TRANSCRIPTAS AND AND THIS WAS 1129 00:47:08,358 --> 00:47:11,094 CRITICAL IN AIDING THE 1130 00:47:11,094 --> 00:47:13,396 DEVELOPMENT OF ANTI VIRAL DRUGS 1131 00:47:13,396 --> 00:47:14,163 THAT WE'RE USING THROUGHOUT THE 1132 00:47:14,163 --> 00:47:16,666 WORLD TODAY. 1133 00:47:16,666 --> 00:47:20,103 AND CONTINUED NIH SUPPORT 1134 00:47:20,103 --> 00:47:22,171 INCLUDING THE SUPPORT OF THE 1135 00:47:22,171 --> 00:47:24,173 CENTERS OF STRUCTURAL BIOLOGY 1136 00:47:24,173 --> 00:47:30,513 AND IN THE 2000 ENABLED SIGN 1137 00:47:30,513 --> 00:47:33,916 TIFFS TO INTEGRATE, TO CAPTURE 1138 00:47:33,916 --> 00:47:36,452 THE THREE DIMENSIONAL 1139 00:47:36,452 --> 00:47:38,287 STRUCTURES OF H.I.V. PROTEINS 1140 00:47:38,287 --> 00:47:40,857 AND THEIR INTERAGENCIES WITH 1141 00:47:40,857 --> 00:47:42,558 CELLULAR COMPONENTS IN 1142 00:47:42,558 --> 00:47:52,935 UNPRECEDENTED DETAIL. 1143 00:48:05,248 --> 00:48:05,648 IV PROTEINS AND THEIR 1144 00:48:05,648 --> 00:48:06,215 INTERAGENCIES WITH CELLULAR 1145 00:48:06,215 --> 00:48:06,783 COMPONENTS IN UNPRECEDENTED 1146 00:48:06,783 --> 00:48:14,424 DETAIL. 1147 00:48:14,424 --> 00:48:17,160 BUT THE CAPSID PROTEINS RANGE 1148 00:48:17,160 --> 00:48:20,163 THEMSELVES INTO REGULAR SHAPES 1149 00:48:20,163 --> 00:48:21,531 AND PENTMERS THAT COME TOGETHER 1150 00:48:21,531 --> 00:48:26,669 IN SORT OF A SOCCER BALL 1151 00:48:26,669 --> 00:48:28,004 ARRANGEMENT THAT IS CALLED THE 1152 00:48:28,004 --> 00:48:30,540 CONE. 1153 00:48:30,540 --> 00:48:32,642 AND LENACAPAVIR LINES WITHIN A 1154 00:48:32,642 --> 00:48:37,580 POCKET WITHIN THIS CAPSID LATIS 1155 00:48:37,580 --> 00:48:40,817 AT VARIOUS POINTS IN THE HIV 1156 00:48:40,817 --> 00:48:42,585 LIFECYCLE. 1157 00:48:42,585 --> 00:48:48,057 SO IN OTHER WORDS, THIS CONE 1158 00:48:48,057 --> 00:48:50,159 STRUCTURE TURNED OUT TO BE A 1159 00:48:50,159 --> 00:48:54,030 GREAT WITH THIS DRUG AND WITH 1160 00:48:54,030 --> 00:48:55,198 THE VULNERABILITIES WHICH 1161 00:48:55,198 --> 00:48:57,733 YOU'LL HEAR MORE ABOUT TODAY. 1162 00:48:57,733 --> 00:48:59,569 WES AND OTHER COLLEAGUES 1163 00:48:59,569 --> 00:49:04,574 COLLABORATE WITHED GIL IAED AND 1164 00:49:04,574 --> 00:49:09,178 HELPED DEVELOP LENACAPAVIR. 1165 00:49:09,178 --> 00:49:15,785 AND THEN GIDIAED INSUPPORTED 1166 00:49:15,785 --> 00:49:18,988 AND NOW NIH SCIENTIST ARE DOING 1167 00:49:18,988 --> 00:49:21,524 RESEARCH TO UNDERSTAND HOW 1168 00:49:21,524 --> 00:49:23,159 RESISTANCE ARISES AND HOW TO 1169 00:49:23,159 --> 00:49:24,093 MONITOR THE ETHICACY OF THE 1170 00:49:24,093 --> 00:49:26,162 DRUG IN THE CLINIC. 1171 00:49:26,162 --> 00:49:28,364 IN TURN, LENACAPAVIR IS TELLING 1172 00:49:28,364 --> 00:49:31,601 US MORE AND MORE ABOUT THE 1173 00:49:31,601 --> 00:49:33,903 CAPSID STRUCTURE HOW IT 1174 00:49:33,903 --> 00:49:35,304 FUNCTIONS DURING INFECTIONS AS 1175 00:49:35,304 --> 00:49:36,839 A FULL CIRCLE IN THE CYCLE OF 1176 00:49:36,839 --> 00:49:38,474 SCIENCE. 1177 00:49:38,474 --> 00:49:42,145 SO NOW, IT IS REALLY MY GREAT 1178 00:49:42,145 --> 00:49:44,847 PLEASURE TO INTRODUCE DR. 1179 00:49:44,847 --> 00:49:46,115 WESLEY WSUNDQUIST WHO WILL 1180 00:49:46,115 --> 00:49:49,485 SPEAK MORE ABOUT THE REMARKABLE 1181 00:49:49,485 --> 00:49:50,419 NIH SUPPORTED BASIC SCIENCE 1182 00:49:50,419 --> 00:49:52,221 THAT LEAD TO THIS GREAT 1183 00:49:52,221 --> 00:49:54,323 BREAKTHROUGH. 1184 00:49:54,323 --> 00:49:58,861 DR. WSUNDQUIST IS THE 1185 00:49:58,861 --> 00:50:00,730 PRESIDENTIAL HAIR CHAIR, 1186 00:50:00,730 --> 00:50:01,297 DISTINGUISHED PROFESSOR AND 1187 00:50:01,297 --> 00:50:03,533 CHAIR OF THE BIOCHEMISTRY AT 1188 00:50:03,533 --> 00:50:07,203 THE UNIVERSITY OF UTAH. 1189 00:50:07,203 --> 00:50:09,739 DR. WSUNDQUIST XLAOED HZ Ph.d 1190 00:50:09,739 --> 00:50:13,109 IN CHEMISTRY FROM MIT, WORKING 1191 00:50:13,109 --> 00:50:18,447 WITH STEVEN J AND WAS A NATO 1192 00:50:18,447 --> 00:50:22,451 POST DOCTORAL AT THE MIC 1193 00:50:22,451 --> 00:50:28,691 LABORATORY OF MALECULAR BIOLOGY 1194 00:50:28,691 --> 00:50:31,894 ELECTED TO THE NATIONAL ACADEMY 1195 00:50:31,894 --> 00:50:33,729 OF SCIENCES AND RECEIVED JUST 1196 00:50:33,729 --> 00:50:41,070 THIS PAST YEAR IN 2024, THE 1197 00:50:41,070 --> 00:50:43,806 HORWITS PRIZE FOR RESEARCH AND 1198 00:50:43,806 --> 00:50:45,975 BIOMEDICAL SCIENCE WITH DR. 1199 00:50:45,975 --> 00:50:47,376 SCOTT 'EMER, WES, REALLY A 1200 00:50:47,376 --> 00:50:49,645 PLEASURE TO HAVE YOU. 1201 00:50:49,645 --> 00:50:54,750 >> THANK YOU, DIANA FOR THAT 1202 00:50:54,750 --> 00:50:56,219 GENEROUS INTRODUCTION. 1203 00:50:56,219 --> 00:50:58,721 PEOPLE CAN SEE IN HERE OKAY? 1204 00:50:58,721 --> 00:51:01,891 >> YES. 1205 00:51:01,891 --> 00:51:04,460 >> THANK YOU, SO IT'S AN HONOR 1206 00:51:04,460 --> 00:51:08,264 TO ADDRESS THIS COMMITTEE. 1207 00:51:08,264 --> 00:51:12,034 AND AS YOU HEARD, THERE IS A 1208 00:51:12,034 --> 00:51:16,105 BREAKTHROUGH WITH LENACAPAVIR 1209 00:51:16,105 --> 00:51:23,379 AND CAP TOURS THE CAPSID 1210 00:51:23,379 --> 00:51:25,248 PROTEIN. 1211 00:51:25,248 --> 00:51:27,817 SO DIANA ASKED ME TO GIVE YOU A 1212 00:51:27,817 --> 00:51:31,020 BACKGROUND THAT SET THE STAGE 1213 00:51:31,020 --> 00:51:31,954 FOR LENACAPAVIR, SO THAT'S THE 1214 00:51:31,954 --> 00:51:33,222 GOAL OF WHAT I'M GOING TO DO 1215 00:51:33,222 --> 00:51:34,056 TODAY. 1216 00:51:34,056 --> 00:51:36,626 SO I THOUGHT I WOULD START WITH 1217 00:51:36,626 --> 00:51:43,032 THE PUNCH LINE, SO AS YOU ALL 1218 00:51:43,032 --> 00:51:47,336 KNOW, 1.3 MILLION PEOPLE WERE 1219 00:51:47,336 --> 00:51:50,339 NEWLY INFECTED WITH HIV AND 1220 00:51:50,339 --> 00:51:52,608 THAT HIGHLIGHTS THE DEVELOPING 1221 00:51:52,608 --> 00:51:54,944 THE PREVENTION LIKE VACCINE OR 1222 00:51:54,944 --> 00:51:56,946 AN EFFECTIVE APPLICATION. 1223 00:51:56,946 --> 00:51:59,081 AND THIS IS A SLIDE THAT I GOT 1224 00:51:59,081 --> 00:52:03,653 FROM TOMAS WHO IS OUR MAJOR 1225 00:52:03,653 --> 00:52:10,860 CONTACT AT GILAD AND HIGHLIGHTS 1226 00:52:10,860 --> 00:52:12,495 THE EXPERIMENT AT THE TRIAL. 1227 00:52:12,495 --> 00:52:16,799 SO WHAT YOU'RE LOOKING AT THIS 1228 00:52:16,799 --> 00:52:20,036 IS A CIS GENDER WOMEN, AS YOU 1229 00:52:20,036 --> 00:52:23,506 HEARD THE PURPOSE 2 IS SIMILAR 1230 00:52:23,506 --> 00:52:25,107 IN MALES AND NON BINARY 1231 00:52:25,107 --> 00:52:26,709 INDIVIDUALS AND THE RESULTS ARE 1232 00:52:26,709 --> 00:52:28,778 THE SAME IN BOTH. 1233 00:52:28,778 --> 00:52:30,846 AND THAT'S IF YOU LOOK AT THE 1234 00:52:30,846 --> 00:52:39,855 INCIDENT OF INFECTION. 1235 00:52:39,855 --> 00:52:43,559 IN AFRICA IT'S ABOUT 2.5 HER 1236 00:52:43,559 --> 00:52:44,293 100 PERSON. 1237 00:52:44,293 --> 00:52:47,797 IF YOU LOOK AT THE REGISTER 1238 00:52:47,797 --> 00:52:51,867 MINUTE, AT THIS IS AND IF YOU 1239 00:52:51,867 --> 00:52:58,441 LOOK AT THE CLINICAL RESULT FOR 1240 00:52:58,441 --> 00:52:59,508 LENACAPAVIR THE DRAMATIC 1241 00:52:59,508 --> 00:53:00,843 RESULTS IS THERE WERE NO 1242 00:53:00,843 --> 00:53:02,545 INFECTIONS. 1243 00:53:02,545 --> 00:53:04,580 SO THE INDEPENDENT GROUP 1244 00:53:04,580 --> 00:53:05,848 STOPPED THE CLINICAL TRIAL THIS 1245 00:53:05,848 --> 00:53:09,652 HAPPENED FOR PURPOSE 2 AND MADE 1246 00:53:09,652 --> 00:53:10,286 LENACAPAVIR AVAILABLE TO EVERY 1247 00:53:10,286 --> 00:53:11,287 ONE. 1248 00:53:11,287 --> 00:53:12,655 SO THESE RESULTS TOGETHER WITH 1249 00:53:12,655 --> 00:53:15,591 THE FACT THAT GILAD ANNOUNCED 1250 00:53:15,591 --> 00:53:18,594 THAT THEY'RE GOING TO ALLOW 1251 00:53:18,594 --> 00:53:21,330 GENERICS FOR THE POOREST OF 100 1252 00:53:21,330 --> 00:53:23,432 COUNTRIES IN THE WORLD, REALLY 1253 00:53:23,432 --> 00:53:26,202 RAISE THE PROMISE THAT THIS IS 1254 00:53:26,202 --> 00:53:28,270 GOING TO BEND THE PROGRESSIVE 1255 00:53:28,270 --> 00:53:30,539 OF HIV EPIDEMIC. 1256 00:53:30,539 --> 00:53:33,409 I WANT TO 'EM EMPHASIZE THAT 1257 00:53:33,409 --> 00:53:36,912 THE DRUG WAS DEVELOPED IN 1258 00:53:36,912 --> 00:53:38,280 GILIAD BUT CAPSID RESEARCHERS 1259 00:53:38,280 --> 00:53:39,682 IN SAYING THAT FIRST OF ALL 1260 00:53:39,682 --> 00:53:41,050 WE'RE REALLY EXCITED ABOUT THE 1261 00:53:41,050 --> 00:53:42,685 PROMISE, BUT SECOND OF ALL, 1262 00:53:42,685 --> 00:53:43,853 WE'RE PRIDE OF OUR 1263 00:53:43,853 --> 00:53:45,521 CONTRIBUTIONS THAT HELP TO MAKE 1264 00:53:45,521 --> 00:53:54,797 IT POSSIBLE TO DEVELOP FOR 1265 00:53:54,797 --> 00:53:57,333 GIDIAD FOR LENACAPAVIR. 1266 00:53:57,333 --> 00:53:59,602 AND THIS IS THE FIRST TIME THAT 1267 00:53:59,602 --> 00:54:02,772 WE'VE SEEN 100 PERCENT 1268 00:54:02,772 --> 00:54:05,274 PROTECTION FOR A PREP TRIAL. 1269 00:54:05,274 --> 00:54:09,812 SO IF WE'RE GOING TO TALK ABOUT 1270 00:54:09,812 --> 00:54:11,180 THE CAPSID, WE HAVE TO TALK 1271 00:54:11,180 --> 00:54:13,516 ABOUT WHERE IT CAME FROM. 1272 00:54:13,516 --> 00:54:16,786 AS YOU KNOW HIV IS A RETRO 1273 00:54:16,786 --> 00:54:20,222 VIRUS AND HAS A SINGLE GENE 1274 00:54:20,222 --> 00:54:21,457 THAT ORGANIZES THE VIRAL 1275 00:54:21,457 --> 00:54:22,958 PARTICLE. 1276 00:54:22,958 --> 00:54:25,795 SO GAG FIRST GETS MADE AS A 1277 00:54:25,795 --> 00:54:29,465 POLY PEPTIDE WHICH HAS A SERIES 1278 00:54:29,465 --> 00:54:31,133 OF SERIOUS REGION THAT THE 1279 00:54:31,133 --> 00:54:34,236 VIRUS USE TO SEE PERFORM 1280 00:54:34,236 --> 00:54:37,273 VARIOUS FUNCTIONS AND IT BINDS 1281 00:54:37,273 --> 00:54:39,341 TO MEMBRANES AND HOW THE VIRUS 1282 00:54:39,341 --> 00:54:42,511 KNOWS TO BIND TO THE MEMBRANE. 1283 00:54:42,511 --> 00:54:47,550 THE CENTRAL C A REGION TAKES 1284 00:54:47,550 --> 00:54:48,951 IMPORTANT PROTEIN PROTEIN 1285 00:54:48,951 --> 00:54:52,354 INTERACTIONS AT THIS STAGE AND 1286 00:54:52,354 --> 00:54:56,926 IT CUTS ON EITHER END OF THE C 1287 00:54:56,926 --> 00:55:00,996 A PROTEIN TO MAKE A NEW 1288 00:55:00,996 --> 00:55:03,265 DISCREET PROTEIN AND I'LL TRY 1289 00:55:03,265 --> 00:55:06,969 TO CALL C A, WE TRY TO CALL 1290 00:55:06,969 --> 00:55:09,138 THIS CA. 1291 00:55:09,138 --> 00:55:12,475 THE CA PROTEIN BUILDS THIS 1292 00:55:12,475 --> 00:55:16,579 CAPSID AND INSIDE THE CAPSID IS 1293 00:55:16,579 --> 00:55:19,348 THE VIRAL RNA AND WE TRY TO 1294 00:55:19,348 --> 00:55:20,683 CALL THIS ENTIRE CAPSID THE 1295 00:55:20,683 --> 00:55:22,318 CORE. 1296 00:55:22,318 --> 00:55:25,354 THEN THE NC IS A BINDING 1297 00:55:25,354 --> 00:55:31,494 PROTEIN, IT CAPTURES THE 1298 00:55:31,494 --> 00:55:35,164 GENEOWED AND WE THINK IT COATS. 1299 00:55:35,164 --> 00:55:40,135 AND P6 IS A REGION OF THE 1300 00:55:40,135 --> 00:55:41,537 PROTEIN THAT RECRUITS PROTEIN 1301 00:55:41,537 --> 00:55:43,439 AND THAT ALLOWS THE VIRUS TO 1302 00:55:43,439 --> 00:55:45,608 PINCH OFF CELLS AND TO SPREAD 1303 00:55:45,608 --> 00:55:46,342 AN INFECTION. 1304 00:55:46,342 --> 00:55:48,744 SO THE POINT I WANT TO MAKE 1305 00:55:48,744 --> 00:55:52,348 HERE IS THAT WE THINK OF THE 1306 00:55:52,348 --> 00:55:55,084 IMMATURE PARTICLE BEFORE GAG 1307 00:55:55,084 --> 00:56:01,657 HAS BEEN COLLEAGUED AS ASSEMBLY. 1308 00:56:01,657 --> 00:56:04,393 AND WHAT PROTO AL SIS DOES IT 1309 00:56:04,393 --> 00:56:07,363 CONVERTS THE ASSEMBLY MACHINE 1310 00:56:07,363 --> 00:56:08,297 INTO A INFECTIOUS PARTICLE AND 1311 00:56:08,297 --> 00:56:10,633 WE THINK OF THAT AS A PARTICLE 1312 00:56:10,633 --> 00:56:13,602 THAT IS ABLE TO ENTER AND 1313 00:56:13,602 --> 00:56:16,906 REPLICATE IN A NEW HOST CELL. 1314 00:56:16,906 --> 00:56:18,741 SO THAT'S THE PURPOSE OF THIS 1315 00:56:18,741 --> 00:56:21,410 TRANSFORMATION. 1316 00:56:21,410 --> 00:56:24,647 SO I'M EXCITE TODAY HAVE A 1317 00:56:24,647 --> 00:56:26,949 COLLEAGUE JANET THAT IS PART OF 1318 00:56:26,949 --> 00:56:35,958 AND SHE IS A MASTER MELACULR, 1319 00:56:35,958 --> 00:56:44,066 IT GOES THROUGH MELACLUR I'M 1320 00:56:44,066 --> 00:56:50,606 GOING TO SHOW YOU HER ANIMATION. 1321 00:56:50,606 --> 00:56:52,708 THESE ARE THE SPIKE PROTEINS, 1322 00:56:52,708 --> 00:56:55,444 THESE ARE THE GAG PROTEIN AND 1323 00:56:55,444 --> 00:56:58,213 SOMETIMES GAG IS MADE AS A 1324 00:56:58,213 --> 00:57:01,884 LONGER PROTEIN THAT'S HOW THE 1325 00:57:01,884 --> 00:57:04,320 ENZYMES GET INTO THE PROTEINS. 1326 00:57:04,320 --> 00:57:06,422 AND IF I RUN THE VAO, YOU SEE 1327 00:57:06,422 --> 00:57:09,458 THAT THEY ORGANIZE THEMSELVES 1328 00:57:09,458 --> 00:57:13,596 UNDER THE MEMBRANE OF INFECTED 1329 00:57:13,596 --> 00:57:14,763 CELL. 1330 00:57:14,763 --> 00:57:18,233 WE THINK VIRUS USES HELP FROM 1331 00:57:18,233 --> 00:57:20,336 HOST PROTEIN TO BEND THE 1332 00:57:20,336 --> 00:57:22,204 MEMBRANE AND WHEN IT REACHES 1333 00:57:22,204 --> 00:57:26,508 THE WHAT WE CALL THE LOLLIPOP 1334 00:57:26,508 --> 00:57:28,844 IT SEVERALS THE NECK AND 1335 00:57:28,844 --> 00:57:30,679 RELEASE THE VIRUS PARTICLE. 1336 00:57:30,679 --> 00:57:38,954 SO VIRUS IS RELEASED AS A 1337 00:57:38,954 --> 00:57:42,625 IMMATURE IT CUTS GAG AND GAG 1338 00:57:42,625 --> 00:57:44,159 PAUL INTO SMALLER PIECES. 1339 00:57:44,159 --> 00:57:46,762 THE NC AND RNA CONDENSED TO THE 1340 00:57:46,762 --> 00:57:51,133 CENTER OF THE VIRUS, AND THE CA 1341 00:57:51,133 --> 00:57:55,471 PROTEIN BUILDS THIS CHRONICLE 1342 00:57:55,471 --> 00:58:00,075 CAPSID THAT SOUNDS THE GENO. 1343 00:58:00,075 --> 00:58:02,111 SO THE THE REST OF THE TALK 1344 00:58:02,111 --> 00:58:09,385 WORE GOING TO TALK ABOUT THIS. 1345 00:58:09,385 --> 00:58:11,654 : SO ONE OF THE THINGS I WANT 1346 00:58:11,654 --> 00:58:13,255 TO EMPHASIZE THIS IS THAT WE'VE 1347 00:58:13,255 --> 00:58:15,124 BEEN DOING THIS FOR SOMETIME. 1348 00:58:15,124 --> 00:58:18,594 AND AS GERRY SAID, BASIC 1349 00:58:18,594 --> 00:58:19,461 RESEARCH, ALMOST FULFILLS 1350 00:58:19,461 --> 00:58:20,596 IMPORTANT PROMISES BUT IT TAKES 1351 00:58:20,596 --> 00:58:21,363 SOMETIME. 1352 00:58:21,363 --> 00:58:24,366 AND SO WHEN WE STARTED OUR WORK 1353 00:58:24,366 --> 00:58:26,001 IN THE 1990s, WE THOUGHT THE 1354 00:58:26,001 --> 00:58:26,935 MOST IMPORTANT THING TO 1355 00:58:26,935 --> 00:58:28,771 UNDERSTAND FIRST WAS WHAT IS 1356 00:58:28,771 --> 00:58:30,839 THE STRUCTURE OF THE PROTEIN? 1357 00:58:30,839 --> 00:58:32,675 BECAUSE WE BELIEVE THE 1358 00:58:32,675 --> 00:58:34,743 STRUCTURE OF PROTEIN DICTATES 1359 00:58:34,743 --> 00:58:36,578 ITS FUNCTION SO. TOGETHER WITH 1360 00:58:36,578 --> 00:58:37,946 MIKE SUMMERS AND CHRIS HILLS, 1361 00:58:37,946 --> 00:58:40,249 WE WERE ABLE TO SHOW THAT THE 1362 00:58:40,249 --> 00:58:42,584 PROTEIN FORMS A DAIMLER, IT 1363 00:58:42,584 --> 00:58:44,420 COMES TOGETHER AS TWO COPIES 1364 00:58:44,420 --> 00:58:46,121 AND DETERMINE THE STRUCTURE OF 1365 00:58:46,121 --> 00:58:47,656 THE DAIMLER. 1366 00:58:47,656 --> 00:58:50,659 SO THE C TERMINAL DOMAIN, WE 1367 00:58:50,659 --> 00:58:52,494 THOUGHT OF PROTEIN OF LOOKING 1368 00:58:52,494 --> 00:58:54,530 LIKE THE HEAD OF A RABBIT. 1369 00:58:54,530 --> 00:58:57,633 SO TWO COPIES OF THE C TERMINAL 1370 00:58:57,633 --> 00:58:59,001 DOMAIN COME TOGETHER SO THAT 1371 00:58:59,001 --> 00:59:00,436 MAKES THE DAIMLER AND THEN THE 1372 00:59:00,436 --> 00:59:02,504 EARS OF THE RABBIT ARE DEFINED 1373 00:59:02,504 --> 00:59:05,074 BY THE END TERMINAL DOMAIN OF 1374 00:59:05,074 --> 00:59:07,743 THE C A PROTEIN. 1375 00:59:07,743 --> 00:59:09,211 SO THAT WAS A GOOD START BUT TO 1376 00:59:09,211 --> 00:59:13,615 GIVE YOU A SENSE OF SCALE, IT 1377 00:59:13,615 --> 00:59:15,284 TAKES ABOUT 750 COPIES OF THIS 1378 00:59:15,284 --> 00:59:18,821 DIME TORE MAKE THE DOM NAL 1379 00:59:18,821 --> 00:59:19,388 CAPSID. 1380 00:59:19,388 --> 00:59:21,457 SO WHAT WE HAD TO UNDERSTAND IS 1381 00:59:21,457 --> 00:59:26,095 HOW DOES THE CA PROTEIN BUILD A 1382 00:59:26,095 --> 00:59:26,295 CONE? 1383 00:59:26,295 --> 00:59:29,765 AND WE HAD A VERY TALENTED 1384 00:59:29,765 --> 00:59:32,434 GRADUATE STUDENT AND SHE WAS 1385 00:59:32,434 --> 00:59:33,836 WORK WITHING PURE PROTEIN IN 1386 00:59:33,836 --> 00:59:34,803 THE LAB. 1387 00:59:34,803 --> 00:59:38,474 AND ONE DAY SHE STUMBLED ON 1388 00:59:38,474 --> 00:59:41,944 CONDITIONS ON THE CA PROTEIN 1389 00:59:41,944 --> 00:59:43,946 WOULD SPONTANEOUSLY FORM THESE 1390 00:59:43,946 --> 00:59:46,548 CAPSIDS. 1391 00:59:46,548 --> 00:59:48,150 IT'S MAKING CONES, SO INS THE 1392 00:59:48,150 --> 00:59:49,985 PROTEIN AND IT'S MAKING ZONES. 1393 00:59:49,985 --> 00:59:53,122 AND THIS IS AN ELECTRON MICRO 1394 00:59:53,122 --> 00:59:54,490 GRAPH ON FILM. 1395 00:59:54,490 --> 00:59:56,792 SO MY CONTRIBUTION TO THIS 1396 00:59:56,792 --> 00:59:59,094 EXPERIMENT WAS TO PUT MY THUMB 1397 00:59:59,094 --> 01:00:01,930 PRINT ON THE NICEST CONES THAT 1398 01:00:01,930 --> 01:00:03,665 WE HAD IN THE LAB. 1399 01:00:03,665 --> 01:00:06,435 AND WHEN YOU LOOK AT THE 1400 01:00:06,435 --> 01:00:08,937 STRUCTURES THEY CAN LOOK 1401 01:00:08,937 --> 01:00:13,709 SIMILAR TO THE CAPSID, SO THESE 1402 01:00:13,709 --> 01:00:15,077 ARE THIN SECTION IMAGES, SO 1403 01:00:15,077 --> 01:00:17,579 THIS IS THE ACTUAL VIRUS, YOU 1404 01:00:17,579 --> 01:00:23,318 CAN SEE THE CON:CA RID. 1405 01:00:23,318 --> 01:00:25,454 THIS IS THE STRUCTURE THAT 1406 01:00:25,454 --> 01:00:28,524 BARBIE WAS MAKING WITH PURE 1407 01:00:28,524 --> 01:00:30,025 PROTEIN AND YOU CAN SEE IT'S 1408 01:00:30,025 --> 01:00:32,761 THE SAME SCALE AND SIZE AND HAS 1409 01:00:32,761 --> 01:00:34,863 THE SAME CONE ANGLE. 1410 01:00:34,863 --> 01:00:37,633 AND IMPORTANTLY, IT LOOKS LIKE 1411 01:00:37,633 --> 01:00:39,701 IT'S CLOSED AT BOTH ENDS. 1412 01:00:39,701 --> 01:00:41,336 SO AT THAT POINT, WE HAD TO 1413 01:00:41,336 --> 01:00:45,707 THINK ABOUT HOW A SINGLE 1414 01:00:45,707 --> 01:00:46,675 PROTEIN SPONTANEOUS LEA SEMBLE 1415 01:00:46,675 --> 01:00:47,509 INTO A CONE. 1416 01:00:47,509 --> 01:00:50,379 SO THE CONE IS A UNUSUAL 1417 01:00:50,379 --> 01:00:51,380 ASSEMBLY IN BIOLOGY, AS FAR AS 1418 01:00:51,380 --> 01:00:54,082 WE'RE AWARE, THIS IS THE ONLY 1419 01:00:54,082 --> 01:00:56,585 EXAMPLE OF CANONICAL ASSEMBLY 1420 01:00:56,585 --> 01:00:56,885 AND BIOLOGY. 1421 01:00:56,885 --> 01:01:01,023 AND AT THE SAME TIME, SAM LEE 1422 01:01:01,023 --> 01:01:01,723 WORKING WITH FINCH, ONLY 1423 01:01:01,723 --> 01:01:03,759 STUDENT IN THE LAB WAS ABLE TO 1424 01:01:03,759 --> 01:01:06,061 SHOW THAT NOT ONLY DID THE 1425 01:01:06,061 --> 01:01:08,363 PROTEIN FORM DIMERS BUT IT 1426 01:01:08,363 --> 01:01:13,669 COULD ALSO FORM HEX AMERI RIGS. 1427 01:01:13,669 --> 01:01:18,674 SO WHEN WE PUT THAT INFORMATION 1428 01:01:18,674 --> 01:01:21,176 TOGETHER, WHICH IS THE DIA NA 1429 01:01:21,176 --> 01:01:26,849 WHAT WE CALL A FULLER EVEN ZONE. 1430 01:01:26,849 --> 01:01:31,186 SO THE SO THE BODY OF THE CONE 1431 01:01:31,186 --> 01:01:33,488 IS COMPOSED OF THESE SIX MEMBER 1432 01:01:33,488 --> 01:01:43,599 RINGS. 1433 01:01:52,441 --> 01:01:55,377 SO THIS IS LUKE A SOCCER BALLS. 1434 01:01:55,377 --> 01:01:59,281 AND THAT TURNS OUT TO BE 1435 01:01:59,281 --> 01:02:00,649 UNIVERSALLY TRUE, IT CAN'T 1436 01:02:00,649 --> 01:02:03,852 CLOSE UNLESS YOU PUT 12 1437 01:02:03,852 --> 01:02:08,457 PENTMERS SO THE VIRUS PUTS 7 1438 01:02:08,457 --> 01:02:11,894 PENTMER AT THE WIDENED AND 5 AT 1439 01:02:11,894 --> 01:02:13,629 THE NARROW END AND THAT FORMS A 1440 01:02:13,629 --> 01:02:14,429 CAPSID. 1441 01:02:14,429 --> 01:02:16,231 SO THE NEXT REALLY IMPORTANT 1442 01:02:16,231 --> 01:02:22,170 BREAKTHROUGH WAS MADE BY OWEN, 1443 01:02:22,170 --> 01:02:27,976 THEY WERE ABLE TO CLEVERLY 1444 01:02:27,976 --> 01:02:31,813 STABILIZE THE HEXMER AND 1445 01:02:31,813 --> 01:02:33,415 PENDMER AND EXTRACT THEM FROM 1446 01:02:33,415 --> 01:02:34,283 THE STRUCTURES THAT I SHOWED 1447 01:02:34,283 --> 01:02:37,819 YOU AND THAT ALLOWED THEM TO 1448 01:02:37,819 --> 01:02:41,290 CRYSTALIZE THE HEXMER AND 1449 01:02:41,290 --> 01:02:43,558 PENTMER AND THAT WAS IMPORTANT 1450 01:02:43,558 --> 01:02:44,760 ADVANCE FOR THREE REASONS. 1451 01:02:44,760 --> 01:02:47,062 ONE, IT PROOFS THAT THERE WERE 1452 01:02:47,062 --> 01:02:50,065 HEXMERS AND PENTMERS SO THAT 1453 01:02:50,065 --> 01:02:52,134 WAS STRONG EVIDENCE IN THE CONE 1454 01:02:52,134 --> 01:02:56,038 MODEL THAT I JUST SHOWED YOU. 1455 01:02:56,038 --> 01:02:57,139 THE SECOND IMPORTANT 1456 01:02:57,139 --> 01:02:59,274 CONTRIBUTION, WAS THAT IT IT 1457 01:02:59,274 --> 01:03:02,311 SHOWED US THE ATOMIC STRUCTURE. 1458 01:03:02,311 --> 01:03:05,747 AND FOR THOSE OF YOU WHO FOLLOW 1459 01:03:05,747 --> 01:03:07,816 VIRUS ASSEMBLY THESE TWO ARE 1460 01:03:07,816 --> 01:03:12,587 RELATED BY WHAT CASPER AND MY 1461 01:03:12,587 --> 01:03:14,790 FORMER POST MASTER CALLED 1462 01:03:14,790 --> 01:03:17,359 EQUIVALENTS. 1463 01:03:17,359 --> 01:03:19,394 THEY LOOK SIMILAR YOU CAN 1464 01:03:19,394 --> 01:03:21,263 REMOVE THE SUB UNIT AND CLOSE 1465 01:03:21,263 --> 01:03:23,432 OUT THE RING AND YOU GET THE 1466 01:03:23,432 --> 01:03:24,933 PENTMER. 1467 01:03:24,933 --> 01:03:29,071 AND THE FINAL IMPORTANT 1468 01:03:29,071 --> 01:03:30,906 CONTRIBUTION, THIS REPRESENTED, 1469 01:03:30,906 --> 01:03:32,774 IT ALLOWED STRUCTURE DESIGN. 1470 01:03:32,774 --> 01:03:35,077 YOU CAN BIND INHIBITOR SXZ SEE 1471 01:03:35,077 --> 01:03:40,382 EXACTLY HOW THEY BOUND AND 1472 01:03:40,382 --> 01:03:45,654 THAT WAS KEY IN MAKING 1473 01:03:45,654 --> 01:03:46,388 LENACAPAVIR THE PRECURSORS 1474 01:03:46,388 --> 01:03:47,055 BETTER AND BETTER. 1475 01:03:47,055 --> 01:03:50,759 SO IT TURNS OUT TO UNDERSTAND 1476 01:03:50,759 --> 01:03:51,727 WHEN LENACAPAVIR IT'S IMPORTANT 1477 01:03:51,727 --> 01:03:54,930 TO UNDERSTAND HOW THE HEXMER 1478 01:03:54,930 --> 01:03:57,165 PACK WITH ONE ANOTHER. 1479 01:03:57,165 --> 01:03:59,501 SO THIS IS HEXMER AS YOU WOULD 1480 01:03:59,501 --> 01:04:03,538 SEE IN THE BODY OF THE CONE AND 1481 01:04:03,538 --> 01:04:05,340 IT PACKS WITH SIX NEAREST 1482 01:04:05,340 --> 01:04:06,274 NEIGHBORS. 1483 01:04:06,274 --> 01:04:10,145 SO THIS IS HEXMER PACKED 1484 01:04:10,145 --> 01:04:11,980 AGAINST THIS HEXMER AND YOU CAN 1485 01:04:11,980 --> 01:04:14,983 SEE THE SEA TERMINAL DOMAIN NZ 1486 01:04:14,983 --> 01:04:17,986 LIGHT GREEN FROM ONE HEXMER AND 1487 01:04:17,986 --> 01:04:20,489 THE LIGHT RED AND THE ANOTHER 1488 01:04:20,489 --> 01:04:22,090 ALL OF THESE TWO HEXMER 1489 01:04:22,090 --> 01:04:22,824 TOGETHER. 1490 01:04:22,824 --> 01:04:24,459 AND IF WE EXTRACT THAT THAT'S 1491 01:04:24,459 --> 01:04:26,294 WHAT THIS LOOKS LIKE AND IF WE 1492 01:04:26,294 --> 01:04:28,196 TURN IT ON ITS SIDE, THAT'S THE 1493 01:04:28,196 --> 01:04:30,265 HEAD OF THE RABBIT SO. THAT 1494 01:04:30,265 --> 01:04:33,035 EXPLAINED HOW AS YOU RAISE THE 1495 01:04:33,035 --> 01:04:34,803 PROTEIN CONCENTRATION, YOU 1496 01:04:34,803 --> 01:04:37,105 FIRST FORMED DIMERS BUT THEN 1497 01:04:37,105 --> 01:04:38,974 THE DIMERS FORMED HEXMERS WHICH 1498 01:04:38,974 --> 01:04:42,677 CAN FORM THIS LATIS. 1499 01:04:42,677 --> 01:04:43,812 LATTICE. 1500 01:04:43,812 --> 01:04:45,647 A LOT OF GROUPS CONTRIBUTED I 1501 01:04:45,647 --> 01:04:47,049 WILL NOT NAME THEM ALL BUT I 1502 01:04:47,049 --> 01:04:48,316 WILL MAKE IT CLEAR THAT THERE 1503 01:04:48,316 --> 01:04:50,952 WERE A LOT OF CONTRIBUTORS 1504 01:04:50,952 --> 01:04:53,021 IMPORTANT WAS CHANG AND ANGELA 1505 01:04:53,021 --> 01:04:54,723 AND CHRIS AIKENS AND THEIR 1506 01:04:54,723 --> 01:04:58,093 COLLEAGUES AND THEY EMPHASISED 1507 01:04:58,093 --> 01:04:59,227 THAT ANOTHER INTERACTION THAT 1508 01:04:59,227 --> 01:05:03,799 HOLDS THE LAT --LATTICE 1509 01:05:03,799 --> 01:05:07,436 TOGETHER IS THIS THREE 1510 01:05:07,436 --> 01:05:08,136 INTERACTION AND THAT'S 1511 01:05:08,136 --> 01:05:09,938 IMPORTANT FOR MAKING THE 1512 01:05:09,938 --> 01:05:11,339 LATTICE. 1513 01:05:11,339 --> 01:05:13,375 AND THEN, MAYBE THE MOST 1514 01:05:13,375 --> 01:05:14,810 IMPORTANT INTERACTION OF ALL, 1515 01:05:14,810 --> 01:05:17,779 IS AN INTERACTION THAT 1516 01:05:17,779 --> 01:05:20,082 STABLELIZED THE HEXMER SO. THIS 1517 01:05:20,082 --> 01:05:23,552 RED SUB AOUPT THE SEA TERMINAL 1518 01:05:23,552 --> 01:05:26,088 DOMAIN PACKS AGAINST THE DOMAIN 1519 01:05:26,088 --> 01:05:27,856 OF ITS NEAREST NEIGHBOR WITHIN 1520 01:05:27,856 --> 01:05:30,425 THE HEXMER SO THE SEA TERMINAL 1521 01:05:30,425 --> 01:05:40,001 SORT OF BUT THE--BUTRESS, IT 1522 01:05:40,001 --> 01:05:42,337 CREATES THIS LARGE CREVICE AND 1523 01:05:42,337 --> 01:05:47,309 IT'S A CONSERVE HYDRO PHOBIC 1524 01:05:47,309 --> 01:05:49,611 CREVICE AND THE VIRUS USES THAT 1525 01:05:49,611 --> 01:05:51,146 CREVICE TO BIND AND HOST 1526 01:05:51,146 --> 01:05:51,446 PROTEINS. 1527 01:05:51,446 --> 01:05:56,985 THIS IS ONE EXAMPLE OF CPSF6 SO 1528 01:05:56,985 --> 01:05:59,988 THE VIRUS NEEDS THESE TO GET 1529 01:05:59,988 --> 01:06:02,324 INTO THE NUCLEUS SO IT 1530 01:06:02,324 --> 01:06:05,193 CONSERVES THEM. 1531 01:06:05,193 --> 01:06:07,729 AND I'LL COME BACK TO THAT IN 1532 01:06:07,729 --> 01:06:09,798 JUST A MOMENT SO. JUST TO 1533 01:06:09,798 --> 01:06:11,933 FINISH THE UNDERING OF THE 1534 01:06:11,933 --> 01:06:12,634 ARCHITECTURE OF CAPSID, ONE OF 1535 01:06:12,634 --> 01:06:14,936 THE THINGS THAT I WANT TO 1536 01:06:14,936 --> 01:06:17,239 EMPHASIS IS HIV HAS BEEN A 1537 01:06:17,239 --> 01:06:20,442 AMAZING TESTING GROUND FOR NEW 1538 01:06:20,442 --> 01:06:25,914 TECHNOLOGY THIS WAS TM 1539 01:06:25,914 --> 01:06:29,184 TOPOGRAPHY, THEY'RE ACTUALLY 1540 01:06:29,184 --> 01:06:30,785 LOOKING AUTHENTIC VIRUS AND USE 1541 01:06:30,785 --> 01:06:32,654 EM BUT IN THREE DIMENSIONS AND 1542 01:06:32,654 --> 01:06:36,291 WHAT YOU CAN SEE, SO WE'RE 1543 01:06:36,291 --> 01:06:38,326 SLABING THROUGH FOUR VIRAL 1544 01:06:38,326 --> 01:06:40,695 PARTICLES, YOU CAN SORT OF MAKE 1545 01:06:40,695 --> 01:06:41,830 OUT THE CONE. 1546 01:06:41,830 --> 01:06:42,998 AND THEY HAVE SUFFICIENT 1547 01:06:42,998 --> 01:06:45,233 RESOLUTION THAT IF WE RENDER 1548 01:06:45,233 --> 01:06:46,334 THOSE CONES YOU CAN SEE THAT 1549 01:06:46,334 --> 01:06:48,370 THE CONES IN THE CENTER OF THE 1550 01:06:48,370 --> 01:06:52,674 VIRUS ARE IN FACT FULLER' CONES. 1551 01:06:52,674 --> 01:06:55,010 SO YOU CAN SEE THAT THERE IS A 1552 01:06:55,010 --> 01:06:58,680 BODY, THERE ARE FIVE PENTMERS 1553 01:06:58,680 --> 01:07:02,617 AND IT LOOKS LIKE WHAT WE 1554 01:07:02,617 --> 01:07:03,251 ANTICIPATED. 1555 01:07:03,251 --> 01:07:04,419 BUT WHAT IS INTERESTING IF YOU 1556 01:07:04,419 --> 01:07:06,488 LOOK AT THE STRUCTURES, YOU CAN 1557 01:07:06,488 --> 01:07:10,625 SEE THAT THEY ALL LOOK SLIGHTLY 1558 01:07:10,625 --> 01:07:12,460 DIFFERENT, HERE, THE PENTMERS 1559 01:07:12,460 --> 01:07:17,232 ARE MOVED OUT INTO THE HEX SO 1560 01:07:17,232 --> 01:07:19,034 IT'S A STUBIER STRUCTUREMENT 1561 01:07:19,034 --> 01:07:24,873 AND HERE THE VIRUS HAS PUT SIX 1562 01:07:24,873 --> 01:07:25,707 PENTMERS ON ONE SIDE AND THE 1563 01:07:25,707 --> 01:07:29,411 OTHER. 1564 01:07:29,411 --> 01:07:33,381 IT'S A HEXAGONAL HEELCAL 1565 01:07:33,381 --> 01:07:34,182 LATTICE. 1566 01:07:34,182 --> 01:07:36,718 I HOPE YOU AGREE THOSE ARE 1567 01:07:36,718 --> 01:07:38,186 BEAUTIFUL STRUCTURE AND I'M NOT 1568 01:07:38,186 --> 01:07:40,822 THE ONLY PERSON THAT THINKS 1569 01:07:40,822 --> 01:07:46,228 THA. I WAS SITTING AT MY DESK 1570 01:07:46,228 --> 01:07:49,397 AND SOMEBODY CALLED, IT WAS A 1571 01:07:49,397 --> 01:07:53,301 GUY THAT BUILT COMPUTER VIRUS. 1572 01:07:53,301 --> 01:07:54,703 WHAT HE MEANT WAS SOMETHING 1573 01:07:54,703 --> 01:07:58,139 DIFFERENT, SO HE TAKES APART 1574 01:07:58,139 --> 01:08:01,142 OLD COMPUTERS AND SCAVENGES THE 1575 01:08:01,142 --> 01:08:03,411 PARTS AND MIRRORS FROM NEW 1576 01:08:03,411 --> 01:08:08,483 COMPUTERS AND REBUILDS THEM 1577 01:08:08,483 --> 01:08:12,887 INTO SCULPTURE AND THIS IS HIS 1578 01:08:12,887 --> 01:08:16,524 SCULPTURE, THIS IS A HIV CONE 1579 01:08:16,524 --> 01:08:18,593 IT'S LIKE A DISCO BALL. 1580 01:08:18,593 --> 01:08:20,262 AND HE'S NOT THE ONLY PERSON, 1581 01:08:20,262 --> 01:08:22,564 THIS IS HIGHLIGHTING ANOTHER 1582 01:08:22,564 --> 01:08:24,633 ARTIST CALLED JOHN WALTER WHO 1583 01:08:24,633 --> 01:08:26,868 IS A MULTI MEDIA ARTIST. 1584 01:08:26,868 --> 01:08:30,171 HE HAD A TRAVELING SHOW A FEW 1585 01:08:30,171 --> 01:08:32,240 YEARS AGO, IT'S CALLED CAPSID, 1586 01:08:32,240 --> 01:08:34,309 THIS IS A PICTURE FROM THE SHOW 1587 01:08:34,309 --> 01:08:36,544 IN THE GALLERY IN LONDON. 1588 01:08:36,544 --> 01:08:39,848 THIS IS JOHN, AND IT'S A MULTI 1589 01:08:39,848 --> 01:08:41,016 MEDIA MULTI LARGE SHOW BUT YOU 1590 01:08:41,016 --> 01:08:43,551 CAN SEE THE BIGGEST SINGLE 1591 01:08:43,551 --> 01:08:49,324 PIECE IS THIS ROUGHLY 15-FOOT 1592 01:08:49,324 --> 01:08:52,327 BY 20-FOOT CENTRAL PIECE AND AT 1593 01:08:52,327 --> 01:08:57,098 THE CENTER IS THE HIV CAPSID. 1594 01:08:57,098 --> 01:08:58,033 IT'S CAPTURED THE IMAGINATION 1595 01:08:58,033 --> 01:08:59,434 OF PEOPLE BECAUSE IT'S A 1596 01:08:59,434 --> 01:09:01,069 STRUCTURE IT HAS NO SYMMETRY, 1597 01:09:01,069 --> 01:09:03,405 IT'S A CONE SO IT LACKS 1598 01:09:03,405 --> 01:09:06,841 SYMMETRY AND ALSO BECAUSE IT 1599 01:09:06,841 --> 01:09:08,677 REPRESENTS BOTH A HUGE AMOUNT 1600 01:09:08,677 --> 01:09:16,951 OF HUMAN SUFFERING BUT ALSO 1601 01:09:16,951 --> 01:09:19,688 ULTIMATELY, THE CURE TO VIRUS. 1602 01:09:19,688 --> 01:09:22,357 WHAT IS IT GOOD FOR? 1603 01:09:22,357 --> 01:09:24,225 AND THIS SLIDE HIGHLIGHTS AN 1604 01:09:24,225 --> 01:09:29,030 EXPERIMENT THAT WAS DONE BY A 1605 01:09:29,030 --> 01:09:31,099 POST DOC AND I WANT TO 1606 01:09:31,099 --> 01:09:33,201 EMPHASIZE THE FIELD HAS MADE A 1607 01:09:33,201 --> 01:09:35,303 LOT OF CONTRIBUTIONS. 1608 01:09:35,303 --> 01:09:38,340 WHAT UTA DID, I TOLD YOU WE 1609 01:09:38,340 --> 01:09:41,109 KNEW THE STRUCTURE SO SHE COULD 1610 01:09:41,109 --> 01:09:43,178 DESIGN SINGLE MUTATION THAT'S 1611 01:09:43,178 --> 01:09:45,480 WERE DESIGNED TO ALTER THE 1612 01:09:45,480 --> 01:09:51,686 SURFACE OF THE CAPSID SLIGHTLY 1613 01:09:51,686 --> 01:09:52,620 BUT WITHOUT ALTERING THE 1614 01:09:52,620 --> 01:09:53,321 STRUCTURE. 1615 01:09:53,321 --> 01:09:58,126 AND SHE MEASURED THE INFECTITY 1616 01:09:58,126 --> 01:09:59,761 AND TO OUR SURPRISE, THEY BUILT 1617 01:09:59,761 --> 01:10:02,964 IN THIS CASE, 50 POINT 1618 01:10:02,964 --> 01:10:06,167 MUTATIONS AND 46 OF THEM WERE 1619 01:10:06,167 --> 01:10:10,672 AT LEAST TWO-FOLD IN 1620 01:10:10,672 --> 01:10:10,972 INFECTIVITY. 1621 01:10:10,972 --> 01:10:18,380 SO WITH WHAT THAT SAID WAS EVEN 1622 01:10:18,380 --> 01:10:20,248 SMALL SURFACES HAVE DETRIMENTAL 1623 01:10:20,248 --> 01:10:24,619 AFFECTS ON VIRAL REPLICATION. 1624 01:10:24,619 --> 01:10:27,889 SO HER MUTUAL, HER SET OF 1625 01:10:27,889 --> 01:10:29,257 COLLECTION OF MUTANTS ARE 1626 01:10:29,257 --> 01:10:31,059 IMPORTANT BECAUSE THEY HELP 1627 01:10:31,059 --> 01:10:32,293 SEPARATE OUT THE FUFRPTIONS OF 1628 01:10:32,293 --> 01:10:32,961 THE PROTEIN. 1629 01:10:32,961 --> 01:10:35,263 SOY TOLD YOU THAT THE CA 1630 01:10:35,263 --> 01:10:38,500 PROTEIN IS PART OF MAKING THE 1631 01:10:38,500 --> 01:10:41,269 IMMATURE VARIANT AND THESE RED 1632 01:10:41,269 --> 01:10:44,806 BALLS ARE MUTATIONS THAT REDUCE 1633 01:10:44,806 --> 01:10:46,908 VIRUS PROTECTION. 1634 01:10:46,908 --> 01:10:49,177 THE GREEN AND BLUE ONE ARE MORE 1635 01:10:49,177 --> 01:10:51,913 INTERESTS THEY MAKE CAPSIDS AND 1636 01:10:51,913 --> 01:11:00,789 IN THE BLUE ONE IS COMPLETELY 1637 01:11:00,789 --> 01:11:02,257 NON INFECTIOUS. 1638 01:11:02,257 --> 01:11:04,292 SO THAT TOLD US THAT THAT HAS 1639 01:11:04,292 --> 01:11:06,394 TO PERFORM IMPORTANT FUNCTIONS. 1640 01:11:06,394 --> 01:11:08,496 WITH CHRIS AIKENS LAB, WE WERE 1641 01:11:08,496 --> 01:11:10,832 ABLE TO SHOW THAT A COUPLE OF 1642 01:11:10,832 --> 01:11:12,901 MUTATIONS WERE MAKING THE CA 1643 01:11:12,901 --> 01:11:16,104 SID MORE STABLE THAN THE WILD 1644 01:11:16,104 --> 01:11:19,340 TYPE CAPSID AND THEY WERE 1645 01:11:19,340 --> 01:11:20,909 POORLY INFECTIOUS SO THIS SET 1646 01:11:20,909 --> 01:11:26,414 UP THIS SORT OF GOLDIE LOX 1647 01:11:26,414 --> 01:11:27,148 SITUATION. 1648 01:11:27,148 --> 01:11:29,451 AND THIS THEN THIS YELLOW 1649 01:11:29,451 --> 01:11:32,921 MUTATION HZ NO, MADE NO CAPSIDS 1650 01:11:32,921 --> 01:11:37,425 AND THEY WERE ALWAYS NON 1651 01:11:37,425 --> 01:11:38,827 INFECTIOUS. 1652 01:11:38,827 --> 01:11:41,996 AND THEN WE KNEW AT THE TIME 1653 01:11:41,996 --> 01:11:46,801 ABOUT ONE POST PROTEIN, AND NOT 1654 01:11:46,801 --> 01:11:48,903 SURPRISINGLY ARE MUTATIONS 1655 01:11:48,903 --> 01:11:50,538 THERE INHIBITED THAT THE 1656 01:11:50,538 --> 01:11:54,442 BINDING OF THAT AND THAT ALSO 1657 01:11:54,442 --> 01:11:55,410 REDUCED VIRAL REPLICATION. 1658 01:11:55,410 --> 01:11:58,646 SO THE TAKE HOME MESSAGE HERE 1659 01:11:58,646 --> 01:12:01,249 IS THAT CA PROTEIN DOES A LOT 1660 01:12:01,249 --> 01:12:04,819 OF DIFFERENT THINGS AND THAT 1661 01:12:04,819 --> 01:12:15,296 IT'S VERY SENSITIVE TO ANY 1662 01:12:16,898 --> 01:12:18,199 PABTRABATION. 1663 01:12:18,199 --> 01:12:22,270 THIS IS A ILLUSTRATION BY JANET 1664 01:12:22,270 --> 01:12:24,706 OF THAT FIRST LIFECYCLE. 1665 01:12:24,706 --> 01:12:28,510 THIS IS THE INFECTIOUS VIRUS, 1666 01:12:28,510 --> 01:12:30,612 WITH PROTEINS THEY INTERACT 1667 01:12:30,612 --> 01:12:33,348 WITH THE CD4 AND COINACCEPTER 1668 01:12:33,348 --> 01:12:35,416 THAT CAUSES FUSION OF THE VIRAL 1669 01:12:35,416 --> 01:12:36,818 AND RELEASES THE CORE PARTICLE 1670 01:12:36,818 --> 01:12:47,128 IN THE CYTO PLASM. 1671 01:12:47,595 --> 01:12:48,696 THEY CAN DEVELOPED RESPONSE 1672 01:12:48,696 --> 01:12:51,299 THAT'S CAN RECOGNIZE THE CORE 1673 01:12:51,299 --> 01:12:52,367 AND INACTIVATE IT. 1674 01:12:52,367 --> 01:12:57,338 BUT IF THE VIRUS ESCAPES THOSE 1675 01:12:57,338 --> 01:12:59,607 SYSTEMS, THEN MOSES HERE ON THE 1676 01:12:59,607 --> 01:13:01,910 COUNCIL HAS SHOWN THAT THEY CAN 1677 01:13:01,910 --> 01:13:05,079 LATCH ON AND MOVE TO MICRO 1678 01:13:05,079 --> 01:13:08,716 TUBIALS TO THE NUCLEAR CORE. 1679 01:13:08,716 --> 01:13:10,084 AND I SHOULD SAY THAT ONE OF 1680 01:13:10,084 --> 01:13:12,687 THE THING THAT HIV RESEARCH HAS 1681 01:13:12,687 --> 01:13:15,657 BEEN USEFUL AND AS DIANA SAID, 1682 01:13:15,657 --> 01:13:17,258 THERE ARE OFTEN THESE FULL 1683 01:13:17,258 --> 01:13:19,928 CYCLES IS TO HELP TO INFORM 1684 01:13:19,928 --> 01:13:20,495 CELL BIOLOGY. 1685 01:13:20,495 --> 01:13:22,997 SO IT WAS THOUGHT THAT THE CORE 1686 01:13:22,997 --> 01:13:25,066 PARTICLE COULDN'T GET INTO THE 1687 01:13:25,066 --> 01:13:26,935 NUCLEUS AND THAT'S BECAUSE 1688 01:13:26,935 --> 01:13:29,003 THEIR CELL BIOLOGY COLLEAGUES 1689 01:13:29,003 --> 01:13:29,771 HAD UNDERESTIMATED THE SIZE OF 1690 01:13:29,771 --> 01:13:31,973 THE POUR. 1691 01:13:31,973 --> 01:13:34,976 BUT IN FACT, GROUPS SHOW THAT 1692 01:13:34,976 --> 01:13:44,285 THE CORE DOES GET INTO THE 1693 01:13:44,285 --> 01:13:45,920 NUCLEI, AND IT TURNS OUT THAT 1694 01:13:45,920 --> 01:13:46,854 IT MAKES SENSE. 1695 01:13:46,854 --> 01:13:51,192 SO DURING ALL OF THESE STEPS, 1696 01:13:51,192 --> 01:13:55,964 THE MOST FAMOUS STEP IN VITRO 1697 01:13:55,964 --> 01:13:58,266 VILLOLOGY IS HAPPENING. 1698 01:13:58,266 --> 01:14:01,235 AND AT SOME POINT, AND WE DON'T 1699 01:14:01,235 --> 01:14:04,205 UNDERSTAND THIS WELL YET, THE 1700 01:14:04,205 --> 01:14:06,708 DNA HAS TO ESCAPE FROM THE 1701 01:14:06,708 --> 01:14:09,944 CAPSID AND DNA TOGETHER WITH 1702 01:14:09,944 --> 01:14:11,346 THE INTEGRATE ENZYME TO 1703 01:14:11,346 --> 01:14:15,683 INTEGRATES INTO THE CRONE ZONE. 1704 01:14:15,683 --> 01:14:16,351 --CHROMOSOME. 1705 01:14:16,351 --> 01:14:19,320 AND THIS IS WHY IT'S SO HARD TO 1706 01:14:19,320 --> 01:14:25,026 TREAT BECAUSE EVERY TIME 1707 01:14:25,026 --> 01:14:28,863 SOMEBODY GETS INFECTED, THERE 1708 01:14:28,863 --> 01:14:30,198 IS A REPLICATION--FIRST LINE 1709 01:14:30,198 --> 01:14:31,833 THERAPY I CAN AS IT COULD BE IF 1710 01:14:31,833 --> 01:14:33,768 WE CAN FIND OTHER DRUGS TO PAIR 1711 01:14:33,768 --> 01:14:34,569 IT WITH. 1712 01:14:34,569 --> 01:14:37,138 SO I THINK THERE IS A VERY 1713 01:14:37,138 --> 01:14:38,573 IMPORTANT ROLE STILL FOR 1714 01:14:38,573 --> 01:14:39,741 DISCOVERING HOW STEPS LIKE THIS 1715 01:14:39,741 --> 01:14:42,010 WORK SO THAT WE CAN UNDERSTAND 1716 01:14:42,010 --> 01:14:44,746 NEW DRUG TARGETS THAT MIGHT 1717 01:14:44,746 --> 01:14:47,115 GIVE RISE TO DRUGS THAT WOULD 1718 01:14:47,115 --> 01:14:50,618 PAIR WELL WITH LENACAPAVIR AND 1719 01:14:50,618 --> 01:14:51,285 OUR OTHER DRUGS. 1720 01:14:51,285 --> 01:15:01,763 SO I WANT TO TURN MIA --MY 1721 01:15:02,563 --> 01:15:04,132 ATTENTION TO HOW LENACAPAVIR 1722 01:15:04,132 --> 01:15:06,834 WORKS. 1723 01:15:06,834 --> 01:15:09,137 HE SAID DO YOU THINK CAPSID 1724 01:15:09,137 --> 01:15:14,575 WOULD BE A GOOD TARGET SO. WHEN 1725 01:15:14,575 --> 01:15:15,943 PHARMACEUTICAL COMPANY ASKED 1726 01:15:15,943 --> 01:15:17,679 THAT QUESTION, YOU SAY YES. 1727 01:15:17,679 --> 01:15:20,281 BUT I DID THINK THERE WAS 1728 01:15:20,281 --> 01:15:21,916 POTENTIAL BECAUSE OF SINGLE 1729 01:15:21,916 --> 01:15:23,584 MUTATIONS ON THE SURFACE ALWAYS 1730 01:15:23,584 --> 01:15:27,922 LEAD TO LESS INFECTIOUS VIRUS. 1731 01:15:27,922 --> 01:15:31,592 SO I WAS A SULT ANT, THIS IS 1732 01:15:31,592 --> 01:15:33,628 ANOTHER SLIDE THAT I GOT FROM 1733 01:15:33,628 --> 01:15:35,263 TOMAS, THEY'VE BEEN GREAT ABOUT 1734 01:15:35,263 --> 01:15:35,897 ACKNOWLEDGING THE CONTRIBUTIONS 1735 01:15:35,897 --> 01:15:38,099 OF THE COMMUNITY. 1736 01:15:38,099 --> 01:15:40,835 AND THEY STARTED STEVEN YEN 1737 01:15:40,835 --> 01:15:41,769 STARTED THEIR SCREENING PROGRAM 1738 01:15:41,769 --> 01:15:46,107 TO LOOK FOR SMALL MOLECULES 1739 01:15:46,107 --> 01:15:49,477 THAT WOULD ALTER CAPSID CA 1740 01:15:49,477 --> 01:15:50,912 INVIDRO. 1741 01:15:50,912 --> 01:15:59,187 SO AS I SHOW YOU, IT WILL 1742 01:15:59,187 --> 01:16:00,088 SPONTANEOUSLY,--AND IT START 1743 01:16:00,088 --> 01:16:01,689 INSIDE 2006 AND THEN DECIDED 1744 01:16:01,689 --> 01:16:02,857 THAT THEIR LEAD COMPOUND WAS 1745 01:16:02,857 --> 01:16:04,392 NOT GOING TO BE A DRUG. 1746 01:16:04,392 --> 01:16:07,028 SO AT THAT POINT, THEY 1747 01:16:07,028 --> 01:16:09,330 RESTARTED ANOTHER PROGRAM WITH 1748 01:16:09,330 --> 01:16:10,932 A SECOND LEAD, I'LL MENTION 1749 01:16:10,932 --> 01:16:11,666 THAT IN A MOMENT. 1750 01:16:11,666 --> 01:16:15,670 AND THEN I THINK REALLY 1751 01:16:15,670 --> 01:16:20,508 HEROICKLY, JOHN LINK LEAD THIS 1752 01:16:20,508 --> 01:16:21,075 MEDICINAL CHEMISTRY EFFORT 1753 01:16:21,075 --> 01:16:23,044 GOING FROM A LEAD COMPOUND TO 1754 01:16:23,044 --> 01:16:24,746 GOING TO LENACAPAVIR. 1755 01:16:24,746 --> 01:16:26,948 AND THE LEAD COMPOUNDS WERE 1756 01:16:26,948 --> 01:16:28,549 INTERESTING BECAUSE THEY 1757 01:16:28,549 --> 01:16:30,618 ACTUALLY PROMOTED ASSEMBLY 1758 01:16:30,618 --> 01:16:31,319 RATHER THAN BLOCKING IT. 1759 01:16:31,319 --> 01:16:33,955 THIS IS THE CHART OF MORE THAN 1760 01:16:33,955 --> 01:16:40,461 4,000 COMPOUNDED THAT GILET 1761 01:16:40,461 --> 01:16:41,162 MADE. 1762 01:16:41,162 --> 01:16:45,166 YOU CAN SEE THAT OVER SIX 1763 01:16:45,166 --> 01:16:47,034 YEARS, THEY END UP WITH 1764 01:16:47,034 --> 01:16:48,970 COMPOUNDS THAT ARE SIX LOGS 1765 01:16:48,970 --> 01:16:50,571 MORE POTENT. 1766 01:16:50,571 --> 01:16:53,474 AND I WOULD EMPHASIZE THAT EVEN 1767 01:16:53,474 --> 01:16:54,842 AT THESE STAGES, THEY WERE 1768 01:16:54,842 --> 01:16:56,244 HELPED BY BASIC SCIENCE. 1769 01:16:56,244 --> 01:16:58,079 SO DURING THIS PERIOD OF TIME, 1770 01:16:58,079 --> 01:17:01,983 THE STRUCTURE OF PENTMER AND 1771 01:17:01,983 --> 01:17:04,051 HEXMER AND PFIZER ALSO CAME OUT 1772 01:17:04,051 --> 01:17:10,291 WITH A MOLECULE CALLED C864 1773 01:17:10,291 --> 01:17:13,961 THAT SERVED AS A PROOF OF 1774 01:17:13,961 --> 01:17:23,404 PRINCIPLE SO EVEN THOUGH IT WAS 1775 01:17:23,404 --> 01:17:24,505 IMPORTANT. 1776 01:17:24,505 --> 01:17:29,177 IT HAS A POLY PEPTIDE BACKBONE 1777 01:17:29,177 --> 01:17:32,580 IT HAS A LARGE NUMBER OF 1778 01:17:32,580 --> 01:17:35,817 MODIFICATIONS AND IT BINDS WITH 1779 01:17:35,817 --> 01:17:36,984 PICAMO OR AFFINITY. 1780 01:17:36,984 --> 01:17:39,520 SO I WOULD LIKE TO TAKE YOU 1781 01:17:39,520 --> 01:17:42,423 THROUGH A PROPERTIES THAT MAKE 1782 01:17:42,423 --> 01:17:47,595 LENACAPAVIR SO SPECIAL. 1783 01:17:47,595 --> 01:17:49,897 SO GELIA HAS SHOWN THAT IT 1784 01:17:49,897 --> 01:17:51,332 BINDS TO THE POCKET. 1785 01:17:51,332 --> 01:17:53,401 YOU CAN GET DRUG RESISTANCE IN 1786 01:17:53,401 --> 01:17:55,236 CULTURE AND THAT OCCURS AT ALL 1787 01:17:55,236 --> 01:18:00,041 OF THESE AMINO ACIDS ZONE. 1788 01:18:00,041 --> 01:18:02,810 BUT WHEN THE VIRUS MAKES THE 1789 01:18:02,810 --> 01:18:07,415 MUTATION TZ GIVES RISE TO 1790 01:18:07,415 --> 01:18:09,851 POORLY REPLICATED VIRUS. 1791 01:18:09,851 --> 01:18:12,220 AND THEY'RE FINDING IT HAS TO 1792 01:18:12,220 --> 01:18:14,188 BE CONSERVED OR THE VIRUS IS 1793 01:18:14,188 --> 01:18:19,227 UNHAPPY. 1794 01:18:19,227 --> 01:18:20,628 THESE PROTEIN HELP THE VIRUS TO 1795 01:18:20,628 --> 01:18:31,005 GET INTO THE NUCLEUS. 1796 01:18:32,240 --> 01:18:36,811 SO THE SECOND PROPERTY OF 1797 01:18:36,811 --> 01:18:38,479 LENACAPAVIR IS ITS REMARKABLE 1798 01:18:38,479 --> 01:18:38,913 POTENCY. 1799 01:18:38,913 --> 01:18:42,116 THIS IS THE PLOT OF POTENCY SO 1800 01:18:42,116 --> 01:18:43,017 LOWER IS BETTER. 1801 01:18:43,017 --> 01:18:53,494 THIS IS LENACAPAVIR GS-CA 1. 1802 01:18:53,861 --> 01:18:56,364 AND YOU CAN SEE IT'S ABOUT A 1803 01:18:56,364 --> 01:18:59,100 ORDER OF MAGNITUDE AND THEY 1804 01:18:59,100 --> 01:19:01,435 ALSO WORK AGAINST OR THE 1805 01:19:01,435 --> 01:19:02,870 CLASSICAL DRUGS AND THEY ALSO 1806 01:19:02,870 --> 01:19:04,972 WORK AGAINST ALL THE DIFFERENT 1807 01:19:04,972 --> 01:19:06,440 SUB TYPES AS YOU WOULD EXPECT 1808 01:19:06,440 --> 01:19:08,075 BECAUSE THIS IS A CONSERVED 1809 01:19:08,075 --> 01:19:09,877 POCKET. 1810 01:19:09,877 --> 01:19:11,746 BUT REALLY THE MOST REMARKABLE 1811 01:19:11,746 --> 01:19:15,416 PROPERTY OF THE DRUG IS THAT 1812 01:19:15,416 --> 01:19:16,784 ITS LONG LASTING CONNECTIVES. 1813 01:19:16,784 --> 01:19:20,521 SO THIS IS FROM THE PHASE ONE 1814 01:19:20,521 --> 01:19:23,257 TRIALS, THEY INJECT PEOPLE WITH 1815 01:19:23,257 --> 01:19:24,659 THE DRUG, DIFFERENT LEVELS OF 1816 01:19:24,659 --> 01:19:26,694 THE DRUG AND THEN MEASURE THE 1817 01:19:26,694 --> 01:19:28,362 LEVELS OF THE DRUG IN THE BLOOD 1818 01:19:28,362 --> 01:19:30,231 AS A FUNCTION OF TIME AND THIS 1819 01:19:30,231 --> 01:19:33,234 RED LINE SHOWS THE EC95 THAT'S 1820 01:19:33,234 --> 01:19:36,437 THE DRUG LEVEL THAT WOULD BE 1821 01:19:36,437 --> 01:19:38,272 EXPECT TODAY INHIBIT 95 PERCENT 1822 01:19:38,272 --> 01:19:39,173 OF THE VIRUS. 1823 01:19:39,173 --> 01:19:41,342 AND YOU WOULD EXPECT AS IT 1824 01:19:41,342 --> 01:19:42,443 SLOWLY DECAYSED BUT THE KEY 1825 01:19:42,443 --> 01:19:44,412 THING IS THAT IT'S VERY SLOW. 1826 01:19:44,412 --> 01:19:48,449 SO THIS IS 24 WEEKS, THESE 1827 01:19:48,449 --> 01:19:50,284 WELL-TOLERATED LEVELS ARE STILL 1828 01:19:50,284 --> 01:19:51,686 ABOVE THE EC95. 1829 01:19:51,686 --> 01:19:55,589 SO THE DRUG WAS APPROVED FOR 1830 01:19:55,589 --> 01:19:58,693 INFECTED THERAPIES TWO YEARS 1831 01:19:58,693 --> 01:20:01,028 AGO FOR SIX-MONTH THERAPIES. 1832 01:20:01,028 --> 01:20:02,430 SO MAYBE, I'LL FINISH THE 1833 01:20:02,430 --> 01:20:03,597 SCIENCE PART BY TELLING YOU 1834 01:20:03,597 --> 01:20:06,334 THAT WE'RE STILL VERY EXCITED 1835 01:20:06,334 --> 01:20:08,402 ABOUT CAPSID RESEARCH, ONE OF 1836 01:20:08,402 --> 01:20:12,473 THE BREAKTHROUGH THAT'S WE HAVE 1837 01:20:12,473 --> 01:20:17,211 MADE TOGETHER WITH OWEN LAB WE 1838 01:20:17,211 --> 01:20:23,351 CAN NOW PURIFY CAPSID AND MAKE 1839 01:20:23,351 --> 01:20:24,485 THEM HOMOGENEOUS PURE, WE DON'T 1840 01:20:24,485 --> 01:20:28,189 HAVE TO LOOK AT LOOK AT ONE 1841 01:20:28,189 --> 01:20:30,725 VIRUS INFECTING A SINGLE CELL. 1842 01:20:30,725 --> 01:20:32,159 AND I HAVE TO SAY THAT THE 1843 01:20:32,159 --> 01:20:34,662 FIELD IS VERY ACTIVE, MAKING 1844 01:20:34,662 --> 01:20:36,063 REALLY IMPORTANT CONTRIBUTIONS. 1845 01:20:36,063 --> 01:20:39,233 AND THESE PURE CAPSIDS HAVE 1846 01:20:39,233 --> 01:20:40,835 EXACTLY THE PROTEIN CONTENT 1847 01:20:40,835 --> 01:20:42,503 THAT YOU WOULD EXPECT SO 1848 01:20:42,503 --> 01:20:49,677 THEY'RE PURE AND THEY'RE 1849 01:20:49,677 --> 01:20:51,379 BIOLOGICALLY ACTIVE. 1850 01:20:51,379 --> 01:20:53,647 YOU MAY HAVE HEARD THERE IS 1851 01:20:53,647 --> 01:20:56,384 BEEN A REVOLUTION IN WHICH WHAT 1852 01:20:56,384 --> 01:21:04,158 IS CALLED CRIO YEM CAN NOW 1853 01:21:04,158 --> 01:21:05,426 DETERMINE STRUCTURES. 1854 01:21:05,426 --> 01:21:10,297 WE CAN USE CRYOEM TO LOOK AT 1855 01:21:10,297 --> 01:21:13,000 THE STRUCTURES. 1856 01:21:13,000 --> 01:21:15,536 AT OUR LABORATORY HERE IN 1857 01:21:15,536 --> 01:21:16,170 UNIVERSITY OF UTAH. 1858 01:21:16,170 --> 01:21:18,105 YOU CAN LOOK AT FREE PARTICLES 1859 01:21:18,105 --> 01:21:21,275 AND IF THEY TREAT THEM WITH 1860 01:21:21,275 --> 01:21:22,176 LENACAPAVIR THE INTERESTING 1861 01:21:22,176 --> 01:21:24,078 THING THAT HAPPENS IS THE 1862 01:21:24,078 --> 01:21:25,479 LATTICE BECOMES MORE RIGID, YOU 1863 01:21:25,479 --> 01:21:27,415 CAN SEE IT'S MORE ANGULAR AND 1864 01:21:27,415 --> 01:21:30,051 THE SIZE OF THE PENTMER ARE 1865 01:21:30,051 --> 01:21:30,785 EJECTED. 1866 01:21:30,785 --> 01:21:32,620 AND WE THINK THAT THIS IS 1867 01:21:32,620 --> 01:21:36,123 PROBABLY THE WAY IN WHICH 1868 01:21:36,123 --> 01:21:37,124 LENACAPAVIR WORKS. 1869 01:21:37,124 --> 01:21:39,860 THIS SAYS THAT IT'S POSSIBLE TO 1870 01:21:39,860 --> 01:21:43,731 SEE THE INDIVIDUAL CA HEXMERS 1871 01:21:43,731 --> 01:21:44,532 AND THE BINDING SITES FOR THE 1872 01:21:44,532 --> 01:21:45,132 DRUGS. 1873 01:21:45,132 --> 01:21:46,534 YOU CAN SEE THAT THE DENSITY 1874 01:21:46,534 --> 01:21:48,369 MATCHED WITH THE LENACAPAVIR. 1875 01:21:48,369 --> 01:21:52,073 SO NOW WE CAN TAKE AUTHENTIC 1876 01:21:52,073 --> 01:21:53,908 VIRUS BIND DRUG TO THEM AND SEE 1877 01:21:53,908 --> 01:21:55,042 WHAT THE AFFECTS ARE. 1878 01:21:55,042 --> 01:21:58,245 AT THE SAME TIME, MY LAB HAS 1879 01:21:58,245 --> 01:22:00,114 BEEN, I DON'T WANT TO GO 1880 01:22:00,114 --> 01:22:01,949 THROUGH ALL OF THESE, BUT MY 1881 01:22:01,949 --> 01:22:03,884 LAB HAS BEEN WORKING ON 1882 01:22:03,884 --> 01:22:04,518 PURIFYING THESE PARTICLES. 1883 01:22:04,518 --> 01:22:07,688 WE CAN DO THAT, WE CAN TAKE 1884 01:22:07,688 --> 01:22:09,957 ADVANTAGE OF DISCOVERIES BY LEO 1885 01:22:09,957 --> 01:22:13,160 AND OWEN THAT A SMALL MOLECULE 1886 01:22:13,160 --> 01:22:14,295 WILL STABILIZE THE CORES AND 1887 01:22:14,295 --> 01:22:17,298 NOW WE CAN DO BIOCHEMISTRY ON 1888 01:22:17,298 --> 01:22:17,765 THEM. 1889 01:22:17,765 --> 01:22:21,035 AND IF WE ADD THE M.P. Ts, THEY 1890 01:22:21,035 --> 01:22:25,840 WILL GO AHEAD AND REPLICATE THE. 1891 01:22:25,840 --> 01:22:29,510 NOW WE CAN MAKE FULL DNA JUST 1892 01:22:29,510 --> 01:22:31,178 AS THE VIRUS WOULD DO IT BUT 1893 01:22:31,178 --> 01:22:32,880 NOW WE'RE DOING IT IN BULK AND 1894 01:22:32,880 --> 01:22:34,949 WE CAN DO THAT AT HIGH 1895 01:22:34,949 --> 01:22:38,385 EFFICIENCY AND IF WE GIVE A 1896 01:22:38,385 --> 01:22:40,020 PLASMA DNA THEN THE VIRUS WILL 1897 01:22:40,020 --> 01:22:41,622 GO AHEAD AND INTEGRATE. 1898 01:22:41,622 --> 01:22:46,660 SO NOW WE CAN DO A FEW STEPS 1899 01:22:46,660 --> 01:22:50,998 WITH PURE HOMOGENEOUS REAGENTS 1900 01:22:50,998 --> 01:22:53,501 SO WE'RE EXCITED ABOUT WATCHING 1901 01:22:53,501 --> 01:22:55,102 THE AND UNDERSTANDING THEM MUCH 1902 01:22:55,102 --> 01:22:56,704 BETTER THAN WE CURRENTLY DO. 1903 01:22:56,704 --> 01:22:59,039 I THOUGHT I WOULD FINISH WITH A 1904 01:22:59,039 --> 01:23:00,875 PERSONAL NOTE OF THANKS AND 1905 01:23:00,875 --> 01:23:02,977 TELL YOU BY MY OWN JOURNEY. 1906 01:23:02,977 --> 01:23:07,815 I STARTED OUR LAB IN 19922 1907 01:23:07,815 --> 01:23:12,019 --1991, --1992 AT THE 1908 01:23:12,019 --> 01:23:13,387 UNIVERSITY OF UTAH, I REALIZES 1909 01:23:13,387 --> 01:23:15,456 THAT I WAS NOT SURE WHAT OUR 1910 01:23:15,456 --> 01:23:16,290 LAB SHOULD WORK ON. 1911 01:23:16,290 --> 01:23:18,159 SO I ASKED FOR A LITTLE BIT OF 1912 01:23:18,159 --> 01:23:20,661 EXTRA TIME BEFORE REPORTING FOR 1913 01:23:20,661 --> 01:23:22,329 DUTY TO THINK ABOUT WHAT WE 1914 01:23:22,329 --> 01:23:23,631 SHOULD WORK ON. 1915 01:23:23,631 --> 01:23:26,867 AND WE WERE FORTUNATE TO BE 1916 01:23:26,867 --> 01:23:30,738 DOWN THE HALL FROM A GOOD HIV 1917 01:23:30,738 --> 01:23:31,038 LAB. 1918 01:23:31,038 --> 01:23:34,041 AND I DECIDED THAT OUR NEW LAB 1919 01:23:34,041 --> 01:23:37,311 WAS GOING TO WORK ON HIV BUT IT 1920 01:23:37,311 --> 01:23:39,446 DIDN'T MAKE SENSE FOR A NEW 1921 01:23:39,446 --> 01:23:45,352 PROFESSOR TO WORK ON THE 'EM 1922 01:23:45,352 --> 01:23:47,288 ENZYMES, THERE WAS ALSO A 1923 01:23:47,288 --> 01:23:48,088 STRATEGY. 1924 01:23:48,088 --> 01:23:50,658 SO WE DECIDE TODAY WORK ON HIV 1925 01:23:50,658 --> 01:23:51,559 ASSEMBLY. 1926 01:23:51,559 --> 01:23:55,496 WE START TODAY GENERATE 1927 01:23:55,496 --> 01:23:57,965 PRELIMINARY DATA AND THREE 1928 01:23:57,965 --> 01:23:59,800 YEARS LATER, I SUBMITTED MY 1929 01:23:59,800 --> 01:24:04,138 FIRST GRANT AND IT GOT TRIAAGED. 1930 01:24:04,138 --> 01:24:07,341 THE FUNDING WAS LOW AND I TOLD 1931 01:24:07,341 --> 01:24:11,645 MY GROUP, WE HAVE TO DO 60 1932 01:24:11,645 --> 01:24:12,780 PERCENTILE BETTER. 1933 01:24:12,780 --> 01:24:14,582 BUT UNFORTUNATELY WE FIGURED 1934 01:24:14,582 --> 01:24:19,186 OUT HOW TO WRITE SUCCESSFUL 1935 01:24:19,186 --> 01:24:20,821 R.O.GRANTS WHICH HAS BEEN 1936 01:24:20,821 --> 01:24:22,423 CRITICAL FOR OUR LAB AND WE'VE 1937 01:24:22,423 --> 01:24:24,258 HAD GREAT PROGRAM OFFICERS LIKE 1938 01:24:24,258 --> 01:24:25,759 CARL AND LEA AND OTHERS ALONG 1939 01:24:25,759 --> 01:24:28,862 THE WAY. 1940 01:24:28,862 --> 01:24:35,436 SO IN 2002, NI G.M. S DECIDE 1941 01:24:35,436 --> 01:24:37,104 TODAY APPLY FOR A PROGRAM AND 1942 01:24:37,104 --> 01:24:40,975 WE APPLIED ON ASSEMBLY AND WE 1943 01:24:40,975 --> 01:24:42,610 DID THAT AND THAT WAS REALLY 1944 01:24:42,610 --> 01:24:46,947 IMPORTANT FOR US BECAUSE WE CAN 1945 01:24:46,947 --> 01:24:49,683 ADD GRAN JOHNSON, MICHAEL K WHO 1946 01:24:49,683 --> 01:24:52,419 WORKS ON ENTRY AND IS A CHEMIST 1947 01:24:52,419 --> 01:24:57,925 SO THAT MEANS WE CAN TACKLE 1948 01:24:57,925 --> 01:24:59,760 PROBLEMS MORE BROADLY. 1949 01:24:59,760 --> 01:25:07,735 IN 2007 THEY TURNED IT INTO A P 1950 01:25:07,735 --> 01:25:10,337 5 PROGRAMS SO NOW WE CAN ADD 1951 01:25:10,337 --> 01:25:13,340 PEOPLE DOING REAL VIROLOGY THAT 1952 01:25:13,340 --> 01:25:15,909 WAS AN EXCITED TIME BECAUSE WE 1953 01:25:15,909 --> 01:25:17,311 CAN TACKLE PROBLEMS FROM THE 1954 01:25:17,311 --> 01:25:18,679 BEGINNING TO THE END. 1955 01:25:18,679 --> 01:25:23,450 AND AS YOU MAY KNOW, IN 2019, 1956 01:25:23,450 --> 01:25:26,053 THAT PROGRAM MOVED IT'S NOW THE 1957 01:25:26,053 --> 01:25:28,055 U54 PROGRAM. 1958 01:25:28,055 --> 01:25:29,790 ART CENTER HAS CONTINUED TO 1959 01:25:29,790 --> 01:25:31,392 GROW AND THIS REPRESENTS THE 1960 01:25:31,392 --> 01:25:35,863 FACT THAT WE'RE NOW IN NIAID 1961 01:25:35,863 --> 01:25:38,198 WE'VE GROWN AND ALSO TACKLED 1962 01:25:38,198 --> 01:25:39,133 SOME ADDITIONAL PROBLEM 1963 01:25:39,133 --> 01:25:41,235 ESPECIALLY IN VIRAL DYNAMICS. 1964 01:25:41,235 --> 01:25:43,337 SO WE NOW HAVE PEOPLE WORKING 1965 01:25:43,337 --> 01:25:44,271 ON LIVING MODEL SYSTEMS AND 1966 01:25:44,271 --> 01:25:46,407 LOOKING AT THE TRANSMISSION AND 1967 01:25:46,407 --> 01:25:49,276 REBOUND OF THE VIRUS. 1968 01:25:49,276 --> 01:25:56,250 SO, DURING THE NI G.M. S DAYS, 1969 01:25:56,250 --> 01:25:58,819 THE PROGRAM WAS RUN BY DAVE AND 1970 01:25:58,819 --> 01:26:02,690 I WANT TO THANK THEM. 1971 01:26:02,690 --> 01:26:05,626 SO DAVE McDONALD IS OUR PROGRAM 1972 01:26:05,626 --> 01:26:08,595 MANAGER, HE'S A VIROLOGIST SO 1973 01:26:08,595 --> 01:26:10,030 HE SPEAKS OUR LANGUAGE, HE 1974 01:26:10,030 --> 01:26:12,299 COMES TO ALL OF OUR VIDEO 1975 01:26:12,299 --> 01:26:14,368 CONFERENCE SXZ MAKES GREAT 1976 01:26:14,368 --> 01:26:15,536 SUGGESTIONS ESPECIALLY HOW WE 1977 01:26:15,536 --> 01:26:17,871 CAN CONNECT TO THERAPEUTIC 1978 01:26:17,871 --> 01:26:18,505 CONVERSATIONS. 1979 01:26:18,505 --> 01:26:20,341 I WANT TO THANK CARL BEINGER 1980 01:26:20,341 --> 01:26:26,647 HE'S HERE, HE'S THE DIRECTOR OF 1981 01:26:26,647 --> 01:26:27,881 DAIDS. 1982 01:26:27,881 --> 01:26:31,118 ABOUT A YEAR AGO, I GOT A CALL 1983 01:26:31,118 --> 01:26:33,921 AND HE ASKED IF I WOULD WRITE A 1984 01:26:33,921 --> 01:26:35,489 LETTER OF REFERENCE. 1985 01:26:35,489 --> 01:26:37,324 SO I WAS TOUCHED AND DID IT. 1986 01:26:37,324 --> 01:26:38,892 IN SPITE OF THAT, HE GOT THE 1987 01:26:38,892 --> 01:26:40,661 JOB AND I THINK HE'S BEEN A 1988 01:26:40,661 --> 01:26:41,495 GREAT DIRECTOR. 1989 01:26:41,495 --> 01:26:44,965 AND THEN I WANT TO THANK LAST 1990 01:26:44,965 --> 01:26:49,336 BUT NOT CERTAINLY LEAST, DIA 1991 01:26:49,336 --> 01:26:51,972 NA, AS YOU HEARD, SHE IS 1992 01:26:51,972 --> 01:26:54,708 RETURNING, FORTUNATE FOR US, TO 1993 01:26:54,708 --> 01:26:56,076 HER PREVIOUS POSITION AND SHE 1994 01:26:56,076 --> 01:27:00,581 HAS BEEN A CHAMPION. 1995 01:27:00,581 --> 01:27:02,850 FOR EXAMPLE WHEN OUR CENTERS 1996 01:27:02,850 --> 01:27:04,918 START TODAY GET TOGETHER, WE 1997 01:27:04,918 --> 01:27:06,754 HELD EVENING MEETINGS AND SHE 1998 01:27:06,754 --> 01:27:09,723 WENT TO ALL MEETINGS AND MADE 1999 01:27:09,723 --> 01:27:11,525 GREAT CONNECTING SUGGESTIONS. 2000 01:27:11,525 --> 01:27:13,360 SHE'S THE FIRST THAT TOLD ME 2001 01:27:13,360 --> 01:27:17,464 ABOUT THE AIDS--PROGRAM SO 2002 01:27:17,464 --> 01:27:19,066 THANKS TO DIA NA. 2003 01:27:19,066 --> 01:27:21,635 I WANT TO EMPHASIZE WHAT GERRY 2004 01:27:21,635 --> 01:27:24,605 SAID AT THE BEGINNING, THIS IS 2005 01:27:24,605 --> 01:27:26,640 BEEN I LONG JOURNEY AND WE 2006 01:27:26,640 --> 01:27:27,941 COULD NOT HAVE DONE IT WITHOUT 2007 01:27:27,941 --> 01:27:31,044 THIS SUPPORT. 2008 01:27:31,044 --> 01:27:33,347 SO DIANA SAID, I COULD MAKE 2009 01:27:33,347 --> 01:27:33,680 SOME OPINIONS. 2010 01:27:33,680 --> 01:27:35,883 I THOUGHT I WOULD MAKE FIVE 2011 01:27:35,883 --> 01:27:39,753 SCIENTIFIC POINTS AND FIVE 2012 01:27:39,753 --> 01:27:41,288 QUICK SORT OF POINTS ON POLICY. 2013 01:27:41,288 --> 01:27:43,190 SO ONE OF THE THINGS I THINK 2014 01:27:43,190 --> 01:27:44,324 WE'VE LEARNED THROUGH OUR WORK 2015 01:27:44,324 --> 01:27:51,832 AND OTHERS, IS THAT NATURE 2016 01:27:51,832 --> 01:27:54,334 COMPARTMENTALIZED, IT HAPPENS 2017 01:27:54,334 --> 01:27:55,702 WITHIN THE CAPSID. 2018 01:27:55,702 --> 01:27:57,371 SO THE VIRUS WANTS TO KEEP ALL 2019 01:27:57,371 --> 01:28:02,376 THE 'EM SIGNS TOGETHER WITH THE 2020 01:28:02,376 --> 01:28:04,678 GENENON AND USE THE CAPSID TO 2021 01:28:04,678 --> 01:28:07,414 CAT LIES THE STAGE OF 2022 01:28:07,414 --> 01:28:08,816 REPLICATION SO WE'RE ACTIVELY 2023 01:28:08,816 --> 01:28:09,950 TRYING TO UNDERSTAND THAT. 2024 01:28:09,950 --> 01:28:14,121 AND THIS IS TRUE, MOST VIRUSES 2025 01:28:14,121 --> 01:28:15,489 BUILD VIRAL REPLICATION 2026 01:28:15,489 --> 01:28:16,123 FACTORIES THAT HOLD EVERYTHING 2027 01:28:16,123 --> 01:28:16,657 TOGETHER. 2028 01:28:16,657 --> 01:28:19,393 ONE OF THE SURPRISES HAS BEEN 2029 01:28:19,393 --> 01:28:24,231 THAT VIRAL CAPSID HAVE BEEN 2030 01:28:24,231 --> 01:28:25,032 GENICKLY FRAGILE. 2031 01:28:25,032 --> 01:28:28,435 SO WHEN THE WORK STARTED EVERY 2032 01:28:28,435 --> 01:28:30,671 ONE THOUGHT OF THE CAPSID AS A 2033 01:28:30,671 --> 01:28:32,473 ROCK AND PURE DRUG TARGET 2034 01:28:32,473 --> 01:28:34,842 BECAUSE THEY HAD TO HIT IT WITH 2035 01:28:34,842 --> 01:28:35,976 MULTIPLE DRUGS. 2036 01:28:35,976 --> 01:28:37,778 AND WHAT WE NOW KNOW IS THAT AT 2037 01:28:37,778 --> 01:28:40,981 LEAST IN THE CASE OF HIV, THE 2038 01:28:40,981 --> 01:28:42,850 CAPSID IS VERY FRAGILE. 2039 01:28:42,850 --> 01:28:44,685 AND I THINK BECAUSE THE CA 2040 01:28:44,685 --> 01:28:46,119 PROTEIN HAS TO DO SO MANY 2041 01:28:46,119 --> 01:28:47,955 THINGS AS I EMPHASIZED. 2042 01:28:47,955 --> 01:28:50,257 BUT ALSO BECAUSE THE CAPSID IS 2043 01:28:50,257 --> 01:28:52,259 SORT OF ENERGETICKLY BALANCED. 2044 01:28:52,259 --> 01:28:54,928 IT HAS TO ASSEMBLE INTO A 2045 01:28:54,928 --> 01:28:58,232 CAPSID BUT THEN DIS ASSEMBLE TO 2046 01:28:58,232 --> 01:29:00,000 REVERSE DNA AND THAT MEANS IT 2047 01:29:00,000 --> 01:29:02,269 DOES NOT HAVE MUCH MARGIN FOR 2048 01:29:02,269 --> 01:29:03,203 ERROR. 2049 01:29:03,203 --> 01:29:05,739 MANY OF YOU WILL KNOW THAT DRUG 2050 01:29:05,739 --> 01:29:08,976 COMPANIES HAVE SHYED AWAY FROM 2051 01:29:08,976 --> 01:29:10,143 PROTEIN PROTEIN INTERACTIONS 2052 01:29:10,143 --> 01:29:12,713 BUT THAT'S WHAT LENACAPAVIR 2053 01:29:12,713 --> 01:29:15,816 TARGETS. 2054 01:29:15,816 --> 01:29:17,885 AND THEY DESERVE CREDIT THAT 2055 01:29:17,885 --> 01:29:20,153 THIS IS A CASE BY CASE BASIS. 2056 01:29:20,153 --> 01:29:22,956 IF YOU HAVE A DEEP CONSERVE 2057 01:29:22,956 --> 01:29:25,292 POCKET THAT PROTEIN PROTEIN 2058 01:29:25,292 --> 01:29:29,863 INTERACTION CAN BE JUST AS GOOD 2059 01:29:29,863 --> 01:29:36,837 AS ENZYME IN TERMS OF 2060 01:29:36,837 --> 01:29:37,604 INHIBATION. 2061 01:29:37,604 --> 01:29:39,439 I'VE BEEN A CONSULTANT FOR 2062 01:29:39,439 --> 01:29:40,607 SEVERAL DRUG COMPANIES AND 2063 01:29:40,607 --> 01:29:44,278 OFTEN TIME WHEN THEY IDENTIFY A 2064 01:29:44,278 --> 01:29:47,247 DRUG SCAFFOLD AND IT'S 2065 01:29:47,247 --> 01:29:49,550 INSOLUBLE, THEY THROW THAT AWAY 2066 01:29:49,550 --> 01:29:52,052 AND THAT'S BECAUSE IF YOU NEED 2067 01:29:52,052 --> 01:29:53,287 AN ACUTE NEED FOR DRUG, YOU 2068 01:29:53,287 --> 01:30:00,661 WANT IT TO BE SOLUBLE. 2069 01:30:00,661 --> 01:30:03,430 BUT LENACAPAVIR IS SLOWLY 2070 01:30:03,430 --> 01:30:04,798 LEECHES OUT AND THAT MEANS THAT 2071 01:30:04,798 --> 01:30:06,667 IT CAN LAST FOR SIX MONTHS. 2072 01:30:06,667 --> 01:30:08,535 BUT THAT ALSO REQUIRES THAT IT 2073 01:30:08,535 --> 01:30:12,205 BE A VERY POTENT INHIBITOR AND 2074 01:30:12,205 --> 01:30:13,340 THAT CREDIT THAT THEY'VE BEEN 2075 01:30:13,340 --> 01:30:16,743 ABLE TO MAKE SUCH POTENT 2076 01:30:16,743 --> 01:30:18,145 INHIBITOR. 2077 01:30:18,145 --> 01:30:19,846 BUT THIS IS A BENEFIT NOT A 2078 01:30:19,846 --> 01:30:21,148 PROBLEM. 2079 01:30:21,148 --> 01:30:27,754 AND FINALLY, NO ONE SHOULD 2080 01:30:27,754 --> 01:30:28,255 UNDERESTIMATE THE HUMAN 2081 01:30:28,255 --> 01:30:29,156 BEHAVIOR. 2082 01:30:29,156 --> 01:30:32,593 I DID NOT TALK ABOUT IT A LOT 2083 01:30:32,593 --> 01:30:38,265 BUT IT WORKS WELL WHEN PEOPLE 2084 01:30:38,265 --> 01:30:40,767 ARE ADHERENT BUT IN OTHER 2085 01:30:40,767 --> 01:30:42,569 COUNTRIES, PEOPLE BECOME NON 2086 01:30:42,569 --> 01:30:43,737 COMPLIANT. 2087 01:30:43,737 --> 01:30:45,606 IN STUDIES IT TURNED OUT AFTER 2088 01:30:45,606 --> 01:30:47,007 SIX MONTHS THAT 80 PERCENT OF 2089 01:30:47,007 --> 01:30:49,109 THE PEOPLE DIDN'T HAVE THE DRUG 2090 01:30:49,109 --> 01:30:50,844 IN THEIR SYSTEM. 2091 01:30:50,844 --> 01:30:54,181 AND SO WHAT SORT OF MAGIC OF 2092 01:30:54,181 --> 01:30:55,816 LENACAPAVIR IT ENFORCES GOOD 2093 01:30:55,816 --> 01:30:56,984 BEHAVIORLE YOU GET ONE 2094 01:30:56,984 --> 01:30:58,719 INJECTION AND IT LAST FOR SIX 2095 01:30:58,719 --> 01:30:59,786 MONTHS. 2096 01:30:59,786 --> 01:31:01,288 SO THAT'S TURNED OUT TO BE VERY 2097 01:31:01,288 --> 01:31:03,423 IMPORTANT. 2098 01:31:03,423 --> 01:31:05,792 THEN, IN SCIENTIFIC TERMS, I 2099 01:31:05,792 --> 01:31:08,095 WANT TO EMPHASIZE THAT LONG 2100 01:31:08,095 --> 01:31:09,930 TERM AND FINANCIAL SUPPORT WERE 2101 01:31:09,930 --> 01:31:11,098 CRITICAL, YOU KNOW WE'VE BEEN 2102 01:31:11,098 --> 01:31:12,966 DOING THIS FOR 30 YEARS AND IT 2103 01:31:12,966 --> 01:31:16,236 WAS REALLY IMPORTANT FOR US TO 2104 01:31:16,236 --> 01:31:17,838 GET CONSISTENT FUNDING AND ALSO 2105 01:31:17,838 --> 01:31:20,807 SUPPORT AS I SAID, WE 2106 01:31:20,807 --> 01:31:21,675 APPRECIATE THE NIH PROGRAM 2107 01:31:21,675 --> 01:31:23,543 SUPPORT. 2108 01:31:23,543 --> 01:31:25,379 SO, I GUESS IT WOULDN'T 2109 01:31:25,379 --> 01:31:27,047 SURPRISE YOU THAT I'M A FAN OF 2110 01:31:27,047 --> 01:31:27,681 BASIC SCIENCE. 2111 01:31:27,681 --> 01:31:30,017 AND I WANT TO EMPHASIZE THAT 2112 01:31:30,017 --> 01:31:32,319 DISCOVERY AND TRANSLATION AND 2113 01:31:32,319 --> 01:31:34,621 IMPLEMENTATION, THE ENTIRE 2114 01:31:34,621 --> 01:31:36,256 SPECTRUM IS CRITICALLY 2115 01:31:36,256 --> 01:31:37,190 IMPORTANT, I TRULY BELIEVE THAT. 2116 01:31:37,190 --> 01:31:42,562 BUT I THINK THAT WE SOMETIMES 2117 01:31:42,562 --> 01:31:43,330 UNDERESTIMATE UNDERSTANDING HOW 2118 01:31:43,330 --> 01:31:43,964 SYSTEMS WORK. 2119 01:31:43,964 --> 01:31:45,832 SO I THINK IT WOULD NOT HAVE 2120 01:31:45,832 --> 01:31:47,434 BEEN EXPECTED THAT THE CAPSID 2121 01:31:47,434 --> 01:31:50,070 WOULD BE A GOOD DRUG TARGET AT 2122 01:31:50,070 --> 01:31:51,838 THE BEGINNING OF THIS JOURNEY 2123 01:31:51,838 --> 01:31:54,508 AND OTHER EVEN BETTER EXAMPLES 2124 01:31:54,508 --> 01:31:55,275 THROUGHOUT BIOLOGY. 2125 01:31:55,275 --> 01:31:59,579 SO AS YOU KNOW, THE INITIAL 2126 01:31:59,579 --> 01:32:01,882 INNATE IMMUNE STUDIES THAT LEAD 2127 01:32:01,882 --> 01:32:05,085 TO THE MRNA VACCINES THAT IS 2128 01:32:05,085 --> 01:32:09,056 TAKING OVER AND REVOLUTIONIZING 2129 01:32:09,056 --> 01:32:09,790 VACCINE DEVELOPMENT, THE SAME 2130 01:32:09,790 --> 01:32:13,794 IS TRUE FOR THE CRISPER 9 2131 01:32:13,794 --> 01:32:15,862 SYSTEM THAT BEGAN AS BASIC 2132 01:32:15,862 --> 01:32:18,832 STUDIES OF BACTERIAL DEFENSE 2133 01:32:18,832 --> 01:32:22,636 SYMPTOMS AND IT'S NOW GOING TO 2134 01:32:22,636 --> 01:32:23,804 REVOLUTIONIZE GENERALITY I CAN 2135 01:32:23,804 --> 01:32:24,638 MEDICINE. 2136 01:32:24,638 --> 01:32:27,874 ON TIMES WE CANNOT PREDICT BUT 2137 01:32:27,874 --> 01:32:29,176 ALMOST ALWAYS TURNED OUT TO BE 2138 01:32:29,176 --> 01:32:32,379 IMPORTANT TO UNDERSTAND IN 2139 01:32:32,379 --> 01:32:42,689 MONTH --MOL ELAR. 2140 01:32:45,726 --> 01:32:51,998 IT CAN BE PAINFUL TO WATCH LABS 2141 01:32:51,998 --> 01:32:54,334 TRY TO DEVELOP INHIBITORS. 2142 01:32:54,334 --> 01:32:56,703 THAT'S TO SAY NOTHING OF 2143 01:32:56,703 --> 01:33:07,047 PRECLINICAL TRIALS. 2144 01:33:09,516 --> 01:33:12,452 BUT I BELIEVE IN THE ACADEMIC 2145 01:33:12,452 --> 01:33:13,153 INDUSTRY. 2146 01:33:13,153 --> 01:33:14,755 PEOPLE SHOULD DO WHAT THEY DO 2147 01:33:14,755 --> 01:33:16,590 WELL AND NOT SURPRISINGLY, I 2148 01:33:16,590 --> 01:33:19,760 THINK THE TWO GROUPS HAVE GREAT 2149 01:33:19,760 --> 01:33:21,828 RESPECT FOR EACH OTHER. 2150 01:33:21,828 --> 01:33:23,864 ONE OF THE THAINGZ WE LEARNED 2151 01:33:23,864 --> 01:33:27,834 IS PROGRAM I CAN SCIENCE CAN BE. 2152 01:33:27,834 --> 01:33:31,505 IF YOU PUT TWO TEAMS IN THE 2153 01:33:31,505 --> 01:33:33,807 SAME ROOM, THEY SHOULD BE ABLE 2154 01:33:33,807 --> 01:33:34,741 TO TACKLE PROBLEM IN DIFFERENT 2155 01:33:34,741 --> 01:33:35,208 WAYS. 2156 01:33:35,208 --> 01:33:42,282 I BELIEVE THAT SCIENTIST HAVE A 2157 01:33:42,282 --> 01:33:44,151 BASIC NEED THAT THEY FEEL LIKE 2158 01:33:44,151 --> 01:33:46,920 THEY'RE IN THE SAME TEAM THAT'S 2159 01:33:46,920 --> 01:33:49,623 THE GREAT THING ABOUT THE UB54 2160 01:33:49,623 --> 01:33:51,291 PROGRAM. 2161 01:33:51,291 --> 01:33:52,692 AND MAYBE CONTROVERSIAL, I 2162 01:33:52,692 --> 01:33:55,195 THOUGH I I BELIEVE IN TEAM 2163 01:33:55,195 --> 01:33:58,398 SCIENCE WE HAVE TO BE CAREFUL 2164 01:33:58,398 --> 01:34:00,000 OF SCALING IT CORRECTLY. 2165 01:34:00,000 --> 01:34:02,969 IF WE UNDERSTAND, THEN IT CAN 2166 01:34:02,969 --> 01:34:05,005 MAKE SENSE TO HAVE LARGE TEAMS. 2167 01:34:05,005 --> 01:34:07,140 BUT WHEN WE DON'T, SOME OF THE 2168 01:34:07,140 --> 01:34:10,010 SECRET SAUCE OF THE U54 PROGRAM 2169 01:34:10,010 --> 01:34:12,078 IS THAT WE HAVE SIX DIFFERENT 2170 01:34:12,078 --> 01:34:13,280 PROGRAMS AND WE'RE ALL BIG 2171 01:34:13,280 --> 01:34:16,016 ENOUGH TO MAKE A DIFFERENCE WE 2172 01:34:16,016 --> 01:34:17,617 OFTEN WORK TOGETHER BUT 2173 01:34:17,617 --> 01:34:20,187 SOMETIMES COMPETE AND TACKLING 2174 01:34:20,187 --> 01:34:22,055 PROBLEM FRZ DIFFERENT ANGLES 2175 01:34:22,055 --> 01:34:23,223 AND THAT'S IMPORTANT FOR THE 2176 01:34:23,223 --> 01:34:24,357 STATE OF OUR UNDERSTANDING. 2177 01:34:24,357 --> 01:34:27,828 SO I'M GOING TO FINISH BY THANK 2178 01:34:27,828 --> 01:34:30,831 WE'VE HAD AMAZING COLLABORATE 2179 01:34:30,831 --> 01:34:32,699 ORS, I TRIED TO MENTION MANY OF 2180 01:34:32,699 --> 01:34:34,034 THEM. 2181 01:34:34,034 --> 01:34:41,508 WE'VE HAD THIS GREAT 2182 01:34:41,508 --> 01:34:42,876 RELATIONSHIP WITH GELIAD, TOM 2183 01:34:42,876 --> 01:34:44,911 ADD ME TO CALL THE GROUP, THE 2184 01:34:44,911 --> 01:34:50,617 GIL YAT TEAM AND THEY DESERVE A 2185 01:34:50,617 --> 01:34:52,419 LOT OF CREDIT FOR DEVELOPING 2186 01:34:52,419 --> 01:34:52,919 LENACAPAVIR. 2187 01:34:52,919 --> 01:34:54,554 I WANT TO ACKNOWLEDGE OUR 2188 01:34:54,554 --> 01:34:57,557 SUPPORT AS THE CHEETAH CENTER 2189 01:34:57,557 --> 01:35:05,932 FROM THE DADES U54 PROGRAM. 2190 01:35:05,932 --> 01:35:09,736 THIS IS THE UNIVERSITY OF UTAH 2191 01:35:09,736 --> 01:35:10,871 HEALTH SCIENCES CENTER. 2192 01:35:10,871 --> 01:35:13,139 I'M SITTING IN THAT BUILDING 2193 01:35:13,139 --> 01:35:15,208 RIGHT THERE TALKING TO YOU. 2194 01:35:15,208 --> 01:35:18,178 THAT'S MY HOUSE, SO I COME UP 2195 01:35:18,178 --> 01:35:20,680 EVERY MORNING A HILL AND I GET 2196 01:35:20,680 --> 01:35:22,382 TO SEE THE MOUNTAINS IN FRONT 2197 01:35:22,382 --> 01:35:23,917 OF ME WHICH I FIND INSPIRING 2198 01:35:23,917 --> 01:35:25,552 AND ALL OF THESE PEOPLE 2199 01:35:25,552 --> 01:35:26,253 INSPIRING AS WELL. 2200 01:35:26,253 --> 01:35:28,321 SO THANKS TO THEM FOR THEIR 2201 01:35:28,321 --> 01:35:29,489 CONTRIBUTIONS AND THANKS TO YOU 2202 01:35:29,489 --> 01:35:30,690 FOR YOUR ATTENTION. 2203 01:35:30,690 --> 01:35:35,595 I'M HAPPY TO TAKE QUESTIONS. 2204 01:35:35,595 --> 01:35:41,101 >> THANK YOU, DR. SUNQUIST FOR 2205 01:35:41,101 --> 01:35:42,002 THAT FASCINATING PRESENTATION. 2206 01:35:42,002 --> 01:35:47,540 I SEE WE HAVE A FEW QUESTIONS. 2207 01:35:47,540 --> 01:35:48,642 DR. KNEELAND I SEE YOUR HAND 2208 01:35:48,642 --> 01:35:49,376 FIRS 2209 01:35:49,376 --> 01:35:51,411 >> THANK YOU DR. SUNQUIST FOR 2210 01:35:51,411 --> 01:35:55,949 COMING IN AND SPEAKING TO US 2211 01:35:55,949 --> 01:35:58,251 TODAY AND THE WORK OF SO MANY 2212 01:35:58,251 --> 01:36:01,454 PEOPLE I LOST COUNT AFTER 20 2213 01:36:01,454 --> 01:36:03,723 CONTRIBUTED TO THE STUDY OF 2214 01:36:03,723 --> 01:36:05,859 LENACAPAVIR AND THE STUDIES YOU 2215 01:36:05,859 --> 01:36:09,763 SHOWED WITH ZERO HIV INFECTIONS 2216 01:36:09,763 --> 01:36:11,131 THAT THAT PREVENTION STUDY. 2217 01:36:11,131 --> 01:36:12,165 SO I HAVE A COMMENT AND A 2218 01:36:12,165 --> 01:36:14,834 QUESTION. 2219 01:36:14,834 --> 01:36:17,404 HIV PRICES ARE A MAJOR BARRIER 2220 01:36:17,404 --> 01:36:19,906 TO ACCESS, DAILY GENERIC, IS 2221 01:36:19,906 --> 01:36:24,511 LESS THAN 150 PER YEAR, 2222 01:36:24,511 --> 01:36:31,184 LENACAPAVIR IS 42,000 PER YEAR 2223 01:36:31,184 --> 01:36:34,220 IN U.S. 2224 01:36:34,220 --> 01:36:37,424 YOU MENTIONED, WOULDN'T CHARGE 2225 01:36:37,424 --> 01:36:42,228 GENERIC CHAMPIONS SIX OF THEM 2226 01:36:42,228 --> 01:36:43,897 TO MANUFACTURE HOPEFUL LOW AT 2227 01:36:43,897 --> 01:36:45,465 LOWER PRICES. 2228 01:36:45,465 --> 01:36:48,001 TWO EXAMPLES BUT LEN WILL NOT 2229 01:36:48,001 --> 01:36:50,070 BE AVAILABLE UNTIL 2027 SO 2230 01:36:50,070 --> 01:36:52,172 THAT'S THREE YEARS AFTER THE 2231 01:36:52,172 --> 01:36:53,073 ANNOUNCEMENT DURING WHICH TIME 2232 01:36:53,073 --> 01:36:55,375 MILLIONS WILL BE INFECTED WITH 2233 01:36:55,375 --> 01:36:56,543 HIV 2234 01:36:56,543 --> 01:36:59,079 AND SECOND MANY INTERMEDIATES 2235 01:36:59,079 --> 01:37:01,715 NECESSARY FOR THE API THAT 2236 01:37:01,715 --> 01:37:04,351 AREN'T COVERED IN THE MEETING 2237 01:37:04,351 --> 01:37:06,186 AND THOSE INGREDIENTS CAN STILL 2238 01:37:06,186 --> 01:37:09,155 BE VERY EXPENSIVE AND THE 2239 01:37:09,155 --> 01:37:10,523 COMPANIES HAVE NOT YET 2240 01:37:10,523 --> 01:37:11,424 ANNOUNCED A PRICE. 2241 01:37:11,424 --> 01:37:12,692 AND THAT'S THE COMMENT AND NOW 2242 01:37:12,692 --> 01:37:14,394 THE QUESTION. 2243 01:37:14,394 --> 01:37:15,862 YOU HAVE BRIDGED FEDERAL AND 2244 01:37:15,862 --> 01:37:16,763 PRIVATE SECTOR SUPPORT. 2245 01:37:16,763 --> 01:37:19,299 AND I GUESS I WONDER WHAT 2246 01:37:19,299 --> 01:37:21,801 SUGGESTIONS DO YOU HAVE TO NIH 2247 01:37:21,801 --> 01:37:25,705 WHERE WE CAN BOTH INCENTIVIZE 2248 01:37:25,705 --> 01:37:36,016 TO DRIVE INNOVATION. 2249 01:37:36,016 --> 01:37:38,084 AND RESULTS AND ALSO THE 2250 01:37:38,084 --> 01:37:40,153 ULTIMATE PRICE ALSO ACCOUNTS 2251 01:37:40,153 --> 01:37:40,987 FOR TAXPAYER INVESTMENT IN THE 2252 01:37:40,987 --> 01:37:43,556 PRODUCT. 2253 01:37:43,556 --> 01:37:46,993 >> YES, SO THOSE ARE OBVIOUSLY 2254 01:37:46,993 --> 01:37:48,628 VERY IMPORTANT QUESTIONS THANKS 2255 01:37:48,628 --> 01:37:49,329 FOR ASKING THEM. 2256 01:37:49,329 --> 01:37:51,431 I THINK I'LL BE CAREFUL ABOUT 2257 01:37:51,431 --> 01:37:52,332 THE POLICY QUESTIONS BECAUSE 2258 01:37:52,332 --> 01:37:54,167 I'M NOT A POLICY PERSON. 2259 01:37:54,167 --> 01:37:57,137 BUT I ACTUALLY WAS REASONABLY 2260 01:37:57,137 --> 01:38:01,007 SHOCKED AT THE TIME SCALE OF 20 2261 01:38:01,007 --> 01:38:03,543 TP WHEN IT CAME OUT SO I SHARE 2262 01:38:03,543 --> 01:38:04,711 YOUR CONCERN WITH THAT. 2263 01:38:04,711 --> 01:38:06,813 I GUESS IT LOOKS LIKE WE HAVE 2264 01:38:06,813 --> 01:38:10,016 AN AMAZING TOOL, THE POLICY AND 2265 01:38:10,016 --> 01:38:11,151 THE IMPLEMENTATION SHOULD MATCH 2266 01:38:11,151 --> 01:38:14,320 THAT TOOL IN 2027 JUST SEEMS 2267 01:38:14,320 --> 01:38:15,989 ALMOST UNACCEPTABLE TO ME, AS 2268 01:38:15,989 --> 01:38:17,323 YOU SAY, THERE IS GOING TO BE 2269 01:38:17,323 --> 01:38:19,426 MILLIONS OF PEOPLE INFECTED. 2270 01:38:19,426 --> 01:38:22,162 SO I GUESS, I DON'T FEEL 2271 01:38:22,162 --> 01:38:24,230 QUALIFIED TO SAY HOW WE SHOULD 2272 01:38:24,230 --> 01:38:26,099 CHANGE IT BUT I BELIEVE WE 2273 01:38:26,099 --> 01:38:27,033 SHOULD CHANGE IT. 2274 01:38:27,033 --> 01:38:29,536 I THINK, YOU KNOW, WE HAVE TO 2275 01:38:29,536 --> 01:38:31,805 THINK ABOUT THIS, IS IT THE 2276 01:38:31,805 --> 01:38:34,140 GATE'S FOUNDATION, THAT IS HUGE 2277 01:38:34,140 --> 01:38:38,311 NUMBERS OR I WANT TO BE CAREFUL 2278 01:38:38,311 --> 01:38:39,679 ABOUT SUGGESTING POLICY BUT 2279 01:38:39,679 --> 01:38:41,314 EVERYTHING HAS TO MOVE FAST 2280 01:38:41,314 --> 01:38:43,149 BECAUSE THESE ARE HUMAN LIVES. 2281 01:38:43,149 --> 01:38:46,119 SO I COMPLETELY AGREE WITH THAT. 2282 01:38:46,119 --> 01:38:50,056 IN TERMS OF, OF PUBLIC PRIVATE 2283 01:38:50,056 --> 01:38:53,026 PARTNERSHIPS, WE HAVE BEEN 2284 01:38:53,026 --> 01:38:58,264 ALTHOUGH I WAS A CONSULTANT FOR 2285 01:38:58,264 --> 01:39:02,102 GILADD AND THEY GAVE US SPONSOR. 2286 01:39:02,102 --> 01:39:04,170 SO IT WAS SORT OF SEMI 2287 01:39:04,170 --> 01:39:06,439 INDEPENDENT, WE WERE TALKING A 2288 01:39:06,439 --> 01:39:08,942 LOT BUT, WE DIDN'T DO THAT, AND 2289 01:39:08,942 --> 01:39:10,977 AT LEAST IN OUR CASE, THAT 2290 01:39:10,977 --> 01:39:15,949 WORKED WELL. 2291 01:39:15,949 --> 01:39:17,350 I THINK THAT WE WERE DOING WHAT 2292 01:39:17,350 --> 01:39:19,419 WE DO BEST AND WE WERE HAVING 2293 01:39:19,419 --> 01:39:20,487 FUN TALKING TO THEM AND THEY 2294 01:39:20,487 --> 01:39:23,356 WERE DOING WHAT THEY DO BEST. 2295 01:39:23,356 --> 01:39:27,026 FOR US, WE DIDN'T REALLY NEED 2296 01:39:27,026 --> 01:39:27,894 AN INCENTIVIZATION TO WORK WITH 2297 01:39:27,894 --> 01:39:28,628 THEM. 2298 01:39:28,628 --> 01:39:30,730 BUT WE DID NEED INDEPENDENT 2299 01:39:30,730 --> 01:39:33,032 FUNDING BECAUSE IF WE HADN'T 2300 01:39:33,032 --> 01:39:34,868 HAD IT, WE WOULD NOT HAVE BEEN 2301 01:39:34,868 --> 01:39:38,538 A PARTNER IF THAT MAKES SENSE. 2302 01:39:38,538 --> 01:39:39,939 I'M AWARE OF THE PROGRAM FOR 2303 01:39:39,939 --> 01:39:42,709 EXAMPLE WHERE IT'S MUCH MORE 2304 01:39:42,709 --> 01:39:43,776 INTEGRATED WITH INDUSTRY. 2305 01:39:43,776 --> 01:39:46,146 AND I GUESS, I DON'T HAVE A 2306 01:39:46,146 --> 01:39:47,780 INTELLIGENT COMMENT TO MAKE. 2307 01:39:47,780 --> 01:39:49,249 I THINK IT'S REALLY IMPORTANT 2308 01:39:49,249 --> 01:39:51,017 TO WORK WITH INDUSTRY. 2309 01:39:51,017 --> 01:39:53,119 WHEN YOU SEE HOW THEY DO 2310 01:39:53,119 --> 01:39:54,954 THINGS, IT'S IMPORTANT FOR LABS 2311 01:39:54,954 --> 01:39:56,322 TO DO THINGS. 2312 01:39:56,322 --> 01:39:58,424 BUT I FEEL LIKE I SHOULD BE 2313 01:39:58,424 --> 01:39:59,826 CAREFUL ABOUT NOT ADVISING ON 2314 01:39:59,826 --> 01:40:03,062 HOW TO DO IT EXCEPT TO DO IT 2315 01:40:03,062 --> 01:40:04,464 HOW IT HAPPENED WITH OUR CASE. 2316 01:40:04,464 --> 01:40:10,570 >> THANKS SO MUCH. 2317 01:40:10,570 --> 01:40:12,172 >> DR. LIGAVI. 2318 01:40:12,172 --> 01:40:15,808 >> THANKS FOR A GREAT TALK. 2319 01:40:15,808 --> 01:40:17,911 AND A GREAT HIGHLIGHT OF THE 2320 01:40:17,911 --> 01:40:19,512 FUNDAMENTAL IMPACT OF THE BASIC 2321 01:40:19,512 --> 01:40:22,715 SCIENCE OF DEVELOPMENT OF 2322 01:40:22,715 --> 01:40:24,317 INNOVATIVE THERAPIES AS 2323 01:40:24,317 --> 01:40:28,421 EVERYBODY ELSE AND GERI AND 2324 01:40:28,421 --> 01:40:29,422 DIANA POINTED OUT. 2325 01:40:29,422 --> 01:40:34,627 SO AS A BIG FAN OF SCIENCE, MY 2326 01:40:34,627 --> 01:40:37,130 QUESTION IS LENACAPAVIR 2327 01:40:37,130 --> 01:40:39,933 FORMATION AND IMMATURE 2328 01:40:39,933 --> 01:40:41,301 PARTICLES. 2329 01:40:41,301 --> 01:40:45,672 IT MENTIONED THAT IT FLATTENS 2330 01:40:45,672 --> 01:40:49,342 THE CAPSID BUT IT DOES IT ALSO 2331 01:40:49,342 --> 01:40:50,043 INHIBIT CAPSID FORMATION? 2332 01:40:50,043 --> 01:40:55,315 OR BOTH? 2333 01:40:55,315 --> 01:40:57,750 SO THOSE ARE PRETTY GOOD GOOD 2334 01:40:57,750 --> 01:40:58,318 QUESTIONS AND I WENT FAST 2335 01:40:58,318 --> 01:41:01,821 THROUGH THAT. 2336 01:41:01,821 --> 01:41:04,424 I WOULD SAY WORK IS AS NICE AS 2337 01:41:04,424 --> 01:41:08,461 ANY RIGHT NOW. 2338 01:41:08,461 --> 01:41:10,964 AND WHAT THEY SHOW ONCE THEY 2339 01:41:10,964 --> 01:41:12,131 FORM A CAPSID. 2340 01:41:12,131 --> 01:41:14,867 THE DRUG WAS DEVELOPED BY 2341 01:41:14,867 --> 01:41:17,237 STIMULATING, SO IT BINDS TO THE 2342 01:41:17,237 --> 01:41:23,276 HEXMER AND THAT MEANS IT GOES 2343 01:41:23,276 --> 01:41:24,544 BETTER. 2344 01:41:24,544 --> 01:41:27,280 BUT IT ALSO STRANGLES THE 2345 01:41:27,280 --> 01:41:29,983 HEXMER, IF YOU THINK ABOUT THE 2346 01:41:29,983 --> 01:41:31,484 CONE, IT HAS TO CHANGE IN THE 2347 01:41:31,484 --> 01:41:33,152 CONE. 2348 01:41:33,152 --> 01:41:40,426 SO WHAT I THINK IT RA DIT FIES 2349 01:41:40,426 --> 01:41:43,129 THE LATTICE AND TO* GO FLATTER 2350 01:41:43,129 --> 01:41:46,332 SO THEY START TO POPOFF SO YOU 2351 01:41:46,332 --> 01:41:50,570 PROBABLY HAVE A MORE FRAGILE 2352 01:41:50,570 --> 01:41:52,505 CAPSID. 2353 01:41:52,505 --> 01:41:54,774 IT DOESN'T BIND TO THE PENTMER 2354 01:41:54,774 --> 01:41:55,675 SO THAT'S KIND OF INTERESTING 2355 01:41:55,675 --> 01:41:59,078 AS WELL. 2356 01:41:59,078 --> 01:42:01,347 SO I THINK THAT'S COMBINATION I 2357 01:42:01,347 --> 01:42:03,182 THINK THAT CAPSID IS POISED AT 2358 01:42:03,182 --> 01:42:04,584 THE RIGHT ENERGY AND IF YOU 2359 01:42:04,584 --> 01:42:07,120 FORCE IT TO ADOPT TO SLIGHTLY 2360 01:42:07,120 --> 01:42:12,592 DIFFERENT LATTICE THAT IT'S NOW 2361 01:42:12,592 --> 01:42:16,429 VERY VULNERABLE I THINK THAT'S 2362 01:42:16,429 --> 01:42:17,130 OUR BEST UNDERSTANDING. 2363 01:42:17,130 --> 01:42:23,269 >> THANKS. 2364 01:42:23,269 --> 01:42:24,804 >> DR. SAWYER. 2365 01:42:24,804 --> 01:42:28,975 >> HI, THIS IS DR. SAWYER. 2366 01:42:28,975 --> 01:42:31,511 WHO DOES GILADD INTEND THE AWED 2367 01:42:31,511 --> 01:42:33,379 UDIENCE FOR THIS DRUG? 2368 01:42:33,379 --> 01:42:36,149 LIKE PEOPLE LIVING HIGH-RISK 2369 01:42:36,149 --> 01:42:40,453 LIFE STYLES ARE OBVIOUSLY. 2370 01:42:40,453 --> 01:42:44,123 BUT ABOUT THE YOUNG WOMEN THAT 2371 01:42:44,123 --> 01:42:46,192 GETS HIV BY GETTING RAPED. 2372 01:42:46,192 --> 01:42:49,796 OR WHAT ABOUT THE WOMEN THAT 2373 01:42:49,796 --> 01:42:53,199 THINKS SHE'S AN MONOGAMOUS 2374 01:42:53,199 --> 01:42:55,468 MARRIAGE AND FINDS OUT SHE'S 2375 01:42:55,468 --> 01:42:56,569 NOT AND GETS AIDS. 2376 01:42:56,569 --> 01:42:58,738 AND IF THE HIGH-RISK POPULATION 2377 01:42:58,738 --> 01:43:01,307 IS THE MAIN TARGET, I WOULD BE 2378 01:43:01,307 --> 01:43:02,442 INTERESTED IN HEARING WHAT 2379 01:43:02,442 --> 01:43:03,576 THEY'RE THINKING ABOUT THAT, IF 2380 01:43:03,576 --> 01:43:06,813 THAT IS THE MAIN TARGET? 2381 01:43:06,813 --> 01:43:09,816 WHAT DOES BEHAVIORAL SCIENCE 2382 01:43:09,816 --> 01:43:11,451 SAYS ABOUT ADHERE WHO THAT 2383 01:43:11,451 --> 01:43:13,453 PEOPLE WILL BE SIX-MONTH 2384 01:43:13,453 --> 01:43:14,220 INTERVENTION LIKE THIS. 2385 01:43:14,220 --> 01:43:16,956 >> SO AS YOU KNOW, I'M AN 2386 01:43:16,956 --> 01:43:20,159 EXPERT ON NONE OF THOSE TOPICS 2387 01:43:20,159 --> 01:43:24,530 BUT I WILL STILL TELL YOU BUT 2388 01:43:24,530 --> 01:43:24,764 CAREFUL. 2389 01:43:24,764 --> 01:43:26,999 I THINK IT'S ENVISIONED AS 2390 01:43:26,999 --> 01:43:29,135 HIGH-RISK BASICALLY AS A 2391 01:43:29,135 --> 01:43:31,170 VACCINE BUT AT THE BEGINNING IT 2392 01:43:31,170 --> 01:43:32,805 WILL BE FOR HIGH-RISK 2393 01:43:32,805 --> 01:43:33,940 POPULATIONS. 2394 01:43:33,940 --> 01:43:36,676 THE ONE THING THAT I DON'T 2395 01:43:36,676 --> 01:43:39,212 AGREE, I AGREE WITH MOST WHAT 2396 01:43:39,212 --> 01:43:40,813 YOU BUT THE VERY LAST THING 2397 01:43:40,813 --> 01:43:42,682 THAT THESE GROUPS ARE NOT 2398 01:43:42,682 --> 01:43:44,350 LIKELY TO BE COMPLIANT. 2399 01:43:44,350 --> 01:43:47,320 THAT'S WHAT I THINK WAS TESTED 2400 01:43:47,320 --> 01:43:48,921 OVER THE ONE-YEAR TIME SCALE 2401 01:43:48,921 --> 01:43:55,328 AND IT SHOWS THAT THEY ARE 2402 01:43:55,328 --> 01:43:57,663 ADHERENT BY VIRTUAL THAT THEY 2403 01:43:57,663 --> 01:43:59,332 GET INJECTION AND NOT JUST SIX 2404 01:43:59,332 --> 01:44:01,367 MONTHS BUT EVEN LONGER. 2405 01:44:01,367 --> 01:44:02,735 THAT'S THEIR BUSINESS BUT NOT 2406 01:44:02,735 --> 01:44:03,669 MINE TO TALK ABOUT. 2407 01:44:03,669 --> 01:44:05,805 I GUESS, I THINK THAT IT 2408 01:44:05,805 --> 01:44:06,973 PROBABLY, YOU KNOW, EVERYBODY 2409 01:44:06,973 --> 01:44:10,209 IS GOING TO HAVE TO DO TOUGH 2410 01:44:10,209 --> 01:44:11,377 COST BENEFIT ANALYSIS, NOT 2411 01:44:11,377 --> 01:44:13,413 EVERY ONE IS GOING TO GEL 2412 01:44:13,413 --> 01:44:16,182 LENACAPAVIR SO ONE HAS TO THINK 2413 01:44:16,182 --> 01:44:18,718 AT WHAT POINT DOES THE COSTS IN 2414 01:44:18,718 --> 01:44:20,586 TERMS OF THE GIVING A DRUG TO 2415 01:44:20,586 --> 01:44:22,422 PEOPLE EXCEED THE BENEFIT 2416 01:44:22,422 --> 01:44:25,491 BECAUSE AS YOU SAY, WE GET HIV 2417 01:44:25,491 --> 01:44:27,093 INFECTIONS FROM ALL DIFFERENT 2418 01:44:27,093 --> 01:44:30,096 DIRECTIONS BUT CLEARLY IN THE 2419 01:44:30,096 --> 01:44:36,335 PREVALENT AREAS, YOU KNOW, 2.4 2420 01:44:36,335 --> 01:44:38,204 INFECTIONS PER 100, SO PEOPLE 2421 01:44:38,204 --> 01:44:40,306 ARE REALLY GETTING INFECTED SO 2422 01:44:40,306 --> 01:44:42,108 THAT POPULATION AND OTHERS 2423 01:44:42,108 --> 01:44:43,943 WOULD BENEFIT FROM THIS IF IT 2424 01:44:43,943 --> 01:44:45,178 CONTINUES TO WORK WHICH IT 2425 01:44:45,178 --> 01:44:46,412 LOOKS LIKE IT WILL. 2426 01:44:46,412 --> 01:44:51,417 >> THANK YOU. 2427 01:44:51,417 --> 01:44:53,820 >> DR.. 2428 01:44:53,820 --> 01:44:55,888 >> THANK YOU, WHAT A GREA 2429 01:44:55,888 --> 01:44:58,157 PRESENTATION, AND I WOULD LIKE 2430 01:44:58,157 --> 01:45:00,893 TO ANSWER DR. SAWYER'S QUESTION 2431 01:45:00,893 --> 01:45:02,595 BUT I'LL HOLD BACK. 2432 01:45:02,595 --> 01:45:05,198 I HAVE HAD AN QUESTION. 2433 01:45:05,198 --> 01:45:06,866 YOU GAVE A GREAT STORY, THIS IS 2434 01:45:06,866 --> 01:45:08,968 THE KIND OF THING THAT NIH 2435 01:45:08,968 --> 01:45:12,371 WANTS TO PUT ON THEIR WEBSITE 2436 01:45:12,371 --> 01:45:16,242 TO SHOW HOW BASIC SCIENCE LEAD 2437 01:45:16,242 --> 01:45:18,344 OVER TWO DECADE PERIOD TO THE 2438 01:45:18,344 --> 01:45:20,613 MOST NEW INNOVATION THAT WE 2439 01:45:20,613 --> 01:45:22,448 HAVE IN HIV PREVENTION IN A 2440 01:45:22,448 --> 01:45:25,151 LONG TIME. 2441 01:45:25,151 --> 01:45:33,092 MY QUESTION, FOR YOU IS, 2442 01:45:33,092 --> 01:45:37,263 IMAGINE, YOU KNOW, YOU'RE DR. 2443 01:45:37,263 --> 01:45:39,532 DONEBERGH AND YOU JUST TOOK 2444 01:45:39,532 --> 01:45:41,167 OVER OAR AND YOU ARE THINKING 2445 01:45:41,167 --> 01:45:43,803 OF HOW TO PRIORITIZE THE MOST 2446 01:45:43,803 --> 01:45:44,704 BASIC SCIENCE, BECAUSE YOU TOLD 2447 01:45:44,704 --> 01:45:47,173 THE STORY OF THE NUMBER RATER, 2448 01:45:47,173 --> 01:45:49,008 THE SUCCESSFUL NUMBER RATER, 2449 01:45:49,008 --> 01:45:51,777 AND YOU WERE SELECTED FOR THIS 2450 01:45:51,777 --> 01:45:55,214 PARTICULAR EVENT BECAUSE YOU 2451 01:45:55,214 --> 01:45:58,818 SUCCEEDED, THERE ARE PROBABLY 9 2452 01:45:58,818 --> 01:46:01,587 OUT OF 10 BASIC SCIENCE STUFF 2453 01:46:01,587 --> 01:46:04,257 HAVE NOT COME TO FRUITION YET 2454 01:46:04,257 --> 01:46:07,260 TO SOMETHING THAT HAS NOT HAD A 2455 01:46:07,260 --> 01:46:08,127 MEANINGFUL AFFECT ON PUBLIC 2456 01:46:08,127 --> 01:46:09,362 HEALTH. 2457 01:46:09,362 --> 01:46:12,398 AND I'M WONDERING ARE THERE 2458 01:46:12,398 --> 01:46:14,467 PARAMETERS OR IDEAS THAT THE 2459 01:46:14,467 --> 01:46:16,969 TEAM USES TO TRY TO 2460 01:46:16,969 --> 01:46:18,804 DIFFERENTIATE EARLY ON, NOT 2461 01:46:18,804 --> 01:46:19,906 BETWEEN QUALITY OF SCIENCE, 2462 01:46:19,906 --> 01:46:20,873 BECAUSE THE QUALITY OF SCIENCE 2463 01:46:20,873 --> 01:46:24,110 CAN BE GREAT BUT MEANINGFULNESS 2464 01:46:24,110 --> 01:46:27,813 OF BASIC SCIENCE SO IT HAS A 2465 01:46:27,813 --> 01:46:29,415 HIGHER LIKELIHOOD OF FINDING A 2466 01:46:29,415 --> 01:46:31,017 HOME IN HEALTHCARE SUCCESS 2467 01:46:31,017 --> 01:46:34,453 WITHIN THE NEXT TWO DECADES? 2468 01:46:34,453 --> 01:46:35,688 BECAUSE HIV TWO DECADES IS A 2469 01:46:35,688 --> 01:46:37,290 LONG TIME. 2470 01:46:37,290 --> 01:46:39,559 >> I'LL START AND I'LL THEN 2471 01:46:39,559 --> 01:46:40,726 CARL SAY WHAT THEY WANT. 2472 01:46:40,726 --> 01:46:42,194 ONE OF THE THINGS THAT I THINK 2473 01:46:42,194 --> 01:46:45,398 WE HAVE TO BE CAREFUL IS, 2474 01:46:45,398 --> 01:46:46,465 MICROMANAGEMENT. 2475 01:46:46,465 --> 01:46:48,568 BECAUSE I THINK IF YOU TAKE ALL 2476 01:46:48,568 --> 01:46:49,435 THE EXAMPLES THAT I TALKED 2477 01:46:49,435 --> 01:46:50,670 ABOUT. 2478 01:46:50,670 --> 01:46:53,639 WE DIDN'T REALLY KNOW THAT 2479 01:46:53,639 --> 01:46:54,407 DISCOVERY THAT WAS GOING TO 2480 01:46:54,407 --> 01:46:55,942 COME OUT AT THE OTHER END. 2481 01:46:55,942 --> 01:46:58,277 SO I THINK, IF YOU HAD SAID 2482 01:46:58,277 --> 01:47:01,314 OKAY, WHAT'S THE MOST LIKELY 2483 01:47:01,314 --> 01:47:03,182 DRUG TARGET, YOU WOULD NOT HAVE 2484 01:47:03,182 --> 01:47:07,019 PICKED THE CAPSID. 2485 01:47:07,019 --> 01:47:11,090 AND SO, OF COURSE FIRST OF ALL, 2486 01:47:11,090 --> 01:47:12,425 FIRST AND FOR MOST, QUALITY IS 2487 01:47:12,425 --> 01:47:14,527 IMPORTANT. 2488 01:47:14,527 --> 01:47:16,395 IT REALLY IS, WE SHOULD BE 2489 01:47:16,395 --> 01:47:19,432 FUNDING THE BEST RESEARCH AND 2490 01:47:19,432 --> 01:47:21,968 THE BEST RESEARCH WHO CAN 2491 01:47:21,968 --> 01:47:24,270 ARTICULATE WHY THE PROBLEM IS 2492 01:47:24,270 --> 01:47:24,570 FUNDAMENTAL. 2493 01:47:24,570 --> 01:47:26,606 SO I DON'T THINK THAT ALL 2494 01:47:26,606 --> 01:47:28,474 RESEARCH IS EQUAL BUT I THINK 2495 01:47:28,474 --> 01:47:31,711 IT'S HARD, AND IT HAS BEEN HARD 2496 01:47:31,711 --> 01:47:33,312 TO MICROMANAGE EXACTLY, SO IT'S 2497 01:47:33,312 --> 01:47:34,747 OBVIOUS AND WE SHOULD DO THIS 2498 01:47:34,747 --> 01:47:36,849 WHEN WE CAN THAT WE SHOULD 2499 01:47:36,849 --> 01:47:42,355 ATTACK THE ENZYMES THAT THAT 2500 01:47:42,355 --> 01:47:46,325 WAS A GOOD PAIR DIME 2501 01:47:46,325 --> 01:47:47,360 THAT--PARADIGM THAT WAS GOING 2502 01:47:47,360 --> 01:47:48,094 TO HAPPEN. 2503 01:47:48,094 --> 01:47:50,262 BUT ONCE YOU UNDERSTAND HOW 2504 01:47:50,262 --> 01:47:52,098 THINGS WORK, THEY'RE OFTEN 2505 01:47:52,098 --> 01:47:55,301 UNEXPECTED SO. MY OWN VIEW IS 2506 01:47:55,301 --> 01:47:58,004 SHOULD BE CAREFUL NOT TO MAKE 2507 01:47:58,004 --> 01:47:58,938 TOO MANY POLICY DECISIONS TOO 2508 01:47:58,938 --> 01:47:59,605 EARLY. 2509 01:47:59,605 --> 01:48:02,375 BUT WHAT WE SHOULD DO, IS 2510 01:48:02,375 --> 01:48:04,477 PEOPLE LIKE MYSELF, TO USE A I 2511 01:48:04,477 --> 01:48:07,680 AND ALL OF THESE TOOLS THAT ARE 2512 01:48:07,680 --> 01:48:08,848 SPEEDING EVERYTHING UP. 2513 01:48:08,848 --> 01:48:11,183 WE HEARD A GREAT TALK 2514 01:48:11,183 --> 01:48:13,819 YESTERDAY, SORT ON THE FUTURE 2515 01:48:13,819 --> 01:48:15,655 OF DRUG DISCOVERY AND THAT WAS 2516 01:48:15,655 --> 01:48:17,690 HIS TAKE HOME MESSAGE. 2517 01:48:17,690 --> 01:48:18,924 THAT WE CANNOT BE SATISFIED 2518 01:48:18,924 --> 01:48:20,660 WITH ONE PERSON LIKE ME 2519 01:48:20,660 --> 01:48:23,029 STUDYING ONE PROTEIN, THE CA 2520 01:48:23,029 --> 01:48:24,664 PROTEIN FOR 25 YEARS, WE HAVE 2521 01:48:24,664 --> 01:48:25,498 TO BE FASTER. 2522 01:48:25,498 --> 01:48:28,234 I BELIEVE NA THAT BUT WE SHOULD 2523 01:48:28,234 --> 01:48:30,670 BE CAREFUL NOT TO MICROMANAGE 2524 01:48:30,670 --> 01:48:32,538 WHAT SCIENCE GETS DONE, THAT'S 2525 01:48:32,538 --> 01:48:33,472 MY OWN OPINION OBVIOUSLY. 2526 01:48:33,472 --> 01:48:35,107 >> I WOULD LIKE TO ADD TO THAT. 2527 01:48:35,107 --> 01:48:39,178 I THINK IT REALLY IS SOMETHING 2528 01:48:39,178 --> 01:48:42,014 WES SAID ABOUT THE DEGREES OF 2529 01:48:42,014 --> 01:48:43,115 COLLABORATION AND THERE IS A 2530 01:48:43,115 --> 01:48:45,851 POINT IN TIME WHERE COMPETITION 2531 01:48:45,851 --> 01:48:46,585 IS ESSENTIAL. 2532 01:48:46,585 --> 01:48:47,553 IN SCIENCE. 2533 01:48:47,553 --> 01:48:51,223 YOU WANT TO BE THE FIRST TO 2534 01:48:51,223 --> 01:48:53,292 DISCOVER SOMETHING BUT AS YOU 2535 01:48:53,292 --> 01:48:55,361 BUILD YOUR GROUP, YOU CAN GET 2536 01:48:55,361 --> 01:48:57,196 MORE INTEGRATED AND ADVANCED 2537 01:48:57,196 --> 01:48:58,364 IDEAS. 2538 01:48:58,364 --> 01:49:01,333 I DO AGREE THAT WE SHOULD NOT 2539 01:49:01,333 --> 01:49:03,669 GET INTO MICROMANAGING, BUT WE 2540 01:49:03,669 --> 01:49:05,938 ALSO CAN DO SOMETHING ABOUT 2541 01:49:05,938 --> 01:49:07,740 LOWERING THE BAR THE ACTIVATION 2542 01:49:07,740 --> 01:49:09,809 ENERGY TO GET INDUSTRY ENGAGED. 2543 01:49:09,809 --> 01:49:11,644 AND THAT IS ONE OF THE THAT'S 2544 01:49:11,644 --> 01:49:13,546 THE MAJOR TOOL THAT WE HAVE 2545 01:49:13,546 --> 01:49:17,883 CONTINUED TO USE HERE AT NIAD 2546 01:49:17,883 --> 01:49:21,287 TO COSTER A COLLABORATION 2547 01:49:21,287 --> 01:49:21,987 BETWEEN PHARMACEUTICAL AND 2548 01:49:21,987 --> 01:49:23,389 PEOPLE WHO ARE DOING BASIC 2549 01:49:23,389 --> 01:49:25,424 RESEARCH TO MAKE IT SO THAT 2550 01:49:25,424 --> 01:49:27,526 WHEN THERE IS SOMETHING THAT IS 2551 01:49:27,526 --> 01:49:29,195 WORTH AT LEAST HAVING A COMPANY 2552 01:49:29,195 --> 01:49:31,030 TAKE A LOOK AT IT, THAT THE 2553 01:49:31,030 --> 01:49:34,800 BRIDGE IS ALREADY BUILT. 2554 01:49:34,800 --> 01:49:36,969 THIS IS, YOU KNOW, A PRIME 2555 01:49:36,969 --> 01:49:39,271 EXAMPLE OF WHERE WE CAN GO WITH 2556 01:49:39,271 --> 01:49:41,373 THIS KIND OF FINDING IS THE 2557 01:49:41,373 --> 01:49:43,442 INFORMATION THAT HAS COME 2558 01:49:43,442 --> 01:49:47,813 AROUND CORONAVIRUS THAT IT TOO 2559 01:49:47,813 --> 01:49:50,783 ASSEMBLES A STRUCTURE THAT IS 2560 01:49:50,783 --> 01:49:55,721 QUITE RESILIENT AND DRUG DOES 2561 01:49:55,721 --> 01:49:58,924 NOT PENETRATE INTO DOES NOT GET 2562 01:49:58,924 --> 01:50:03,429 INTO THAT AREA AND SO THERE IS 2563 01:50:03,429 --> 01:50:08,834 A FORM LOGICAL PRIVILEGE SITE 2564 01:50:08,834 --> 01:50:12,071 THAO IT IT'S NOT AFFECTIVE. 2565 01:50:12,071 --> 01:50:14,140 SO YOU CAN LEARN FROM WES AND 2566 01:50:14,140 --> 01:50:16,041 THE CAPSID WORK IS ASSEMBLED 2567 01:50:16,041 --> 01:50:21,046 BUT NOW WE HAVE TO APPLY THAT 2568 01:50:21,046 --> 01:50:22,214 TO OTHER VIRUS. 2569 01:50:22,214 --> 01:50:23,415 BASIC RESEARCH IS ONE OF THE 2570 01:50:23,415 --> 01:50:25,484 CORE PURPOSES OF THE NIH AND AS 2571 01:50:25,484 --> 01:50:27,720 LONG AS WE ARE IN THE BUSINESS, 2572 01:50:27,720 --> 01:50:30,756 WE NEED TO MAKE SURE THAT WE 2573 01:50:30,756 --> 01:50:32,625 ARE SUPPORTING ENOUGH BASIC 2574 01:50:32,625 --> 01:50:34,193 RESEARCH SO THAT WE DON'T MISS 2575 01:50:34,193 --> 01:50:34,693 IDEAS. 2576 01:50:34,693 --> 01:50:36,529 THERE HAS TO BE ENOUGH WATER IN 2577 01:50:36,529 --> 01:50:40,566 THE STREAM TO FLOAT THE BOAT. 2578 01:50:40,566 --> 01:50:43,502 >> I'D ALSO JUST LIKE TO ADD 2579 01:50:43,502 --> 01:50:48,073 THAT BASIC SCIENCE IT IS AS YOU 2580 01:50:48,073 --> 01:50:49,408 SAY EXPENSE BUT NOBODY ELSE IN 2581 01:50:49,408 --> 01:50:52,378 THE WORLD THAT HAS THE 2582 01:50:52,378 --> 01:50:54,680 FINANCIAL ABILITIES TO BE ABLE 2583 01:50:54,680 --> 01:50:57,049 TO SUPPORT THIS TYPE OF WORK AT 2584 01:50:57,049 --> 01:50:58,284 THIS LEVEL. 2585 01:50:58,284 --> 01:51:01,153 I CANNOT THINK OF, I MEAN THERE 2586 01:51:01,153 --> 01:51:02,788 IS SOME COUNTRIES WHERE THERE 2587 01:51:02,788 --> 01:51:04,390 ARE BITS AND PIECES. 2588 01:51:04,390 --> 01:51:07,159 BUT YOU KNOW, THE NIH SUPPORT 2589 01:51:07,159 --> 01:51:09,461 IS REALLY BEYOND AND IT'S, YOU 2590 01:51:09,461 --> 01:51:15,434 KNOW IT'S A CROWN JEWEL IN THE 2591 01:51:15,434 --> 01:51:16,602 UNITED STATES BUT ALSO FOR THE 2592 01:51:16,602 --> 01:51:17,736 WORLD BECAUSE YOU JUST DON'T 2593 01:51:17,736 --> 01:51:19,338 KNOW WHERE YOU'RE GOING TO NEED 2594 01:51:19,338 --> 01:51:25,477 TO HAVE THIS FUNDAMENTAL 2595 01:51:25,477 --> 01:51:27,079 UNDERSTANDING WHAT PATHOGENS 2596 01:51:27,079 --> 01:51:29,014 REALLY LOOK LIKE IN DETAIL AND 2597 01:51:29,014 --> 01:51:33,052 HOW THEY IMPACT ON THE SCALES 2598 01:51:33,052 --> 01:51:36,255 THAT WES WAS DESCRIBING. 2599 01:51:36,255 --> 01:51:37,857 SO THAT'S MY PLUG FOR THE WORLD. 2600 01:51:37,857 --> 01:51:39,491 I THINK THAT THERE ARE OTHER 2601 01:51:39,491 --> 01:51:42,628 ASPECTS OF BEHAVIOR WHICH CAN 2602 01:51:42,628 --> 01:51:46,966 BE DONE IN OTHER PLACES. 2603 01:51:46,966 --> 01:51:50,569 SO AGAIN, I THINK BASIC SCIENCE 2604 01:51:50,569 --> 01:51:53,939 HOLDS A VERY IMPORTANT SPOT 2605 01:51:53,939 --> 01:51:59,178 ESPECIALLY AT THE NIH. 2606 01:51:59,178 --> 01:52:01,213 >> NOT SURPRISINGLY I AGREE WE 2607 01:52:01,213 --> 01:52:02,815 HAVINGER THAT WAS SAID. 2608 01:52:02,815 --> 01:52:04,650 BUT I WILL SAY THAT THE PROGRAM 2609 01:52:04,650 --> 01:52:06,518 HAS BEEN GOOD ABOUT PUSHING US 2610 01:52:06,518 --> 01:52:08,153 TO THINK ABOUT TRANSLATION AND 2611 01:52:08,153 --> 01:52:09,555 THAT'S OUR NEXT STEP. 2612 01:52:09,555 --> 01:52:12,324 SO I ALSO THINK THAT'S BEEN AN 2613 01:52:12,324 --> 01:52:15,761 IMPORTANT ROLE WITH DIANA AND 2614 01:52:15,761 --> 01:52:16,695 OTHERS HAVE PERFORMED. 2615 01:52:16,695 --> 01:52:19,899 I DON'T THINK WE SHOULD BE ABLE 2616 01:52:19,899 --> 01:52:22,701 TO A STUDY THAT INTERESTS US 2617 01:52:22,701 --> 01:52:23,903 BUT SOMETHING THAT MATTERS AND 2618 01:52:23,903 --> 01:52:25,938 CAN AND SHOULD BE TRANSLATED. 2619 01:52:25,938 --> 01:52:30,509 BUT I HATE AS A CHAIR OF 2620 01:52:30,509 --> 01:52:32,111 BIOCHEMISTRY DEPARTMENT AND 2621 01:52:32,111 --> 01:52:37,683 MEDICAL SCHOOL, WE HAVE TO MORE 2622 01:52:37,683 --> 01:52:38,517 TRANSLATION AL, WHAT PEOPLE 2623 01:52:38,517 --> 01:52:40,452 NEED TO DO IS REALLY GOOD 2624 01:52:40,452 --> 01:52:41,887 SCIENCE AND GOOD THINGS WILL 2625 01:52:41,887 --> 01:52:44,223 HAPPEN BUT WE CANNOT EXACTLY 2626 01:52:44,223 --> 01:52:45,524 PREDICT HOW. 2627 01:52:45,524 --> 01:52:53,499 >> WE HAVE TIME FOR ONE MORE 2628 01:52:53,499 --> 01:52:54,433 COMMENT, DR. MONTANER. 2629 01:52:54,433 --> 01:53:00,306 >> I WAS JUST GOING TO ECHO THE 2630 01:53:00,306 --> 01:53:01,440 POINT OF ENGAGEMENT. 2631 01:53:01,440 --> 01:53:04,410 I'LL PERHAPS BE MORE SPECIFIC, 2632 01:53:04,410 --> 01:53:09,615 DR. SUNQUIST, I MEAN YOU HAVE 2633 01:53:09,615 --> 01:53:11,684 30-YEAR TIME SPAN IN YOUR 2634 01:53:11,684 --> 01:53:13,552 CAREER THAT HAS EXPERIENCED THE 2635 01:53:13,552 --> 01:53:15,421 SUCCESS AND ADVANCE WHAT 2636 01:53:15,421 --> 01:53:19,091 ULTIMATELY LEAD TO A SUCCESSFUL 2637 01:53:19,091 --> 01:53:19,692 SUCCESSFUL INDUSTRY AND NOW 2638 01:53:19,692 --> 01:53:20,492 DRUG. 2639 01:53:20,492 --> 01:53:22,728 AS YOU LOOK BACK, DO YOU THINK 2640 01:53:22,728 --> 01:53:25,464 WHAT TYPE OF SUGGESTIONS DO YOU 2641 01:53:25,464 --> 01:53:26,632 HAVE FOR NEW ACADEMIC 2642 01:53:26,632 --> 01:53:27,099 PARTNERSHIPS? 2643 01:53:27,099 --> 01:53:29,868 WE HAVE THE SBRR AND THEY WRITE 2644 01:53:29,868 --> 01:53:32,404 THOSE, THEY ADD US AS 2645 01:53:32,404 --> 01:53:33,572 COLLABORATERS, BUT WE DON'T 2646 01:53:33,572 --> 01:53:36,108 REALLY HAVE AN INDUSTRY PIECE 2647 01:53:36,108 --> 01:53:38,844 THAT IS FUNDED DIRECTLY AT 2648 01:53:38,844 --> 01:53:42,047 LEAST MOST GRANTS DON'T HAVE A 2649 01:53:42,047 --> 01:53:49,021 COMPONENT GOING TO MARK OR 2650 01:53:49,021 --> 01:53:50,823 GILAD SO TRY TO INCENTIVE 2651 01:53:50,823 --> 01:53:51,957 GROUPS TO WORK AND GET THEIR 2652 01:53:51,957 --> 01:53:52,458 GRANTS. 2653 01:53:52,458 --> 01:53:54,793 BUT WHEN YOU LOOK AT YOUR WHOLE 2654 01:53:54,793 --> 01:53:57,429 TIME LINE, I MEAN, DO YOU, DO 2655 01:53:57,429 --> 01:54:00,632 YOU, WHAT TYPE OF TOOLS OR 2656 01:54:00,632 --> 01:54:02,868 GRANT INSTRUMENTS DO YOU THINK 2657 01:54:02,868 --> 01:54:04,703 WOULD HAVE ACCELERATED THIS 2658 01:54:04,703 --> 01:54:07,673 TYPE OF RELATIONSHIP? 2659 01:54:07,673 --> 01:54:09,541 BECAUSE YOU KNOW, I GUESS IT'S 2660 01:54:09,541 --> 01:54:12,745 ADVISORY WE HAVE TO BE KIND OF 2661 01:54:12,745 --> 01:54:15,014 LIKE TROUBLESHOOT NEW THINGS 2662 01:54:15,014 --> 01:54:17,116 THAT COULD BE ADVANCE THE FIELD. 2663 01:54:17,116 --> 01:54:20,552 I'M INTERESTED TO HEAR WHAT 2664 01:54:20,552 --> 01:54:22,588 YOUR PERSPECTIVE IS ABOUT WHAT 2665 01:54:22,588 --> 01:54:25,391 TYPE OF GRANT STRUCTURE OR TYPE 2666 01:54:25,391 --> 01:54:27,659 OF INITIATIVE WOULD YOU HAVE 2667 01:54:27,659 --> 01:54:31,997 LIKED TO HAVE SEEN? 2668 01:54:31,997 --> 01:54:34,533 >> THAT'S A REALLY GOOD 2669 01:54:34,533 --> 01:54:36,602 QUESTION AND I WISH I WAS 2670 01:54:36,602 --> 01:54:39,171 BETTER PREPARED TO GIVE YOU A 2671 01:54:39,171 --> 01:54:40,706 GOOD ANSWER. 2672 01:54:40,706 --> 01:54:42,775 I NEVER FELT THAT THERE WERE 2673 01:54:42,775 --> 01:54:45,778 BARRIERS, WE HAD GOOD 2674 01:54:45,778 --> 01:54:46,912 RELATIONSHIPS, THEY WERE DOING 2675 01:54:46,912 --> 01:54:49,214 THEIR OWN THING AND WE WERE 2676 01:54:49,214 --> 01:54:50,816 DOING OUR OWN THING. 2677 01:54:50,816 --> 01:54:54,520 BUT I REALLY ENJOYED GIVING 2678 01:54:54,520 --> 01:54:56,221 THEM ADVISE AND HEARING ABOUT 2679 01:54:56,221 --> 01:54:57,456 THEIR ADVANCES. 2680 01:54:57,456 --> 01:55:00,793 IN MY OWN CASE, THAT WOULD HAVE 2681 01:55:00,793 --> 01:55:03,495 BEEN HARDER TO INCENTIVIZE. 2682 01:55:03,495 --> 01:55:04,897 BUT IN MY DEPARTMENT, SOMETHING 2683 01:55:04,897 --> 01:55:06,265 THAT I SEE HAPPENING 2684 01:55:06,265 --> 01:55:06,732 SUCCESSFULLY. 2685 01:55:06,732 --> 01:55:08,567 ONE OF THE THINGS THAT WE 2686 01:55:08,567 --> 01:55:10,836 DIDN'T DO WELL, IS 2687 01:55:10,836 --> 01:55:11,970 COMMERCIALIZE THINGS AND THAT'S 2688 01:55:11,970 --> 01:55:14,573 WE HAVE A NEW GENERATION OF 2689 01:55:14,573 --> 01:55:15,941 YOUNG FACULTY WHO ARE DOING 2690 01:55:15,941 --> 01:55:17,342 THAT BETTER BY STARTING 2691 01:55:17,342 --> 01:55:18,977 COMPANIES AND NOT RUNNING THEM, 2692 01:55:18,977 --> 01:55:20,579 TRYING TO RUN COMPANIES BUT 2693 01:55:20,579 --> 01:55:21,713 THEY SHOULD TRY TO SPIN THEM 2694 01:55:21,713 --> 01:55:21,980 OFF. 2695 01:55:21,980 --> 01:55:24,783 SO I THINK THAT INCENTIVIZING 2696 01:55:24,783 --> 01:55:27,886 THAT IS OFTEN, THOSE ARE OFTEN 2697 01:55:27,886 --> 01:55:29,188 DIRECTLY DIRECTED TO THE 2698 01:55:29,188 --> 01:55:30,322 DISCOVERIES THAT THEY'VE MADE 2699 01:55:30,322 --> 01:55:33,092 AND THEY ENSURE THAT SOMETHING 2700 01:55:33,092 --> 01:55:37,129 IS MAKING DOING SOME MEDICINAL 2701 01:55:37,129 --> 01:55:39,465 DISCOVERY AND THEY'RE OFTEN 2702 01:55:39,465 --> 01:55:40,666 PICKED UP BY BIGGER DRUG 2703 01:55:40,666 --> 01:55:41,333 COMPANIES. 2704 01:55:41,333 --> 01:55:43,435 THAT'S SOMETHING THAT I'VE SEEN 2705 01:55:43,435 --> 01:55:44,837 IN MY DEPARTMENT, JERED ONE OF 2706 01:55:44,837 --> 01:55:46,438 THE LEADERS IS DOING 2707 01:55:46,438 --> 01:55:48,073 DIFFERENTLY FROM WHAT WE DID 2708 01:55:48,073 --> 01:55:50,375 AND MAY HAVE MADE A DIFFERENCE 2709 01:55:50,375 --> 01:55:51,777 IN OUR CASE. 2710 01:55:51,777 --> 01:55:53,846 BUT IN OUR CASE, WE WERE SMART 2711 01:55:53,846 --> 01:55:55,914 NOT TO DO DRUG DEVELOPMENT AND 2712 01:55:55,914 --> 01:55:58,450 ESPECIALLY HAVING SEEN. 2713 01:55:58,450 --> 01:56:05,557 AT ONE POINT, THEY HAD 25 2714 01:56:05,557 --> 01:56:07,192 DIFFERENT CHEMIST ACADEMIC LABS 2715 01:56:07,192 --> 01:56:08,127 SHOULD NOT DO THAT. 2716 01:56:08,127 --> 01:56:10,162 >> THIS IS BEEN A FABULOUS 2717 01:56:10,162 --> 01:56:12,231 CONVERSATION. 2718 01:56:12,231 --> 01:56:13,132 I KNOW -- 2719 01:56:13,132 --> 01:56:14,900 ~>> IVY CAN I MAKE ONE MORE 2720 01:56:14,900 --> 01:56:18,837 COMMENT. 2721 01:56:18,837 --> 01:56:20,873 >> YES, I DIDN'T SEE YOUR HAND. 2722 01:56:20,873 --> 01:56:23,008 >> YES, I THINK THE OTHER SORT 2723 01:56:23,008 --> 01:56:25,744 OF THROUGH LINE IN DR. SUNQUIST 2724 01:56:25,744 --> 01:56:28,480 TALK WAS THE TOOL DEVELOPMENT. 2725 01:56:28,480 --> 01:56:34,486 AND THAT WAS THE IMPROVEMENT IN 2726 01:56:34,486 --> 01:56:36,054 MICROSCOPY, THE IMPROVEMENT 2727 01:56:36,054 --> 01:56:39,424 WHERE YOU CAN NOW LITERALLY 2728 01:56:39,424 --> 01:56:42,861 DETERMINATION USING CRIO EM. 2729 01:56:42,861 --> 01:56:46,765 AND THE STRENGTH OF THE U54 2730 01:56:46,765 --> 01:56:49,835 PROGRAMS BOTH THE G.M. WAS 2731 01:56:49,835 --> 01:56:52,070 MAINTAINING THIS, THAT THE GOAL 2732 01:56:52,070 --> 01:56:54,573 IS NOT JUST DISCOVERY OF 2733 01:56:54,573 --> 01:56:57,075 BIOLOGY BUT ALSO IMPROVEMENT OF 2734 01:56:57,075 --> 01:56:59,378 THE TOOLS THAT WERE WE'RE USING 2735 01:56:59,378 --> 01:57:03,081 TO MAKE SHE'S DISCOVERIES. 2736 01:57:03,081 --> 01:57:06,552 SO G.M. AND NI A ID HAVE 2737 01:57:06,552 --> 01:57:08,420 INVESTED CLOSE TO 15-20 YEARS 2738 01:57:08,420 --> 01:57:11,423 AND THAT IS ANOTHER MAJOR 2739 01:57:11,423 --> 01:57:14,393 FACTOR IN THIS. 2740 01:57:14,393 --> 01:57:18,063 SO IN MY MANY WAYS HIV WAS THE 2741 01:57:18,063 --> 01:57:20,098 TEST CASE FOR AN AIDS WAS THE 2742 01:57:20,098 --> 01:57:22,167 PLACE TO DO THAT BECAUSE WE HAD 2743 01:57:22,167 --> 01:57:24,436 THE LEVEL OF SUPPORT THAT 2744 01:57:24,436 --> 01:57:26,271 ALLOWED FOR THESE CENTERS TO 2745 01:57:26,271 --> 01:57:30,142 COME TOGETHER AND ENGAGE IN 2746 01:57:30,142 --> 01:57:31,310 OPERATIVE TOOL DEVELOPMENT 2747 01:57:31,310 --> 01:57:33,378 WHILE SOLVING THE MOST 2748 01:57:33,378 --> 01:57:34,546 IMPORTANT PROBLEMS FOR WHAT I 2749 01:57:34,546 --> 01:57:36,114 CONSIDER THE MOST IMPORTANT 2750 01:57:36,114 --> 01:57:40,719 DISEASE, STILL IN THE WORLD. 2751 01:57:40,719 --> 01:57:43,021 >> I KNOW WE'RE RUNNING LATE ON 2752 01:57:43,021 --> 01:57:45,557 TIME, BUT I SHOULD HAVE SAID 2753 01:57:45,557 --> 01:57:46,992 THAT, I ENDORSE THAT 100 2754 01:57:46,992 --> 01:57:49,728 PERCENT. 2755 01:57:49,728 --> 01:57:52,898 WE HAD ELI HERE YESTERDAY, THEY 2756 01:57:52,898 --> 01:57:56,568 BUILT THEIR ENTIRE FACILITY. 2757 01:57:56,568 --> 01:57:59,538 AND THAT CAME OUT BECAUSE 2758 01:57:59,538 --> 01:58:03,242 EVERYBODY SHOWED THE CRIO EM 2759 01:58:03,242 --> 01:58:12,217 AND HOW FAR SRS BECAUSE THEY 2760 01:58:12,217 --> 01:58:13,619 KNEW HOW TO DO IT. 2761 01:58:13,619 --> 01:58:15,520 SO WOO CARL SAID WAS 100 2762 01:58:15,520 --> 01:58:16,421 PERCENT CORRECT. 2763 01:58:16,421 --> 01:58:18,257 >> THANK YOU ALL FOR THIS 2764 01:58:18,257 --> 01:58:19,391 ENGAGEMENT IN THIS FABULOUS 2765 01:58:19,391 --> 01:58:21,927 INFORMATION. 2766 01:58:21,927 --> 01:58:23,762 DR. SUNQUIST THANK YOU AGAIN 2767 01:58:23,762 --> 01:58:26,131 FOR YOUR PRESENTATION, IT'S NOW 2768 01:58:26,131 --> 01:58:27,499 1:58 WE'RE GOING TO TAKE A 2769 01:58:27,499 --> 01:58:28,734 SHORT BREAK. 2770 01:58:28,734 --> 01:58:33,438 PLEASE BE BACK AT 2:05? 2771 01:58:33,438 --> 01:58:36,208 AND SO THAT WE CAN CONTINUE 2772 01:58:36,208 --> 01:58:37,809 WITH OUR MEETING AGENDA. 2773 01:58:37,809 --> 01:58:40,046 THANK YOU ALL. 2774 01:58:40,891 --> 01:58:41,625 WELCOME BACK FROM THE BREAK 2775 01:58:41,625 --> 01:58:42,526 EVERY ONE. 2776 01:58:42,526 --> 01:58:46,563 WE WILL BEGIN WITH THE OAR TASK 2777 01:58:46,563 --> 01:58:49,099 FORCES, REGARDING THE STRATEGIC 2778 01:58:49,099 --> 01:58:51,401 PLAN WITH HIV RELATED RESEARCH. 2779 01:58:51,401 --> 01:58:55,105 TO INTRODUCE THE TASK FORCE, IS 2780 01:58:55,105 --> 01:58:58,075 DR. BOND SOL, TASK FORCE 2781 01:58:58,075 --> 01:59:01,044 COORDINATOR AND SENIOR SCIENCE 2782 01:59:01,044 --> 01:59:04,882 ADVISOR FROM OAR. 2783 01:59:04,882 --> 01:59:15,425 PLEASE BEGIN WHEN YOU'RE READY. 2784 01:59:20,564 --> 01:59:24,134 I WILL PRESENT INFORMATION FOR 2785 01:59:24,134 --> 01:59:25,068 THE FORCES CONVENED. 2786 01:59:25,068 --> 01:59:27,337 AS PART OF THE DEVELOPMENT OF 2787 01:59:27,337 --> 01:59:30,374 THE ANNEX STRATEGIC PLAN FOR 2788 01:59:30,374 --> 01:59:32,175 RELATED RESEARCH. 2789 01:59:32,175 --> 01:59:34,912 SO I WANT TO START BY 2790 01:59:34,912 --> 01:59:36,413 ACKNOWLEDGING THE PEOPLE BEHIND 2791 01:59:36,413 --> 01:59:46,623 THIS EFFORT. 2792 01:59:47,057 --> 01:59:47,958 WITH COLLEAGUES AND THED 2793 01:59:47,958 --> 01:59:52,763 FORMATION OF THE EXTRA TAOEMG 2794 01:59:52,763 --> 01:59:57,200 --STRATEGIC PLAN AS THEY TASK 2795 01:59:57,200 --> 01:59:59,069 FORCE. 2796 01:59:59,069 --> 02:00:00,938 AND ALSO HERE TODAY AND I WOULD 2797 02:00:00,938 --> 02:00:03,273 LIKE TO ACKNOWLEDGE THE TASK 2798 02:00:03,273 --> 02:00:06,243 FORCE TEAM MY COLLEAGUES, DR. 2799 02:00:06,243 --> 02:00:09,479 LESLIE MARSHAL AND MS. AMBER 2800 02:00:09,479 --> 02:00:11,515 WILSON THAT SERVED AS THE 2801 02:00:11,515 --> 02:00:16,687 SECRETARIES FOR THE TASK FORCES 2802 02:00:16,687 --> 02:00:18,555 AND PROVIDED THE ADMIN SUPPORT. 2803 02:00:18,555 --> 02:00:23,527 NEXT SLIDE PLEASE. 2804 02:00:23,527 --> 02:00:28,565 SO AS DR. DONENBERG, THE 2805 02:00:28,565 --> 02:00:30,867 PROCESS YOU SEE THE ONSCREEN. 2806 02:00:30,867 --> 02:00:32,502 TASK FORCES ARE A PART OF THIS 2807 02:00:32,502 --> 02:00:35,272 ON GOING PROCESS AND ARE 2808 02:00:35,272 --> 02:00:35,973 REPORTING OUT THEIR 2809 02:00:35,973 --> 02:00:37,307 RECOMMENDATIONS TO THE ADVISORY 2810 02:00:37,307 --> 02:00:38,976 COUNCIL TODAY. 2811 02:00:38,976 --> 02:00:40,110 THE ADVISORY COUNCIL 2812 02:00:40,110 --> 02:00:42,379 RECOMMENDATIONS WILL BE SHARED 2813 02:00:42,379 --> 02:00:44,948 WITH THE DIRECTOR FOR HER 2814 02:00:44,948 --> 02:00:50,120 REVIEW AND INPUT AND NHICs 2815 02:00:50,120 --> 02:00:51,822 PORTFOLIO. 2816 02:00:51,822 --> 02:00:52,990 SO TODAY'S RECOMMENDATION ARE 2817 02:00:52,990 --> 02:00:54,625 NOT THE FINAL PRODUCT. 2818 02:00:54,625 --> 02:01:04,968 NEXT SLIDE, PLEASE. 2819 02:01:09,272 --> 02:01:10,374 GRATEFUL TO OUR CHAIRS FOR 2820 02:01:10,374 --> 02:01:13,343 THEIR HARD WORK IN MAKE THISING 2821 02:01:13,343 --> 02:01:16,980 EFFORT POSSIBLE AND THE MEMBER 2822 02:01:16,980 --> 02:01:20,817 OF OAR SCIENCE TEAM IN 2823 02:01:20,817 --> 02:01:24,321 FACILITATING THE AGENDAS AND 2824 02:01:24,321 --> 02:01:25,756 NEEDING MATERIALS ET CETERA. 2825 02:01:25,756 --> 02:01:36,066 NEXT SLIDE PLEASE. 2826 02:01:41,872 --> 02:01:43,640 THESE GROUPS WERE PURPOSEFULLY 2827 02:01:43,640 --> 02:01:45,709 PUT TOGETHER TO REPRESENT A 2828 02:01:45,709 --> 02:01:50,714 BROAD DIVERSITY OF SUBJECT 2829 02:01:50,714 --> 02:01:51,882 MATTERS EXPERIENCE IN PRACTICE 2830 02:01:51,882 --> 02:01:53,183 AND POLICY AS WELL AS LIVED 2831 02:01:53,183 --> 02:01:54,384 EXPERIENCES. 2832 02:01:54,384 --> 02:01:57,120 WE AIM TO REACH PARTICIPANT 2833 02:01:57,120 --> 02:02:00,824 WITH GLOBAL AND DOMESTIC 2834 02:02:00,824 --> 02:02:01,758 EXPERIENCE INCLUDING ACROSS 2835 02:02:01,758 --> 02:02:03,794 ACTION REPRESENTATION AS WELL. 2836 02:02:03,794 --> 02:02:06,963 NEXT SLIDE, PLEASE. 2837 02:02:06,963 --> 02:02:08,865 AND WE ARE REALLY THANKFUL FOR 2838 02:02:08,865 --> 02:02:11,134 ALL THE MEMBERS FOR THEIR HARD 2839 02:02:11,134 --> 02:02:12,803 WORK AND COMMITMENT TO THIS 2840 02:02:12,803 --> 02:02:13,837 IMPORTANT EFFORT. 2841 02:02:13,837 --> 02:02:15,639 NEXT SLIDE. 2842 02:02:15,639 --> 02:02:19,576 SO THE TASK FORCES WERE CHARGED 2843 02:02:19,576 --> 02:02:22,312 WITH DEVELOPING OR IDENTIFYING 2844 02:02:22,312 --> 02:02:24,314 A SHORT LIST FOR THE NEXT 5 2845 02:02:24,314 --> 02:02:25,882 FISCAL YEARS. 2846 02:02:25,882 --> 02:02:28,318 ALL TASK FORCE MEMBERS WERE 2847 02:02:28,318 --> 02:02:31,254 PROVIDED OBJECTIVE HOUT THE 2848 02:02:31,254 --> 02:02:33,323 PRIMARILY TASK FORCES WAS 2849 02:02:33,323 --> 02:02:34,991 IDENTIFYING PRIORITIES FOR 2850 02:02:34,991 --> 02:02:37,060 OBJECTIVES THAT ALIGN WITH THE 2851 02:02:37,060 --> 02:02:38,462 TASK FORCE EXPERTISE. 2852 02:02:38,462 --> 02:02:42,566 AND THE DELIVERABLE WAS A 2853 02:02:42,566 --> 02:02:44,634 FRAMEWORK WITH RECOMMENDED 2854 02:02:44,634 --> 02:02:53,844 PRIORITIES UNDER EACH OBJECTIVE. 2855 02:02:53,844 --> 02:02:55,245 SO THIS SHOWS THE TIMELINE AND 2856 02:02:55,245 --> 02:02:57,414 STRUCTURE OF THE MEETINGS. 2857 02:02:57,414 --> 02:02:59,816 WE START WITHED KICKOFF MEETING 2858 02:02:59,816 --> 02:03:01,451 WHICH WAS JOINT MEETING FOR ALL 2859 02:03:01,451 --> 02:03:02,652 TASK FORCES TO ENSURE THAT 2860 02:03:02,652 --> 02:03:04,955 EVERY ONE RECEIVES THE SAME 2861 02:03:04,955 --> 02:03:06,523 INFORMATION AND RESOURCES. 2862 02:03:06,523 --> 02:03:09,960 EACH TASK FORCE MET TWICE WITH 2863 02:03:09,960 --> 02:03:10,927 ADDITIONAL COMMUNICATION IN 2864 02:03:10,927 --> 02:03:12,362 BETWEEN FOR REVIEW AND ANY 2865 02:03:12,362 --> 02:03:14,564 ADDITIONAL SUGGESTIONS. 2866 02:03:14,564 --> 02:03:16,867 AND THE WRAP UP MEETING WAS 2867 02:03:16,867 --> 02:03:18,268 AGAIN JOINED FOR ALL TASK 2868 02:03:18,268 --> 02:03:21,037 FORCES TO BE ABLE TO SEE AND 2869 02:03:21,037 --> 02:03:23,106 DISCUSS EACH OTHER'S WORK AND 2870 02:03:23,106 --> 02:03:24,241 HOW EVERYTHING FIT TOGETHER AND 2871 02:03:24,241 --> 02:03:26,243 IF THERE WERE ANY MAJOR 2872 02:03:26,243 --> 02:03:27,444 OMISSIONS. 2873 02:03:27,444 --> 02:03:29,479 AND THE DELIVERABLE FROM THESE 2874 02:03:29,479 --> 02:03:32,048 TASK FORCES IS BEING THIS 2875 02:03:32,048 --> 02:03:33,683 PRIORITY RECOMMENDATION THAT'S 2876 02:03:33,683 --> 02:03:35,752 ARE REPORT TODAY OARAC TODAY BY 2877 02:03:35,752 --> 02:03:38,722 THE TASK FORCE CHAIRS. 2878 02:03:38,722 --> 02:03:42,125 NEXT SLIDE, PLEASE. 2879 02:03:42,125 --> 02:03:44,861 SO THE EXTRA TAOEMG I CAN 2880 02:03:44,861 --> 02:03:47,631 FRAMEWORK HAS ONE CAPACITY GOAL. 2881 02:03:47,631 --> 02:03:48,698 EACH THREE TO FOUR 2882 02:03:48,698 --> 02:03:50,400 OBJECTIVITIES. 2883 02:03:50,400 --> 02:03:52,035 THE FOCUS WAS ON RECOMMENDING 2884 02:03:52,035 --> 02:03:54,671 THE FUNDING PRIORITY UNDER 2885 02:03:54,671 --> 02:03:56,173 SPECIFIC OBJECTIVES. 2886 02:03:56,173 --> 02:03:58,241 NEXT SLIDE, PLEASE. 2887 02:03:58,241 --> 02:04:00,677 SO THIS SLIDE SHOWS SPECIFIC 2888 02:04:00,677 --> 02:04:02,145 OBJECTIVES THAT WERE THE 2889 02:04:02,145 --> 02:04:03,146 PRIMARILY FOCUS FOR EACH OF THE 2890 02:04:03,146 --> 02:04:06,516 TASK FORCE. 2891 02:04:06,516 --> 02:04:07,884 DIFFERENT FUNCTIONAL AREAS OF 2892 02:04:07,884 --> 02:04:09,519 SCIENCE WERE REPRESENTED WITH 2893 02:04:09,519 --> 02:04:11,121 EACH GOAL AS YOU CAN SEE. 2894 02:04:11,121 --> 02:04:12,522 AND THEREFORE DIFFERENT TASK 2895 02:04:12,522 --> 02:04:14,124 FORCES WORKED ON DIFFERENT 2896 02:04:14,124 --> 02:04:15,725 OBJECTIVES WITHIN THE SAME GOAL. 2897 02:04:15,725 --> 02:04:18,962 ALL THE TASK FORCES WEIGHED IN 2898 02:04:18,962 --> 02:04:20,363 ON OBJECTIVES RELATED TO 2899 02:04:20,363 --> 02:04:23,133 COMMUNITY AND ENGAGED RESEARCH 2900 02:04:23,133 --> 02:04:24,501 AND INFRASTRUCTURE AND CAPACITY 2901 02:04:24,501 --> 02:04:26,336 BUILDING AND THAT WAS DONE TO 2902 02:04:26,336 --> 02:04:29,306 BRING THE PERSPECTIVE FROM ALL 2903 02:04:29,306 --> 02:04:30,440 THE FUNCTIONAL AREAS OF SCIENCE. 2904 02:04:30,440 --> 02:04:34,878 SO TODAY IN ADDITION TO 2905 02:04:34,878 --> 02:04:36,246 PRESENTING RECOMMENDATIONS FOR 2906 02:04:36,246 --> 02:04:40,150 THEIR SPECIFIC OBJECTIVE EACH 2907 02:04:40,150 --> 02:04:40,884 WILL PRESENT RECOMMENDATIONS 2908 02:04:40,884 --> 02:04:42,886 FOR THE SHARED OBJECTIVES. 2909 02:04:42,886 --> 02:04:46,289 NEXT SLIDE. 2910 02:04:46,289 --> 02:04:48,792 TASK FORCE RECEIVED SAME 2911 02:04:48,792 --> 02:04:51,294 INFORMATION, SAME MATERIALS AND 2912 02:04:51,294 --> 02:04:52,229 WHILE DEVELOPING PRIORITIES 2913 02:04:52,229 --> 02:04:54,764 WERE ASKED TO CONSIDER THESE 2914 02:04:54,764 --> 02:04:56,833 THREE THINGS, FIRST THE 2915 02:04:56,833 --> 02:04:59,102 STRATEGIC PLAN FOUNDATIONAL 2916 02:04:59,102 --> 02:05:01,905 PRINCIPALS WHICH ARE EQUITY, 2917 02:05:01,905 --> 02:05:03,573 INCLUSIVENESS OF ALL 2918 02:05:03,573 --> 02:05:04,941 POPULATIONS AND SETTINGS, 2919 02:05:04,941 --> 02:05:06,343 COMMUNITY ENGAGEMENT AND 2920 02:05:06,343 --> 02:05:08,445 POTENTIAL FOR GREATEST PUBLIC 2921 02:05:08,445 --> 02:05:10,914 HEALTH IMPACT. 2922 02:05:10,914 --> 02:05:12,749 THEY HAVE PROVICED REFERENCE 2923 02:05:12,749 --> 02:05:15,685 AND RESOURCES WHICH ARE INPUT 2924 02:05:15,685 --> 02:05:18,922 THAT OARAC RECEIVED FROM 2925 02:05:18,922 --> 02:05:26,329 VARIOUS SOURCES AS DR. DO 2926 02:05:26,329 --> 02:05:27,430 NOT--DONENBERG MENTIONED. 2927 02:05:27,430 --> 02:05:31,067 AND KEEPING IN MIND, THE MULTI 2928 02:05:31,067 --> 02:05:32,836 DISCIPLINARY NATURE OF 2929 02:05:32,836 --> 02:05:33,336 PORTFOLIO. 2930 02:05:33,336 --> 02:05:38,174 SO NOW I WILL HAND OVER TO THE 2931 02:05:38,174 --> 02:05:42,579 CHAIRS. 2932 02:05:42,579 --> 02:05:46,283 >> I WILL START BY THANKING ALL 2933 02:05:46,283 --> 02:05:47,651 THE EXECUTIVE SECRETARIES FOR 2934 02:05:47,651 --> 02:05:48,652 THEIR INCREDIBLE SUPPORT, ON 2935 02:05:48,652 --> 02:05:52,422 BEHALF OF ALL THE CHAIRS, WE 2936 02:05:52,422 --> 02:05:54,090 REALLY HAD AMAZING SUPPORT 2937 02:05:54,090 --> 02:06:04,601 THROUGHOUT THE ENTIRE PROCESS. 2938 02:06:18,648 --> 02:06:20,183 PRIORITY SO IF WE START WITH 2939 02:06:20,183 --> 02:06:22,519 GOAL NUMBER 1 WHICH IS REALLY 2940 02:06:22,519 --> 02:06:25,689 ONE FOCUS ON DISCOVERY AND 2941 02:06:25,689 --> 02:06:27,791 BASIC RESEARCH BUT FUNDAMENTAL 2942 02:06:27,791 --> 02:06:30,093 RESEARCH, THE GOAL IS TO 2943 02:06:30,093 --> 02:06:33,997 PHYSIOLOGICAL AND INTERPERSONAL 2944 02:06:33,997 --> 02:06:36,066 AND SOCIAL MEMBERISMS WITH HIV 2945 02:06:36,066 --> 02:06:40,403 HOW IT OPERATES AS A VIRUS AND 2946 02:06:40,403 --> 02:06:41,338 INFECTIOUS DISEASE AND 2947 02:06:41,338 --> 02:06:42,339 INDIVIDUAL COMMUNITY AND 2948 02:06:42,339 --> 02:06:43,440 POPULATION LEVEL. 2949 02:06:43,440 --> 02:06:45,041 THIS REALLY IS THE FOUNDATION 2950 02:06:45,041 --> 02:06:48,979 FOR THE DEVELOPMENT OF SAFE AND 2951 02:06:48,979 --> 02:06:50,113 AFFECTIVE AND DESIRABLE TOOLS 2952 02:06:50,113 --> 02:06:52,849 TO PREVENT AND CURE PERSONS 2953 02:06:52,849 --> 02:06:55,418 LIVING WITH HIV AS WELL AS 2954 02:06:55,418 --> 02:06:59,089 REDICED RISK OF COMPLICATION 2955 02:06:59,089 --> 02:07:00,023 AND COMORBID CONDITIONS. 2956 02:07:00,023 --> 02:07:02,292 SO NOW WE'LL GO THROUGH EACH OF 2957 02:07:02,292 --> 02:07:03,693 THE OBJECTIVE SXZ SOME OF THE 2958 02:07:03,693 --> 02:07:04,661 PRIORITIES THAT WERE IDENTIFIED. 2959 02:07:04,661 --> 02:07:08,098 SO IF WE CAN GO TO THE NEXT 2960 02:07:08,098 --> 02:07:09,499 SLIDE, OBJECTIVE 1.1. 2961 02:07:09,499 --> 02:07:12,469 THIS ONE, WAS TACKLED BY THE 2962 02:07:12,469 --> 02:07:13,403 BASIC ENVIRONMENTAL RESEARCH 2963 02:07:13,403 --> 02:07:15,905 TASK FORCE AND REALLY ADDRESSES 2964 02:07:15,905 --> 02:07:22,078 THE UNDERSTANDING OF HIV 2965 02:07:22,078 --> 02:07:25,482 BIOLOGY, VIROLOGY AND 2966 02:07:25,482 --> 02:07:28,418 PATHOGENSIS. 2967 02:07:28,418 --> 02:07:35,025 BREAD, TRANSITION AND 2968 02:07:35,025 --> 02:07:37,394 PATHOGENSIS OF HIV 2969 02:07:37,394 --> 02:07:41,431 WITH EMPHASIS OF PROTECTIVE 2970 02:07:41,431 --> 02:07:42,832 IMMUNE RESPONSE. 2971 02:07:42,832 --> 02:07:45,368 THE TASK FORCE SORT OF DEFINED 2972 02:07:45,368 --> 02:07:47,904 THIS TO BE AREAS FOR FUNDING 2973 02:07:47,904 --> 02:07:50,006 PRIORITIES THAT WERE ADVANCE 2974 02:07:50,006 --> 02:07:54,411 THE UNDERING OF BASIC AND HOST 2975 02:07:54,411 --> 02:07:55,311 MECHANISMS ESTABLISHMENT 2976 02:07:55,311 --> 02:08:00,350 SPREAD, TRANSMISSION AND 2977 02:08:00,350 --> 02:08:03,486 PATHOGENSIS OF HIV THROUGHOUT 2978 02:08:03,486 --> 02:08:04,621 THE LIFE SPAN. 2979 02:08:04,621 --> 02:08:09,893 AND REALLY EMPHASIZE THE LIVE 2980 02:08:09,893 --> 02:08:15,398 SPAN AND STRATEGIC PLAN. 2981 02:08:15,398 --> 02:08:17,500 UNDERSTANDING THE MECHANIC SIFM 2982 02:08:17,500 --> 02:08:20,236 OF REACTIVATION PERSISTENT AND 2983 02:08:20,236 --> 02:08:22,072 TISSUE BASE RESERVOIR DYNAMIC 2984 02:08:22,072 --> 02:08:24,140 TO DEVELOP STRATEGIES FOR 2985 02:08:24,140 --> 02:08:28,511 ELIMINATING OR CONTROLLING HIV 2986 02:08:28,511 --> 02:08:29,345 RESERVOIR INCLUDING RESISTANCE 2987 02:08:29,345 --> 02:08:30,380 BARRIERS. 2988 02:08:30,380 --> 02:08:31,981 THIS DISCUSSION REALLY 2989 02:08:31,981 --> 02:08:33,817 EMPHASIZE THAT APART FROM THE 2990 02:08:33,817 --> 02:08:36,352 BASIC TENANTS OF ALL OF THESE 2991 02:08:36,352 --> 02:08:37,987 CORE OBJECTIVES, THE DIE 2992 02:08:37,987 --> 02:08:41,224 VERSUSITY AND CELL TYPE IS AN 2993 02:08:41,224 --> 02:08:42,826 AREA THAT WE ALL RECOGNIZE 2994 02:08:42,826 --> 02:08:46,930 WHICH IS AN IMPORTANT NEXT 2995 02:08:46,930 --> 02:08:47,831 FRONTIER. 2996 02:08:47,831 --> 02:08:52,836 NEXT IS EVALUATE RESPONSE TO 2997 02:08:52,836 --> 02:08:57,173 VACCINATION TO NEUTRALIZING 2998 02:08:57,173 --> 02:08:59,442 ANTIBODIES SUCH AS GENE THERAPY. 2999 02:08:59,442 --> 02:09:01,044 THERE WAS A LOT OF DISCUSSION 3000 02:09:01,044 --> 02:09:02,445 THAT PRIORITY OF VACCINE AND 3001 02:09:02,445 --> 02:09:05,215 HOW WE NEED TO UNDERSTAND THE 3002 02:09:05,215 --> 02:09:08,418 UNDERSTAND OF DEVELOPING A 3003 02:09:08,418 --> 02:09:11,154 AFFECTIVE VACCINE. 3004 02:09:11,154 --> 02:09:15,492 ENHANCES EXISTING OR DEVELOPING 3005 02:09:15,492 --> 02:09:18,495 NEW TECHNOLOGY FOR ACHIEVING 3006 02:09:18,495 --> 02:09:20,330 BROAD HIV IMMUNITY IN THIS SORT 3007 02:09:20,330 --> 02:09:22,665 OF REFLECTS SOME OF THE EARLIER 3008 02:09:22,665 --> 02:09:23,066 DISCUSSIONS ABOUT 3009 02:09:23,066 --> 02:09:23,600 PRIORITIZATION. 3010 02:09:23,600 --> 02:09:26,469 THERE IS SOME INDICATION THAT 3011 02:09:26,469 --> 02:09:27,604 THESE DELIVERY COULD BE 3012 02:09:27,604 --> 02:09:28,771 BENEFICIAL AND I THINK WE NEED 3013 02:09:28,771 --> 02:09:31,007 TO SORT OF I GUESS, THERE WAS A 3014 02:09:31,007 --> 02:09:31,941 COLLECTIVE ASSESSMENT THAT WE 3015 02:09:31,941 --> 02:09:35,378 NEED TO DOUBLE DOWN TO 3016 02:09:35,378 --> 02:09:37,447 DETERMINE EXACTLY WHAT 3017 02:09:37,447 --> 02:09:38,314 TRANSLATION THESE STRATEGIES 3018 02:09:38,314 --> 02:09:39,282 MAY HOLD. 3019 02:09:39,282 --> 02:09:40,950 NEXT SLIDE, PLEASE. 3020 02:09:40,950 --> 02:09:43,720 ADVANCE UNDERSTANDING OF 3021 02:09:43,720 --> 02:09:46,489 INTRINSIC AND CONTROL 3022 02:09:46,489 --> 02:09:48,558 PROTECTIVE IMMUNE RESPONSE, 3023 02:09:48,558 --> 02:09:50,827 DYSFUNCTION, IMMUNE ACTIVATION 3024 02:09:50,827 --> 02:09:53,096 AND INFLAMMATION INCLUDING 3025 02:09:53,096 --> 02:09:55,598 RESPONSE TO CHRONIC HIV, 3026 02:09:55,598 --> 02:09:57,567 INCLUDING A I OR MACHINE 3027 02:09:57,567 --> 02:09:58,801 LEARNING STRATEGIES. 3028 02:09:58,801 --> 02:10:02,505 AND HERE'S WHERE ARTIFICIAL 3029 02:10:02,505 --> 02:10:03,907 STRATEGIST STARTED TO COME IN. 3030 02:10:03,907 --> 02:10:07,377 YOU'LL SEE IT IN MULTIPLE OTHER 3031 02:10:07,377 --> 02:10:08,945 OBJECTIVES AS TRYING TO 3032 02:10:08,945 --> 02:10:12,582 RECOGNIZE THAT HIGH DENSITY OF 3033 02:10:12,582 --> 02:10:15,118 DATA COULD POTENTIALLY BENEFIT 3034 02:10:15,118 --> 02:10:17,887 FROM INTERFACING MORE ACTIVELY. 3035 02:10:17,887 --> 02:10:22,892 UTILIZE THE UNDERSTANDING OF 3036 02:10:22,892 --> 02:10:30,400 INTRINSIC TO ENHANCE THE IMMUNE. 3037 02:10:30,400 --> 02:10:33,803 UNDERSTAND SUB TYPE DIFFERENCES 3038 02:10:33,803 --> 02:10:35,338 IN PRO POPULATION PERSON 3039 02:10:35,338 --> 02:10:37,941 SPECIFIC FACTORS FOR EXAMPLE, 3040 02:10:37,941 --> 02:10:39,509 TIMING OR TREATMENT INITIAL 3041 02:10:39,509 --> 02:10:42,045 TATION, MA MATERIAL AL FACTORS 3042 02:10:42,045 --> 02:10:46,883 AND SENSITIVITY IN INFANCY 3043 02:10:46,883 --> 02:10:48,051 CHILDHOOD, AFFECTING 3044 02:10:48,051 --> 02:10:49,419 PATHOGENSIS AND CURE STRATEGIES. 3045 02:10:49,419 --> 02:10:53,556 AND THIS WAS OUR ATTEMPT TO TRY 3046 02:10:53,556 --> 02:10:56,059 TO ENCOMPASS OUR NEED OF 3047 02:10:56,059 --> 02:10:58,061 UNDERSTANDING OUR BIOLOGIST 3048 02:10:58,061 --> 02:11:02,098 OUTSIDE THE CURRENT SUB TYPE IN 3049 02:11:02,098 --> 02:11:04,634 U.S. AND EUROPE AND THE 3050 02:11:04,634 --> 02:11:06,970 INFORMATION THAT STILL NEEDS TO 3051 02:11:06,970 --> 02:11:08,771 ADVANCE TO DEPLOY THE ADVANCES 3052 02:11:08,771 --> 02:11:10,640 ACROSS THE GLOBAL FRAMEWORK. 3053 02:11:10,640 --> 02:11:13,142 LASTLY, EVALUATION OF THE 3054 02:11:13,142 --> 02:11:16,879 IMPACT OF CURRENT THERAPIES AND 3055 02:11:16,879 --> 02:11:19,082 POLY PHARMACY ON IMMUNE AND 3056 02:11:19,082 --> 02:11:19,782 HEALTH. 3057 02:11:19,782 --> 02:11:22,986 THIS LAST ONE WAS THE COMMUNITY 3058 02:11:22,986 --> 02:11:25,922 TRYING TO HIGHLIGHT THE 3059 02:11:25,922 --> 02:11:36,399 PHARMACY ASPECT OF CURRENT 3060 02:11:46,876 --> 02:11:49,078 REJI REGIMEN. 3061 02:11:49,078 --> 02:11:50,813 WE'RE STARTING TO LOOK AT INTER 3062 02:11:50,813 --> 02:11:59,022 AXES. 3063 02:11:59,022 --> 02:12:00,390 INCLUDING THOSE THAT CONTRIBUTE 3064 02:12:00,390 --> 02:12:02,458 TO ACQUISITION, TRANSITION AND 3065 02:12:02,458 --> 02:12:03,826 VIRAL PERSISTENCE, AFTER 3066 02:12:03,826 --> 02:12:08,731 THERAPY SUCH AS OPPORTUNISTIC 3067 02:12:08,731 --> 02:12:10,333 INFECTIONS OR SUBSTANCE USE 3068 02:12:10,333 --> 02:12:14,137 DISORDER AND OTHER CAUSES OF 3069 02:12:14,137 --> 02:12:16,673 COMORBIDITY. 3070 02:12:16,673 --> 02:12:21,244 TRYING TO FOCUS ON ETOOOLOGY 3071 02:12:21,244 --> 02:12:24,881 REGIONAL ENVIRONMENTAL 3072 02:12:24,881 --> 02:12:27,150 DETERMINANTS ON COMORBID, 3073 02:12:27,150 --> 02:12:31,954 INCLUDING INTERACTIONS AT THE 3074 02:12:31,954 --> 02:12:37,260 MONTH ELECTRICLAR SUB TYPE. 3075 02:12:37,260 --> 02:12:39,329 THE NOVELTY WAS IS THE NEED TO 3076 02:12:39,329 --> 02:12:42,999 UNDERSTAND MORE REGIONAL AND 3077 02:12:42,999 --> 02:12:43,733 ENVIRONMENTAL DETERMINANT AS 3078 02:12:43,733 --> 02:12:46,069 THEY MAY IMPACT THESE CORE 3079 02:12:46,069 --> 02:12:47,637 AREAS THAT WE'VE BEEN INVESTING 3080 02:12:47,637 --> 02:12:50,373 ACROSS THIS PRIORITY. 3081 02:12:50,373 --> 02:12:50,873 STIMULATING TECHNOLOGY 3082 02:12:50,873 --> 02:12:53,176 DEVELOPMENT ON THE USE OF A I, 3083 02:12:53,176 --> 02:12:54,644 USE OF OUTPATIENT DATA AND 3084 02:12:54,644 --> 02:12:56,846 COMPUTING APPROACHES TO ADDRESS 3085 02:12:56,846 --> 02:13:00,149 MULTI FACT TORE AL INTERACTIONS 3086 02:13:00,149 --> 02:13:04,053 INCLUDING HOW HIV MAY IMPACT 3087 02:13:04,053 --> 02:13:05,188 PATH O GENESIS. 3088 02:13:05,188 --> 02:13:09,258 THIS IS THE CALL FOR MORE 3089 02:13:09,258 --> 02:13:13,796 INTERACTION WITH AI 3090 02:13:13,796 --> 02:13:14,497 INTELLIGENCE AND DATABASES 3091 02:13:14,497 --> 02:13:16,332 WHETHER IT'S FROM INSURANCE OR 3092 02:13:16,332 --> 02:13:18,201 MEDICAID OR OTHER TYPES OF 3093 02:13:18,201 --> 02:13:19,836 LARGE POPULATION BASE 3094 02:13:19,836 --> 02:13:21,270 ASSESSMENTS THAT THEY MAY 3095 02:13:21,270 --> 02:13:23,806 PROVIDE OPPORTUNITIES FOR 3096 02:13:23,806 --> 02:13:24,507 DISCOVERY REGARDING 3097 02:13:24,507 --> 02:13:26,309 INTERACTIONS THAT SHOULD 3098 02:13:26,309 --> 02:13:29,312 POTENTIALLY RECEIVE PRIORITY. 3099 02:13:29,312 --> 02:13:32,749 CHARACTERIZE THE MECHANISM OF 3100 02:13:32,749 --> 02:13:39,422 INFLAMMATION AND HIV 3101 02:13:39,422 --> 02:13:41,491 COMORBIDITY OR USING 3102 02:13:41,491 --> 02:13:41,991 GENERALEDERR AFFIRMING 3103 02:13:41,991 --> 02:13:44,026 THERAPIST. 3104 02:13:44,026 --> 02:13:50,233 INVESTIGATE THE HIV NON COMMUNE 3105 02:13:50,233 --> 02:13:52,535 CAL DISEASES INCLUDING, 3106 02:13:52,535 --> 02:13:54,370 CARDIOVASCULAR DISEASE AND 3107 02:13:54,370 --> 02:13:55,972 SUBSTANCE USE DISORDER AND 3108 02:13:55,972 --> 02:13:59,008 THEIR INTERACTIONS WITH HIV 3109 02:13:59,008 --> 02:14:06,315 STUDY THE FUNDAMENTAL MECHANISM 3110 02:14:06,315 --> 02:14:08,251 ASSOCIATED WITH CHRONIC TREATED 3111 02:14:08,251 --> 02:14:09,852 HIV 3112 02:14:09,852 --> 02:14:11,954 AND PERHAPS A--THE LAST THREE 3113 02:14:11,954 --> 02:14:15,591 IS REALLY TRYING TO INCOMPASS 3114 02:14:15,591 --> 02:14:17,193 THE BREATH OF TOPICS THAT ALL 3115 02:14:17,193 --> 02:14:23,332 OF THESE AREAS OF COMORBID 3116 02:14:23,332 --> 02:14:25,401 INTERFACE AND HOW ALL OF THEM 3117 02:14:25,401 --> 02:14:26,536 BECOME A PRIORITY. 3118 02:14:26,536 --> 02:14:28,404 THE NEXT I'LL SUMMARIZE THE 3119 02:14:28,404 --> 02:14:31,340 CLINICAL TASK FORCE ALTHOUGH 3120 02:14:31,340 --> 02:14:33,576 THIS IS ALREADY NOTED LEAD BY 3121 02:14:33,576 --> 02:14:35,978 TRIP--. 3122 02:14:35,978 --> 02:14:37,146 >> LUIS, I'M HERE. 3123 02:14:37,146 --> 02:14:40,550 >> OKAY, I WAS JUST FOLLOWING 3124 02:14:40,550 --> 02:14:42,618 THIS GUIDELINES BUT GO AHEAD. 3125 02:14:42,618 --> 02:14:44,654 >> NO, I'M HAPPY TO JUMPMENT 3126 02:14:44,654 --> 02:14:48,624 GOOD AFTERNOON, THIS IS TRIP 3127 02:14:48,624 --> 02:14:49,992 FROM WILD CORNELL. 3128 02:14:49,992 --> 02:14:51,661 I WAS PLEASE TODAY CHAIR THE 3129 02:14:51,661 --> 02:14:52,728 TASK FORCE. 3130 02:14:52,728 --> 02:14:58,634 I WANT TODAY ECHO LUIS'S THANKS 3131 02:14:58,634 --> 02:15:00,036 TO OARAC PROGRAM AND I WANTED 3132 02:15:00,036 --> 02:15:01,304 TO ACKNOWLEDGE THE TASK FORCE 3133 02:15:01,304 --> 02:15:03,573 MEMBERS AND FOUR OF YOU SIT ON 3134 02:15:03,573 --> 02:15:09,912 OARAC AND HERE TODAY. 3135 02:15:09,912 --> 02:15:13,349 COURTNEY FLETCHER, SLUD IMETA 3136 02:15:13,349 --> 02:15:18,087 AND SANTA MARIA. 3137 02:15:18,087 --> 02:15:25,161 THIS IS OBJECTIVITY 3138 02:15:25,161 --> 02:15:27,864 EPIDEMIOLOGY, COMORBIDITY AND 3139 02:15:27,864 --> 02:15:30,833 COMPLICATIONS WITH PEOPLE HIV 3140 02:15:30,833 --> 02:15:33,302 CROSS THE LIVE SPAN INCLUDING 3141 02:15:33,302 --> 02:15:34,537 POPULARITY POPULATIONS. 3142 02:15:34,537 --> 02:15:38,207 WITHIN THAT, TO DEVELOP NOVEL 3143 02:15:38,207 --> 02:15:42,778 APPROACHES TO EXAM DISEASE 3144 02:15:42,778 --> 02:15:44,614 BURDEN, DISTRIBUTION, POTENTIAL 3145 02:15:44,614 --> 02:15:46,682 RISK AND FACTORS IN SPECIFIC 3146 02:15:46,682 --> 02:15:48,784 POPULATION SXZ NATURAL HISTORY 3147 02:15:48,784 --> 02:15:53,389 STUDIES TO OBSERVE TRANSMISSION 3148 02:15:53,389 --> 02:15:55,258 DYNAMICS AND PATTERNS TRENDS IN 3149 02:15:55,258 --> 02:15:57,994 THE PREVENTION AND TREATMENT 3150 02:15:57,994 --> 02:16:02,331 CASCADES, EARLY STAGES OF 3151 02:16:02,331 --> 02:16:05,134 INFECTION AND PROGRESSION OF 3152 02:16:05,134 --> 02:16:08,371 HIV AND COMORBIDITY AND 3153 02:16:08,371 --> 02:16:10,873 COMPLICATIONS IN BOTH DOMESTIC 3154 02:16:10,873 --> 02:16:12,508 AND INTERNATIONAL SETTINGS TO 3155 02:16:12,508 --> 02:16:15,678 GUIDE PREVENTION AND TREATMENT 3156 02:16:15,678 --> 02:16:17,313 STRATEGIES AND OUR SPECIFIC 3157 02:16:17,313 --> 02:16:21,484 RECOMMENDATIONS FOR THIS 3158 02:16:21,484 --> 02:16:22,184 OBJECTIVES, THE PRIORITIES THAT 3159 02:16:22,184 --> 02:16:25,154 WE WERE TO IDENTIFY, WAS TO 3160 02:16:25,154 --> 02:16:27,423 DEVELOP NOVEL APPROACHES TO 3161 02:16:27,423 --> 02:16:28,591 UNDERSTAND HIV BURDEN, 3162 02:16:28,591 --> 02:16:31,327 DISTRIBUTION AND POTENTIAL RISK 3163 02:16:31,327 --> 02:16:33,362 AND PROTECTIVE FACTORS 3164 02:16:33,362 --> 02:16:37,533 INCLUDING THOSE THAT INFLUENCE 3165 02:16:37,533 --> 02:16:41,437 HIV TRANSMISSION, VIRAL 3166 02:16:41,437 --> 02:16:42,572 RESERVOIRS AND DISEASE 3167 02:16:42,572 --> 02:16:46,008 PROGRESSION IN PEOPLE WITH HIV 3168 02:16:46,008 --> 02:16:53,182 SECONDLY TO INCORPORATE ADVANCE 3169 02:16:53,182 --> 02:16:57,787 EPIOLOGY TO MONITORING OF 3170 02:16:57,787 --> 02:16:59,388 INDENSE AND TO IDENTIFY 3171 02:16:59,388 --> 02:17:01,157 HOTSPOTS AND TRENDS. 3172 02:17:01,157 --> 02:17:05,161 ALSO TO CONDUCT LONGITUDINAL 3173 02:17:05,161 --> 02:17:06,996 ASSESSMENTS OF PEOPLE AT-RISK 3174 02:17:06,996 --> 02:17:09,532 OR WITH HIV INCLUDING 3175 02:17:09,532 --> 02:17:10,900 SUPPORTING COHORT STUDIES TO 3176 02:17:10,900 --> 02:17:12,935 OBSERVE THE INCIDENTS AND 3177 02:17:12,935 --> 02:17:17,940 COURSE OF HIV FOCUSING ON 3178 02:17:17,940 --> 02:17:19,308 PHYSIOLOGICAL CELLULAR, BIO 3179 02:17:19,308 --> 02:17:20,977 CHEMICAL AND STRUCTURAL AND 3180 02:17:20,977 --> 02:17:23,079 BEHAVIORAL FACTORS IN BOTH 3181 02:17:23,079 --> 02:17:24,914 DOMESTIC AND INTERNATIONAL 3182 02:17:24,914 --> 02:17:26,749 SETTINGS TO GUIDE PREVENTION 3183 02:17:26,749 --> 02:17:29,752 AND TREATMENT STRATEGIES. 3184 02:17:29,752 --> 02:17:31,821 FOURTHLY TO CONDUCT STUDIES TO 3185 02:17:31,821 --> 02:17:34,624 BETTER UNDERSTAND THE IMPACT, 3186 02:17:34,624 --> 02:17:36,459 BURDEN, DISTRIBUTION, RISK 3187 02:17:36,459 --> 02:17:40,329 FACTORS AND DISEASE PROGRESSION 3188 02:17:40,329 --> 02:17:41,931 ASSOCIATED WITH COINFECTIONS, 3189 02:17:41,931 --> 02:17:50,573 CORE MORBIDITY AND SIN 3190 02:17:50,573 --> 02:17:51,741 --SYNDEMIC. 3191 02:17:51,741 --> 02:17:54,744 AND FINALLY TO CONDUCT STUDIES 3192 02:17:54,744 --> 02:17:57,046 TO ASSESS THE AGING WITH PEOPLE 3193 02:17:57,046 --> 02:17:59,548 LIVING WITH HIV INCLUDING 3194 02:17:59,548 --> 02:18:00,950 CLINICAL, SOCIAL AND STRUCTURAL 3195 02:18:00,950 --> 02:18:03,386 OUTCOMES. 3196 02:18:03,386 --> 02:18:05,388 IF WE GO TO THE NEXT SLIDE, 3197 02:18:05,388 --> 02:18:08,457 I'LL TURN IT OVER TO OMAR. 3198 02:18:08,457 --> 02:18:16,499 >> THANK YOU. 3199 02:18:16,499 --> 02:18:17,566 OBJECTIVE 1.4 IS ABOUT 3200 02:18:17,566 --> 02:18:19,235 PROCESSES. 3201 02:18:19,235 --> 02:18:21,737 THE TASK FORCE RECOMMENDATIONS 3202 02:18:21,737 --> 02:18:24,707 FOR PRIORITIES IS SPECIFICALLY 3203 02:18:24,707 --> 02:18:30,846 WHERE STUDIES THE CAUSAL 3204 02:18:30,846 --> 02:18:34,483 PATHWAYS OF SOCIAL DETERMINISM, 3205 02:18:34,483 --> 02:18:37,520 FOR EXAMPLE, SYSTEMIC RACISM, 3206 02:18:37,520 --> 02:18:41,857 POLITICAL CLIMATE, ECONOMIC, 3207 02:18:41,857 --> 02:18:44,193 HOUSING INSECURITY AS WELL AS 3208 02:18:44,193 --> 02:18:45,261 STRUCTURAL VIOLENCE. 3209 02:18:45,261 --> 02:18:49,165 ON THE RISK OF HIV ACQUISITION 3210 02:18:49,165 --> 02:18:51,233 AND HIV OUTCOMES TO AID IN THE 3211 02:18:51,233 --> 02:18:55,137 DEVELOPMENT OF AFFECTIVE AND 3212 02:18:55,137 --> 02:18:56,672 EQUITABLE PREVENTION AND CURE 3213 02:18:56,672 --> 02:18:58,808 INTERVENTIONS. 3214 02:18:58,808 --> 02:19:03,579 THE NEXT ITEM WAS RESEARCHING 3215 02:19:03,579 --> 02:19:09,218 THE ASSOCIATIONS AMONG AND 3216 02:19:09,218 --> 02:19:10,619 IMPACT OF COOCCURING INCLUDING 3217 02:19:10,619 --> 02:19:14,256 MENTAL HEALTH AND SUBSTANCE USE 3218 02:19:14,256 --> 02:19:17,026 AND RESILIENCE WITH RESPECT TO 3219 02:19:17,026 --> 02:19:19,528 HIV TRANSMISSION DISEASE 3220 02:19:19,528 --> 02:19:23,132 PROGRESSION CARE AND CURE. 3221 02:19:23,132 --> 02:19:30,606 THE NEXT ITEM WAS ELUCIDATING 3222 02:19:30,606 --> 02:19:34,744 STRUCTURAL STRUCTURE UNDER 3223 02:19:34,744 --> 02:19:35,911 DIFFERENTIAL OUTCOMES 3224 02:19:35,911 --> 02:19:38,914 SPECIFICALLY THOSE AFFECTED BY 3225 02:19:38,914 --> 02:19:40,282 HIV IN DIVERSE SETTINGS. 3226 02:19:40,282 --> 02:19:50,392 NEXT. 3227 02:19:51,660 --> 02:19:53,262 WE'RE BACK TO--GOAL 2. 3228 02:19:53,262 --> 02:19:57,533 >> SO GOAL 2 IS TO ADVANCE THE 3229 02:19:57,533 --> 02:20:01,470 DEVELOPMENT OF ASSESSMENT OF 3230 02:20:01,470 --> 02:20:02,772 NOVEL INTERVENTIONS FOR HIV 3231 02:20:02,772 --> 02:20:06,108 PREVENTION. 3232 02:20:06,108 --> 02:20:08,077 KNOWLEDGE FROM FUNDAMENTAL IN 3233 02:20:08,077 --> 02:20:10,279 FORMS CLINICAL TRIALS AND OTHER 3234 02:20:10,279 --> 02:20:12,148 INTERVENTION STUDIES THAT TEST 3235 02:20:12,148 --> 02:20:14,683 THE MOST PROMISING TOOLS OR 3236 02:20:14,683 --> 02:20:16,752 PRODUCT FOR HIV PREVENT, 3237 02:20:16,752 --> 02:20:21,524 TREATMENT AND CURE FOR HIV 3238 02:20:21,524 --> 02:20:23,159 RIGOROUS CONTROL TRIALS 3239 02:20:23,159 --> 02:20:27,663 OBSERVATION AL STUDIES AND 3240 02:20:27,663 --> 02:20:29,498 OTHER METHODOLOGY BY SOCIAL 3241 02:20:29,498 --> 02:20:31,834 OUTCOMES OF NOVEL INTERVENTION 3242 02:20:31,834 --> 02:20:34,136 SXZ THEIR VISIBILITY AND 3243 02:20:34,136 --> 02:20:35,304 EFFECTIVENESS IN DIVERSE 3244 02:20:35,304 --> 02:20:38,307 POPULATIONS AND ACROSS THE LIFE 3245 02:20:38,307 --> 02:20:38,507 SPAN. 3246 02:20:38,507 --> 02:20:41,043 SO THIS GOAL REALLY INTERFACES 3247 02:20:41,043 --> 02:20:42,611 THREE OBJECTIVES. 3248 02:20:42,611 --> 02:20:43,879 THE FIRST ONE WAS TACKLED BY 3249 02:20:43,879 --> 02:20:44,847 THE TASK FORCE. 3250 02:20:44,847 --> 02:20:46,816 NEXT SLIDE. 3251 02:20:46,816 --> 02:20:49,618 AND IT REALLY ADDRESSES THE 3252 02:20:49,618 --> 02:20:50,786 PRECLINICAL AND TRANSLATIONAL 3253 02:20:50,786 --> 02:20:52,254 RESEARCH SPACE IN THIS 3254 02:20:52,254 --> 02:20:53,522 PARTICULAR GOAL. 3255 02:20:53,522 --> 02:20:55,791 TRYING TO SUPPORT PRECLINICAL 3256 02:20:55,791 --> 02:20:57,893 STUDIES TO DEVELOP, EVALUATE 3257 02:20:57,893 --> 02:21:01,831 AND VALIDATE AND OP MIEZ THE 3258 02:21:01,831 --> 02:21:03,699 BIOMEDICAL RESEARCH DISCOVERIES 3259 02:21:03,699 --> 02:21:05,501 OF AGENTS, TARGETS AND 3260 02:21:05,501 --> 02:21:08,704 STRATEGIES TO BE TESTED FOR HIV 3261 02:21:08,704 --> 02:21:10,272 TREATMENT AND CORE MORBIDITY 3262 02:21:10,272 --> 02:21:11,273 AND CURE. 3263 02:21:11,273 --> 02:21:13,375 THE SPECIFIC RECOMMENDATION WAS 3264 02:21:13,375 --> 02:21:15,477 TO EMPHASIZE THE STUDY, THE 3265 02:21:15,477 --> 02:21:17,279 INTERACTIONS BETWEEN HIV AND 3266 02:21:17,279 --> 02:21:21,817 WHOLE CELLS TO IDENTIFY NEW 3267 02:21:21,817 --> 02:21:23,886 THERAPEUTIC TARGETS. 3268 02:21:23,886 --> 02:21:25,754 WE HEARD EARLIER ADDITIONAL 3269 02:21:25,754 --> 02:21:29,692 AREAS THAT REMAIN TO BE 3270 02:21:29,692 --> 02:21:31,727 ADVANCED FOR EXAMPLE. 3271 02:21:31,727 --> 02:21:33,596 NEXT TEST CANDIDATES INCLUDING 3272 02:21:33,596 --> 02:21:34,964 DRUGS DELIVERY SYSTEMS, VACCINE 3273 02:21:34,964 --> 02:21:36,398 AND CURE STRATEGIES. 3274 02:21:36,398 --> 02:21:38,601 WHICH ARE OBVIOUSLY, A CENTRAL 3275 02:21:38,601 --> 02:21:42,238 COME POENT--COMPONENT OF OUR ON 3276 02:21:42,238 --> 02:21:45,174 GOING EFFORT. 3277 02:21:45,174 --> 02:21:46,075 ARTIFICIAL INTELLIGENCE AND 3278 02:21:46,075 --> 02:21:49,011 PREDICT I HAVE MODELS TO 3279 02:21:49,011 --> 02:21:51,080 FORECAST TREATMENT OUTCOMES AND 3280 02:21:51,080 --> 02:21:52,982 THERAPEUTIC RESPONSE AND TO 3281 02:21:52,982 --> 02:21:54,850 INFORM CURE STRATEGIES. 3282 02:21:54,850 --> 02:21:57,119 ENHANCE EXISTING AND DEVELOP 3283 02:21:57,119 --> 02:21:58,988 NEW PRECLINICAL MODELS AND USE 3284 02:21:58,988 --> 02:22:03,859 OF CLINICAL RESOURCES TO STUDY 3285 02:22:03,859 --> 02:22:06,428 HIV PERSISTENT RESERVOIR 3286 02:22:06,428 --> 02:22:07,796 DYNAMIC, REPLICATION, ANTI 3287 02:22:07,796 --> 02:22:11,934 VIRAL STRATEGIES AND ART AND 3288 02:22:11,934 --> 02:22:13,569 SPREAD COINFECTIOUS AND OTHER 3289 02:22:13,569 --> 02:22:15,204 SUCH AS SUBSTANCE USE DISORDER. 3290 02:22:15,204 --> 02:22:17,740 AND THIS IS AN AREA THAT DREW A 3291 02:22:17,740 --> 02:22:19,341 LOT OF DISCUSSION ABOUT THE 3292 02:22:19,341 --> 02:22:22,044 NEED TO REALLY TRY TO MAXIMIZE 3293 02:22:22,044 --> 02:22:25,014 THE POTENTIAL OF NO HE WILL 3294 02:22:25,014 --> 02:22:26,882 PRECLINICAL MODELS WHETHER IT 3295 02:22:26,882 --> 02:22:30,085 ANIMAL OF PRIMATE OR HUMANIZED 3296 02:22:30,085 --> 02:22:33,289 MICE. 3297 02:22:33,289 --> 02:22:35,357 ELUCIDATE FACTORS THAT INFORM 3298 02:22:35,357 --> 02:22:37,426 DIAGNOSIS OF TREATMENT OF WOMEN 3299 02:22:37,426 --> 02:22:41,330 AND GIRLS LIVING WITH HIV 3300 02:22:41,330 --> 02:22:43,832 ACROSS LIFESTYLE, INCLUDING SEX 3301 02:22:43,832 --> 02:22:44,533 DIFFERENCES AND ARV. 3302 02:22:44,533 --> 02:22:47,569 NEXT SLIDE. 3303 02:22:47,569 --> 02:22:48,470 IMPLEMENT TRANSLATIONAL 3304 02:22:48,470 --> 02:22:51,440 RESEARCH INITIATIVE TO OPTIMIZE 3305 02:22:51,440 --> 02:22:53,275 HIV TREATMENT AND STRATEGIES 3306 02:22:53,275 --> 02:22:54,643 FOR DIVERSE POPULATIONS 3307 02:22:54,643 --> 02:22:56,478 BRIDGING THE GAP BETWEEN BASIC 3308 02:22:56,478 --> 02:22:58,514 RESEARCH AND APPLICATION TO SEE 3309 02:22:58,514 --> 02:23:00,582 BRING NEW TREATMENT AND 3310 02:23:00,582 --> 02:23:02,618 PREVENTIVE MEASURES TO PATIENTS. 3311 02:23:02,618 --> 02:23:05,421 AND IMPLEMENT AND SUSTAIN 3312 02:23:05,421 --> 02:23:07,056 PROGRAMS FOR ALL PHASES OF 3313 02:23:07,056 --> 02:23:09,525 CLINICAL DEVELOPMENT FOR CURE 3314 02:23:09,525 --> 02:23:11,160 DIRECT STRATEGIES INCLUDING 3315 02:23:11,160 --> 02:23:14,363 PROCESS AND G.M. P AND CLINICAL 3316 02:23:14,363 --> 02:23:18,467 PRODUCTION AND FORMULATION, AND 3317 02:23:18,467 --> 02:23:20,769 ASSOCIATED TASK LEADING TO THE 3318 02:23:20,769 --> 02:23:22,338 FILING OF INVESTIGATION ON NEW 3319 02:23:22,338 --> 02:23:25,741 DRUG APPLICATIONS AND THIS ALSO 3320 02:23:25,741 --> 02:23:27,376 DREW A LOT OF DISCUSSION ABOUT 3321 02:23:27,376 --> 02:23:30,379 TRYING TO BRIDGE THAT VALUE OF 3322 02:23:30,379 --> 02:23:32,881 DEATH, THAT COMPONENT OF 3323 02:23:32,881 --> 02:23:33,449 ACADEMIC DEVELOPMENT THAT 3324 02:23:33,449 --> 02:23:35,651 THEY'VE BEEN TRYING TO BRIDGE 3325 02:23:35,651 --> 02:23:37,252 THROUGH APPLICATION, ON GOING 3326 02:23:37,252 --> 02:23:38,454 INITIATIVES IN THIS REGARD AND 3327 02:23:38,454 --> 02:23:40,990 I THINK THAT MORE OF THAT WAS 3328 02:23:40,990 --> 02:23:42,891 VIEWED TO BE A PRIORITY MOVING 3329 02:23:42,891 --> 02:23:48,530 FORWARD. 3330 02:23:48,530 --> 02:23:50,699 AND WE TRANSITION NOW TO TRIP 3331 02:23:50,699 --> 02:23:52,234 ON CLINICAL. 3332 02:23:52,234 --> 02:23:53,836 >> RIGHT, SO CLINICAL TASK 3333 02:23:53,836 --> 02:23:55,871 FORCE TOOK ON THE NEXT TWO 3334 02:23:55,871 --> 02:23:56,638 OBJECTIVES. 3335 02:23:56,638 --> 02:23:58,941 THE ONE YOU SEE HERE, RESEARCH, 3336 02:23:58,941 --> 02:24:01,243 TRIALS AND OTHER INTERVENTION 3337 02:24:01,243 --> 02:24:05,547 STUDIES OF HIV PREVENTION 3338 02:24:05,547 --> 02:24:12,154 INCLUDING VACCINES, TREATMENT 3339 02:24:12,154 --> 02:24:15,624 COMORBIDITY WITH PEOPLE AT-RISK 3340 02:24:15,624 --> 02:24:17,726 INCLUDING UNDER STUDIED AND 3341 02:24:17,726 --> 02:24:18,894 PRIORITY POPULATIONS, MORE 3342 02:24:18,894 --> 02:24:20,496 SPECIFICALLY TO CONDUCT 3343 02:24:20,496 --> 02:24:21,630 CLINICAL RESEARCH INCLUDING ALL 3344 02:24:21,630 --> 02:24:25,701 THE WAY FROM FIRST IN HUMAN TO 3345 02:24:25,701 --> 02:24:29,171 PHASE 4 TRIALS TO ASSESS THE 3346 02:24:29,171 --> 02:24:32,875 SAFETY, ETHICACY AND ADHERENCE 3347 02:24:32,875 --> 02:24:38,781 TO HIV PREVENTION, TREATMENT, 3348 02:24:38,781 --> 02:24:41,183 CORE MORBIDITY AND METHODS 3349 02:24:41,183 --> 02:24:42,885 INCLUDING THOSE CONNECTED TO 3350 02:24:42,885 --> 02:24:45,854 VACCINE TREATMENT AND CURE, 3351 02:24:45,854 --> 02:24:47,489 EITHER USED ALONE OR IN 3352 02:24:47,489 --> 02:24:49,158 COMBINATION TO REDUCE THE 3353 02:24:49,158 --> 02:24:53,295 REDUCTION OF HIV AND RELATED 3354 02:24:53,295 --> 02:24:55,397 SEXUALLY TRANSMITTED DISEASES, 3355 02:24:55,397 --> 02:24:59,001 UNINTENDED PREGNANCY AS WELL AS 3356 02:24:59,001 --> 02:25:01,170 VIRAL RESERVOIR AND OTHER 3357 02:25:01,170 --> 02:25:02,671 ADVERSE EVENTS. 3358 02:25:02,671 --> 02:25:04,773 O OUR SPECIFIC RECOMMENDATION 3359 02:25:04,773 --> 02:25:07,109 START TO CONDUCT FIRST IN HUMAN 3360 02:25:07,109 --> 02:25:10,412 PHASE 4 CLINICAL STUDIES TO 3361 02:25:10,412 --> 02:25:13,382 ACCELERATE EVALUATION OF SAFETY 3362 02:25:13,382 --> 02:25:15,684 ETHICACY AND OPTIMAL DOSING AND 3363 02:25:15,684 --> 02:25:17,453 ADHERENCE IN THE FOLLOWING 3364 02:25:17,453 --> 02:25:19,388 BROAD AREAS. 3365 02:25:19,388 --> 02:25:22,791 NUMBER 1, HIV PREVENTION 3366 02:25:22,791 --> 02:25:24,860 INCLUDING ANTI RETRI VIRAL 3367 02:25:24,860 --> 02:25:26,728 VACCINE AND IMMUNE BASE 3368 02:25:26,728 --> 02:25:28,597 PREVENTION MULTI PURPOSE 3369 02:25:28,597 --> 02:25:29,998 PREVENTION TECHNOLOGIES AND 3370 02:25:29,998 --> 02:25:31,600 OTHER INNOVATIONS FOR PEOPLE 3371 02:25:31,600 --> 02:25:34,203 WHO ARE AT-RISK FOR HIV 3372 02:25:34,203 --> 02:25:36,472 SECONDLY, IS THE THERAPEUTIC 3373 02:25:36,472 --> 02:25:40,843 NEW AND NOVEL THERAPEUTIC 3374 02:25:40,843 --> 02:25:46,515 INTERVENTION SXZ ITS ASSOCIATED 3375 02:25:46,515 --> 02:25:47,282 COINFECTIONS, COMORBIDITY AND 3376 02:25:47,282 --> 02:25:51,086 SIN DEMIC CONDITIONS WITH 3377 02:25:51,086 --> 02:25:53,622 PEOPLE WITH HIV 3378 02:25:53,622 --> 02:25:55,724 THIRDLY HIV CURE AND REVISION 3379 02:25:55,724 --> 02:25:58,360 STRATEGIES FOR PEOPLE WITH HIV, 3380 02:25:58,360 --> 02:26:08,604 NEXT SLIDE. 3381 02:26:08,604 --> 02:26:12,307 AND AND LONG TERM SIDE AFFECTS 3382 02:26:12,307 --> 02:26:14,143 AND CURE INTERVENTIONS THROUGH 3383 02:26:14,143 --> 02:26:16,845 EXTENDED FOLLOW-UP STUDIES. 3384 02:26:16,845 --> 02:26:21,884 TO INVESTIGATE CAUSAL MODELING 3385 02:26:21,884 --> 02:26:23,318 AND AFFECTIVE OF INTERVENTIONS 3386 02:26:23,318 --> 02:26:25,854 AIMED AT IMPROVING OUTCOMES 3387 02:26:25,854 --> 02:26:29,124 WHILE ALSO REDUCING STIGMA AND 3388 02:26:29,124 --> 02:26:31,393 IMPROVING MENTAL HEALTH, USING 3389 02:26:31,393 --> 02:26:37,366 REAL WORLD DATA REFLECTING THE 3390 02:26:37,366 --> 02:26:38,267 COMPLEXITIES. 3391 02:26:38,267 --> 02:26:40,369 AND FINALLY, UNDER THE 3392 02:26:40,369 --> 02:26:43,839 OBJECTIVE TO ADAPT AND A TAR 3393 02:26:43,839 --> 02:26:45,174 EVIDENCE BASE INTERVENTIONS 3394 02:26:45,174 --> 02:26:48,143 INCLUDING BEHAVIORAL SOCIAL AND 3395 02:26:48,143 --> 02:26:49,278 STRUCTURAL INTERVENTIONS TO 3396 02:26:49,278 --> 02:26:51,313 MEET THE SPECIFIC NEEDS OF 3397 02:26:51,313 --> 02:26:54,550 PEOPLE AT-RISK OR WITH HIV IN 3398 02:26:54,550 --> 02:26:56,652 DIVERSE AND UNDER STUDIED 3399 02:26:56,652 --> 02:26:57,119 STUDIES. 3400 02:26:57,119 --> 02:27:00,989 NEXT. 3401 02:27:00,989 --> 02:27:02,858 IS OBJECTIVE 2.3 AND THIS IS 3402 02:27:02,858 --> 02:27:06,028 FOCUSING REALLY ON MODELS OF 3403 02:27:06,028 --> 02:27:08,597 CARE TO DEVELOP AND EVALUATE 3404 02:27:08,597 --> 02:27:10,899 AND INNOVATIVE AND INTEGRATED 3405 02:27:10,899 --> 02:27:14,836 MODELS OF CARE AND SERVICES FOR 3406 02:27:14,836 --> 02:27:18,473 HIV TREATMENT, PREVENTION CARE 3407 02:27:18,473 --> 02:27:23,245 AND HIV COMPLICATION SXZ 3408 02:27:23,245 --> 02:27:23,946 COMORBIDITY AND COINFECTIONS 3409 02:27:23,946 --> 02:27:27,649 BOTH IN PEOPLE AT-RISK OR ARE 3410 02:27:27,649 --> 02:27:30,018 HIV INCLUDING UNDER STUDIED AND 3411 02:27:30,018 --> 02:27:31,787 PRIORITY POPULATIONS. 3412 02:27:31,787 --> 02:27:34,089 AND MORE SPECIFIC TO DEVELOP 3413 02:27:34,089 --> 02:27:37,259 AND EVALUATE THE ETHICACY OF 3414 02:27:37,259 --> 02:27:39,561 INTEGRATED MODELS THAT COMBINED 3415 02:27:39,561 --> 02:27:43,932 BIO MEDICAL AND BEHAVIORAL AND 3416 02:27:43,932 --> 02:27:46,034 SOCIAL SCIENCE APPROACHES TO 3417 02:27:46,034 --> 02:27:48,804 HIV CARE, SUPPORT AS WELL AS 3418 02:27:48,804 --> 02:27:51,073 CURE RESEARCH AND SERVICES. 3419 02:27:51,073 --> 02:27:55,477 TO PROMOTE ASSESSMENT OF NOVEL 3420 02:27:55,477 --> 02:27:57,045 STRATEGIES USING NEW TECHNOLOGY 3421 02:27:57,045 --> 02:27:58,714 FOR EXAMPLE, TELE MEDICINE AND 3422 02:27:58,714 --> 02:28:02,150 THE USE OF NON CLINICAL SETTING 3423 02:28:02,150 --> 02:28:03,752 SUCH AS COMMUNITY BASE 3424 02:28:03,752 --> 02:28:05,087 ORGANIZATION TO DELIVER HIV 3425 02:28:05,087 --> 02:28:06,021 SERVICES. 3426 02:28:06,021 --> 02:28:08,790 LE ALSO TO INVESTIGATE THE 3427 02:28:08,790 --> 02:28:11,326 POTENTIAL OF INTEGRATED HIV 3428 02:28:11,326 --> 02:28:13,195 BEHAVIORAL HEALTH AND OTHER 3429 02:28:13,195 --> 02:28:16,431 CHRONIC AND NON COMMUNICABLE 3430 02:28:16,431 --> 02:28:17,032 DISEASE SERVICES. 3431 02:28:17,032 --> 02:28:20,302 AND TO DEVELOP AN EVALUATE 3432 02:28:20,302 --> 02:28:22,804 PERSON CENTER AND 3433 02:28:22,804 --> 02:28:24,406 COMMUNITY-LEAD SERVICE MODELS. 3434 02:28:24,406 --> 02:28:26,675 AND UNDER THAT OBJECTIVE, WE 3435 02:28:26,675 --> 02:28:28,043 HAD SPECIFIC RECOMMENDATIONS 3436 02:28:28,043 --> 02:28:30,379 FOR PRIORITY TO DEVELOP AND 3437 02:28:30,379 --> 02:28:32,247 ASSESS THE EFFECTIVENESS OF 3438 02:28:32,247 --> 02:28:33,649 PREVENTION AND TREATMENT 3439 02:28:33,649 --> 02:28:36,818 DELIVERY MODELS THAT INTEGRATE 3440 02:28:36,818 --> 02:28:39,121 BIO MEDICAL BEHAVIORAL AND 3441 02:28:39,121 --> 02:28:42,291 STRUCTURAL INTERVENTIONS TO 3442 02:28:42,291 --> 02:28:43,692 REDUCE HIV INCIDENTS WITH 3443 02:28:43,692 --> 02:28:44,593 PEOPLE AT-RISK WITH HIV 3444 02:28:44,593 --> 02:28:50,565 AND TO IMPROVE TREATMENT AND 3445 02:28:50,565 --> 02:28:51,733 IMPROVE COMORBIDITY OUTCOMES IN 3446 02:28:51,733 --> 02:28:53,869 PEOPLE LIVING WITH HIV 3447 02:28:53,869 --> 02:28:56,838 SECONDLY TO DEVELOP AND 3448 02:28:56,838 --> 02:28:58,507 EVALUATE COME PREHENCE, 3449 02:28:58,507 --> 02:29:00,342 INNOVATIVE PATIENT CENTERED OR 3450 02:29:00,342 --> 02:29:02,177 PERSON CENTERED, I SHOULD SAY, 3451 02:29:02,177 --> 02:29:05,213 CARE MODELS THAT INTEGRATE HIV 3452 02:29:05,213 --> 02:29:06,548 PREVENTION AND TREATMENT WITH 3453 02:29:06,548 --> 02:29:08,850 OTHER SERVICES AND SETTINGS 3454 02:29:08,850 --> 02:29:10,952 THROUGH PARTNERSHIPS WITH OTHER 3455 02:29:10,952 --> 02:29:16,658 GROUPS TO MANAGE COINFECTIONS, 3456 02:29:16,658 --> 02:29:17,259 COMORBIDITIES, COMPLICATIONS 3457 02:29:17,259 --> 02:29:22,631 AND SIN DIMIC CONDITIONS WITH 3458 02:29:22,631 --> 02:29:22,998 PEOPLE WITH HIV 3459 02:29:22,998 --> 02:29:23,799 NEXT. 3460 02:29:23,799 --> 02:29:27,469 TO DEVELOP AND EVALUATE THE 3461 02:29:27,469 --> 02:29:30,005 EFFECTIVE OF NOVEL STRATEGIES 3462 02:29:30,005 --> 02:29:31,373 PREVENTION AND TREATMENT 3463 02:29:31,373 --> 02:29:33,241 SERVICE DELIVERY, TO EXPLORE 3464 02:29:33,241 --> 02:29:35,711 AND EVALUATE CLINICAL AND 3465 02:29:35,711 --> 02:29:39,348 COMMUNITY BASE SERVICE DELIVERY 3466 02:29:39,348 --> 02:29:41,416 MODELS, TO ENHANCE STAINABLE 3467 02:29:41,416 --> 02:29:42,317 PROGRAMMING, COMMUNITY 3468 02:29:42,317 --> 02:29:43,952 ENGAGEMENT AND RETENTION IN 3469 02:29:43,952 --> 02:29:46,288 PREVENTION AND CARE AND FINALLY 3470 02:29:46,288 --> 02:29:48,790 TO LEVERAGE RESEARCH MODELS 3471 02:29:48,790 --> 02:29:51,560 THAT ASSESS THE IMPACT OF 3472 02:29:51,560 --> 02:29:53,829 SOCIAL AND STRUCTURAL 3473 02:29:53,829 --> 02:29:54,963 DETERMINANTS OF HEALTH AND 3474 02:29:54,963 --> 02:29:56,798 LOCAL STATE AND FEDERAL AND 3475 02:29:56,798 --> 02:29:58,233 GLOBAL POLICIES ON THE HEALTH 3476 02:29:58,233 --> 02:30:00,335 OF PEOPLE LIVING WITH AND 3477 02:30:00,335 --> 02:30:05,607 AFFECTED BY HIV IN DIVERSE AND 3478 02:30:05,607 --> 02:30:07,642 UNDER STUDIED SETTINGS. 3479 02:30:07,642 --> 02:30:14,149 NEXT SLIDE. 3480 02:30:14,149 --> 02:30:16,585 I THINK THIS IS OMAR. 3481 02:30:16,585 --> 02:30:19,187 >> YES, SO THIS IS GOAL 3 AND 3482 02:30:19,187 --> 02:30:21,723 THE GOAL HERE IS OPTIMIZING 3483 02:30:21,723 --> 02:30:26,361 PUBLIC HEALTH IMPACT OF HIV 3484 02:30:26,361 --> 02:30:27,763 DISCOVERY THROUGH DIS SEM 3485 02:30:27,763 --> 02:30:28,697 NATION OF MINDINGS. 3486 02:30:28,697 --> 02:30:30,999 IT WAS REALLY INTERESTING TO 3487 02:30:30,999 --> 02:30:32,401 HEAR THE PRESENTATIONS EARLIER 3488 02:30:32,401 --> 02:30:34,469 AND REALIZE IT HAS TAKEN 30 3489 02:30:34,469 --> 02:30:41,176 YEARS SINCE THE INITIAL THE 3490 02:30:41,176 --> 02:30:49,951 BASIC SCIENCE. 3491 02:30:49,951 --> 02:30:51,620 HOW DO WE BECOME MORE EFFICIENT 3492 02:30:51,620 --> 02:30:52,587 AT DOING THIS. 3493 02:30:52,587 --> 02:30:56,925 SO THE SPECIFIC OBJECTIVES ARE 3494 02:30:56,925 --> 02:31:00,595 3.1 ENHANCING IMPLEMENTATION 3495 02:31:00,595 --> 02:31:04,733 SCIENCE 3.2 PROMOTING RESEARCH 3496 02:31:04,733 --> 02:31:08,103 AND OBJECTIVE 3.3 IMPROVING DID 3497 02:31:08,103 --> 02:31:09,838 I SIM NATION THROUGH 3498 02:31:09,838 --> 02:31:10,338 COMMUNICATION RESEARCH. 3499 02:31:10,338 --> 02:31:14,443 NEXT. 3500 02:31:14,443 --> 02:31:16,978 SO THE LEMATION FOR OBJECTIVE 3501 02:31:16,978 --> 02:31:19,748 3.1 IN TERMS OF ENHANCING 3502 02:31:19,748 --> 02:31:20,749 IMPLEMENTATION SCIENCE ARE 3503 02:31:20,749 --> 02:31:22,751 FIRST, CONDUCTING 3504 02:31:22,751 --> 02:31:27,389 IMPLEMENTATION RESEARCH TO OP 3505 02:31:27,389 --> 02:31:29,024 MIEZ--OPTIMIZE THE REAL WORLD 3506 02:31:29,024 --> 02:31:30,325 ACTIVITY IN MULTIPLE SITES AND 3507 02:31:30,325 --> 02:31:31,393 SETTINGS. 3508 02:31:31,393 --> 02:31:33,728 THEN TO EVALUATE THE SCALE 3509 02:31:33,728 --> 02:31:37,199 ABILITY AND SUSTAINABILITY OF 3510 02:31:37,199 --> 02:31:38,333 EVIDENCE HIV INTERVENTION 3511 02:31:38,333 --> 02:31:39,968 MODELS IN DIVERSE POPULATION 3512 02:31:39,968 --> 02:31:42,504 SXZ SETTINGS INCLUDING RESEARCH 3513 02:31:42,504 --> 02:31:43,004 LIMITED SETTINGS. 3514 02:31:43,004 --> 02:31:46,208 THEN WE HAVE IDENTIFYING AND 3515 02:31:46,208 --> 02:31:48,977 ADDRESSING FACTORS AFFECTING 3516 02:31:48,977 --> 02:31:49,644 INTERVENTION, AND 3517 02:31:49,644 --> 02:31:52,647 SUSTAINABILITY TO PROMOTE 3518 02:31:52,647 --> 02:31:55,250 EQUITABLE UP TAKE AND IMPACT OF 3519 02:31:55,250 --> 02:31:56,818 HIV INTERVENTIONS. 3520 02:31:56,818 --> 02:31:59,855 THEN WE HAVE DEVELOPING AND 3521 02:31:59,855 --> 02:32:02,090 EVALUATE HEALTH SYSTEM 3522 02:32:02,090 --> 02:32:06,394 INTERVENTIONS THAT SUPPORT THE 3523 02:32:06,394 --> 02:32:11,066 COMPREHENSIVE HIV AS WELL AS TO 3524 02:32:11,066 --> 02:32:12,901 STRENGTHEN SERVICE DELIVERY 3525 02:32:12,901 --> 02:32:13,468 SUPPLY CHAIN MANAGEMENT ET 3526 02:32:13,468 --> 02:32:15,203 CETERA. 3527 02:32:15,203 --> 02:32:16,805 NEXT, STUDYING THE IMPACT OF 3528 02:32:16,805 --> 02:32:19,174 LOCAL STATE AND FEDERAL 3529 02:32:19,174 --> 02:32:22,844 POLICIES FOR EXAMPLE, HIV 3530 02:32:22,844 --> 02:32:26,915 CRIMINALIZATION LAWS, ANTI 3531 02:32:26,915 --> 02:32:30,318 TRANSGENDER, ANTI ABORTION AND 3532 02:32:30,318 --> 02:32:32,587 OTHER POLICIES AND REGULATORY 3533 02:32:32,587 --> 02:32:36,291 ENVIRONMENT ON IMPLEMENT OF HIV 3534 02:32:36,291 --> 02:32:37,926 AND CURE INTERVENTION TO 3535 02:32:37,926 --> 02:32:39,528 ADDRESS THE STRUCTURAL 3536 02:32:39,528 --> 02:32:42,330 IMPLEMENTATION BARRIERS. 3537 02:32:42,330 --> 02:32:44,833 DEVELOPING AND UTILIZING 3538 02:32:44,833 --> 02:32:47,102 IMPLEMENTATION SCIENCE FRAME 3539 02:32:47,102 --> 02:32:49,604 WORKEDS TO GUIDE DATA 3540 02:32:49,604 --> 02:32:52,574 COLLECTION AND SCIENCE AND 3541 02:32:52,574 --> 02:32:55,777 APPLICATION IN REAL LIFE 3542 02:32:55,777 --> 02:32:57,145 SETTINGS SUSTAINABILITY OF 3543 02:32:57,145 --> 02:32:59,681 INTERVENTION IN COMMUNITIES 3544 02:32:59,681 --> 02:33:00,649 DISPROPORTIONATE LEA 3545 02:33:00,649 --> 02:33:01,216 FEBRUARIEDING BY HIV 3546 02:33:01,216 --> 02:33:10,392 NEXT. 3547 02:33:10,392 --> 02:33:12,460 OBJECTIVE 3.2, IT'S ABOUT 3548 02:33:12,460 --> 02:33:14,729 PROMOTING COMMUNITY ENGAGE AND 3549 02:33:14,729 --> 02:33:16,598 COMMUNITY LEAD HIV RESEARCH. 3550 02:33:16,598 --> 02:33:18,867 THIS SPECIFIC RECOMMENDATIONS 3551 02:33:18,867 --> 02:33:21,670 AND THIS IS ALREADY INCLUDING 3552 02:33:21,670 --> 02:33:26,274 ALL OF THE TASK FORCES, 3553 02:33:26,274 --> 02:33:27,876 INCLUDES ENGAGING PERSON'S 3554 02:33:27,876 --> 02:33:30,612 LIVING WITH HIV ADVOCATE AND 3555 02:33:30,612 --> 02:33:32,213 PARTNERS NATIONALLY AND 3556 02:33:32,213 --> 02:33:33,381 GLOBALLY IN FULL RESEARCH 3557 02:33:33,381 --> 02:33:35,250 PROCESS. 3558 02:33:35,250 --> 02:33:36,685 FOR EXAMPLE, RESEARCH 3559 02:33:36,685 --> 02:33:40,088 QUESTIONS, STUDY DESIGN, 3560 02:33:40,088 --> 02:33:41,690 PROJECT RECOMMENDATION TO 3561 02:33:41,690 --> 02:33:43,959 ENSURE CULTURAL RELEVANCE AND 3562 02:33:43,959 --> 02:33:44,693 ACCEPTANCE INCLUDING THROUGH 3563 02:33:44,693 --> 02:33:47,329 THE USE OF COMMUNITY BASE 3564 02:33:47,329 --> 02:33:48,663 RESEARCH METHODS. 3565 02:33:48,663 --> 02:33:52,734 THEN WE HAVE DEVELOPED AND 3566 02:33:52,734 --> 02:33:53,702 EVALUATE COMMUNITY LEAD 3567 02:33:53,702 --> 02:33:59,307 INTERVENTION. 3568 02:33:59,307 --> 02:34:02,510 INCLUDING THOSE FOCUSED ON 3569 02:34:02,510 --> 02:34:03,244 ASSOCIATED INTERSECTIONAL 3570 02:34:03,244 --> 02:34:04,546 DISCRIMINATION AS WELL AS 3571 02:34:04,546 --> 02:34:06,615 MENTAL HEALTH AND SUBSTANCE 3572 02:34:06,615 --> 02:34:07,082 YOUTH. 3573 02:34:07,082 --> 02:34:09,150 AND WE ALSO HAVE SUPPORT, 3574 02:34:09,150 --> 02:34:10,752 COMMUNITY AND EDUCATION 3575 02:34:10,752 --> 02:34:12,153 STRATEGIES AND PUBLIC HEALTH 3576 02:34:12,153 --> 02:34:22,330 CAMPAIGNS. 3577 02:34:34,175 --> 02:34:35,243 COMMUNITY LEAD INTERVENTION 3578 02:34:35,243 --> 02:34:37,545 INCLUDING MONITORING AND 3579 02:34:37,545 --> 02:34:42,117 EVALUATE IN XLES DM*ES 3580 02:34:42,117 --> 02:34:44,686 --DOMESTIC SETTINGS. 3581 02:34:44,686 --> 02:34:46,588 HIV-RELATED OUTCOME INCLUDING 3582 02:34:46,588 --> 02:34:47,722 THROUGH ESTABLISHED NETWORK 3583 02:34:47,722 --> 02:34:52,961 ALREADY SERVING THE MOST 3584 02:34:52,961 --> 02:34:54,596 AFFECTED COMMUNITIES, AND 3585 02:34:54,596 --> 02:34:58,900 INSTITUTIONS WITH CLINICAL 3586 02:34:58,900 --> 02:35:04,539 TRANSLATIONAL SCIENCE CTSIs 3587 02:35:04,539 --> 02:35:06,875 RESEARCH, SUCH THAT HIV 3588 02:35:06,875 --> 02:35:07,809 RESEARCH AND INTERVENTION 3589 02:35:07,809 --> 02:35:10,845 DEVELOPED MEET THE NEEDS OF ALL 3590 02:35:10,845 --> 02:35:13,148 PEOPLE, IMPACTED BY HIV 3591 02:35:13,148 --> 02:35:15,216 SUPPORT SUSTAINABLE OF LONG 3592 02:35:15,216 --> 02:35:17,252 TERM RESEARCH EN DERING 3593 02:35:17,252 --> 02:35:18,153 INCLUDING THOSE INVOLVING YOUTH 3594 02:35:18,153 --> 02:35:21,556 AND THE NEXT GENERATION OF 3595 02:35:21,556 --> 02:35:22,924 COMMUNITY REPRESENTATIVES AND 3596 02:35:22,924 --> 02:35:24,292 SUPPORT RECOGNITION OF LIVED 3597 02:35:24,292 --> 02:35:26,528 EXPERIENCE IN HIV RESEARCH. 3598 02:35:26,528 --> 02:35:36,638 NEXT. 3599 02:35:41,443 --> 02:35:44,379 DEVELOPING AND IMPLEMENT AND 3600 02:35:44,379 --> 02:35:46,915 VALUE ATE INNOVATIVE TAYLOR 3601 02:35:46,915 --> 02:35:48,316 COMMUNICATION STRATEGY TO 3602 02:35:48,316 --> 02:35:51,553 TRANSLATE AND CLEARLY CONVEY 3603 02:35:51,553 --> 02:35:53,621 COMPLEX INFORMATION RELATED 3604 02:35:53,621 --> 02:35:54,989 RESEARCH FINDINGS TO DIVERSE 3605 02:35:54,989 --> 02:35:57,525 AUDIENCES. 3606 02:35:57,525 --> 02:35:59,127 THEN, TRAIN RESEARCHERS AND 3607 02:35:59,127 --> 02:36:01,863 COMMUNITY BASE ORGANIZATION ON 3608 02:36:01,863 --> 02:36:06,201 AFFECTIVE SCIENCE COMMUNICATION 3609 02:36:06,201 --> 02:36:07,635 TECHNIQUES INCLUDING THOSE 3610 02:36:07,635 --> 02:36:09,003 ADDRESSING THIS, ACCURATE 3611 02:36:09,003 --> 02:36:10,505 RESEARCH FINDINGS THROUGH 3612 02:36:10,505 --> 02:36:15,143 VARIOUS OUTLETS. 3613 02:36:15,143 --> 02:36:16,745 DEVELOP AFFECTIVE FRAME WORKS 3614 02:36:16,745 --> 02:36:18,146 AND PARTNERSHIPS BETWEEN 3615 02:36:18,146 --> 02:36:19,514 RESEARCH AND COMMUNITY MEMBERS 3616 02:36:19,514 --> 02:36:21,750 TO TRANSLATE RESEARCH FINDINGS 3617 02:36:21,750 --> 02:36:22,951 INTO ACTIONABLE PROGRAMS AND 3618 02:36:22,951 --> 02:36:24,352 POLICIES. 3619 02:36:24,352 --> 02:36:26,688 AND USE PRACTICES SUCH AS 3620 02:36:26,688 --> 02:36:28,289 COMMUNITY BASE RESEARCH TO 3621 02:36:28,289 --> 02:36:38,733 ENSURE THAT THE DID 3622 02:36:38,733 --> 02:36:39,567 DISSEMINATE, AND INFORM 3623 02:36:39,567 --> 02:36:45,740 DECISION MAKING. 3624 02:36:45,740 --> 02:36:46,441 NEXT. 3625 02:36:46,441 --> 02:36:48,510 >> SOING THIS IS ME AGAIN. 3626 02:36:48,510 --> 02:36:49,677 GOAL NUMBER 4 IS THE CAPACITY 3627 02:36:49,677 --> 02:36:50,812 GOAL. 3628 02:36:50,812 --> 02:36:53,982 OVERALL TO BUILD RESEARCH 3629 02:36:53,982 --> 02:36:56,351 WORKFORCE AND INFRASTRUCTURE 3630 02:36:56,351 --> 02:37:00,021 CAPACITY TO ENHANCE SUSTAINABLE 3631 02:37:00,021 --> 02:37:04,292 OF HIV DISCOVERY. 3632 02:37:04,292 --> 02:37:07,495 AND THE THOUGHTS HERE, AND ITS 3633 02:37:07,495 --> 02:37:09,097 APPLICATION REQUIRES ROBUST 3634 02:37:09,097 --> 02:37:15,637 SUPPORT FOR RESEARCH TOOLS AND 3635 02:37:15,637 --> 02:37:16,171 INSTRUMENTATION, METHODS 3636 02:37:16,171 --> 02:37:18,640 RESOURCES DATA AND WORKFORCE 3637 02:37:18,640 --> 02:37:19,774 DEVELOPMENT. 3638 02:37:19,774 --> 02:37:20,708 PARTICULARLY IN INSTITUTION 3639 02:37:20,708 --> 02:37:23,511 THAT'S SERVE UNDER REPRESENTED 3640 02:37:23,511 --> 02:37:28,983 OR HIGH HIV BURDEN POPULATIONS 3641 02:37:28,983 --> 02:37:30,585 OR HISTORICALLY BEING UNDER 3642 02:37:30,585 --> 02:37:33,588 FUNDED IN U.S. AND GLOBAL'. 3643 02:37:33,588 --> 02:37:36,157 SUCH ENHANCE EFFORTS WILL 3644 02:37:36,157 --> 02:37:37,559 PROMOTE DIVERSITY AND INCLUSION 3645 02:37:37,559 --> 02:37:39,894 IN THE HIV RESEARCH WORKFORCE. 3646 02:37:39,894 --> 02:37:41,763 THAT'S THE OVERALL GLOBALSINGER 3647 02:37:41,763 --> 02:37:45,233 THE THREE OBJECTIVES TO EXPAND, 3648 02:37:45,233 --> 02:37:47,535 WORKFORCE CAPACITY, STRENGTHEN 3649 02:37:47,535 --> 02:37:48,703 RESEARCH INFRASTRUCTURE AND 3650 02:37:48,703 --> 02:37:52,373 CAPACITY AND FINALLY TO ENHANCE 3651 02:37:52,373 --> 02:37:53,541 METHODS AND TECHNOLOGIES. 3652 02:37:53,541 --> 02:37:56,578 NEXT, SO AGAIN THIS IS A SHARED 3653 02:37:56,578 --> 02:37:58,179 OBJECTIVE, AMONG THE THREE 3654 02:37:58,179 --> 02:38:00,715 GROUPS, THE THREE TASK FORCES 3655 02:38:00,715 --> 02:38:02,650 TO CONSIDER EXPANDING WORKFORCE 3656 02:38:02,650 --> 02:38:03,451 CAPACITY. 3657 02:38:03,451 --> 02:38:06,221 THAT IS TRAINING AND MENTORING 3658 02:38:06,221 --> 02:38:08,056 ACTIVITIES TO SUPPORT CAREER 3659 02:38:08,056 --> 02:38:11,359 DEVELOPMENT AND STRENGTHEN THE 3660 02:38:11,359 --> 02:38:12,961 CAPACITY OF BIOMEDICAL, 3661 02:38:12,961 --> 02:38:15,496 BEHAVIORAL SOCIAL AND COMMUNITY 3662 02:38:15,496 --> 02:38:18,299 BASE HIV RESEARCHERS IN DIVERSE 3663 02:38:18,299 --> 02:38:20,802 SETTINGS AND INSTITUTIONS. 3664 02:38:20,802 --> 02:38:24,472 AND TO PROMOTE ACTIVITIES TO 3665 02:38:24,472 --> 02:38:26,774 INKRESS, ENHANCE AND SUSTAIN 3666 02:38:26,774 --> 02:38:29,244 DIVERSITY IN THE HIV WORKFORCE 3667 02:38:29,244 --> 02:38:30,845 IN THE U.S. AND GLOBALLY. 3668 02:38:30,845 --> 02:38:31,813 THIS SPECIFIC RECOMMENDATION 3669 02:38:31,813 --> 02:38:33,381 SXZ AGAIN, THESE ARE SHARED 3670 02:38:33,381 --> 02:38:35,650 BETWEEN THE THREE TASK FORCES, 3671 02:38:35,650 --> 02:38:39,287 TO DEVELOP COMPREHENSIVE INTER 3672 02:38:39,287 --> 02:38:40,221 DISCIPLINARY TRAINING PROGRAMS 3673 02:38:40,221 --> 02:38:43,958 THAT INCLUDE THE LATEST 3674 02:38:43,958 --> 02:38:45,560 BIOMEDICAL, BIOBEHAVIORAL AND 3675 02:38:45,560 --> 02:38:50,131 SOCIAL SCIENCE RESEARCH METH 3676 02:38:50,131 --> 02:38:51,499 YTHOLOGIES TO ENHANCE SKILL AND 3677 02:38:51,499 --> 02:38:53,301 KNOWLEDGE OF THE RESEARCH. 3678 02:38:53,301 --> 02:38:57,272 NEXT TO IMPLEMENT STRUCTURE AND 3679 02:38:57,272 --> 02:38:57,972 SUSTAINED MENTORSHIP 3680 02:38:57,972 --> 02:39:00,041 INITIATIVES TO SUPPORT EARLY 3681 02:39:00,041 --> 02:39:03,678 AND MID-CAREER HIV RESEARCHERS, 3682 02:39:03,678 --> 02:39:05,513 INVESTIGATES NEW TO HIV 3683 02:39:05,513 --> 02:39:09,417 RESEARCH AND COMMUNITY REPS IN 3684 02:39:09,417 --> 02:39:13,488 DIVERSE SETTINGS AND USING 3685 02:39:13,488 --> 02:39:14,889 DIVERSE METHODSES TO ENSURE 3686 02:39:14,889 --> 02:39:17,191 EXPANSION OF THE NEXT 3687 02:39:17,191 --> 02:39:19,527 GENERATION OF HIV WORKFORCE. 3688 02:39:19,527 --> 02:39:22,030 ALSO TO SUPPORT CAREER 3689 02:39:22,030 --> 02:39:27,769 DEVELOPMENT TO LONGITUDE THAT 3690 02:39:27,769 --> 02:39:30,305 PROVIDE FUNDING SKILLS BUILDING 3691 02:39:30,305 --> 02:39:31,239 MENTORSHIP AND LEADERSHIP 3692 02:39:31,239 --> 02:39:34,909 OPPORTUNITIES TO FACILITATE 3693 02:39:34,909 --> 02:39:36,344 TRANSITIONS FROM TRAINEE TO 3694 02:39:36,344 --> 02:39:39,047 INDEPENDENT RESEARCH. 3695 02:39:39,047 --> 02:39:40,014 RESEARCHER, AND FINALLY TO 3696 02:39:40,014 --> 02:39:43,184 DEVELOP AND IMPLEMENT 3697 02:39:43,184 --> 02:39:44,819 COMPREHENSIVE AND SUSTAINED 3698 02:39:44,819 --> 02:39:46,688 INITIATIVE TO INCREASE AND SUS 3699 02:39:46,688 --> 02:39:48,056 STAINT REPRESENTATION OF WOMEN, 3700 02:39:48,056 --> 02:39:52,260 RAISH I CAN'T AND ETHNIC 3701 02:39:52,260 --> 02:39:53,494 MINORITIES AND OTHER UNDER 3702 02:39:53,494 --> 02:39:54,929 REPRESENTED GROUPS IN THE HIV 3703 02:39:54,929 --> 02:39:55,496 WORKFORCE. 3704 02:39:55,496 --> 02:39:58,466 NEXT. 3705 02:39:58,466 --> 02:40:00,535 THREE OTHERS, ESTABLISH AND 3706 02:40:00,535 --> 02:40:02,603 EXPAND GLOBAL TRAINING NETWORKS 3707 02:40:02,603 --> 02:40:04,172 TO ENHANCE CAPACITY BUILDING, 3708 02:40:04,172 --> 02:40:06,474 SHARED KNOWLEDGE AND PROMOTE 3709 02:40:06,474 --> 02:40:08,776 CAREER DEVELOPMENT AND BEST 3710 02:40:08,776 --> 02:40:12,013 PRACTICES ACROSS DIFFERENT 3711 02:40:12,013 --> 02:40:12,947 SETTINGS, STRENGTHEN 3712 02:40:12,947 --> 02:40:17,051 PARTNERSHIPS BETWEEN ACADEMIC 3713 02:40:17,051 --> 02:40:17,952 INSTITUTIONS, HEALTHCARE 3714 02:40:17,952 --> 02:40:18,686 ORGANIZATION SXZ COMMUNITY BASE 3715 02:40:18,686 --> 02:40:20,288 ORGANIZATION TO SEE ENHANCE 3716 02:40:20,288 --> 02:40:22,190 RESEARCH TRAIN ANDING CAREER 3717 02:40:22,190 --> 02:40:24,025 DEVELOPMENT AND FINALLY, TO 3718 02:40:24,025 --> 02:40:26,761 SUPPORT RESEARCH LITERACY 3719 02:40:26,761 --> 02:40:28,596 PROGRAMS AND PROMOTE 3720 02:40:28,596 --> 02:40:31,099 COOPERATION AMONG MEDICAL 3721 02:40:31,099 --> 02:40:32,233 SCIENCE TRAINEE GROUPS. 3722 02:40:32,233 --> 02:40:39,240 NEXT. 3723 02:40:39,240 --> 02:40:43,344 >> NEXT IS ANOTHER SHARED 3724 02:40:43,344 --> 02:40:46,080 OBJECTIVE 4.2 STRENGTHEN THE 3725 02:40:46,080 --> 02:40:47,448 INFRASTRUCTURE AND CAPACITY. 3726 02:40:47,448 --> 02:40:49,317 TO ENABLE AND SUPPORT 3727 02:40:49,317 --> 02:40:51,853 STATE-OF-THE-ART SCIENCE AND 3728 02:40:51,853 --> 02:40:53,287 AFFECTIVE DATA MANAGEMENT 3729 02:40:53,287 --> 02:40:56,024 ACCESSIBILITY AND ANALYSIS. 3730 02:40:56,024 --> 02:40:58,793 ENSURE ACCESS TO RESOURCES AND 3731 02:40:58,793 --> 02:41:01,829 COHORTS FOR CONDUCTING 3732 02:41:01,829 --> 02:41:03,031 FUNDAMENTAL AND PRECLINICAL AND 3733 02:41:03,031 --> 02:41:04,866 OTHER INTERVENTION AL RESEARCH 3734 02:41:04,866 --> 02:41:06,000 INCLUDING CLINICAL TRIALS IN 3735 02:41:06,000 --> 02:41:08,536 DOMESTIC AND INTERNATIONAL 3736 02:41:08,536 --> 02:41:10,872 SITES AND IMPLEMENTATION 3737 02:41:10,872 --> 02:41:12,006 STUDIES SCIENTIFIC ENVIRONMENT 3738 02:41:12,006 --> 02:41:14,342 TO MEET TODAY'S CHALLENGES AND 3739 02:41:14,342 --> 02:41:16,878 OPPORTUNITIES IN HIV RESEARCH. 3740 02:41:16,878 --> 02:41:17,612 THE SPECIFIC RECOMMENDATIONS 3741 02:41:17,612 --> 02:41:20,515 WERE TO IMPROVE AND EXPAND 3742 02:41:20,515 --> 02:41:22,417 RESEARCH AND ANIMAL BREEDING 3743 02:41:22,417 --> 02:41:24,052 FACILITIES TO SUPPORT HIV 3744 02:41:24,052 --> 02:41:25,219 RESEARCH AND AGAIN THROUGH A 3745 02:41:25,219 --> 02:41:26,621 LOT OF DISCUSSION ABOUT THE 3746 02:41:26,621 --> 02:41:28,256 LIMITS OF OUR CURRENT 3747 02:41:28,256 --> 02:41:31,959 INFRASTRUCTURE WHEN IT COMES TO 3748 02:41:31,959 --> 02:41:33,227 AVAILABLE NON HUMAN 3749 02:41:33,227 --> 02:41:34,729 PRIMATEDSMENT NEXT IS INVEST IN 3750 02:41:34,729 --> 02:41:37,231 THE UPGRADE AND EXPANSION OF 3751 02:41:37,231 --> 02:41:38,633 ADVANCE LABORATORY 3752 02:41:38,633 --> 02:41:40,034 INFRASTRUCTURE AND ENSURE 3753 02:41:40,034 --> 02:41:42,136 EQUITABLE AND DIVERSE ACCESS TO 3754 02:41:42,136 --> 02:41:43,971 THESE AND EQUIPMENT AND 3755 02:41:43,971 --> 02:41:47,608 TECHNOLOGY TO SUPPORT CUTTING 3756 02:41:47,608 --> 02:41:49,210 EDGE HIV RESEARCH NATIONALLY 3757 02:41:49,210 --> 02:41:50,611 AND GLOBALLY. 3758 02:41:50,611 --> 02:41:53,347 SUSTAIN AND EXPAND 3759 02:41:53,347 --> 02:41:53,948 INFRASTRUCTURE INCLUDING 3760 02:41:53,948 --> 02:41:55,616 CLINICAL TRIAL SITES AND 3761 02:41:55,616 --> 02:41:56,617 RECRUITMENT SYSTEMS AND 3762 02:41:56,617 --> 02:41:58,619 REGULATORY SUPPORT. 3763 02:41:58,619 --> 02:42:00,521 IMPLEMENT AND SUSTAIN THAT A 3764 02:42:00,521 --> 02:42:02,323 MANAGEMENT SYSTEM THAT 3765 02:42:02,323 --> 02:42:03,958 FACILITATE THAT SHARING AND 3766 02:42:03,958 --> 02:42:05,326 COOPERATION AMONG RESEARCHER 3767 02:42:05,326 --> 02:42:11,566 AND ENHANCE IMPLEMENTATION AND 3768 02:42:11,566 --> 02:42:15,603 CARE. 3769 02:42:15,603 --> 02:42:17,205 ACADEMIC INDUSTRY PARTNERSHIP 3770 02:42:17,205 --> 02:42:19,974 TO FOSTER A I TECHNOLOGY. 3771 02:42:19,974 --> 02:42:22,977 AND THIS IS ANOTHER TOPIC AS 3772 02:42:22,977 --> 02:42:24,812 DISCUSSED EARLIER TODAY, THERE 3773 02:42:24,812 --> 02:42:27,115 IS GOOD THINGS ACADEMIA DOES 3774 02:42:27,115 --> 02:42:29,150 AND INDUSTRY DOES AND WE NEED 3775 02:42:29,150 --> 02:42:32,854 TO BRIDGE THE MAGNITUDE OF THE 3776 02:42:32,854 --> 02:42:35,857 INDUSTRY CAPACITY IN MORE 3777 02:42:35,857 --> 02:42:36,491 INNOVATIVE PARTNERSHIPS MOVING 3778 02:42:36,491 --> 02:42:36,791 FORWARD. 3779 02:42:36,791 --> 02:42:39,293 NEXT SLIDE. 3780 02:42:39,293 --> 02:42:40,928 ENHANCE SUPPORT FOR REGULATORY 3781 02:42:40,928 --> 02:42:43,664 SUPPORT AND PRODUCT PRODUCTION 3782 02:42:43,664 --> 02:42:48,236 FOR ACADEMIC AND STUDIES, THIS 3783 02:42:48,236 --> 02:42:50,505 IS SOMEWHAT ANOTHER STRESS 3784 02:42:50,505 --> 02:42:52,240 POINT THAT WE THOUGHT IN 3785 02:42:52,240 --> 02:42:56,511 EARLIER RECOMMENDATIONS. 3786 02:42:56,511 --> 02:42:59,547 ENSURE DEVELOP AND SUPPORT 3787 02:42:59,547 --> 02:43:01,382 COLLABORATIVE RESEARCH NETWORKS 3788 02:43:01,382 --> 02:43:03,217 TO FACILITATE SHARING AND MULTI 3789 02:43:03,217 --> 02:43:08,756 SITE STUDIES BY PROMOTING 3790 02:43:08,756 --> 02:43:11,225 DIRECTIONS BETWEEN CLINICAL 3791 02:43:11,225 --> 02:43:12,393 CENTERS AND PHILANTHROPIC 3792 02:43:12,393 --> 02:43:13,761 INDUSTRIES AND THIS IS ANOTHER 3793 02:43:13,761 --> 02:43:15,596 POINT THAT YOU ARE ALL 3794 02:43:15,596 --> 02:43:17,965 DISCUSSION TRYING TO TAP INTO 3795 02:43:17,965 --> 02:43:19,033 EXISTING NETWORKS. 3796 02:43:19,033 --> 02:43:22,270 ENHANCE OR DEVELOP RESEARCH 3797 02:43:22,270 --> 02:43:24,071 INFRASTRUCTURE TARGETING 3798 02:43:24,071 --> 02:43:26,374 SPECIFIC LEVELS OF EDGE FUND TO 3799 02:43:26,374 --> 02:43:28,509 GO ENHANCE GREATER WORKFORCE 3800 02:43:28,509 --> 02:43:30,711 DIVERSITY. 3801 02:43:30,711 --> 02:43:32,813 AND ENHANCE FULT MULTI 3802 02:43:32,813 --> 02:43:35,349 INVESTIGATOR RESOURCE BY ADDED 3803 02:43:35,349 --> 02:43:36,984 CONTRACT STRATEGIES DO 3804 02:43:36,984 --> 02:43:40,388 INTRODUCE CONSUMABLE AND 3805 02:43:40,388 --> 02:43:43,891 EXPANSION OF TISSUE DEPOSITORY 3806 02:43:43,891 --> 02:43:46,627 AND AGAIN THROUGH A LOT OF 3807 02:43:46,627 --> 02:43:49,630 DISCUSSION TRYING TO I GUESS, 3808 02:43:49,630 --> 02:43:52,633 FOSTER THAT THESE AGENT REPOS 3809 02:43:52,633 --> 02:43:58,606 TORIES CAN BE EXPAND ED TO 3810 02:43:58,606 --> 02:44:00,041 EXPRESS COMMON THAT 3811 02:44:00,041 --> 02:44:01,542 INVESTIGATORS USE AS FAR AS 3812 02:44:01,542 --> 02:44:03,377 INTER LOOKING TOO AND THINGS 3813 02:44:03,377 --> 02:44:06,781 THAT ARE KIND OF IN MOST 3814 02:44:06,781 --> 02:44:07,481 PEOPLE'S CONSUMABLE BUCKETS. 3815 02:44:07,481 --> 02:44:11,085 NEXT SLIDE. 3816 02:44:11,085 --> 02:44:14,355 REGARDING THE OBJECTIVE 4.3 3817 02:44:14,355 --> 02:44:15,756 ENHANCE METHODS AND TECHNOLOGY. 3818 02:44:15,756 --> 02:44:17,625 THIS IS AN OBJECTIVE THAT LOOKS 3819 02:44:17,625 --> 02:44:19,927 TO FURTHER DEVELOP AND OP MIEZ 3820 02:44:19,927 --> 02:44:21,996 CRITICAL METHODS SUCH AS 3821 02:44:21,996 --> 02:44:27,301 INSTRUMENTAL AND SOFTWARE AND 3822 02:44:27,301 --> 02:44:30,071 IMAGING, BIOENGINEERING, INFO 3823 02:44:30,071 --> 02:44:31,639 MATICS, BIOMARKERS FOR DID I 3824 02:44:31,639 --> 02:44:32,807 VERSE PROGRESSIVE AND 3825 02:44:32,807 --> 02:44:33,941 TREATMENT, NEW COMMUNICATION 3826 02:44:33,941 --> 02:44:37,612 AND SOCIAL MEDIA TECHNOLOGIES, 3827 02:44:37,612 --> 02:44:41,249 ARTIFICIAL INTELLIGENCE AND 3828 02:44:41,249 --> 02:44:42,483 NATURAL LANGUAGE FOR TREATMENT 3829 02:44:42,483 --> 02:44:43,117 AND CURE. 3830 02:44:43,117 --> 02:44:46,120 THE PRIORITIES WERE TO INVEST 3831 02:44:46,120 --> 02:44:47,722 INSTRUMENTAL AND TECHNOLOGY 3832 02:44:47,722 --> 02:44:49,991 INCLUDING ADVANCE IMAGING AND 3833 02:44:49,991 --> 02:44:53,661 SAMPLING TECHNOLOGY TO ENABLE 3834 02:44:53,661 --> 02:44:54,795 HIGH-QUALITY TRANSLATIONAL 3835 02:44:54,795 --> 02:44:55,763 BIOMEDICAL AND SOCIAL SCIENCE 3836 02:44:55,763 --> 02:44:58,766 RESEARCH. 3837 02:44:58,766 --> 02:45:02,703 ENHANCE COMPUTATIONAL RESOURCES 3838 02:45:02,703 --> 02:45:04,171 PATIENT OUTCOME DATA SETS AND 3839 02:45:04,171 --> 02:45:06,374 MODELING IN SUPPORT OF LARGE 3840 02:45:06,374 --> 02:45:09,143 SCALE HIV RESEARCH. 3841 02:45:09,143 --> 02:45:11,245 INVEST AND DEVELOPING DEPLOYING 3842 02:45:11,245 --> 02:45:13,781 TECHNOLOGIES AND SYSTEMS THAT 3843 02:45:13,781 --> 02:45:15,149 FACILITATE IMPLEMENTATION OF 3844 02:45:15,149 --> 02:45:17,451 NEW AND PREVENTION TREATMENT 3845 02:45:17,451 --> 02:45:19,954 INCLUDING HIV STATUS TESTING, 3846 02:45:19,954 --> 02:45:20,921 MONITORING AND ADHERENCE 3847 02:45:20,921 --> 02:45:23,424 TESTING INCLUDING AT POINT OF 3848 02:45:23,424 --> 02:45:25,993 CARE AND SELF HOME MONITORING. 3849 02:45:25,993 --> 02:45:28,029 NEXT SLIDE. 3850 02:45:28,029 --> 02:45:32,133 NEXT TWO OBJECTIVES WERE 3851 02:45:32,133 --> 02:45:34,235 LETHBRIDGE EQUITABLE USE OF 3852 02:45:34,235 --> 02:45:35,403 ARTIFICIAL INTELLIGENCE AND 3853 02:45:35,403 --> 02:45:37,004 NATURAL LANGUAGE PROCESSING AND 3854 02:45:37,004 --> 02:45:38,639 MACHINE LEARNING TECHNOLOGY TO 3855 02:45:38,639 --> 02:45:41,175 ANALYZE LARGE AND IDENTIFY 3856 02:45:41,175 --> 02:45:44,345 PATTERNS OF HIV PROGRESSION AND 3857 02:45:44,345 --> 02:45:45,746 EN PANS INCLUDING PREDICT I 3858 02:45:45,746 --> 02:45:48,716 HAVE MODELING AND DATA ANALYSIS. 3859 02:45:48,716 --> 02:45:51,519 AND LASTLY DEVELOP AND 3860 02:45:51,519 --> 02:45:52,953 IMPLEMENT AND SUSTAIN NEW 3861 02:45:52,953 --> 02:46:03,497 COMMUNITIES FOR DID I DID DIS 3862 02:46:08,736 --> 02:46:10,004 SEM NATION. 3863 02:46:10,004 --> 02:46:14,842 THIS WAS DREW A LO INVEST IN 3864 02:46:14,842 --> 02:46:16,677 MARKETING, EDUCATING BOTH 3865 02:46:16,677 --> 02:46:18,045 CLINICAL AND LATE COMMUNITIES 3866 02:46:18,045 --> 02:46:21,048 ABOUT THE NEED TO INTERFACE AND 3867 02:46:21,048 --> 02:46:23,117 COLLABORATE IN BASIC RESEARCH 3868 02:46:23,117 --> 02:46:24,952 INITIATIVE WHICH WAS A NOVEL 3869 02:46:24,952 --> 02:46:27,755 CAPACITY FROM A POINT OF VIEW 3870 02:46:27,755 --> 02:46:30,424 OF OUR WORDS. 3871 02:46:30,424 --> 02:46:34,595 I THINK THAT CONCLUDES OUR 3872 02:46:34,595 --> 02:46:40,901 DISCUSSION, THANK YOU. 3873 02:46:40,901 --> 02:46:42,737 >> THANK YOU SO MUCH. 3874 02:46:42,737 --> 02:46:53,180 THANK YOU SO DR.S BONSAL, 3875 02:46:56,417 --> 02:47:03,824 MONANER AND GALICK, NOW WE HAVE 3876 02:47:03,824 --> 02:47:04,792 TIME FOR DISCUSSION. 3877 02:47:04,792 --> 02:47:07,928 IF YOU HAVE ANY QUESTIONS OR 3878 02:47:07,928 --> 02:47:08,596 COMMENTS, PLEASE RAISE YOUR 3879 02:47:08,596 --> 02:47:14,635 HAND. 3880 02:47:14,635 --> 02:47:16,337 YES, DR. DONENBERG, YOU HAVE TO 3881 02:47:16,337 --> 02:47:17,405 UNMUTE YOURSELF. 3882 02:47:17,405 --> 02:47:21,675 >> THANK YOU, FIRST I WANT TO 3883 02:47:21,675 --> 02:47:26,714 THANK THE TASK FORCES, SO MUCH 3884 02:47:26,714 --> 02:47:28,315 WORK WENT INTO THOSE 3885 02:47:28,315 --> 02:47:29,683 RECOMMENDATION SXZ KUDOS TO YOU. 3886 02:47:29,683 --> 02:47:31,118 I THINK MY QUESTION AND MAYBE 3887 02:47:31,118 --> 02:47:33,654 WITH MY HAT ON AS OAR DIRECTOR, 3888 02:47:33,654 --> 02:47:35,623 THERE WERE A LOT OF 3889 02:47:35,623 --> 02:47:36,223 DATIONS. 3890 02:47:36,223 --> 02:47:39,560 ACROSS ALL OF THAT AND OF 3891 02:47:39,560 --> 02:47:40,928 COURSE, WHILE EVERY SINGLE ONE 3892 02:47:40,928 --> 02:47:43,864 OF THEM IS IMPORTANT AND 3893 02:47:43,864 --> 02:47:49,937 CERTAIN WELL JUSTIFIED GIVEN THE 3894 02:47:49,937 --> 02:47:55,409 THIS PHASE OF THE EPIDEMIC, MY 3895 02:47:55,409 --> 02:47:57,211 SUGGESTION WOULD BE TO PRIOR 3896 02:47:57,211 --> 02:48:01,282 TICE AND MAYBE THE TASK FORCES 3897 02:48:01,282 --> 02:48:04,318 OR OARAC TO SAY WHICH OF ALL OF 3898 02:48:04,318 --> 02:48:05,619 THESE RECOMMENDATIONS ARE THE 3899 02:48:05,619 --> 02:48:07,254 ONES THAT SHOULD RISE FOR THE 3900 02:48:07,254 --> 02:48:09,089 TOP FOR FUNDING AT THIS STAGE? 3901 02:48:09,089 --> 02:48:13,027 AND I THINK WE'VE HEARD VERY 3902 02:48:13,027 --> 02:48:13,994 COMPELLING JUSTIFICATION FOR 3903 02:48:13,994 --> 02:48:14,895 WHY BASIC SCIENCE IS VERY 3904 02:48:14,895 --> 02:48:18,933 IMPORTANT. 3905 02:48:18,933 --> 02:48:22,369 WE HEARD JUSTIFICATION FOR 3906 02:48:22,369 --> 02:48:22,970 INFRASTRUCTURE AND CAPACITY 3907 02:48:22,970 --> 02:48:24,205 BUILDING. 3908 02:48:24,205 --> 02:48:25,606 SO I'M INTERESTED IN HEARING 3909 02:48:25,606 --> 02:48:29,977 FROM THE TASK FORCE LEADERS AND 3910 02:48:29,977 --> 02:48:31,145 OARAC MEMBERS WHAT PROCESS 3911 02:48:31,145 --> 02:48:35,683 WOULD YOU GO THROUGH TO 3912 02:48:35,683 --> 02:48:37,718 IDENTIFY THE PRIORITIES TO 3913 02:48:37,718 --> 02:48:39,019 MATCH WITH FUN 3914 02:48:39,019 --> 02:48:39,653 UNITIES? 3915 02:48:39,653 --> 02:48:41,088 THANK YOU. 3916 02:48:41,088 --> 02:48:45,559 >> THANK YOU, DOCTOR. 3917 02:48:45,559 --> 02:48:48,929 I'LL START BUT I WANT TO 3918 02:48:48,929 --> 02:48:50,798 CLARIFY THAT OUR CHARTS FOR THE 3919 02:48:50,798 --> 02:48:54,668 TASK FORCES WAS TO ENUMERATE 5 3920 02:48:54,668 --> 02:48:57,905 TO 6 PRIORITIES AND WE WERE 3921 02:48:57,905 --> 02:48:58,906 SPECIFICALLY INSTRUCTED NOT TO 3922 02:48:58,906 --> 02:48:59,874 RANK THEM. 3923 02:48:59,874 --> 02:49:02,076 THERE WERE MEMBERS OF OUR TASK 3924 02:49:02,076 --> 02:49:04,144 FORCE THAT'S ASKED A SIMILAR 3925 02:49:04,144 --> 02:49:07,548 QUESTION AS YOU'RE RAISING. 3926 02:49:07,548 --> 02:49:09,583 WE'RE PRETTY MUCH BEING SO 3927 02:49:09,583 --> 02:49:14,688 INCLUSIVE THAT WE'RE NOT 3928 02:49:14,688 --> 02:49:16,490 PRIORITIZING ANY ONE AREA THAN 3929 02:49:16,490 --> 02:49:17,691 ANOTHER. 3930 02:49:17,691 --> 02:49:19,760 SO IT WOULD REPRESENT A 3931 02:49:19,760 --> 02:49:21,629 DIFFERENT EXERCISE IN WHAT WE 3932 02:49:21,629 --> 02:49:24,765 UNDERTOOK CAUSE WE WERE MORE 3933 02:49:24,765 --> 02:49:28,402 FOCUSED ON BEING INCLUSIVE OVER 3934 02:49:28,402 --> 02:49:31,405 OUR CURRENT EFFORTS BUT ADDING 3935 02:49:31,405 --> 02:49:33,908 COMPONENTS THAT WERE AS 3936 02:49:33,908 --> 02:49:36,243 EMPHASIZED FOR EXAMPLE, 3937 02:49:36,243 --> 02:49:37,711 ARTIFICIAL INTELLIGENCE, PRIET 3938 02:49:37,711 --> 02:49:39,213 AT RESOURCES THINGS THAT WE 3939 02:49:39,213 --> 02:49:41,115 THOUGHT AND PERHAPS I'M BEING 3940 02:49:41,115 --> 02:49:45,386 BIASED BECAUSE, I'M HAOUR TRIP 3941 02:49:45,386 --> 02:49:46,520 AND OTHERS WILL HAVE OTHER 3942 02:49:46,520 --> 02:49:48,355 TOPIC. 3943 02:49:48,355 --> 02:49:49,890 BUT YOU'RE RAISING A REALLY 3944 02:49:49,890 --> 02:49:53,527 IMPORTANT QUESTION BUT IT WOULD 3945 02:49:53,527 --> 02:49:55,563 BE US RANKING THEM HERE, AS FAR 3946 02:49:55,563 --> 02:49:57,464 AS HOW WE WOULD RANK THEM BUT 3947 02:49:57,464 --> 02:50:01,101 THAT'S NOT THE WHAT TASK FORCE 3948 02:50:01,101 --> 02:50:03,003 WAS REQUESTED TO REPORT. 3949 02:50:03,003 --> 02:50:05,339 >> YEAH, I'LL JUMP IN AFTER 3950 02:50:05,339 --> 02:50:08,042 LUIS AND ECHO THAT. 3951 02:50:08,042 --> 02:50:09,176 WE WERE SPECIFICALLY NOT 3952 02:50:09,176 --> 02:50:11,946 THINKING ABOUT RANKING THEM IN 3953 02:50:11,946 --> 02:50:12,680 TERMS OF PRIORITY. 3954 02:50:12,680 --> 02:50:14,815 AND JUST TO POINT OUT HOW 3955 02:50:14,815 --> 02:50:16,617 DIFFICULT THAT WOULD BE, 3956 02:50:16,617 --> 02:50:19,286 BECAUSE WE WERE DIVIDE INTO 3957 02:50:19,286 --> 02:50:21,422 THREE TASK FORCES BASED ON OUR 3958 02:50:21,422 --> 02:50:24,291 EXPERTISE AND OF COURSE ALONG 3959 02:50:24,291 --> 02:50:26,093 WITH EXPERTISE COMES OUR 3960 02:50:26,093 --> 02:50:27,928 EXPERIENCE AND IMPORTANTLY, THE 3961 02:50:27,928 --> 02:50:30,030 AREAS WE'RE WORKING IN NOW AND 3962 02:50:30,030 --> 02:50:31,432 ALTHOUGH WE ALL LIKE TO BE 3963 02:50:31,432 --> 02:50:34,201 OBJECTIVE AND LOOK AT THE BIG 3964 02:50:34,201 --> 02:50:36,270 PICTURE, TIME AND TIME AGAIN, 3965 02:50:36,270 --> 02:50:38,572 WE WERE FACED WITH ADVOCATING 3966 02:50:38,572 --> 02:50:42,409 FOR OUR OWN AREAS OF INTEREST. 3967 02:50:42,409 --> 02:50:44,445 , PARTICULARLY WHEN WH 3968 02:50:44,445 --> 02:50:47,014 DIVIDE US INTO THREE GROUPS, 3969 02:50:47,014 --> 02:50:48,382 BASIC CLINICAL AND SOCIAL 3970 02:50:48,382 --> 02:50:49,950 SCIENCE AND BEHAVIORAL. 3971 02:50:49,950 --> 02:50:52,286 SO THAT REINFORCED THE IDEA 3972 02:50:52,286 --> 02:50:53,921 THAT WE WERE GOING TO LOOK AT 3973 02:50:53,921 --> 02:50:55,789 OUR OWN AREAS AND TRY TO COME 3974 02:50:55,789 --> 02:50:57,758 WUP THE TOP PRIORITIES WITHOUT 3975 02:50:57,758 --> 02:50:58,225 RANKING THEM. 3976 02:50:58,225 --> 02:51:00,628 BUT I WOULD THINK THAT YOU 3977 02:51:00,628 --> 02:51:02,229 WOULD NEED A GROUP OF 3978 02:51:02,229 --> 02:51:04,698 INDIVIDUALS WHO AGREED TO LEAVE 3979 02:51:04,698 --> 02:51:05,633 BIAS SXZ PERSONAL INTEREST AT 3980 02:51:05,633 --> 02:51:07,968 THE DOOR AND TAKE A LOOK AT THE 3981 02:51:07,968 --> 02:51:09,336 BIG PICTURE, BECAUSE I THINK 3982 02:51:09,336 --> 02:51:11,205 JUST TO STATE THE OBVIOUS, THAT 3983 02:51:11,205 --> 02:51:14,174 WE APPRECIATE ALL THREE AREAS 3984 02:51:14,174 --> 02:51:15,342 AND WHAT THEY'VE CONTRIBUTED 3985 02:51:15,342 --> 02:51:17,177 AND WE'RE ONLY HERE TODAY 3986 02:51:17,177 --> 02:51:19,680 BECAUSE WE INVESTED IN ALL OF 3987 02:51:19,680 --> 02:51:21,181 THREE OF THOSE AREAS. 3988 02:51:21,181 --> 02:51:22,750 OMAR, YOU GET THE LAST WORD 3989 02:51:22,750 --> 02:51:24,118 FROM THE TASK FORCE GUYS. 3990 02:51:24,118 --> 02:51:32,059 >> THANK YOU. 3991 02:51:32,059 --> 02:51:33,694 >> THANK YOU, I THINK WE 3992 02:51:33,694 --> 02:51:35,496 STRUGGLED AS A HEALTH ECONOMIST. 3993 02:51:35,496 --> 02:51:37,364 I WENT IN SAYING, WELL WE NEED 3994 02:51:37,364 --> 02:51:39,266 TO RANK ORDER THIS AND THERE 3995 02:51:39,266 --> 02:51:41,735 ARE METHODS, WE CAN USE DELTA 3996 02:51:41,735 --> 02:51:44,038 METH OR EXPERIMENTS THAT'S MY 3997 02:51:44,038 --> 02:51:46,140 AREA OF EXPERTISE AND THAT'S 3998 02:51:46,140 --> 02:51:47,341 HOW WE HAVE PREFERENCE AND WHAT 3999 02:51:47,341 --> 02:51:49,376 WE HAVE HERE IS A CONSTITUENCY 4000 02:51:49,376 --> 02:51:54,815 AND WE HAVE TO MAP THE 4001 02:51:54,815 --> 02:51:56,684 PREFERENCES, I WAS LIKE, THIS 4002 02:51:56,684 --> 02:51:59,887 IS NOT IDEAL BUT I HAD TO DIAL 4003 02:51:59,887 --> 02:52:01,922 THAT BACK AND SAY THOSE ARE 4004 02:52:01,922 --> 02:52:03,524 BULLETS AND NOT RANKED. 4005 02:52:03,524 --> 02:52:04,692 THAT WAS OUR ASK. 4006 02:52:04,692 --> 02:52:07,227 THAT'S IT, I WILL SAY THAT JUST 4007 02:52:07,227 --> 02:52:10,631 TALKING ABOUT THE BEHAVIORAL 4008 02:52:10,631 --> 02:52:13,167 SOCIAL SCIENCE TASK FORCE, THAT 4009 02:52:13,167 --> 02:52:15,069 YOU KNOW, THE KEY HERE, AND I 4010 02:52:15,069 --> 02:52:17,337 THINK I'M SPEAKING ON BEHALF OF 4011 02:52:17,337 --> 02:52:18,906 THE WHOLE TASK FORCE 4012 02:52:18,906 --> 02:52:20,974 PERHAPS, YOU KNOW, THE FIELD 4013 02:52:20,974 --> 02:52:23,043 THAT WE REALLY NEED TO LISTEN 4014 02:52:23,043 --> 02:52:24,078 TO TH CLOSEST TO THE 4015 02:52:24,078 --> 02:52:29,783 PAIN. 4016 02:52:29,783 --> 02:52:30,951 AND GIVEN A SEAT AT THE TABLE 4017 02:52:30,951 --> 02:52:33,520 AND I THINK IT'S JUST THAT 4018 02:52:33,520 --> 02:52:36,557 IDEA, AND AGAIN, IT'S THE FOR 4019 02:52:36,557 --> 02:52:37,691 IMPLEMENTATION SCIENCE POINT OF 4020 02:52:37,691 --> 02:52:41,095 YOU, IT'S THE SO WHAT WE KNOW A 4021 02:52:41,095 --> 02:52:44,465 LOT OF THESE DISPARITIES, IT'S 4022 02:52:44,465 --> 02:52:46,467 BEEN 40 YEARS AND NOW IT'S WHAT 4023 02:52:46,467 --> 02:52:47,768 DO WE DO ABOUT IT? 4024 02:52:47,768 --> 02:52:50,804 AND HOW DO WE REDUCE THESE 4025 02:52:50,804 --> 02:52:53,340 DISPARITIES AND WHAT ARE THE 4026 02:52:53,340 --> 02:52:55,676 AFFECTIVE INTERVENTIONS TO GET, 4027 02:52:55,676 --> 02:52:58,645 YOU KNOW, PEOPLE TO TAKE THEIR 4028 02:52:58,645 --> 02:53:01,281 PILLS OR TO TAKE A SHOT IN THE 4029 02:53:01,281 --> 02:53:01,448 ARM. 4030 02:53:01,448 --> 02:53:04,585 SO TO ME, IS THAT BEING 4031 02:53:04,585 --> 02:53:06,186 PRACTICAL ABOUT THOSE POINTS? 4032 02:53:06,186 --> 02:53:09,990 AND AGAIN, I MEAN, I, I AM VERY 4033 02:53:09,990 --> 02:53:12,192 HUMBLED TO HAVE BEEN CHAIRING 4034 02:53:12,192 --> 02:53:13,594 THIS BUT IT'S A LOT OF PEOPLE 4035 02:53:13,594 --> 02:53:15,429 THAT WERE THERE AND IT'S THE, 4036 02:53:15,429 --> 02:53:18,932 THE BRAINS OF A LOT OF PEOPLE 4037 02:53:18,932 --> 02:53:21,001 THAT PARTICIPATED, THE EX 4038 02:53:21,001 --> 02:53:23,103 EXECUTOR AND TASK FORCE MEMBERS 4039 02:53:23,103 --> 02:53:24,772 WERE REACTIVE AND THOUGHTFUL IN 4040 02:53:24,772 --> 02:53:26,306 THEIR CONTRIBUTIONS. 4041 02:53:26,306 --> 02:53:27,808 SO I'M VERY THOUGHTFUL FOR THAT. 4042 02:53:27,808 --> 02:53:35,482 >> THANK YOU. 4043 02:53:35,482 --> 02:53:37,551 >> THANK YOU I WANT TO THANK 4044 02:53:37,551 --> 02:53:42,356 THE TASK FORCE FOR CREATING 4045 02:53:42,356 --> 02:53:43,056 AEFR ARCHING STRUCTURE. 4046 02:53:43,056 --> 02:53:48,529 THIS IS A NOT, A SET OF 4047 02:53:48,529 --> 02:53:51,298 PRIORITY, PRIORITIES OCCUR AT 4048 02:53:51,298 --> 02:53:57,037 THE, WE'RE THE NUNS HAVE THE 4049 02:53:57,037 --> 02:53:58,272 FUNDINGS AND EXECUTION OF THE 4050 02:53:58,272 --> 02:54:02,509 RESEARCH THAT WE ARE ASSIGNED 4051 02:54:02,509 --> 02:54:04,011 BY STATUTE TO PERFORM. 4052 02:54:04,011 --> 02:54:07,281 SO I THINK THAT THERE IS ENOUGH 4053 02:54:07,281 --> 02:54:09,550 HERE THAT ALLOWS THE INSTITUTES 4054 02:54:09,550 --> 02:54:19,393 TO FIT THEIR PRIORITIES WITHIN 4055 02:54:19,393 --> 02:54:20,861 THE OVER ARCHING STRUCTURE. 4056 02:54:20,861 --> 02:54:23,997 AS I WAS WILL IS NOTING, THE 4057 02:54:23,997 --> 02:54:25,132 CLARITY CAME THROUGH, WHEN I 4058 02:54:25,132 --> 02:54:27,634 GET TO MY PRESENTATION WHICH IS 4059 02:54:27,634 --> 02:54:28,802 GOING TO TALK ABOUT THE NEXT 4060 02:54:28,802 --> 02:54:31,605 STEPS ONE OF MY SLIDES IS ABOUT 4061 02:54:31,605 --> 02:54:32,706 THE CENTRAL OF COMMUNITY. 4062 02:54:32,706 --> 02:54:35,576 SO THERECOITAREAS OF ALIGNMENT 4063 02:54:35,576 --> 02:54:38,445 AND ULTIMATELY THIS IS AT THE 4064 02:54:38,445 --> 02:54:40,447 INSTITUTE LEVEL. 4065 02:54:40,447 --> 02:54:41,148 WHERE FUNDING DECISIONS ARE 4066 02:54:41,148 --> 02:54:43,717 MADE. 4067 02:54:43,717 --> 02:54:53,961 >> THANK YOU,. 4068 02:54:55,696 --> 02:55:00,834 >> DR. NEILAN. 4069 02:55:00,834 --> 02:55:11,078 >> THANK YOU. 4070 02:55:19,086 --> 02:55:19,953 IT SHOULD BE INTERESTING TO 4071 02:55:19,953 --> 02:55:23,156 HAVE A LITTLE MORE INSIDE TO 4072 02:55:23,156 --> 02:55:23,924 PLANS EVIOUS STRATEGI 4073 02:55:23,924 --> 02:55:25,893 AND USED THAT AS A STARTING 4074 02:55:25,893 --> 02:55:36,003 PLACE. 4075 02:55:37,471 --> 02:55:38,105 >> DR. A. 4076 02:55:38,105 --> 02:55:42,876 >> THANKS SO MUCH, I WOULD LIKE 4077 02:55:42,876 --> 02:55:44,311 TO COMMEND THE TEAMS S WHAT 4078 02:55:44,311 --> 02:55:54,554 THEY'VE DONE. 4079 02:56:05,933 --> 02:56:07,901 TO CLUT MANUFACTURING FAACCESS 4080 02:56:07,901 --> 02:56:10,170 SO I JUST WANTED TO HIGHLIGHT 4081 02:56:10,170 --> 02:56:12,439 THIS VERY THOROUGH AND INCLUDED 4082 02:56:12,439 --> 02:56:16,076 SOME VERY CRITICAL COMPONENTS. 4083 02:56:16,076 --> 02:56:18,145 MY SECOND COMMENT WOULD BE IN 4084 02:56:18,145 --> 02:56:20,247 THE SECTION 3., 3 IN GENERAL 4085 02:56:20,247 --> 02:56:20,948 3.2 IN PARTICULAR. 4086 02:56:20,948 --> 02:56:23,717 I THINK DID A VERY GOOD JOB OF 4087 02:56:23,717 --> 02:56:25,352 POINTING OUT A LOT OF THE 4088 02:56:25,352 --> 02:56:27,854 IMPORTANCE OF LOOKING AT 4089 02:56:27,854 --> 02:56:30,590 RESOURCE LIMITED AND GLOBAL 4090 02:56:30,590 --> 02:56:31,758 SETTINGS, WHERE HIV HITS THE 4091 02:56:31,758 --> 02:56:35,195 HARDEST SO I THINK AT'S AN 4092 02:56:35,195 --> 02:56:36,330 IMPORTANT IT'S AN IMPORTANT 4093 02:56:36,330 --> 02:56:38,865 THEME THAT IS MENTIONED BUT 4094 02:56:38,865 --> 02:56:40,701 PARTICULARLY WELL IN THAT AND 4095 02:56:40,701 --> 02:56:42,102 IN THAT SESSION BECAUSE WE CAN 4096 02:56:42,102 --> 02:56:44,671 DO A LOT OF WORK HERE IN THE 4097 02:56:44,671 --> 02:56:50,944 STATES AND IT'S NOT JUST 4098 02:56:50,944 --> 02:56:52,546 IMPLEMENTATION SCIENCE BUT 4099 02:56:52,546 --> 02:56:54,147 ACROSS THE SPECTRUM UNTIL IT 4100 02:56:54,147 --> 02:56:56,450 REACHES THE COMMUNITIES WHERE 4101 02:56:56,450 --> 02:56:59,886 THE EPIDEMIC IMPACTS THE MOST, 4102 02:56:59,886 --> 02:57:01,355 WE WILL NOT HAVE THE RESULTS WE 4103 02:57:01,355 --> 02:57:01,755 WANT TO SEE. 4104 02:57:01,755 --> 02:57:05,625 SO THANK YOU FOR CAPTURING THAT. 4105 02:57:05,625 --> 02:57:06,526 >> THANK YOU. 4106 02:57:06,526 --> 02:57:08,362 I JUST WANT TO HIGHLIGHT ONE 4107 02:57:08,362 --> 02:57:10,664 THING, I WOULD AFTER THE FINAL 4108 02:57:10,664 --> 02:57:13,633 RECOMMEND AS ARE SHARED, IT 4109 02:57:13,633 --> 02:57:14,801 MIGHT BE USEFUL FOR THE 4110 02:57:14,801 --> 02:57:16,670 INSTITUTIONS TO LOOK AT THE 4111 02:57:16,670 --> 02:57:18,205 WERE DRAFTED BY 4112 02:57:18,205 --> 02:57:20,107 EACH OF THE TASK FORCE, WE HAVE 4113 02:57:20,107 --> 02:57:22,609 THEM TOGETHER BUT EACH ONE HAD 4114 02:57:22,609 --> 02:57:25,345 THEIR OWN VERSION OF THE 4115 02:57:25,345 --> 02:57:26,480 CAPACITY PRIORITIES THAT WERE 4116 02:57:26,480 --> 02:57:29,216 THEN KIND OF CONDENSED INTO 4117 02:57:29,216 --> 02:57:30,150 FOUR TO SIX. 4118 02:57:30,150 --> 02:57:32,652 BUT FOR EXAMPLE, THERE WERE 4119 02:57:32,652 --> 02:57:34,488 EXAMPLES THAT WERE PRIORITIZED 4120 02:57:34,488 --> 02:57:37,057 THAT WE'RE TALKING ABOUT HOW 4121 02:57:37,057 --> 02:57:38,225 PROFESSIONAL DEVELOPMENT 4122 02:57:38,225 --> 02:57:39,593 PROGRAMS COULD POTENTIALLY BE 4123 02:57:39,593 --> 02:57:41,895 MORE INTENTIONAL ABOUT A TYPE 4124 02:57:41,895 --> 02:57:43,764 AWARD WITH A SUPPORT 4125 02:57:43,764 --> 02:57:44,398 INTERNATIONAL INVESTIGATOR TO 4126 02:57:44,398 --> 02:57:46,566 GO BACK TO THE HOME COUNTRY 4127 02:57:46,566 --> 02:57:49,536 WITH REMAINDER OF OUR OLE FACE 4128 02:57:49,536 --> 02:57:51,138 FOR EXAMPLE OR SOME OTHER 4129 02:57:51,138 --> 02:57:52,973 PROGRAMS THAT WERE HIGHLIGHTED 4130 02:57:52,973 --> 02:57:54,608 BY OTHER INSTITUTIONS THAT WERE 4131 02:57:54,608 --> 02:57:56,510 REALLY LOOKED AT MODELS. 4132 02:57:56,510 --> 02:57:58,712 AND SOME OF THESE WERE SORT OF 4133 02:57:58,712 --> 02:58:01,381 REMOVED BY TRYING TO HAVING A 4134 02:58:01,381 --> 02:58:08,522 STANDARD REDUCTIVE 4-6 THAT 4135 02:58:08,522 --> 02:58:10,357 INFORMATION IS AVAILABLE SO I 4136 02:58:10,357 --> 02:58:13,360 INVITE OTHER INSTITUTES TO LOOK 4137 02:58:13,360 --> 02:58:14,428 AT THAT IF THEY HAVE AN 4138 02:58:14,428 --> 02:58:15,462 INTEREST. 4139 02:58:15,462 --> 02:58:18,198 >> I GUESS, ONE OTHER THING TO 4140 02:58:18,198 --> 02:58:21,134 HIGHLIGHT THAT, EACH OF THREE 4141 02:58:21,134 --> 02:58:22,702 TASK FORCE CONSIDERED WAS WE 4142 02:58:22,702 --> 02:58:24,971 TRIED TO KEEP THINGS BROAD, 4143 02:58:24,971 --> 02:58:27,040 RATHER THAN GETTING TOO 4144 02:58:27,040 --> 02:58:31,011 SPECIFIC OR TOO SCRIPT IVE AND 4145 02:58:31,011 --> 02:58:35,582 CARL, I THINK THAT DUCK TAILS 4146 02:58:35,582 --> 02:58:37,451 GOOD ON HOW EACH INSTITUTES 4147 02:58:37,451 --> 02:58:38,085 LOOK AT THIS. 4148 02:58:38,085 --> 02:58:43,690 WE TRIED NOT TO MAKE LISTTHAT 4149 02:58:43,690 --> 02:58:45,792 ALLOWED FLEXIBLE OR ALLOW 4150 02:58:45,792 --> 02:58:46,893 FUTURE INNOVATION FOR WHATEVER 4151 02:58:46,893 --> 02:58:56,236 COMES NEXT. 4152 02:58:56,236 --> 02:58:57,504 >> THANK YOU, ANY OTHER 4153 02:58:57,504 --> 02:58:58,505 COMMENTS, QUESTIONS? 4154 02:58:58,505 --> 02:59:01,241 BEFORE WE MOVE ON TO OUR NEXT 4155 02:59:01,241 --> 02:59:06,680 SESSION? 4156 02:59:06,680 --> 02:59:09,816 IT ULD BE IMPORTANT FOR THE 4157 02:59:09,816 --> 02:59:11,885 OARAC TO UNDERSTAND THAT A BIT 4158 02:59:11,885 --> 02:59:14,254 MORE ABOUT THE NEXT STEPS AFTER 4159 02:59:14,254 --> 02:59:16,323 THIS MOMENT. 4160 02:59:16,323 --> 02:59:22,629 I KNOW DR. DONENBERG ELUDED IN 4161 02:59:22,629 --> 02:59:23,497 THEY ARE TALK. 4162 02:59:23,497 --> 02:59:24,564 WHAT THE CHAIRS WILL BE DOING, 4163 02:59:24,564 --> 02:59:26,500 THE CHAIRS OF THE TASK FORCES 4164 02:59:26,500 --> 02:59:28,135 WILL BE COMPILING A WRITTEN 4165 02:59:28,135 --> 02:59:29,970 REPORT FROM THE MATERIAL YOU 4166 02:59:29,970 --> 02:59:35,342 SAW TODAY WITH DR. TURNBUAND 4167 02:59:35,342 --> 02:59:38,478 WE WILL SHARE IT WITH OARAC FOR 4168 02:59:38,478 --> 02:59:40,547 FINAL COMMENT BEFORE IT'S 4169 02:59:40,547 --> 02:59:41,214 SUBMITTED AS RECOMMENDATION 4170 02:59:41,214 --> 02:59:42,549 FROM THE OARAC. 4171 02:59:42,549 --> 02:59:45,352 SO WE'RE VERY CLOSE TO THAT, 4172 02:59:45,352 --> 02:59:48,121 BUT IT, BUT IT'S SORT OF PUBLIC 4173 02:59:48,121 --> 02:59:58,632 DELIBERATION OF THAT MATERIAL. 4174 02:59:59,299 --> 03:00:03,103 SO WE'RE ASKING FOR ANY 4175 03:00:03,103 --> 03:00:03,970 ADDITIONAL COMMENTS ORCO 4176 03:00:03,970 --> 03:00:05,305 QUESTIOROR CLARIFICATION TO IC 4177 03:00:05,305 --> 03:00:07,474 SEE COME IN IN ABOUT THE NEXT 4178 03:00:07,474 --> 03:00:12,412 TWO WEEKS OR SO SO THAT REPORT 4179 03:00:12,412 --> 03:00:13,813 CAN HAPPEN WELL BEFORE THE END 4180 03:00:13,813 --> 03:00:24,191 OF THE CALENDAR YEAR. 4181 03:00:33,033 --> 03:00:36,469 WE WILL NOW HEAR FROM UPDATE 4182 03:00:36,469 --> 03:00:41,007 FROM NIH ADVISORY COUNCIL 4183 03:00:41,007 --> 03:00:46,746 REPRESENTATIVE WE'LL HAVE 4184 03:00:46,746 --> 03:00:48,315 MARGARITA AND MELONY OTT AND 4185 03:00:48,315 --> 03:00:58,858 I'M NOT SURE IF CO RETTE BYRD. 4186 03:01:49,075 --> 03:01:50,944 >> THE NIH INVESTMENT IN THE 4187 03:01:50,944 --> 03:01:52,012 CLINICAL TRIALS NETWORK. 4188 03:01:52,012 --> 03:01:52,712 THE STATUS REPORT OF WHERE WE 4189 03:01:52,712 --> 03:01:53,713 ARE. 4190 03:01:53,713 --> 03:01:57,117 NEXT SLIDE PLEASE. 4191 03:01:57,117 --> 03:02:02,088 SO EVER 7 YEARS WE 4192 03:02:02,088 --> 03:02:02,722 COMPETITIVELY RENEW OUR 4193 03:02:02,722 --> 03:02:04,824 NETWORKS. 4194 03:02:04,824 --> 03:02:06,493 THE COMPETITIVE IS THE AWARDS 4195 03:02:06,493 --> 03:02:09,696 WILL BE IN 2027. 4196 03:02:09,696 --> 03:02:10,997 SO STARTING NOW HALFWAY THROUGH 4197 03:02:10,997 --> 03:02:12,699 THE CYCLE, WE ARE GOING THROUGH 4198 03:02:12,699 --> 03:02:15,669 A PLANNING PROCESS WITH 4199 03:02:15,669 --> 03:02:17,704 COMMUNITY, WITH RESEARCHERS, 4200 03:02:17,704 --> 03:02:21,374 AND OTHER ACADEMICS TO DEFINE 4201 03:02:21,374 --> 03:02:23,443 THE FORWARD LOOKING RESEARCH 4202 03:02:23,443 --> 03:02:25,078 AGENDA WHICH WILL DETERMINE THE 4203 03:02:25,078 --> 03:02:28,515 FOCUS STRUCTURE OR THE NETWORKS 4204 03:02:28,515 --> 03:02:30,817 PRIME AURLY RESEARCH AGENDA 4205 03:02:30,817 --> 03:02:31,785 THROUGH 2024, WE'RE TRYING TO 4206 03:02:31,785 --> 03:02:33,653 MAKE THIS A TEN-YEAR VISION. 4207 03:02:33,653 --> 03:02:37,090 NEXT SLIDE, PLEASE. 4208 03:02:37,090 --> 03:02:39,392 SO WE HAVE ESTABLISHED AN OUT 4209 03:02:39,392 --> 03:02:41,261 REACH SYSTEM TO STAKEHOLDERS. 4210 03:02:41,261 --> 03:02:42,996 THIS IS OUR WEBSITE WHERE 4211 03:02:42,996 --> 03:02:44,998 PEOPLE CAN GO IN AND READ WHAT 4212 03:02:44,998 --> 03:02:46,032 HAS BEEN POSTED. 4213 03:02:46,032 --> 03:02:49,636 THERE IS BEEN A SERIES OF 4214 03:02:49,636 --> 03:02:52,539 ENGAGEMENTS WHERE THERE WERE 4215 03:02:52,539 --> 03:02:54,574 EXTENSIVE QUESTIONS ASKED AND 4216 03:02:54,574 --> 03:02:56,643 THEN ANSWERED AND THE ANSWERS 4217 03:02:56,643 --> 03:02:59,446 ARE POSTED ON THIS SITE. 4218 03:02:59,446 --> 03:03:02,415 ADDITIONALLY, THERE IS A 4219 03:03:02,415 --> 03:03:04,250 HISTORY LESSON ON THE LEFT HAND 4220 03:03:04,250 --> 03:03:05,885 SIDE OF THE SCREEN IS A BOX 4221 03:03:05,885 --> 03:03:07,020 THAT INCLUDES ALL THE 4222 03:03:07,020 --> 03:03:09,989 INFORMATION FROM THE PREVIOUS 4223 03:03:09,989 --> 03:03:10,857 RECOMPETITION. 4224 03:03:10,857 --> 03:03:12,225 SO YOU CAN SEE HOW THESE 4225 03:03:12,225 --> 03:03:14,094 CONTINUE TO BE EVOLVED. 4226 03:03:14,094 --> 03:03:15,462 NEXT SLIDE, PLEASE. 4227 03:03:15,462 --> 03:03:20,100 SO AS EXAMPLE OF OUT REACH 4228 03:03:20,100 --> 03:03:23,570 ACTIVITIES, WE'VE HELD, THROUGH 4229 03:03:23,570 --> 03:03:25,438 OUR HIV NETWORK COMMUNITY 4230 03:03:25,438 --> 03:03:32,879 ACTIVITIES, WE'VE HAD TWO OF 4231 03:03:32,879 --> 03:03:34,013 THESE WEBINARS WHERE IN EACH 4232 03:03:34,013 --> 03:03:36,483 CASE WE HAD OVER 500 PEOPLE 4233 03:03:36,483 --> 03:03:38,985 REGISTERED FOR THESE AND THEY 4234 03:03:38,985 --> 03:03:40,820 CAME ON, AND HEARD PRESENTATION 4235 03:03:40,820 --> 03:03:45,658 SXZ FOR ABOUT 90 MINUTES TO 2 4236 03:03:45,658 --> 03:03:47,060 HOURS, THEY ASKED QUESTIONS, WE 4237 03:03:47,060 --> 03:03:49,129 CAPTURED THE QUESTIONS THAT 4238 03:03:49,129 --> 03:03:49,829 COULDN'T BE ANSWERED AT THE 4239 03:03:49,829 --> 03:03:51,698 TIME AND POSTED THOSE QUESTIONS. 4240 03:03:51,698 --> 03:03:55,335 WE INTEND TO HAVE ONE MORE OF 4241 03:03:55,335 --> 03:03:58,805 THESE HIGH-LEVEL VERY LARGE NAR. 4242 03:03:58,805 --> 03:04:00,673 IN THE MEANTIME, NEXT SLIDE, 4243 03:04:00,673 --> 03:04:04,778 WE'VE HAD THE ABILITY TO TALK 4244 03:04:04,778 --> 03:04:09,082 TO COMMUNITY AT NETWORK 4245 03:04:09,082 --> 03:04:10,450 MEETINGS AND RESENT AND I HAD 4246 03:04:10,450 --> 03:04:11,851 TWO SESSION WZ COMMUNITY. 4247 03:04:11,851 --> 03:04:14,354 BUT I WANT TO START FROM THE 4248 03:04:14,354 --> 03:04:17,123 PERSPECTIVE JUST LIKE WE JUST 4249 03:04:17,123 --> 03:04:20,326 HEARD FROM THE STRATEGIC PLAN 4250 03:04:20,326 --> 03:04:22,629 THAT OAR IS PUTTING TOGETHER, 4251 03:04:22,629 --> 03:04:23,563 IT'S CENTERED ON COMMUNITY. 4252 03:04:23,563 --> 03:04:25,632 SO WHAT WE WOULD LIKE TO DO IS 4253 03:04:25,632 --> 03:04:28,868 JUST CENTER OUR NETWORK 4254 03:04:28,868 --> 03:04:29,903 ACTIVITIES AS THEY'VE HAVE BEEN 4255 03:04:29,903 --> 03:04:32,338 ON COMMUNITY. 4256 03:04:32,338 --> 03:04:34,207 COMMUNITY PLAYS ESSENTIAL ROLES 4257 03:04:34,207 --> 03:04:36,910 WITH ENGAGEMENT, AND INPUT. 4258 03:04:36,910 --> 03:04:39,212 THEY HELP INFORM NETWORK 4259 03:04:39,212 --> 03:04:40,346 RESEARCH PRIORITIES, THEY 4260 03:04:40,346 --> 03:04:42,682 PARTICIPATE IN OUR SCIENTIFIC 4261 03:04:42,682 --> 03:04:45,018 COMMUNITIES IN OUR SCIENTIFIC 4262 03:04:45,018 --> 03:04:47,854 COMMITTEES, THEY PARTICIPATE ON 4263 03:04:47,854 --> 03:04:49,622 PROTOCOL TEAMS, THEY ARE THERE 4264 03:04:49,622 --> 03:04:52,058 TO VOICE CONCERNS ABOUT TRIALS, 4265 03:04:52,058 --> 03:04:54,227 THE WAY THEY'RE IT BEING 4266 03:04:54,227 --> 03:04:56,963 DEVELOPED, ABOUT HOW THEY'RE 4267 03:04:56,963 --> 03:04:58,631 BEING IMPLEMENTED IN OUTCOMES 4268 03:04:58,631 --> 03:05:02,235 AND REALLY HELPS ENSURE 4269 03:05:02,235 --> 03:05:03,636 ININFORMED CON SENSE. 4270 03:05:03,636 --> 03:05:05,238 AND ADVOCATE ON TRIAL 4271 03:05:05,238 --> 03:05:06,873 PARTICIPANTS AND THEY ALSO 4272 03:05:06,873 --> 03:05:08,441 SERVE A ROLE IN THE COMMUNITY 4273 03:05:08,441 --> 03:05:10,477 TO SELF EDUCATION AND INCREASE 4274 03:05:10,477 --> 03:05:12,579 THE KNOWLEDGE AROUND HIV AND 4275 03:05:12,579 --> 03:05:13,513 INCREASE AWARENESS OF WHAT IS 4276 03:05:13,513 --> 03:05:15,215 GOING ON IN EACH OF THESE 4277 03:05:15,215 --> 03:05:16,716 IMPORTANT AREAS. 4278 03:05:16,716 --> 03:05:18,117 THEY'RE ALSO ESSENTIAL FOR 4279 03:05:18,117 --> 03:05:21,488 HELPING US INTERPRET AND 4280 03:05:21,488 --> 03:05:24,491 DISSEMINATE RESULTS AND ALSO 4281 03:05:24,491 --> 03:05:26,192 HELP US PROMOTE ETHICAL 4282 03:05:26,192 --> 03:05:26,926 RESEARCH PRACTICES. 4283 03:05:26,926 --> 03:05:28,862 THOSE ARE THE FOUR NETWORKS 4284 03:05:28,862 --> 03:05:30,096 THAT RECURRENTLY HAVE LISTED AT 4285 03:05:30,096 --> 03:05:31,598 THE BOTTOM OF THE SCREEN. 4286 03:05:31,598 --> 03:05:33,132 NEXT SLIDE, PLEASE. 4287 03:05:33,132 --> 03:05:35,101 SO HERE'S WHERE OUR CURRENT 4288 03:05:35,101 --> 03:05:37,070 THINKING LIES. 4289 03:05:37,070 --> 03:05:38,938 WE ARE PROPOSING AT THIS POINT 4290 03:05:38,938 --> 03:05:41,608 TO MAINTAIN THE FOUR EXISTING 4291 03:05:41,608 --> 03:05:42,709 LEADERSHIP GROUPS. 4292 03:05:42,709 --> 03:05:46,246 WE HAVE OVER ARCHING THEME THAT 4293 03:05:46,246 --> 03:05:48,081 WE ARE MOVING, THAT WE HAVE 4294 03:05:48,081 --> 03:05:50,016 THAT WE'RE MOVING FORWARD WITH 4295 03:05:50,016 --> 03:05:50,984 THIS RENEWAL. 4296 03:05:50,984 --> 03:05:53,653 AND THOSE ARE INNOVATION AND 4297 03:05:53,653 --> 03:05:58,124 COLLABORATION. 4298 03:05:58,124 --> 03:05:59,792 AS WE LOOK AT JUST THE 4299 03:05:59,792 --> 03:06:01,160 PROGRESS, THE GROUND BREAKING 4300 03:06:01,160 --> 03:06:05,965 STUDIES THAT HAVE SPROUTED FROM 4301 03:06:05,965 --> 03:06:07,133 THESE COLLABORATIONS MANY OF 4302 03:06:07,133 --> 03:06:11,070 THEM WITHIN THE NETWORK, WITH 4303 03:06:11,070 --> 03:06:13,139 INSTITUTES WITHIN THE NIH. 4304 03:06:13,139 --> 03:06:19,312 LISTED THERE ARE THE, NIH 4305 03:06:19,312 --> 03:06:21,114 NETWORKS THAT ARE CURRENTLY 4306 03:06:21,114 --> 03:06:25,018 ENGAGED WITHIN THE CLINICAL 4307 03:06:25,018 --> 03:06:26,219 TRIALS INFRASTRUCTURE AND ALL 4308 03:06:26,219 --> 03:06:27,820 OF THEM HAVE SIGNIFICANT AREAS 4309 03:06:27,820 --> 03:06:29,455 OF EMPHASIS THAT THEY BRING TO 4310 03:06:29,455 --> 03:06:31,291 THE TABLE TO HELP US MAKE THE 4311 03:06:31,291 --> 03:06:32,892 RESEARCH THAT WE'RE SUPPORTING 4312 03:06:32,892 --> 03:06:33,826 THROUGH THE NETWORKS MORE 4313 03:06:33,826 --> 03:06:36,963 COMPLETE. 4314 03:06:36,963 --> 03:06:39,032 MOVING FORWARD WE WOULD LIKE TO 4315 03:06:39,032 --> 03:06:41,568 EXPAND OUT THIS LEVEL OF 4316 03:06:41,568 --> 03:06:42,235 COLLABORATION PARTICULARLY WHEN 4317 03:06:42,235 --> 03:06:44,704 WE GET TO THE NEED OF RESURGE 4318 03:06:44,704 --> 03:06:46,139 INTO OUR PLANS. 4319 03:06:46,139 --> 03:06:48,341 IF WE THINK ABOUT THE 4320 03:06:48,341 --> 03:06:49,008 IMPLEMENTING PARTNERS THAT ARE 4321 03:06:49,008 --> 03:06:54,080 PART OF THE SYSTEM, CDC, AND 4322 03:06:54,080 --> 03:06:56,082 OTHERS WHAT ARE THEIR STRATEGIC 4323 03:06:56,082 --> 03:07:03,156 NEEDS AS IMPLEMENTER THAT WE AS 4324 03:07:03,156 --> 03:07:05,491 RESEARCHERS CAN HELP WITH. 4325 03:07:05,491 --> 03:07:08,661 BUILT WITH THAT IS ARE THE 4326 03:07:08,661 --> 03:07:10,730 IDEAS THAT WERE ADDRESSED THE 4327 03:07:10,730 --> 03:07:16,169 NEEDS OF THE PARTNERS WILL BE 4328 03:07:16,169 --> 03:07:16,669 ESSENTIALLY CRITICALLY 4329 03:07:16,669 --> 03:07:21,841 IMPORTANT. 4330 03:07:21,841 --> 03:07:24,143 ADDITIONALLY, SINCE 20 19, 4331 03:07:24,143 --> 03:07:27,380 2020, THE CLINICAL TRIALS 4332 03:07:27,380 --> 03:07:30,316 ENTERPRISE THAT NIH SUPPORT 4333 03:07:30,316 --> 03:07:33,987 REALLY PROVED ITS MEDAL, TO 4334 03:07:33,987 --> 03:07:36,055 OPEN UP AND ADDRESS THE 4335 03:07:36,055 --> 03:07:38,791 PANDEMIC RESPONSE IN TERMS OF 4336 03:07:38,791 --> 03:07:39,726 PERFORMING THE THERAPEUTIC 4337 03:07:39,726 --> 03:07:43,129 STUDIES THROUGH ACTIVE AND 4338 03:07:43,129 --> 03:07:47,967 THROUGH COV.P. N THE STUDIES OF 4339 03:07:47,967 --> 03:07:48,901 ANTIBODIES AND VACCINES. 4340 03:07:48,901 --> 03:07:50,303 IT'S ESSENTIAL THAT THEY 4341 03:07:50,303 --> 03:07:52,805 MAINTAIN THIS THAT IS ABLE TO 4342 03:07:52,805 --> 03:07:56,009 TURN ON A DIME AND BE READY IF 4343 03:07:56,009 --> 03:07:57,610 AND WHEN THE NEXT PANDEMIC 4344 03:07:57,610 --> 03:07:58,745 ARISES. 4345 03:07:58,745 --> 03:08:00,580 NEXT SLIDE, PLEASE. 4346 03:08:00,580 --> 03:08:03,583 SO ONE OF THE AREAS THAT CAN 4347 03:08:03,583 --> 03:08:05,818 BE, WHAT ARE THE AREAS THAT WE 4348 03:08:05,818 --> 03:08:07,654 CAN PILE IT BETWEEN NOW AND THE 4349 03:08:07,654 --> 03:08:12,258 END OF THE CURRENT CYCLE? 4350 03:08:12,258 --> 03:08:15,428 AND THE FUNCTION FOR SCIENTIFIC 4351 03:08:15,428 --> 03:08:16,929 DISCOVERY THAT CAN BE MADE NOW 4352 03:08:16,929 --> 03:08:18,898 THAT WILL HELP US ACCELERATE 4353 03:08:18,898 --> 03:08:20,533 THE PACE OF DISCOVERY. 4354 03:08:20,533 --> 03:08:21,734 NEXT SLIDE, PLEASE. 4355 03:08:21,734 --> 03:08:23,136 SO JUST TO REMIND EVERYBODY 4356 03:08:23,136 --> 03:08:27,440 THIS IS OUR BASIC STRUCTURE, 4357 03:08:27,440 --> 03:08:31,978 EACH STRUCTURE CONSIST OF 4358 03:08:31,978 --> 03:08:37,684 LABORATORY, AND A LABORATORY, A 4359 03:08:37,684 --> 03:08:39,986 DATA MANAGEMENT SYSTEM CENTER, 4360 03:08:39,986 --> 03:08:41,821 A LEADERSHIP AND OPERATIONS 4361 03:08:41,821 --> 03:08:42,989 CENTER AND THEN AROUND THE 4362 03:08:42,989 --> 03:08:46,392 SIDES ARE THE TYPES OF NETWORK 4363 03:08:46,392 --> 03:08:48,961 OVERSIGHT AND COORDINATION THAT 4364 03:08:48,961 --> 03:08:52,932 WE SEEK TO USE TO OVERSEE THESE 4365 03:08:52,932 --> 03:08:55,134 NETWORK ACTIVITIES, AT THE 4366 03:08:55,134 --> 03:08:57,136 BOTTOM, THE LITTLE VIRUS LIKE 4367 03:08:57,136 --> 03:08:58,671 PARTICLES WITH THE CLINICAL 4368 03:08:58,671 --> 03:09:00,773 TRIALS UNITS AT THE CENTER AND 4369 03:09:00,773 --> 03:09:02,141 THE CLINICAL RESEARCH SITES 4370 03:09:02,141 --> 03:09:05,311 WHICH ARE THE KNOBS ON THE END 4371 03:09:05,311 --> 03:09:06,245 OF THIS FOLKS. 4372 03:09:06,245 --> 03:09:08,314 HERE'S A LITTLE BIT OF DETAILS 4373 03:09:08,314 --> 03:09:10,183 ABOUT HOW THOSE STRUCTURES 4374 03:09:10,183 --> 03:09:12,985 EXIST, AT LEAST THREE MODELS 4375 03:09:12,985 --> 03:09:15,955 FOR HOW CLINICAL RESEARCH UNITS 4376 03:09:15,955 --> 03:09:18,024 ARE CAN BE BROUGHT IN. 4377 03:09:18,024 --> 03:09:20,293 AND IT'S IMPORTANT THAT WE 4378 03:09:20,293 --> 03:09:22,095 MAINTAIN THIS FLEXIBILITY AS WE 4379 03:09:22,095 --> 03:09:23,696 MOVE FORWARD CAUSE NOT ALL 4380 03:09:23,696 --> 03:09:27,567 RESEARCH IS DONE IN AN ACADEMIC 4381 03:09:27,567 --> 03:09:27,800 SETTING. 4382 03:09:27,800 --> 03:09:28,835 FOR EXAMPLE, RIGHT NOW WE HAVE 4383 03:09:28,835 --> 03:09:33,372 A STUDY IN BARBER SHOPS AND 4384 03:09:33,372 --> 03:09:35,641 WE'RE USING, NON TRADITIONAL 4385 03:09:35,641 --> 03:09:36,943 SITES TO PERFORM THESE TYPES OF 4386 03:09:36,943 --> 03:09:39,278 STUDIES. 4387 03:09:39,278 --> 03:09:41,114 BY HAVING PROTOCOL SPECIFIC 4388 03:09:41,114 --> 03:09:44,751 SITES, WE CAN UTILIZE THAT KIND 4389 03:09:44,751 --> 03:09:45,752 OF IMPORTANT ACTIVITY AND 4390 03:09:45,752 --> 03:09:48,221 COMMUNITY TO HELP US REACH THE 4391 03:09:48,221 --> 03:09:49,188 POPULATIONS WE ARE SEEKING TO 4392 03:09:49,188 --> 03:09:50,323 REACH. 4393 03:09:50,323 --> 03:09:52,158 NEXT SLIDE, PLEASE. 4394 03:09:52,158 --> 03:09:54,427 SO, I HAVE A LITTLE BIT ABOUT 4395 03:09:54,427 --> 03:09:57,196 EACH OF THE AREAS BUT A LOT OF 4396 03:09:57,196 --> 03:09:59,031 THIS, IS VERY WELL KNOWN TO 4397 03:09:59,031 --> 03:10:02,735 THIS GROUP ABOUT WHAT EACH OF 4398 03:10:02,735 --> 03:10:04,437 THESE NETWORK ACTIVITIES COVER. 4399 03:10:04,437 --> 03:10:06,439 SO I WILL GO THROUGH THIS 4400 03:10:06,439 --> 03:10:07,106 RELATIVELY QUICKLY IN THE 4401 03:10:07,106 --> 03:10:10,543 INTEREST OF TIME. 4402 03:10:10,543 --> 03:10:12,612 CLEARLY FOR HIV PREVENTION, IT 4403 03:10:12,612 --> 03:10:15,815 IS ABOUT SUPPORTING BIO MEDICAL 4404 03:10:15,815 --> 03:10:17,416 PREVENTION INTERVENTIONS THAT 4405 03:10:17,416 --> 03:10:20,620 CAN CHANGE CLINICAL PRACTICE 4406 03:10:20,620 --> 03:10:22,722 AND REDUCE INCIDENTS. 4407 03:10:22,722 --> 03:10:24,123 THE OVER ARCHING GOAL THAT WE 4408 03:10:24,123 --> 03:10:27,827 SEE FOR OUR PREVENTION RESEARCH 4409 03:10:27,827 --> 03:10:29,462 FOR HIV VACCINES AND PREVENTION 4410 03:10:29,462 --> 03:10:30,863 IS DEVELOP THE TOOLS AND 4411 03:10:30,863 --> 03:10:34,534 TECHNOLOGY THAT WILL REDUCE HIV 4412 03:10:34,534 --> 03:10:40,006 INCIDENTS BOTH DOMESTICALLY AND 4413 03:10:40,006 --> 03:10:40,907 GLOBALLY. 4414 03:10:40,907 --> 03:10:45,244 WE'VE SEEN THAT THROUGH THE 4415 03:10:45,244 --> 03:10:47,814 MALE CIRCUMCISION, WE'VE SEEN U 4416 03:10:47,814 --> 03:10:50,349 WEEKALS U BECOME A MAJOR TOOL 4417 03:10:50,349 --> 03:10:55,454 AND RECENTLY WE HAVE SEEN 4418 03:10:55,454 --> 03:10:57,990 VAGTIER FOR MEN AND WOMEN. 4419 03:10:57,990 --> 03:11:00,827 LENACAPAVIR IS IN THE PROCESS 4420 03:11:00,827 --> 03:11:05,431 OF FILING FOR APPROVAL SO AS OF 4421 03:11:05,431 --> 03:11:10,036 RIGHT NOW, LENACAPAVIR, REMAINS 4422 03:11:10,036 --> 03:11:11,637 THE INJECT AB THAT HAS BEEN 4423 03:11:11,637 --> 03:11:14,640 AVAILABLE FOR USE AND SAFE TO 4424 03:11:14,640 --> 03:11:16,776 BE PREGNANCY SO IT CAN BE USED 4425 03:11:16,776 --> 03:11:18,411 ACROSS THE LIFE SPAN. 4426 03:11:18,411 --> 03:11:20,246 NEXT SLIDE, PLEASE. 4427 03:11:20,246 --> 03:11:24,150 FOR EACH OF THESE AREAS, I 4428 03:11:24,150 --> 03:11:27,119 LISTED THE PARTNERSHIP, WE WORK 4429 03:11:27,119 --> 03:11:31,691 CLOSE WITH THE INSTITUTIONS, 4430 03:11:31,691 --> 03:11:34,894 COLLABORATION WITH CDV, 4431 03:11:34,894 --> 03:11:36,562 INTERNATIONAL GOVERNMENTS, AND 4432 03:11:36,562 --> 03:11:37,230 INDUSTRY. 4433 03:11:37,230 --> 03:11:42,668 THIS IS NOT JUST ABOUT ADULTS 4434 03:11:42,668 --> 03:11:44,971 BUT ALSO ABOUT PEDIATRICS, THIS 4435 03:11:44,971 --> 03:11:47,306 IS AN OPPORTUNITY FOR US TO 4436 03:11:47,306 --> 03:11:50,743 REALLY TAKE NEW STRATEGIES TO 4437 03:11:50,743 --> 03:11:57,650 HELP US REDUCE VERTICAL 4438 03:11:57,650 --> 03:11:58,384 TRANSMISSION BY COORDINATING 4439 03:11:58,384 --> 03:11:59,552 WHAT WE'RE DOING IN THE AREAS 4440 03:11:59,552 --> 03:12:02,321 OF PREVENTION AS WELL AS 4441 03:12:02,321 --> 03:12:04,857 THERAPEUTICS AND CURE RESEARCH 4442 03:12:04,857 --> 03:12:09,061 IN THOSE INCREDIBLY POPULAR 4443 03:12:09,061 --> 03:12:10,997 POPULATIONS. 4444 03:12:10,997 --> 03:12:12,465 AN ESSENTIAL PARTNER FOR ALL OF 4445 03:12:12,465 --> 03:12:14,433 OUR PREVENTION WORK AND FRANKLY 4446 03:12:14,433 --> 03:12:17,470 OUR WORK ACROSS THE BOARD IS A 4447 03:12:17,470 --> 03:12:20,439 PART OF NIH, ANOTHER INSTITUTE 4448 03:12:20,439 --> 03:12:22,742 NATIONAL INSTITUTE FOR MENTAL 4449 03:12:22,742 --> 03:12:27,947 HEALTH, THAT IS COLOCATED WITH 4450 03:12:27,947 --> 03:12:31,150 THE DIVISION OF AIDS HERE AT 4451 03:12:31,150 --> 03:12:32,985 FISHERS LANE AND BECAUSE OF 4452 03:12:32,985 --> 03:12:36,622 THEIR STRENGTH AS BEING 4453 03:12:36,622 --> 03:12:37,356 BEHAVIORAL SCIENTISTS, WE 4454 03:12:37,356 --> 03:12:42,628 REALLY HAVE THE BEST OF BOTH 4455 03:12:42,628 --> 03:12:45,164 WORLD'S WITH THE STRONG 4456 03:12:45,164 --> 03:12:49,702 BIOMEDICAL PROGRAMS THAT NI A 4457 03:12:49,702 --> 03:12:52,471 ID CAN DEVELOP BUT THEN PARTNER 4458 03:12:52,471 --> 03:12:57,476 WITH NIH AND BRING THE BEST 4459 03:12:57,476 --> 03:12:59,011 BEHAVIORAL AND SOCIAL SCIENCE 4460 03:12:59,011 --> 03:13:00,379 ALL BETTER. 4461 03:13:00,379 --> 03:13:02,114 AS EVERYBODY KNOWS, PILLS AND 4462 03:13:02,114 --> 03:13:03,149 SHOTS AND MEDICINES, DO NOT 4463 03:13:03,149 --> 03:13:03,950 TAKE THEMSELVES. 4464 03:13:03,950 --> 03:13:05,151 THIS IS ONE OF THE STATEMENTS 4465 03:13:05,151 --> 03:13:06,585 THAT WE MAKE TO EACH OTHER ALL 4466 03:13:06,585 --> 03:13:09,055 THE TIME. 4467 03:13:09,055 --> 03:13:10,923 BUT BEHAVIORAL COME POENTS ARE 4468 03:13:10,923 --> 03:13:12,758 CRITICAL ACROSS THE ENTIRE 4469 03:13:12,758 --> 03:13:16,829 SPECTRUM. 4470 03:13:16,829 --> 03:13:18,931 NEXT SLIDE, VACCINE ALTHOUGH AN 4471 03:13:18,931 --> 03:13:19,865 AREA THAT REMAIN IMPORTANT. 4472 03:13:19,865 --> 03:13:21,934 ONE OF THE QUESTION THAT IS 4473 03:13:21,934 --> 03:13:23,336 CONSTANTLY BEING ASKED IS WHY 4474 03:13:23,336 --> 03:13:26,772 DON'T WE JUST STOP AND THE 4475 03:13:26,772 --> 03:13:28,841 ANSWER, I THOUGHT THAT WAS VERY 4476 03:13:28,841 --> 03:13:32,478 CLEAR TODAY FROM THE DISCUSSION 4477 03:13:32,478 --> 03:13:35,348 ON LENACAPAVIR, YOU CANNOT 4478 03:13:35,348 --> 03:13:37,283 ACHIEVE CONTROL OF THE GLOBAL 4479 03:13:37,283 --> 03:13:40,486 PANDEMIC THROUGH THE USE OF 4480 03:13:40,486 --> 03:13:41,187 LENACAPAVIR OR INJECTABLES, 4481 03:13:41,187 --> 03:13:43,456 IT'S NOT COST AFFECTIVE EVER, 4482 03:13:43,456 --> 03:13:45,591 WE ARE GOING TO NEED, FIRST OF 4483 03:13:45,591 --> 03:13:47,426 ALL GOVERNMENTS ARE ONLY GOING 4484 03:13:47,426 --> 03:13:51,497 TO BUY ENOUGH MATERIAL TO 4485 03:13:51,497 --> 03:13:57,870 PROVIDE SERVICES TO THE MOST 4486 03:13:57,870 --> 03:13:59,939 VULNERABLE AND MORE AT-RISK 4487 03:13:59,939 --> 03:14:00,639 POPULATIONS. 4488 03:14:00,639 --> 03:14:03,175 THE GOAL OF WHICH IS SAFE 4489 03:14:03,175 --> 03:14:04,210 AFFECTIVE AND DURABLE AND DOES 4490 03:14:04,210 --> 03:14:06,679 NOT NEED TO BE REGIVEN EVERY 4491 03:14:06,679 --> 03:14:09,181 SIX MONTHS REMAINS OUR GOAL. 4492 03:14:09,181 --> 03:14:10,716 SO THAT'S ALL I'LL SAY ABOUT 4493 03:14:10,716 --> 03:14:11,684 VACCINES. 4494 03:14:11,684 --> 03:14:13,285 NEXT SLIDE, PLEASE. 4495 03:14:13,285 --> 03:14:16,255 PARTNERS, ARE LISTED THERE. 4496 03:14:16,255 --> 03:14:18,791 WITHIN THIS IS ALSO NOT JUST 4497 03:14:18,791 --> 03:14:22,661 PREVENTION OF HIV BUT ALSO 4498 03:14:22,661 --> 03:14:27,933 PREVENTION OF COMORBIDITY, 4499 03:14:27,933 --> 03:14:32,538 INCLUDING WORK ON TB VACCINES, 4500 03:14:32,538 --> 03:14:37,510 TB RETAINS THE SINGLE BIGGEST 4501 03:14:37,510 --> 03:14:41,380 COST OF MORBIDITY WITH PEOPLE 4502 03:14:41,380 --> 03:14:43,916 LIVING WITH HIV SO TREATING TB 4503 03:14:43,916 --> 03:14:45,084 IS ESSENTIAL GOING FORWARD. 4504 03:14:45,084 --> 03:14:52,224 NEXT SLIDE PLEASE. 4505 03:14:52,224 --> 03:14:53,793 FOR HIV THERAPEUTICS, THIS IS 4506 03:14:53,793 --> 03:14:54,960 AN IMPORTANT ONE. 4507 03:14:54,960 --> 03:14:57,296 ONE OF THE AREAS THAT WE FEEL 4508 03:14:57,296 --> 03:14:59,598 VERY STRONGLY ABOUT, IS IN 4509 03:14:59,598 --> 03:15:05,738 TERMS OF DEVELOPMENT OF 4510 03:15:05,738 --> 03:15:07,807 MEDICINES FOR TREATING AND 4511 03:15:07,807 --> 03:15:09,642 CURING HIV, WE IN MANY WAYS ARE 4512 03:15:09,642 --> 03:15:13,045 ESSENTIAL TO THE PIPELINE. 4513 03:15:13,045 --> 03:15:17,917 BUT WHEN IT COMES TO THE NON 4514 03:15:17,917 --> 03:15:18,984 INFECTIOUS COMORBIDITY, WE'RE 4515 03:15:18,984 --> 03:15:21,320 NOT THE INSTITUTE FOR HEART 4516 03:15:21,320 --> 03:15:23,656 DISEASE OR LUNG BE SEAS OR 4517 03:15:23,656 --> 03:15:28,260 KIDNEY DISEASE OR BONE 4518 03:15:28,260 --> 03:15:30,129 DISEASE, THE DISCOVERY IN THOSE 4519 03:15:30,129 --> 03:15:31,230 DISEASES EXIST IN OTHER 4520 03:15:31,230 --> 03:15:31,764 INSTITUTES. 4521 03:15:31,764 --> 03:15:34,767 SO THE ABILITY TO FORM 4522 03:15:34,767 --> 03:15:38,804 PARTNERSHIPS ACROSS THE NIH TO 4523 03:15:38,804 --> 03:15:43,375 HELP BRING FORWARD NOVEL 4524 03:15:43,375 --> 03:15:48,013 STRATEGIES TO DEAL WITH 4525 03:15:48,013 --> 03:15:50,249 MORBIDITY, SO WE CAN CREATE AS 4526 03:15:50,249 --> 03:15:53,519 AS WE REFER TO AS THE 495 OR 4527 03:15:53,519 --> 03:15:55,588 THE LAST 95 WHERE THE PEOPLE 4528 03:15:55,588 --> 03:15:57,990 LIVING WITH HIV ARE LIVING 4529 03:15:57,990 --> 03:16:03,963 HEALTHY LIVES. 4530 03:16:03,963 --> 03:16:05,564 WITH SIGNIFICANTLY REDUCED 4531 03:16:05,564 --> 03:16:08,767 LEVELS OF COMORBIDITY AND THAT 4532 03:16:08,767 --> 03:16:11,303 HAS TO BE AN NIH ACTIVITY AND 4533 03:16:11,303 --> 03:16:12,471 THAT'S SOMETHING THAT WE WOULD 4534 03:16:12,471 --> 03:16:16,308 LIKE TO SEE AS PARTNERSHIP 4535 03:16:16,308 --> 03:16:18,477 MOVING FORWARD. 4536 03:16:18,477 --> 03:16:20,746 THERE WAS A FAIR AMOUNT OF 4537 03:16:20,746 --> 03:16:22,214 DISCUSSION THAT WE JUST HEARD 4538 03:16:22,214 --> 03:16:27,153 ABOUT THAT KIND OF ACTIVITY TO 4539 03:16:27,153 --> 03:16:28,721 ENGAGE THE RESEARCH COMMUNITY 4540 03:16:28,721 --> 03:16:32,091 AS WELL AS ENGAGE COMMUNITY AND 4541 03:16:32,091 --> 03:16:33,826 IDENTIFYING THOSE NEEDS AS WELL 4542 03:16:33,826 --> 03:16:35,761 AS INDUSTRY. 4543 03:16:35,761 --> 03:16:38,197 BUT, BRINGING THE INSTITUTES TO 4544 03:16:38,197 --> 03:16:42,067 THE TABLE, TO HAVE THOSE LINKS 4545 03:16:42,067 --> 03:16:43,235 IN THOSE INDUSTRIES WILL BE 4546 03:16:43,235 --> 03:16:45,337 ESSENTIAL FOR THE AIDS 4547 03:16:45,337 --> 03:16:53,179 COMMUNITY TO HELP TACKLE NON 4548 03:16:53,179 --> 03:16:54,146 INFECTIOUS COMORBIDITY. 4549 03:16:54,146 --> 03:16:56,148 SO IT'S ABOUT CREATING EQUITY 4550 03:16:56,148 --> 03:17:01,287 FOR ALL THROUGH THE DEVELOPMENT 4551 03:17:01,287 --> 03:17:04,690 OF NOVEL THERAPISTS, SO 4552 03:17:04,690 --> 03:17:08,827 OPTIMIZE BOTH PEDIATRIC DAILY, 4553 03:17:08,827 --> 03:17:11,096 THAT WILL BE IMPORTANT AS THESE 4554 03:17:11,096 --> 03:17:14,800 CHILDREN AGE UP INTO 4555 03:17:14,800 --> 03:17:15,768 ADOLESCENCE AND WE WANT TO BE 4556 03:17:15,768 --> 03:17:19,205 ABLE TO WORK WITH PARTNERS TO 4557 03:17:19,205 --> 03:17:24,076 IMENT --IMPLEMENT OUR 4558 03:17:24,076 --> 03:17:24,977 DISCOVERIES. 4559 03:17:24,977 --> 03:17:30,983 NEXT SLIDE, PLEASE. 4560 03:17:30,983 --> 03:17:34,587 HIV CURE REMAINS ABSOLUTELY 4561 03:17:34,587 --> 03:17:36,689 ESSENTIAL ON GOAL FOR OUR 4562 03:17:36,689 --> 03:17:38,724 RESEARCH WE WANT TO BE ABLE TO 4563 03:17:38,724 --> 03:17:40,593 CONTINUE TO DEVELOP STRATEGIES 4564 03:17:40,593 --> 03:17:45,397 THAT ERADICATE REPLICATION AND 4565 03:17:45,397 --> 03:17:47,233 CONFIDENT RESERVOIR OR DEVELOP 4566 03:17:47,233 --> 03:17:50,903 STRATEGIES TO CONTROL VIRAL 4567 03:17:50,903 --> 03:17:55,674 REBOUND WITHOUT IV ERADICATION 4568 03:17:55,674 --> 03:17:58,877 IN THE ABSENCE OR SUSTAIN VIRAL 4569 03:17:58,877 --> 03:17:59,745 REMISSION. 4570 03:17:59,745 --> 03:18:01,347 IT'S ALSO ESSENTIAL THAT WE 4571 03:18:01,347 --> 03:18:04,650 WORK ACROSS THE LIFE SPAN IN 4572 03:18:04,650 --> 03:18:05,150 THIS AREA. 4573 03:18:05,150 --> 03:18:08,053 THERE IS A UNIQUE OPLATION OF 4574 03:18:08,053 --> 03:18:13,726 BABIES THAT ARE BORN INFECTED. 4575 03:18:13,726 --> 03:18:16,695 AND THE NETWORK THAT'S JUST 4576 03:18:16,695 --> 03:18:18,998 COMPLETED A PROTOCOL TRYING TO 4577 03:18:18,998 --> 03:18:19,999 REPLICATE THE MISSISSIPPI CHILD 4578 03:18:19,999 --> 03:18:21,066 EXPERIENCE. 4579 03:18:21,066 --> 03:18:24,937 AND THAT REALLY PROVED TO BE 4580 03:18:24,937 --> 03:18:27,039 INCREDIBLY VALUABLE AS THAT HAS 4581 03:18:27,039 --> 03:18:28,207 BEEN COMPLETE ASKED NOW WE'RE 4582 03:18:28,207 --> 03:18:30,075 MOVING ON TO ADDITIONAL, A 4583 03:18:30,075 --> 03:18:31,710 SECOND VERSION OF THAT PROTOCOL 4584 03:18:31,710 --> 03:18:34,179 THAT WE CAN EXPAND TO A POINT 4585 03:18:34,179 --> 03:18:38,717 WHERE THROUGH THE USE OF LONG 4586 03:18:38,717 --> 03:18:40,753 ACTING MEDICINES, PLUS EARLY 4587 03:18:40,753 --> 03:18:44,456 TREATMENT, WE CAN REDUCE 4588 03:18:44,456 --> 03:18:49,028 SIGNIFICANTLY THE LEVEL OF HIV 4589 03:18:49,028 --> 03:18:56,335 ACQUISITION THAT A OCCUR 4590 03:18:56,335 --> 03:18:57,936 VERTICAL OR THROUGH BREAST 4591 03:18:57,936 --> 03:18:59,805 FEEDING AND THE CHILD CAN GO 4592 03:18:59,805 --> 03:19:01,340 INTO A PROTOCOL AND BE TREATED 4593 03:19:01,340 --> 03:19:04,677 IN A WAY THAT WILL ALLOW THEM 4594 03:19:04,677 --> 03:19:07,413 TO, HAVE A CHANCE OF HAVING 4595 03:19:07,413 --> 03:19:09,281 THEIR HIV CURED. 4596 03:19:09,281 --> 03:19:12,251 SO IT'S, IT'S AN INTERESTING 4597 03:19:12,251 --> 03:19:15,587 MODEL, IT'S AN INTERESTING 4598 03:19:15,587 --> 03:19:18,123 APPROACH FOR TACKLING PEDIATRIC 4599 03:19:18,123 --> 03:19:20,059 HIV AND ONE THAT WE CAN START 4600 03:19:20,059 --> 03:19:22,561 WITH QUICKLY AND EXPAND THROUGH 4601 03:19:22,561 --> 03:19:24,596 THE RENEWAL. 4602 03:19:24,596 --> 03:19:28,400 ADDITIONALLY BEING ABLE TO MOVE 4603 03:19:28,400 --> 03:19:29,601 CURE ACTIVITIES FOR DISCOVERY 4604 03:19:29,601 --> 03:19:33,439 AS WELL AS TRANSLATION OUTSIDE 4605 03:19:33,439 --> 03:19:38,010 OF THE LOWER 48 STATES IS 4606 03:19:38,010 --> 03:19:40,312 EXTREMELY IMPORTANT AND WE ARE 4607 03:19:40,312 --> 03:19:43,248 BUSY DESIGNING PROGRAMS TO 4608 03:19:43,248 --> 03:19:44,383 IMPLEMENT CLINICAL ACTIVITIES 4609 03:19:44,383 --> 03:19:46,485 IN LOW AND MIDDLE INCOME 4610 03:19:46,485 --> 03:19:47,886 COUNTRIES AND WISH TO CONTINUE 4611 03:19:47,886 --> 03:19:51,557 TO EXPAND THAT AS THE 4612 03:19:51,557 --> 03:19:53,692 OPPORTUNITIES CONTINUE TO 4613 03:19:53,692 --> 03:19:54,993 PRESENT THEMSELVES. 4614 03:19:54,993 --> 03:19:55,661 NEXT SLIDE, PLEASE. 4615 03:19:55,661 --> 03:19:58,230 THESE ARE THE CHALLENGES, 4616 03:19:58,230 --> 03:20:00,499 THEY'RE NOT, THEY REMAIN 4617 03:20:00,499 --> 03:20:02,735 SIGNIFICANT CHALLENGES AND WE 4618 03:20:02,735 --> 03:20:06,605 WILL CONTINUE TO DEVELOP THE 4619 03:20:06,605 --> 03:20:07,606 TOOLS AND TECHNOLOGIES TO 4620 03:20:07,606 --> 03:20:08,474 ADDRESS THESE. 4621 03:20:08,474 --> 03:20:09,174 NEXT SLIDE, PLEASE. 4622 03:20:09,174 --> 03:20:12,544 AND THAT'S IT FOR ME. 4623 03:20:12,544 --> 03:20:13,946 AGAIN, I THOUGHT I WAS REALLY 4624 03:20:13,946 --> 03:20:17,216 IMPORTANT TO GIVE THE OARAC AN 4625 03:20:17,216 --> 03:20:18,784 OVERVIEW OF WHAT WE ARE 4626 03:20:18,784 --> 03:20:21,553 CONSIDERING AND WHERE WE ARE. 4627 03:20:21,553 --> 03:20:27,626 OUR TIMELINE ALLOWS US NOW TO 4628 03:20:27,626 --> 03:20:31,697 TAKE FEEDBACK FROM PEOPLE WHO 4629 03:20:31,697 --> 03:20:33,532 WISH TO TO CONTINUE 4630 03:20:33,532 --> 03:20:35,434 CONVERSATIONS ABOUT THIS. 4631 03:20:35,434 --> 03:20:39,204 WITH A GOAL TOWARD HELPING TO 4632 03:20:39,204 --> 03:20:41,240 SHAPE THE NETWORK STRUCTURES 4633 03:20:41,240 --> 03:20:45,577 INTO SOMETHING THAT IS 4634 03:20:45,577 --> 03:20:48,147 OPTIMIZED FOR COLLABORATION AND 4635 03:20:48,147 --> 03:20:52,718 INNOVATION BETWEEN NOW AND 2034. 4636 03:20:52,718 --> 03:20:57,923 THANK YOU. 4637 03:20:57,923 --> 03:20:59,792 >> THANK YOU, WE'LL WAIT UNTIL 4638 03:20:59,792 --> 03:21:01,360 ALL THE PRESENTATION RIGHT SIDE 4639 03:21:01,360 --> 03:21:03,562 MADE AND IF ANY MEMBERS HAVE 4640 03:21:03,562 --> 03:21:04,496 QUESTIONS, WE'LL GET TO THAT 4641 03:21:04,496 --> 03:21:07,633 THEN. 4642 03:21:07,633 --> 03:21:09,802 CAN, DR. LIGHTFOOT, YOU MAY 4643 03:21:09,802 --> 03:21:11,970 BEGIN. 4644 03:21:11,970 --> 03:21:15,641 >> THANK YOU, DR. TURNBULL. 4645 03:21:15,641 --> 03:21:17,709 IT'S MY PLEASURE TO PROVIDE AN 4646 03:21:17,709 --> 03:21:21,146 UPDATE ON ACTIVITY OF NIMH. 4647 03:21:21,146 --> 03:21:27,352 ONE OF THE BIGGEST PIECES THAT 4648 03:21:27,352 --> 03:21:29,121 THEY HAVE A NEW INTERIM 4649 03:21:29,121 --> 03:21:32,157 DIRECTOR AND THIS IS A NICE 4650 03:21:32,157 --> 03:21:33,792 WORK OF WHAT SHELLEY PUT 4651 03:21:33,792 --> 03:21:35,360 TOGETHER ABOUT WHAT HER WORK 4652 03:21:35,360 --> 03:21:38,096 HAS PUT TOGETHER. 4653 03:21:38,096 --> 03:21:44,903 SHE CAME TO NIH IN 2001 AND 4654 03:21:44,903 --> 03:21:51,677 JOINED THE NIMH AS A SCIENTIST 4655 03:21:51,677 --> 03:21:54,012 AND MOVED IN 2005. 4656 03:21:54,012 --> 03:21:54,713 ULTIMATELY VERY BECAME THE 4657 03:21:54,713 --> 03:21:57,683 CHIEF OF THE DEVELOPMENTAL 4658 03:21:57,683 --> 03:21:58,817 TRAJECTORY MENTAL HEALTH 4659 03:21:58,817 --> 03:21:59,985 DISORDER BRANCH. 4660 03:21:59,985 --> 03:22:03,188 WHILE THERE, SHE LEAD THE PAOED 4661 03:22:03,188 --> 03:22:05,958 ATTRITION TRANSFORM PORTFOLIO 4662 03:22:05,958 --> 03:22:09,561 AND THAT REORIENTING EMPHASIS 4663 03:22:09,561 --> 03:22:10,496 ON BEHAVIORAL DEVELOPMENT TRO 4664 03:22:10,496 --> 03:22:12,531 JEKT REESE OF ILLNESS AND 4665 03:22:12,531 --> 03:22:15,868 IDENTIFICATION OF EARLY 4666 03:22:15,868 --> 03:22:17,603 BIOLOGICAL BEHAVIORAL. 4667 03:22:17,603 --> 03:22:21,306 SHE IS ALSO DEVELOPED SEVERAL 4668 03:22:21,306 --> 03:22:22,908 RESEARCH PROGRAMS FOCUSED ON 4669 03:22:22,908 --> 03:22:30,315 DEPRESSION AND BIPOLAR AND 4670 03:22:30,315 --> 03:22:31,216 CHRONIC IRITIABLEITY IN 4671 03:22:31,216 --> 03:22:32,251 CHILDREN. 4672 03:22:32,251 --> 03:22:37,189 AND A COUPLE OF OTHER MAJOR 4673 03:22:37,189 --> 03:22:42,227 STAFF CHANGES WHERE NICOLE 4674 03:22:42,227 --> 03:22:45,264 MARTINO WAS APPOINT 4675 03:22:45,264 --> 03:22:48,700 APPROXIMATED NIMH EXECUTIVE 4676 03:22:48,700 --> 03:22:51,637 OFFICER DEPUTY DIRECTOR. 4677 03:22:51,637 --> 03:22:54,072 AND SHE WAS PREVIOUSLY ACTING 4678 03:22:54,072 --> 03:22:56,041 EXECUTIVE OFFICER FOR THE PAST 4679 03:22:56,041 --> 03:23:00,879 SIX MONTHS, SHE IS SUCCEED WHO 4680 03:23:00,879 --> 03:23:02,614 WAS EXECUTIVE OFFER BEFORE 4681 03:23:02,614 --> 03:23:04,816 RETIRING IN FEBRUARY OF 2024. 4682 03:23:04,816 --> 03:23:10,956 THE SECOND MAJOR STAFF CHANGE 4683 03:23:10,956 --> 03:23:18,063 IS SUSAN COESTER AS APPOINTED 4684 03:23:18,063 --> 03:23:22,200 ACTING NIMH DEPUTY DIRECTOR IN 4685 03:23:22,200 --> 03:23:28,273 NUERO SCIENCE AND GENO TYPE 4686 03:23:28,273 --> 03:23:31,944 EXPRESSION. 4687 03:23:31,944 --> 03:23:34,947 ONE OF THE LARGEST ACTIVITY 4688 03:23:34,947 --> 03:23:36,381 THAT NIMH HAS BEEN ENGAGED IN 4689 03:23:36,381 --> 03:23:39,851 IN THE LAST YEAR, IS 75th 4690 03:23:39,851 --> 03:23:43,055 CELEBRATIONS AND THAT CONCLUDE 4691 03:23:43,055 --> 03:23:45,557 THE CELEBRATION AND ANNIVERSARY 4692 03:23:45,557 --> 03:23:48,060 FINAL AND FINAL SYMPOSIUM WHICH 4693 03:23:48,060 --> 03:23:50,128 OCCURED ON SEPTEMBER 20, 2024 4694 03:23:50,128 --> 03:23:54,466 AND THAT SYMPOSIUM FOCUSED ON 4695 03:23:54,466 --> 03:23:58,837 THE INSPIRATION DRIVING NIMH 4696 03:23:58,837 --> 03:24:00,238 RESEARCH. 4697 03:24:00,238 --> 03:24:04,042 THE FIRST WAS SHARYL BELLMY WHO 4698 03:24:04,042 --> 03:24:07,012 COWROTE A BOOK AND PLAYS IN 4699 03:24:07,012 --> 03:24:09,314 MONOLOGUES THAT WAS CALLED 4700 03:24:09,314 --> 03:24:11,350 POSITIVE NEGATIVE, WOMEN OF 4701 03:24:11,350 --> 03:24:14,553 COLOR AND WOMEN OF AGE AND TOLD 4702 03:24:14,553 --> 03:24:18,190 HER STORY HER PROJECTORY IN 4703 03:24:18,190 --> 03:24:21,593 JOURNEY BEGAN WITH THE 4704 03:24:21,593 --> 03:24:22,995 ATTENDING UNIVERSITY OF 4705 03:24:22,995 --> 03:24:25,030 MICHIGAN TO DO RESEARCH. 4706 03:24:25,030 --> 03:24:28,266 THE SECOND PERSON SPOTLIGHTED 4707 03:24:28,266 --> 03:24:32,404 IN NIMH SIM POSIAL WAS A 4708 03:24:32,404 --> 03:24:36,975 DOCTORAL STUDENTS NAMED JOHN 4709 03:24:36,975 --> 03:24:38,844 JERAMILIO AT THE HEALTH 4710 03:24:38,844 --> 03:24:41,113 UNIVERSITY OF MIAMI. 4711 03:24:41,113 --> 03:24:43,749 RESEARCH IS CENTERED ON HEALTH 4712 03:24:43,749 --> 03:24:46,151 OF MINORITY WITH INTEGRATING 4713 03:24:46,151 --> 03:24:47,052 IDENTITY AND CULTURE 4714 03:24:47,052 --> 03:24:49,521 CONSIDERATION IN THE HEALTH 4715 03:24:49,521 --> 03:24:52,924 PROMOTION FOR THAT POPULATION. 4716 03:24:52,924 --> 03:24:55,227 THEY HAVE ALSO WORKED WITH 4717 03:24:55,227 --> 03:24:57,763 DEVELOPING AND TESTING 4718 03:24:57,763 --> 03:24:58,930 INTERVENTION AND CULTURAL 4719 03:24:58,930 --> 03:25:01,233 CONFIDENT CARE FOR COMMUNITIES 4720 03:25:01,233 --> 03:25:02,567 IN SOUTH FLORIDA. 4721 03:25:02,567 --> 03:25:06,672 SO I THOUGHT IT WAS WONDERFUL 4722 03:25:06,672 --> 03:25:08,040 THAT NIMH WAS INCLUDED. 4723 03:25:08,040 --> 03:25:10,108 AND SPOT LINE ON MATERNAL 4724 03:25:10,108 --> 03:25:12,377 HEALTH AND THAT OCCURED ON 4725 03:25:12,377 --> 03:25:14,479 SEPTEMBER 16th WHERE THE OFFICE 4726 03:25:14,479 --> 03:25:16,481 OF DISPARITY RESEARCH WORKFORCE 4727 03:25:16,481 --> 03:25:18,917 DIVERSITY ALONG WITH THE NIH 4728 03:25:18,917 --> 03:25:21,653 OFFICE OF RESEARCH OF WOMEN'S 4729 03:25:21,653 --> 03:25:22,788 HEALTH CO-HOSTED A ROUNDTABLE 4730 03:25:22,788 --> 03:25:26,792 AS PART OF THE NIH EVALUATING 4731 03:25:26,792 --> 03:25:29,361 WOMEN'S VOICE TO SEE IMPROVE 4732 03:25:29,361 --> 03:25:30,729 MATERNAL HEALTH SERIES. 4733 03:25:30,729 --> 03:25:32,664 SO THIS IN PARTICULAR, I THINK 4734 03:25:32,664 --> 03:25:37,636 IS WHILE IT WAS NOT SPECIFIC TO 4735 03:25:37,636 --> 03:25:38,804 HIV, IT REPRESENTS AN 4736 03:25:38,804 --> 03:25:41,339 OPPORTUNITY TO REALLY HIGHLIGHT 4737 03:25:41,339 --> 03:25:42,941 HIV RESEARCH AND ITS IMPACT ON 4738 03:25:42,941 --> 03:25:44,810 THE HEALTH OF WOMEN OF COLOR. 4739 03:25:44,810 --> 03:25:48,046 SO DURING THIS ROUNDTABLE, 4740 03:25:48,046 --> 03:25:49,648 SPEAKERS HIGHLIGHTED HIGH 4741 03:25:49,648 --> 03:25:51,750 PRIORITY RELATED TO WOMEN'S 4742 03:25:51,750 --> 03:25:54,720 HEALTH DURING PREGNANCY AND 4743 03:25:54,720 --> 03:25:57,189 POST PARTUM PERIOD AND EXPLORED 4744 03:25:57,189 --> 03:25:59,024 HOW RESEARCH CAN REDUCE THE 4745 03:25:59,024 --> 03:26:01,860 BURDEN OF MENTAL ILLNESS THAT 4746 03:26:01,860 --> 03:26:04,763 CONTRIBUTE TO IMMORTALITY. 4747 03:26:04,763 --> 03:26:06,398 AND THEN THE LAST THING WAS 4748 03:26:06,398 --> 03:26:11,903 THAT THERE WAS A THAT MAY BE OF 4749 03:26:11,903 --> 03:26:14,840 INTEREST OF THIS GROUP IS 4750 03:26:14,840 --> 03:26:16,708 RESPONSIBLE USE OF ARTIFICIAL 4751 03:26:16,708 --> 03:26:17,676 INTELLIGENCE AND RESEARCH IN 4752 03:26:17,676 --> 03:26:19,177 THERE IF ANYONE IS INTERESTED 4753 03:26:19,177 --> 03:26:20,112 IN THAT. 4754 03:26:20,112 --> 03:26:21,747 NEXT SLIDE, PLEASE. 4755 03:26:21,747 --> 03:26:24,816 SO YOU'VE HEARD A LOT ABOUT THE 4756 03:26:24,816 --> 03:26:27,519 BUDGETS SO JUST IN TERMS OF 4757 03:26:27,519 --> 03:26:29,254 THOSE IMPACTS ON AND I MENTION 4758 03:26:29,254 --> 03:26:31,623 SPECIFICALLY, SO AS YOU ALL 4759 03:26:31,623 --> 03:26:33,692 KNOW, PRESIDENT BIDEN SIGNED 4760 03:26:33,692 --> 03:26:36,027 THAT APPROPRIATIONS ACT IN 4761 03:26:36,027 --> 03:26:37,662 2024, THAT PROVIDED FUNDS 4762 03:26:37,662 --> 03:26:38,563 THROUGH SEPTEMBER 30th. 4763 03:26:38,563 --> 03:26:41,600 SO THAT LAW PROVIDE ABOUT 2.3 4764 03:26:41,600 --> 03:26:45,504 MILLION DOLLARS TO NIMH AND 4765 03:26:45,504 --> 03:26:46,671 THAT APPROPRIATION REFLECTED 4766 03:26:46,671 --> 03:26:49,107 THAT INCLUDED FUND TO GO NIMH 4767 03:26:49,107 --> 03:26:50,675 THAT INCLUDED AN INCREASE OF 4768 03:26:50,675 --> 03:26:52,978 ABOUT 75 MILLION TO SUPPORT 4769 03:26:52,978 --> 03:26:55,981 RESEARCH FOCUSED ON DEVELOPING 4770 03:26:55,981 --> 03:26:57,115 TARGETS PREVENTIVE INTER 4771 03:26:57,115 --> 03:26:59,417 INTENTIONS AND TREATMENT FOR 4772 03:26:59,417 --> 03:27:03,722 MENTAL ILLNESS AND ALSO, 4773 03:27:03,722 --> 03:27:05,090 APPROPRIATION INCLUDE INCLUDES 4774 03:27:05,090 --> 03:27:08,360 130 MILLION REDUCTION IN THE 4775 03:27:08,360 --> 03:27:11,263 21st CENTURY FOR THE BRAIN 4776 03:27:11,263 --> 03:27:12,631 RESEARCH THROUGH ADVANCING 4777 03:27:12,631 --> 03:27:15,100 NUERO TECHNOLOGY SO THAT BRAIN 4778 03:27:15,100 --> 03:27:16,301 INITIATIVE. 4779 03:27:16,301 --> 03:27:20,438 IN TERMS OF NEW GRANTS AWARDED, 4780 03:27:20,438 --> 03:27:24,342 WHAT YOU SEE HERE ON THIS 4781 03:27:24,342 --> 03:27:27,112 SLIDE, NIMH INTENDS TO AWARD 4782 03:27:27,112 --> 03:27:29,848 ABOUT 600 NEW COMPETING 4783 03:27:29,848 --> 03:27:31,883 PROJECTS IN 2024, GIVEN THAT 4784 03:27:31,883 --> 03:27:35,053 FUND THATING WAS AVAILABLE AND 4785 03:27:35,053 --> 03:27:36,721 WITH ESTIMATED SUCCESS ABOUT 22 4786 03:27:36,721 --> 03:27:39,491 PERCENT WE IS REFLECTIVE OF 4787 03:27:39,491 --> 03:27:41,092 ABOUT WHAT IT'S BEEN IN THE 4788 03:27:41,092 --> 03:27:43,562 LAST COUPLE OF YEARS. 4789 03:27:43,562 --> 03:27:44,062 NEXT SLIDE, PLEASE. 4790 03:27:44,062 --> 03:27:45,463 OKAY. 4791 03:27:45,463 --> 03:27:49,334 SO IN TERMS OF AN UPDATED ABOUT 4792 03:27:49,334 --> 03:27:52,370 THE APPROPRIATIONS, AND HOW 4793 03:27:52,370 --> 03:27:57,642 IT'S IMPACTING NIMH ON THE 4794 03:27:57,642 --> 03:28:01,246 REQUEST FOR NIMH WAS ABOUT 2.5 4795 03:28:01,246 --> 03:28:02,380 MILLION THAT REQUESTED INCLUDED 4796 03:28:02,380 --> 03:28:05,383 10 MILLION FOR IMPLEMENTATION 4797 03:28:05,383 --> 03:28:07,619 INITIATIVE AND 190 MILLION FOR 4798 03:28:07,619 --> 03:28:11,022 OTHER MENTAL HEALTH RESEARCH 4799 03:28:11,022 --> 03:28:16,328 SUPPORTING BETTER DIAGNOSTICS 4800 03:28:16,328 --> 03:28:18,864 AND ENHANCE PREVISION. 4801 03:28:18,864 --> 03:28:22,334 : THE HEALTH INCLUDED ABOUT 3.2 4802 03:28:22,334 --> 03:28:24,169 MILLION COMBINING AN INCREASE 4803 03:28:24,169 --> 03:28:28,006 OF 23 MILLION OF GENERAL 4804 03:28:28,006 --> 03:28:29,407 APPROPRIATION WITH A 3.1 4805 03:28:29,407 --> 03:28:33,478 MILLION AND THEN THE SENATE 4806 03:28:33,478 --> 03:28:34,946 APPROPRIATIONS BILL WOULD 4807 03:28:34,946 --> 03:28:38,917 APPROPRIATE 2.7 MILLION TO NIMH 4808 03:28:38,917 --> 03:28:41,853 RESTORING FUNDING FOR THE BRAIN 4809 03:28:41,853 --> 03:28:45,457 INITIATIVE AND PROVIDING 275 4810 03:28:45,457 --> 03:28:48,426 MILLION TO SUPPORT RESEARCH 4811 03:28:48,426 --> 03:28:50,962 FOCUSED ON TARGETED PREVENTION 4812 03:28:50,962 --> 03:28:52,831 OF AND FOR MENTAL ILLNESS. 4813 03:28:52,831 --> 03:28:54,699 THAT GIVES YOU THE SENSE OF 4814 03:28:54,699 --> 03:28:57,102 WHAT THE BUDGET FOR NIMH IS 4815 03:28:57,102 --> 03:28:58,603 LOOKING LIKE. 4816 03:28:58,603 --> 03:29:06,378 NEXT SLIGHTED, PLAS ALSO THE 4817 03:29:06,378 --> 03:29:09,180 LAST NIMH MEETING FEW 4818 03:29:09,180 --> 03:29:10,548 SPOTLIGHTS ON RESEARCH. 4819 03:29:10,548 --> 03:29:15,153 TWO OF WHICH WERE HIV-RELATED. 4820 03:29:15,153 --> 03:29:19,190 THE FIRST, IT'S ANOTHER INFECTS 4821 03:29:19,190 --> 03:29:21,459 THE NERVOUS SYSTEM AND 4822 03:29:21,459 --> 03:29:23,395 ESTABLISHES PERSISTENT VIRAL 4823 03:29:23,395 --> 03:29:24,462 INFECTION THAT MAKES IT 4824 03:29:24,462 --> 03:29:27,499 DIFFICULT TO ERADICATE THE 4825 03:29:27,499 --> 03:29:29,301 VIRUS. 4826 03:29:29,301 --> 03:29:31,403 SO HIV IS BELIEVED AS YOU ALL 4827 03:29:31,403 --> 03:29:33,505 KNOW, BELIEVED TO PREDOMINANT 4828 03:29:33,505 --> 03:29:38,944 PERSIST IN A DOR MENT STATE IN 4829 03:29:38,944 --> 03:29:44,182 BRAIN CELLS, BMCs AND PLAY 4830 03:29:44,182 --> 03:29:45,650 CRITICAL ROLE IN RESPONDING TO 4831 03:29:45,650 --> 03:29:48,787 THE INFECTION. 4832 03:29:48,787 --> 03:29:51,323 SO DR. YAWNING OVER THE 4833 03:29:51,323 --> 03:29:53,391 UNIVERSITY OF, A SINGLE CELL 4834 03:29:53,391 --> 03:29:55,927 TECHNOLOGY TO IDENTIFY FACTORS 4835 03:29:55,927 --> 03:30:04,970 SIGNALING PATHWAYS THAT CONTROL 4836 03:30:04,970 --> 03:30:07,005 DORMENT. 4837 03:30:07,005 --> 03:30:11,109 SO THIS RESEARCH DR. SEANING 4838 03:30:11,109 --> 03:30:13,378 AIMS TO BETTER UNDERSTAND 4839 03:30:13,378 --> 03:30:15,413 PERSISTENT WITHIN THE CENTRAL 4840 03:30:15,413 --> 03:30:17,983 SYSTEM AND DEVELOP NOVEL TERMS 4841 03:30:17,983 --> 03:30:20,518 IN THE BMCs SO HOPEFULLY MOVING 4842 03:30:20,518 --> 03:30:23,388 US ONE STEP CLOSER TO 4843 03:30:23,388 --> 03:30:25,390 ERADICATING HIV IN THE BRAIN. 4844 03:30:25,390 --> 03:30:29,361 THE SECOND SPOTLIGHT I THOUGHT 4845 03:30:29,361 --> 03:30:31,663 THIS WAS REALLY RELEVANT FOR A 4846 03:30:31,663 --> 03:30:34,199 POPULATION THAT IS HIGHLY 4847 03:30:34,199 --> 03:30:36,434 VULNERABLE TO HIV AND THE 4848 03:30:36,434 --> 03:30:43,475 FINDINGS WILL BE RELEVANT TO HIV 4849 03:30:43,475 --> 03:30:46,411 TRANSGENDER AND NON BINARY 4850 03:30:46,411 --> 03:30:52,450 THOSE WHO IS IDENTITY DOES NOT 4851 03:30:52,450 --> 03:30:56,788 RELATE TO SEX ASSIGNED TO THEM 4852 03:30:56,788 --> 03:30:59,958 AT BIRTH, THEY'RE TWICE LIKELY 4853 03:30:59,958 --> 03:31:01,860 TO EXPRESS DEPRESSION AND 4854 03:31:01,860 --> 03:31:06,531 SUICIDE BEHAVIORS. 4855 03:31:06,531 --> 03:31:09,134 HIGH QUAUNT HEALTHCARE DUE TO 4856 03:31:09,134 --> 03:31:11,436 THE STIGMA, DUE TO SHORTAGE IN 4857 03:31:11,436 --> 03:31:13,171 SPECIALIZED SERVICES. 4858 03:31:13,171 --> 03:31:17,108 SO WITH FUNDING AND SERVICES 4859 03:31:17,108 --> 03:31:19,811 AND INTERVENTION RESEARCH DR. 4860 03:31:19,811 --> 03:31:22,113 CHEN FROM CHILDREN HOSPITAL IN 4861 03:31:22,113 --> 03:31:25,316 CHICAGO AIMED TO PILOT TEST A 4862 03:31:25,316 --> 03:31:26,718 MOBILE PHONE APPLICATION, A 4863 03:31:26,718 --> 03:31:29,254 PHONE APP THAT IS BASED ON 4864 03:31:29,254 --> 03:31:39,597 BEHAVIORAL THERAPY. 4865 03:31:47,772 --> 03:31:50,909 INTERNIZE TRANS PHOBIA NEGATIVE 4866 03:31:50,909 --> 03:31:52,777 FUTURE EXPECTATIONS, IDENTITY, 4867 03:31:52,777 --> 03:31:57,348 NON DISCLOSURE AND NON GENDER 4868 03:31:57,348 --> 03:32:00,819 IDENTITY PRIDE, SO COACHING SO 4869 03:32:00,819 --> 03:32:02,487 EITHER BY PHONER OWE I WILL CAN 4870 03:32:02,487 --> 03:32:03,555 IMPROVE. 4871 03:32:03,555 --> 03:32:05,390 SO THE RESULTS CAN YIELD 4872 03:32:05,390 --> 03:32:12,897 CRITICAL DATA TO INFORM LARGE I 4873 03:32:12,897 --> 03:32:15,400 IMPLEMENTATION. 4874 03:32:15,400 --> 03:32:17,936 FOR ALL OF THESE YOUNG PEOPLE. 4875 03:32:17,936 --> 03:32:20,405 NEXT SLIDE, PLEASE. 4876 03:32:20,405 --> 03:32:26,411 THERE WAS ALSO ONE HIV-RELATED 4877 03:32:26,411 --> 03:32:27,212 CONCEPT CLEARANCE PRESENTED, SO 4878 03:32:27,212 --> 03:32:30,115 THE PURPOSE OF THIS CONCEPT WAS 4879 03:32:30,115 --> 03:32:31,416 TO IDENTIFY MODIFIABLE TARGETS 4880 03:32:31,416 --> 03:32:35,887 AND MECHANISM TO SEE ALLEVIATE 4881 03:32:35,887 --> 03:32:37,088 CLINICALLY CENTRAL SERVICE 4882 03:32:37,088 --> 03:32:40,525 COMPLICATION SXZ DEVELOP 4883 03:32:40,525 --> 03:32:41,860 COMPREHENSIVE VALIDATED 4884 03:32:41,860 --> 03:32:44,796 TREATMENT STRATEGIES TO IMPROVE 4885 03:32:44,796 --> 03:32:47,332 OUTCOMES PEOPLE LIVING WITH HIV 4886 03:32:47,332 --> 03:32:50,535 BUT IMPROVE QUALITY OF LIFE AND 4887 03:32:50,535 --> 03:32:54,873 REDUCE SYSTEM SEVERITY AND 4888 03:32:54,873 --> 03:32:57,342 EXPERIENCING ADVERSITY. 4889 03:32:57,342 --> 03:32:59,444 FURTHERMORE, THE CONCEPT TO 4890 03:32:59,444 --> 03:33:01,980 REALLY ENCOURAGE ADOPTING MILD 4891 03:33:01,980 --> 03:33:06,117 BASE, GO NO GO IN TREATMENT 4892 03:33:06,117 --> 03:33:09,287 STRATEGIES DESIGN COUPLED WITH 4893 03:33:09,287 --> 03:33:11,589 TESTING TO VALIDATE TARGET EN 4894 03:33:11,589 --> 03:33:13,691 GIJMENT AND CHANGES OUTCOMES 4895 03:33:13,691 --> 03:33:17,595 AND ENSURING THAT ONLY 4896 03:33:17,595 --> 03:33:19,230 PROMISING ARE INVOLVED. 4897 03:33:19,230 --> 03:33:20,365 IN TRAIL PHASES. 4898 03:33:20,365 --> 03:33:24,469 SO THIS CONCEPT EXTENDS AND 4899 03:33:24,469 --> 03:33:28,940 IT'S EXPERIMENTAL PARADIGM TO 4900 03:33:28,940 --> 03:33:30,975 TREATMENT STRATEGIES. 4901 03:33:30,975 --> 03:33:33,278 SO THE MOST TREATABLE TRADES 4902 03:33:33,278 --> 03:33:39,150 CONTRIBUTE TO GO PATH O 4903 03:33:39,150 --> 03:33:40,552 GENESIS AND PEOPLE LIVING WITH 4904 03:33:40,552 --> 03:33:43,555 HIV AND THIS CONCEPT OF LISTED 4905 03:33:43,555 --> 03:33:45,590 APPROVED BY COUNCIL. 4906 03:33:45,590 --> 03:33:46,491 NEXT SLIDE PLEASE. 4907 03:33:46,491 --> 03:33:50,361 AND THEN, THERE ARE TWO FEATURE 4908 03:33:50,361 --> 03:33:51,362 FUNDING MECHANISMS. 4909 03:33:51,362 --> 03:33:55,767 THE FIRST IS NIMH RESEARCH 4910 03:33:55,767 --> 03:33:57,602 MENTORING FOR HIV RESEARCHERS. 4911 03:33:57,602 --> 03:34:00,171 THIS MECHANISM HAS FUNDED HIV 4912 03:34:00,171 --> 03:34:02,941 PROGRAMS FOR A WHILE AND IT'S 4913 03:34:02,941 --> 03:34:04,309 INTENDED TO SUPPORT AND 4914 03:34:04,309 --> 03:34:07,078 CONTINUED TO SUPPORT RESEARCH 4915 03:34:07,078 --> 03:34:09,047 ACTIVITIES. 4916 03:34:09,047 --> 03:34:12,250 THE OVER ARCHING GOAL OF THE 4917 03:34:12,250 --> 03:34:14,752 R25 PROGRAM IS TO SUPPORT 4918 03:34:14,752 --> 03:34:16,154 ACTIVITIES AND ENHANCE THE 4919 03:34:16,154 --> 03:34:19,791 WORKFORCE TO MEET THE NATION'S 4920 03:34:19,791 --> 03:34:23,962 BIO MEDICAL BEHAVIOR. 4921 03:34:23,962 --> 03:34:30,134 THE SECOND, THE SECOND IS FOR 4922 03:34:30,134 --> 03:34:32,670 MECHANISM BETWEEN HIV NUERO 4923 03:34:32,670 --> 03:34:34,505 INFLAMMATION AND SEEING 4924 03:34:34,505 --> 03:34:38,443 PERSISTENT HOW THE IMPLICATIONS 4925 03:34:38,443 --> 03:34:48,953 ARE IN HIV NUERO PATHOGENSIS. 4926 03:34:50,355 --> 03:34:53,258 NUERO INFLAMMATION AND HIV 4927 03:34:53,258 --> 03:34:54,892 PERSISTENCE AND TO RESEARCH 4928 03:34:54,892 --> 03:34:57,695 DEFINING THE ROLE AND 4929 03:34:57,695 --> 03:35:00,465 MECHANISMS OF DEFECTIVE PRO 4930 03:35:00,465 --> 03:35:05,303 VIRUSES HIV PROTEINS AND 4931 03:35:05,303 --> 03:35:06,170 REDUCING INFLAMMATION. 4932 03:35:06,170 --> 03:35:07,171 I THINK THAT'S IT, THANK YOU 4933 03:35:07,171 --> 03:35:10,708 VERY MUCH. 4934 03:35:10,708 --> 03:35:13,911 >> THANK YOU SO MUCH, DR. 4935 03:35:13,911 --> 03:35:17,849 LIGHTFOOT FOR THAT UPDATE. 4936 03:35:17,849 --> 03:35:20,351 DR. OTT, PLEASE PROCEED. 4937 03:35:20,351 --> 03:35:24,088 >> YEP. 4938 03:35:24,088 --> 03:35:25,456 HELLO EVERYBODY, I'M SLIGHTED 4939 03:35:25,456 --> 03:35:27,525 TO PROVIDE SOME HIGHLIGHTS FROM 4940 03:35:27,525 --> 03:35:31,095 THE NATIONAL INSTITUTE OF DRUG 4941 03:35:31,095 --> 03:35:33,931 ABUSE, NAIDA. 4942 03:35:33,931 --> 03:35:36,034 WOULD LIKE TO HIGHLIGHT ONE OF 4943 03:35:36,034 --> 03:35:39,003 THE PAPERS, ONE OF THEIR PAPERS 4944 03:35:39,003 --> 03:35:40,705 IN THEIR PORTFOLIO THAT WAS 4945 03:35:40,705 --> 03:35:45,710 GENERATED BY ONE OF THEIR A 4946 03:35:45,710 --> 03:35:48,713 VANGUARD AWARD RECIPIENTS, LEO 4947 03:35:48,713 --> 03:35:52,350 WINEBERGER HE HAS USED TIPS 4948 03:35:52,350 --> 03:35:53,284 THERAPEUTIC INTERFERING 4949 03:35:53,284 --> 03:35:57,588 PARTICLES WHICH ARE DERIVED 4950 03:35:57,588 --> 03:35:58,956 FROM DEFECTIVE INTERFERING 4951 03:35:58,956 --> 03:36:02,160 PARTICLES TO INTERFERE WITH HIV 4952 03:36:02,160 --> 03:36:05,763 AND IT'S ACTUALLY BEAUTIFULLY 4953 03:36:05,763 --> 03:36:08,032 FITTING INTO WHAT WES HAS TOLD 4954 03:36:08,032 --> 03:36:12,403 US EARLIER ABOUT CAPSID AND HIV 4955 03:36:12,403 --> 03:36:13,905 ASSEMBLY. 4956 03:36:13,905 --> 03:36:15,940 NEXT SLIDE. 4957 03:36:15,940 --> 03:36:19,377 BECAUSE THESE TIPS ARE 4958 03:36:19,377 --> 03:36:24,649 BASICALLY MINI HIV VIRUSES OR G 4959 03:36:24,649 --> 03:36:27,452 NODES THAT RELY ON 4960 03:36:27,452 --> 03:36:31,055 COMPLIMENTATION OF CRITICAL 4961 03:36:31,055 --> 03:36:36,527 VIRAL PROTEINS EN VIERRAL SO 4962 03:36:36,527 --> 03:36:40,498 THE TIP STEALS PROTEINS FROM 4963 03:36:40,498 --> 03:36:44,168 THE VIRUS AND TO PROPAGATE ITS 4964 03:36:44,168 --> 03:36:47,171 OWN REPLICATION AND A MAJOR 4965 03:36:47,171 --> 03:36:51,042 POINT OF, OF INTERACTION IS THE 4966 03:36:51,042 --> 03:36:53,010 CAPSID THAT THAT IS BEING 4967 03:36:53,010 --> 03:36:54,445 EXCHANGED. 4968 03:36:54,445 --> 03:37:01,786 AND SO THE MODEL IS THAT THESE 4969 03:37:01,786 --> 03:37:02,954 ENGINEERED DEFECTIVE PARTICLES 4970 03:37:02,954 --> 03:37:04,589 ARE SHORTER, THEY REPLICATE 4971 03:37:04,589 --> 03:37:06,891 FASTER AND THAT'S WHY, THEY YOU 4972 03:37:06,891 --> 03:37:09,927 KNOW, DOMINATE OVER THE FULL 4973 03:37:09,927 --> 03:37:11,662 LENGTH VIRUS IN THE CELL AND 4974 03:37:11,662 --> 03:37:15,266 THIS HAS BEEN ZONE IN THIS 4975 03:37:15,266 --> 03:37:19,370 PAPER, ALSO IN MONKEYS WHERE A 4976 03:37:19,370 --> 03:37:21,873 SINGLE DOSE OF THE TIP 4977 03:37:21,873 --> 03:37:25,109 PREVENTED THE MAJORITY OF 4978 03:37:25,109 --> 03:37:29,347 ANIMALS THAT GOT INFECTED WITH 4979 03:37:29,347 --> 03:37:35,219 THE SHIFT VIRUS FROM DEVELOPING 4980 03:37:35,219 --> 03:37:37,088 PATHOGENSIS AND STAYED 4981 03:37:37,088 --> 03:37:38,456 RELATIVELY HIGH OVER A MULTIPLE 4982 03:37:38,456 --> 03:37:47,765 MONTHS. 4983 03:37:47,765 --> 03:37:51,869 TTSZ NOT AFFECTIVE AS 4984 03:37:51,869 --> 03:37:54,372 LENACAPAVIR, WHICH WE HEARD A 4985 03:37:54,372 --> 03:37:58,943 LOT ABOUT TODAY, A PROMISING 4986 03:37:58,943 --> 03:38:01,913 AND POTENT CAPSID INHIBITOR, WE 4987 03:38:01,913 --> 03:38:03,514 HEARD ABOUT PURPOSE ONE AND 4988 03:38:03,514 --> 03:38:05,349 PURPOSE 2 STUDIES. 4989 03:38:05,349 --> 03:38:06,717 I WANT TO DRAW YOUR ATTENTION 4990 03:38:06,717 --> 03:38:08,619 TO THE PURPOSE 4 STUDIES WHICH 4991 03:38:08,619 --> 03:38:11,556 IS DESIGNED FOR PEOPLE WHO 4992 03:38:11,556 --> 03:38:13,891 INJECT DRUGS AND IT'S CURRENTLY 4993 03:38:13,891 --> 03:38:18,663 NOT ROLLING AND WILL HOPEFULLY 4994 03:38:18,663 --> 03:38:22,733 ESTABLISH A SIMILAR HIGH 4995 03:38:22,733 --> 03:38:29,073 EFFECTIVENESS OF TWICE A YEAR 4996 03:38:29,073 --> 03:38:30,475 INJECTION IN PREVENTING 4997 03:38:30,475 --> 03:38:32,977 ACQUISITION ALONG PEOPLE WHO 4998 03:38:32,977 --> 03:38:34,178 INJECT. 4999 03:38:34,178 --> 03:38:36,347 NEXT SLIDE. 5000 03:38:36,347 --> 03:38:39,484 I WANT TO POINT OUT ANOTHER 5001 03:38:39,484 --> 03:38:42,887 VERY IMPORTANT ASPECT OF HIV 5002 03:38:42,887 --> 03:38:46,290 CARE, IS THAT CURRENTLY, 5003 03:38:46,290 --> 03:38:49,260 OVERDOSE IS AMONG THE GREATEST 5004 03:38:49,260 --> 03:38:51,829 THREATS TO PEOPLE WITH HIV 5005 03:38:51,829 --> 03:38:54,732 THIS WAS SHOWN IN A 2017 5006 03:38:54,732 --> 03:38:58,269 ANALYSIS IN NEW YORK WHERE, 5007 03:38:58,269 --> 03:39:00,605 WHERE HIV SURVEILLANCE FOUND 5008 03:39:00,605 --> 03:39:02,139 OUT THAT THE RATE OF OVERDOSE 5009 03:39:02,139 --> 03:39:04,909 DEATH OF PEOPLE LIVING WITH HIV 5010 03:39:04,909 --> 03:39:11,282 WAS MORE THAN DOUBLE WITH THE 5011 03:39:11,282 --> 03:39:12,183 OVERALL OVERDOSE DEATH RATES. 5012 03:39:12,183 --> 03:39:18,055 SO PEOPLE WITH HIV DIE ALMOST, 5013 03:39:18,055 --> 03:39:23,361 YOU KNOW, MORE THAN DOUBLE IN 5014 03:39:23,361 --> 03:39:25,029 RATES ON BY OVERDOSE. 5015 03:39:25,029 --> 03:39:27,999 AND THIS IS NOT BECAUSE THEY 5016 03:39:27,999 --> 03:39:30,701 ARE FALLING THROUGH THE CARE, 5017 03:39:30,701 --> 03:39:34,405 THE MOST OF THEM ARE 98 OF THEM 5018 03:39:34,405 --> 03:39:37,642 ARE IN CARE AND THEY ARE 5019 03:39:37,642 --> 03:39:40,011 ACTUALLY, LOOKED AFTER AND 5020 03:39:40,011 --> 03:39:42,280 RETAINED AND CARE AND MORE THAN 5021 03:39:42,280 --> 03:39:46,350 HALF OF THEM WERE VIRALLY 5022 03:39:46,350 --> 03:39:46,651 SUPPRESSED. 5023 03:39:46,651 --> 03:39:49,520 SO THIS IS NOT AN NEGLIGENCE 5024 03:39:49,520 --> 03:39:54,425 ISSUE BUT I THINK AS DR. NORA, 5025 03:39:54,425 --> 03:39:57,194 DIRECTOR OF NIDA AND DIRECTOR 5026 03:39:57,194 --> 03:39:59,697 OF NID POINTED OUT, IT'S A 5027 03:39:59,697 --> 03:40:01,732 SPECIFIC RESPONSIBILITY FOR 5028 03:40:01,732 --> 03:40:04,402 THESE HIV CARE CENTERS TO 5029 03:40:04,402 --> 03:40:08,739 INCLUDE EDUCATION AND 5030 03:40:08,739 --> 03:40:11,008 POTENTIALLY TRAINING 5031 03:40:11,008 --> 03:40:13,945 APPLICATION IN THESE, IN 5032 03:40:13,945 --> 03:40:15,646 INCORPORATE THAT INTO THE HIV 5033 03:40:15,646 --> 03:40:16,647 CARE. 5034 03:40:16,647 --> 03:40:18,616 AND I THINK HAVING THESE PEOPLE 5035 03:40:18,616 --> 03:40:21,886 IN HERE, IS REALLY UNIQUE 5036 03:40:21,886 --> 03:40:25,056 OPPORTUNITY HERE TO PREVENT 5037 03:40:25,056 --> 03:40:27,592 THIS LARGE OVERDOSE DEATH BY 5038 03:40:27,592 --> 03:40:28,793 OVERDOSE RATE IN ORDER TO MAKE 5039 03:40:28,793 --> 03:40:32,296 A DIFFERENCE IN THE FUTURE. 5040 03:40:32,296 --> 03:40:35,232 THE NEXT SLIDE. 5041 03:40:35,232 --> 03:40:37,101 ANOTHER IMPORTANT ASPECT THAT 5042 03:40:37,101 --> 03:40:44,709 WE WOULD LIKE TO HIGHLIGHT IS 5043 03:40:44,709 --> 03:40:47,078 THE HIV INFECTION IN PEOPLE WHO 5044 03:40:47,078 --> 03:40:48,412 ARE ASSOCIATED WITH THE 5045 03:40:48,412 --> 03:40:49,547 CRIMINAL LEGAL SYSTEM. 5046 03:40:49,547 --> 03:40:53,484 THERE IS A SPECIAL NIDA NETWORK 5047 03:40:53,484 --> 03:40:56,554 THAT HAS BEEN FORMED THE 5048 03:40:56,554 --> 03:40:58,322 COLLABORATIVE NETWORK TO END 5049 03:40:58,322 --> 03:41:01,292 THE HIV EPIDEMIC AND ADDRESS 5050 03:41:01,292 --> 03:41:03,060 ADDICTION IN THE CRIMINAL 5051 03:41:03,060 --> 03:41:03,561 JUSTICE SYSTEM. 5052 03:41:03,561 --> 03:41:07,264 AND THIS IS BASICALLY AN 5053 03:41:07,264 --> 03:41:09,133 INITIATIVE THAT CONSIST OF 8 5054 03:41:09,133 --> 03:41:10,735 GRANTS INCLUDING 7 ACADEMIC 5055 03:41:10,735 --> 03:41:13,504 RESEARCH HUBS AND A PATIENT 5056 03:41:13,504 --> 03:41:15,773 ENGAGEMENT RESOURCE CENTER WITH 5057 03:41:15,773 --> 03:41:19,877 THE GOAL OF, OF RESEARCH AND 5058 03:41:19,877 --> 03:41:21,946 CAPACITY BUILDING, BUILDING 5059 03:41:21,946 --> 03:41:24,248 RESEARCH AND CAPACITY BUILDING 5060 03:41:24,248 --> 03:41:26,784 PROJECT TO REALLY ADDRESS THE 5061 03:41:26,784 --> 03:41:29,120 UNIQUE NEEDS OF INDIVIDUALS 5062 03:41:29,120 --> 03:41:32,990 WITH HIV AND SUBSTANCE USE 5063 03:41:32,990 --> 03:41:34,592 DISORDER, AS THEY TRANSITION 5064 03:41:34,592 --> 03:41:35,793 BETWEEN THE CRIMINAL LEGAL 5065 03:41:35,793 --> 03:41:37,428 SYSTEM AND THE COMMUNITY. 5066 03:41:37,428 --> 03:41:39,730 SO THIS IS A NEW INITIATIVE 5067 03:41:39,730 --> 03:41:43,367 THAT REALLY ADDRESSES THIS 5068 03:41:43,367 --> 03:41:45,670 UNIQUE ASPECT OF HIV CARE THAT 5069 03:41:45,670 --> 03:41:48,406 IS ASSOCIATED WITH NIDA AND I 5070 03:41:48,406 --> 03:41:50,608 THINK THESE ARE ALL MY UPDATES 5071 03:41:50,608 --> 03:41:54,845 FOR TODAY. 5072 03:41:54,845 --> 03:41:59,817 >> THANK YOU SO MUCH, DR. OTT. 5073 03:41:59,817 --> 03:42:01,719 OUR FINAL UPDATE FOR TODAY WILL 5074 03:42:01,719 --> 03:42:05,089 COME FROM THE HIV CLINICAL 5075 03:42:05,089 --> 03:42:06,957 GUIDELINES WORKING GROUP OF 5076 03:42:06,957 --> 03:42:10,394 OARAC, JUST LET ME SAY BEFORE I 5077 03:42:10,394 --> 03:42:18,669 CONTINUE, WE HAD SCHEDULED MRS. 5078 03:42:18,669 --> 03:42:23,441 CORETTE BYRD BUT WE HAVE 5079 03:42:23,441 --> 03:42:24,809 RESCHEDULED SO SHE'LL BE 5080 03:42:24,809 --> 03:42:25,743 PRESENTING AT OUR FEBRUARY 5081 03:42:25,743 --> 03:42:26,677 MEETING. 5082 03:42:26,677 --> 03:42:31,849 OUR FINAL WILL BE FROM THE 5083 03:42:31,849 --> 03:42:33,451 GUIDELINE THESE INCLUDE BOTH 5084 03:42:33,451 --> 03:42:41,992 GUIDELINES AND PANEL UPDATE. 5085 03:42:41,992 --> 03:42:44,028 DR. DHANIREDDY WILL PROVIDE 5086 03:42:44,028 --> 03:42:45,029 UPDATES ON OPPORTUNISTIC 5087 03:42:45,029 --> 03:42:48,632 INFECTIONS. 5088 03:42:48,632 --> 03:42:50,000 DR. DHANIREDDY OVER TO YOU. 5089 03:42:50,000 --> 03:42:57,007 >> THANK YOU FOR INVITING ME. 5090 03:42:57,007 --> 03:42:58,375 THANK YOU FOR HAVING ME TODAY. 5091 03:42:58,375 --> 03:42:59,710 IF YOU CAN ADVANCE TO THE NEXT 5092 03:42:59,710 --> 03:43:01,812 SLIDE. 5093 03:43:01,812 --> 03:43:08,219 I THINK IT'S ON DR. BYRD. 5094 03:43:08,219 --> 03:43:09,620 >> WE'RE JUST PULLING UP YOUR 5095 03:43:09,620 --> 03:43:10,988 SLIDES, IT WILL TAKE A SECOND. 5096 03:43:10,988 --> 03:43:21,165 THANK YOU. 5097 03:43:38,415 --> 03:43:42,253 I'M ONE THE CO-CHAIR FOR THE 5098 03:43:42,253 --> 03:43:48,893 GUIDE LIESED OF OPPORTUNISTIC 5099 03:43:48,893 --> 03:43:50,995 INFECTION NEXT SLIDE. 5100 03:43:50,995 --> 03:43:53,764 WE HAVE PREPARATION FROM NIH, 5101 03:43:53,764 --> 03:43:59,069 TWO OF THEM INFECTIOUS AND HIV 5102 03:43:59,069 --> 03:44:01,272 MEDICAL ASSOCIATION. 5103 03:44:01,272 --> 03:44:02,673 THE CDC HAD ALSO HAD A 5104 03:44:02,673 --> 03:44:04,275 REPRESENTATIVE BUT AN UPDATE AS 5105 03:44:04,275 --> 03:44:07,278 OF THIS YEAR IS THAT CDC HAS 5106 03:44:07,278 --> 03:44:10,548 CHOSEN TO NOT APPOINT A 5107 03:44:10,548 --> 03:44:13,083 CO-CHAIR AND HAVE A FORMAL 5108 03:44:13,083 --> 03:44:16,720 RECOGNITION ON THIS GUIDELINE. 5109 03:44:16,720 --> 03:44:18,589 AT DR. BURKS HAD BEEN SERVING 5110 03:44:18,589 --> 03:44:22,259 AS IN THAT ROLE BUT HE RECENTLY 5111 03:44:22,259 --> 03:44:24,395 RETIRED WILL BE AN INDEPENDENT 5112 03:44:24,395 --> 03:44:26,230 CO-CHAIR WITH KNOWLEDGE IN THIS 5113 03:44:26,230 --> 03:44:28,566 AREA AND LONG TIME MEMBER OF 5114 03:44:28,566 --> 03:44:30,501 THE GUIDELINE. 5115 03:44:30,501 --> 03:44:33,304 THERE ARE 151 MEMBERS, 36 NEW 5116 03:44:33,304 --> 03:44:34,505 MEMBERS HAVE REPLACED RETIRING 5117 03:44:34,505 --> 03:44:37,074 MEMBERS OVER THE PAST YEAR. 5118 03:44:37,074 --> 03:44:44,148 AND WE HAVE 25 SUBJECT REPLETE, 5119 03:44:44,148 --> 03:44:47,084 SO THEY'RE EXPERTS IN THEIR 5120 03:44:47,084 --> 03:44:48,886 PARTICULAR AREAS THAT ARE 5121 03:44:48,886 --> 03:44:50,454 REPRESENTATIVES IN THE 5122 03:44:50,454 --> 03:44:52,289 GUIDELINES AND THEY LEAD A 5123 03:44:52,289 --> 03:44:53,924 GROUP OF OTHER MEMBERS IN THE 5124 03:44:53,924 --> 03:44:55,326 SUBCOMMITTEE THAT ALSO HAVE A 5125 03:44:55,326 --> 03:44:57,628 WIDE RANGE OF EXPERIENCE 5126 03:44:57,628 --> 03:44:58,696 RESEARCH AND CLINICAL, IN THAT 5127 03:44:58,696 --> 03:44:59,730 AREA. 5128 03:44:59,730 --> 03:45:02,466 AND WE'VE HAD 7 NEW SUBJECT 5129 03:45:02,466 --> 03:45:04,969 REPLETES THAT ARE REPLACED 5130 03:45:04,969 --> 03:45:07,471 RETIRING IN THE PAST YEAR. 5131 03:45:07,471 --> 03:45:10,941 WE HAVE 30 CHAPTERS AND THOSE 5132 03:45:10,941 --> 03:45:11,709 CHAPTERS ARE CONTINUOUSLY 5133 03:45:11,709 --> 03:45:13,444 REVIEWED. 5134 03:45:13,444 --> 03:45:17,114 WE HAVE REGULAR LITERARY 5135 03:45:17,114 --> 03:45:18,983 SEARCHES THAT ARE PUT THROUGH 5136 03:45:18,983 --> 03:45:23,988 AND ANY UPDATES THAT MAY IMPACT 5137 03:45:23,988 --> 03:45:26,757 THESE GUIDELINES ARE REVIEW AND 5138 03:45:26,757 --> 03:45:29,093 MATERIAL IS REVISED AS NEEDED. 5139 03:45:29,093 --> 03:45:32,997 NEXT SLIDE. 5140 03:45:32,997 --> 03:45:36,634 SO I KNOW DR. BULLIC IS ON HERE 5141 03:45:36,634 --> 03:45:38,969 AND ABLE TO TALK ABOUT THE 5142 03:45:38,969 --> 03:45:39,937 TREATMENT GUIDELINES AND YOU 5143 03:45:39,937 --> 03:45:41,906 CAN SEE WE'RE IN SECOND PLACE 5144 03:45:41,906 --> 03:45:43,540 IN THE TREATMENT GUIDELINES, WE 5145 03:45:43,540 --> 03:45:45,643 HAVE OVER HALF A MILLION VIEWS 5146 03:45:45,643 --> 03:45:47,077 THROUGH DECEMBER OF LAST YEAR 5147 03:45:47,077 --> 03:45:48,913 FOR THE YEAR AND WE ARE ON PAR 5148 03:45:48,913 --> 03:45:51,348 TO HAVE THAT OR MORE FOR THIS 5149 03:45:51,348 --> 03:45:53,217 YEAR. 5150 03:45:53,217 --> 03:45:57,288 NEXT SLIDE. 5151 03:45:57,288 --> 03:45:59,356 AND THIS IS AN INCREASE 5152 03:45:59,356 --> 03:46:01,225 COMPARED TO THE YEAR BEFORE, 5153 03:46:01,225 --> 03:46:07,865 AND WE KNOW THAT WE'RE SEEING 5154 03:46:07,865 --> 03:46:12,336 MORE LATE DIAGNOSES OF HIV THAT 5155 03:46:12,336 --> 03:46:13,938 CONTINUE SO THESE GUIDE LINES 5156 03:46:13,938 --> 03:46:16,707 ARE STILL RELEVANT FOR MANY, 5157 03:46:16,707 --> 03:46:20,811 EVEN THOUGH WE HAVE AREAS WITH 5158 03:46:20,811 --> 03:46:21,745 HIGHLIGHTS OF VIROLOGY, WE 5159 03:46:21,745 --> 03:46:23,113 CONTINUE TO SEE PEOPLE WITH 5160 03:46:23,113 --> 03:46:24,248 LATE STAGE DISEASE. 5161 03:46:24,248 --> 03:46:25,416 NEXT SLIDE. 5162 03:46:25,416 --> 03:46:27,051 THEN YOU CAN SEE A BREAK DOWN 5163 03:46:27,051 --> 03:46:29,853 OF ALL THE DIFFERENT SUBJECTS, 5164 03:46:29,853 --> 03:46:32,589 THAT BY PAGE VIEWS AND THE BLUE 5165 03:46:32,589 --> 03:46:34,525 OF BAR IS FROM THIS PAST YEAR 5166 03:46:34,525 --> 03:46:38,295 IN 2023. 5167 03:46:38,295 --> 03:46:41,031 PNEUMONIA IS THE MOST 5168 03:46:41,031 --> 03:46:43,300 FREQUENTED WEBSITE ON OUR IN 5169 03:46:43,300 --> 03:46:45,336 OUR GUIDELINES AS PEOPLE 5170 03:46:45,336 --> 03:46:51,108 REFERENCE TREATMENT AS WELL AS 5171 03:46:51,108 --> 03:46:55,045 PROFOLIX AND THEN WE HAD A 5172 03:46:55,045 --> 03:46:57,481 INCREASE USE FOR IMMUNIZATION 5173 03:46:57,481 --> 03:46:59,383 GUIDELINES THERE IS A NICE 5174 03:46:59,383 --> 03:47:01,585 TABLE REVIEWING ALL THE 5175 03:47:01,585 --> 03:47:02,853 RECOMMENDED VACCINES FOR PEOPLE 5176 03:47:02,853 --> 03:47:04,355 WITH HIV 5177 03:47:04,355 --> 03:47:08,592 NEXT SLIDE. 5178 03:47:08,592 --> 03:47:10,461 THIS SHOWS SORT OF BY COUNTY 5179 03:47:10,461 --> 03:47:12,096 EVEN THOUGH THESE ARE 5180 03:47:12,096 --> 03:47:14,932 GUIDELINES REALLY FOR THE 5181 03:47:14,932 --> 03:47:16,266 UNITED STATES, AND THAT'S WHERE 5182 03:47:16,266 --> 03:47:19,236 THE MAJORITY OF PEOPLE ARE THAT 5183 03:47:19,236 --> 03:47:20,437 ACCESS THE GUIDELINES. 5184 03:47:20,437 --> 03:47:21,805 YOU CAN SEE THAT THERE ARE A 5185 03:47:21,805 --> 03:47:23,874 NUMBER OF COUNTRIES THAT ALSO 5186 03:47:23,874 --> 03:47:26,210 USE THESE GUIDELINES FOR AND 5187 03:47:26,210 --> 03:47:27,144 INDIVIDUALS USE THESE 5188 03:47:27,144 --> 03:47:29,013 GUIDELINES IN THEIR PRACTICE 5189 03:47:29,013 --> 03:47:30,614 AND OTHER COUNTIES, INDIA BEING 5190 03:47:30,614 --> 03:47:36,487 THE BIG ONE HERE OUTSIDE OF U.S. 5191 03:47:36,487 --> 03:47:37,488 NEXT SLIDE. 5192 03:47:37,488 --> 03:47:42,359 SO WE HAVE A NUMBER OF RECENTLY 5193 03:47:42,359 --> 03:47:43,394 PUBLISHED UPDATES. 5194 03:47:43,394 --> 03:47:48,665 SO IN TERMS OF SECTIONS, WE 5195 03:47:48,665 --> 03:47:51,435 HAVE MTB VEX, WE WENT THROUGH A 5196 03:47:51,435 --> 03:47:52,369 HUGE OVERHAUL AND CONTINUES TO 5197 03:47:52,369 --> 03:47:56,807 HAVE AN UPDATE THAT IS 5198 03:47:56,807 --> 03:48:01,211 PUBLISHING, I'LL TALK MORE 5199 03:48:01,211 --> 03:48:06,316 ABOUT HPV. 5200 03:48:06,316 --> 03:48:16,827 AND LEASH MANSIS AND MYCO NN 5201 03:48:19,930 --> 03:48:21,331 BCTIUM. 5202 03:48:21,331 --> 03:48:23,133 SO NEXT SLIDE. 5203 03:48:23,133 --> 03:48:25,235 THE UPDATES THAT ARE GOING TO 5204 03:48:25,235 --> 03:48:27,304 BE PUBLISHED SOON, ARE THESE 5205 03:48:27,304 --> 03:48:29,840 AND I THINK THERE WAS A SLIDE 5206 03:48:29,840 --> 03:48:31,241 MISSING, BUT I'LL GET BACK TO 5207 03:48:31,241 --> 03:48:35,579 YOU IN A SECOND. 5208 03:48:35,579 --> 03:48:44,221 SO HISTO AND CRYPTO AND 5209 03:48:44,221 --> 03:48:46,190 SISCICCO ARE GOING TO HAVE 5210 03:48:46,190 --> 03:48:46,423 UPDATES. 5211 03:48:46,423 --> 03:48:48,158 SO FOR A SECOND, I WANT TODAY 5212 03:48:48,158 --> 03:48:52,296 TALK ABOUT THE HPV GUIDELINES. 5213 03:48:52,296 --> 03:48:54,631 SO THE HPV WENT A HUGE OVERALL 5214 03:48:54,631 --> 03:48:59,369 THIS YEAR AND REALLY IN 5215 03:48:59,369 --> 03:49:01,438 RESPONSE TO DATA FROM THE 5216 03:49:01,438 --> 03:49:03,273 ANCHOR STUDY WHICH CAME OUT A 5217 03:49:03,273 --> 03:49:06,743 COUPLE OF YEARS PRIOR, LOOKING 5218 03:49:06,743 --> 03:49:10,414 AT ANAL CANCER, THE TREATMENT 5219 03:49:10,414 --> 03:49:13,650 OF HIGH GRADE LESIONS AND THE 5220 03:49:13,650 --> 03:49:18,455 PRIMARY POINT WAS PROGRESSION 5221 03:49:18,455 --> 03:49:21,959 TO ANAL CANCER. 5222 03:49:21,959 --> 03:49:30,601 AND BASED ON THAT, THERE WERE 5223 03:49:30,601 --> 03:49:32,669 GUIDELINES THAT WERE PUBLISHED 5224 03:49:32,669 --> 03:49:39,810 BIT ANAL NEO PLACIA THAT 5225 03:49:39,810 --> 03:49:41,845 ADDRESSED ANAL CANCER SCREENING. 5226 03:49:41,845 --> 03:49:44,181 THESE WERE GENERAL GUIDELINES 5227 03:49:44,181 --> 03:49:46,483 AND OUR HPV GROUP MET AND 5228 03:49:46,483 --> 03:49:48,085 REVIEWED ALL OF THE GUIDANCE 5229 03:49:48,085 --> 03:49:51,321 AND THE DATA AND CAME OUT WITH 5230 03:49:51,321 --> 03:49:53,657 THE FIRST-EVER PUBLISHED 5231 03:49:53,657 --> 03:49:55,926 GUIDELINES FOR ANAL CANCER 5232 03:49:55,926 --> 03:49:58,228 SCREEN ANDING PEOPLE WITH HIV, 5233 03:49:58,228 --> 03:50:03,233 WHY THIS IS IMPORTANT ANAL HAS 5234 03:50:03,233 --> 03:50:05,169 A HIGHER INCIDENT WITH PEOPLE 5235 03:50:05,169 --> 03:50:08,238 ARE HIV AND WE KNOW THAT 5236 03:50:08,238 --> 03:50:10,574 IDENTIFYING HIGH GRADE LESIONS 5237 03:50:10,574 --> 03:50:12,209 AND TREATING THEM CAN PREVENT 5238 03:50:12,209 --> 03:50:14,278 THE DEVELOPMENT OF ANAL CANCER 5239 03:50:14,278 --> 03:50:18,849 WHICH IS A VERY HAS HIGH 5240 03:50:18,849 --> 03:50:21,585 MORBIDITY IN OUR PATIENTS AND 5241 03:50:21,585 --> 03:50:24,054 LEADS TO VERY DIMINISHED 5242 03:50:24,054 --> 03:50:24,988 QUALITY OF LIFE. 5243 03:50:24,988 --> 03:50:27,991 SO WE EXPECT TO SEE SOME 5244 03:50:27,991 --> 03:50:30,060 FURTHER ADJUSTMENTS AND 5245 03:50:30,060 --> 03:50:31,261 AMENDMENTS TO THESE GUIDELINES 5246 03:50:31,261 --> 03:50:33,797 AS WE GET MORE DATA AND AS 5247 03:50:33,797 --> 03:50:35,866 PEOPLE ARE STARTING TO 5248 03:50:35,866 --> 03:50:37,100 SCREENING MORE OVER THE NEXT 5249 03:50:37,100 --> 03:50:43,340 COUPLE OF YEARS. 5250 03:50:43,340 --> 03:50:43,874 THANK YOU. 5251 03:50:43,874 --> 03:50:45,375 >> THANK YOU. 5252 03:50:45,375 --> 03:50:52,449 THE NEXT UPDATE IS FROM DR. 5253 03:50:52,449 --> 03:50:56,720 TRIP GULICK. 5254 03:50:56,720 --> 03:50:58,155 DR. GULICK, YOU HAVE THE FLOOR. 5255 03:50:58,155 --> 03:50:59,456 >> THANKS VERY MUCH. 5256 03:50:59,456 --> 03:51:02,092 SO ANOTHER ROLE I SERVE IS 5257 03:51:02,092 --> 03:51:05,295 ACADEMIC CO-CHAIR OF THE ADULT 5258 03:51:05,295 --> 03:51:08,999 AND ADOLESCENT ANTI ANTI VIRAL 5259 03:51:08,999 --> 03:51:11,401 GUIDELINES, CLIFF IS THE NIH 5260 03:51:11,401 --> 03:51:13,170 CHAIR AND ALICE POWELL IS OUR 5261 03:51:13,170 --> 03:51:15,606 EXECUTIVE SECRETARY. 5262 03:51:15,606 --> 03:51:17,507 SO I'M PRESENTING ON BEHALF OF 5263 03:51:17,507 --> 03:51:18,475 THE PANEL. 5264 03:51:18,475 --> 03:51:19,910 SOL WHAT IS NEW WITH US, NEXT 5265 03:51:19,910 --> 03:51:24,748 SLIDE. 5266 03:51:24,748 --> 03:51:28,819 SHERISH JUST SHOWED YOU SOME 5267 03:51:28,819 --> 03:51:34,458 PAGES AND WE CONTINUE TO--PAGE 5268 03:51:34,458 --> 03:51:36,059 VIEWS CONTINUE ABOUT COUPLE 5269 03:51:36,059 --> 03:51:37,461 THOUSANDS AND THAT'S GONE UP 5270 03:51:37,461 --> 03:51:39,062 FROM ABOUT A HALF A MILLION. 5271 03:51:39,062 --> 03:51:41,632 SO IT CONTINUES TO BE A POPULAR 5272 03:51:41,632 --> 03:51:43,500 RESOURCE FOR PEOPLE TAKING CARE 5273 03:51:43,500 --> 03:51:48,238 OF PEOPLE CAN HIV 5274 03:51:48,238 --> 03:51:51,642 NEXT, COUPLE OF UPDATES FOR US, 5275 03:51:51,642 --> 03:51:54,411 SO IN FEBRUARY OF THIS YEAR, WE 5276 03:51:54,411 --> 03:51:57,381 CAME OUT WITH FORMAL 5277 03:51:57,381 --> 03:52:02,219 RECOMMENDATIONS FOR STATEN USE 5278 03:52:02,219 --> 03:52:05,122 WITH PEOPLE WITH HIV FOR CARD I 5279 03:52:05,122 --> 03:52:11,595 CAN'T VASCULAR--CARDIO VASCULAR 5280 03:52:11,595 --> 03:52:13,697 DISEASE, AND THIS SHOWING 5281 03:52:13,697 --> 03:52:15,732 DECREASE FOR CARD I CAN'T 5282 03:52:15,732 --> 03:52:18,335 VASCULAR BY A THIRD SO VERY 5283 03:52:18,335 --> 03:52:19,303 IMPRESSIVE RESULTS. 5284 03:52:19,303 --> 03:52:20,304 JUST LAST MONTH IN SEPTEMBER, 5285 03:52:20,304 --> 03:52:23,140 WE HAD A RELEASE OF NEW 5286 03:52:23,140 --> 03:52:24,508 GUIDELINES UPDATES, I'LL SHOW 5287 03:52:24,508 --> 03:52:25,842 YOU WHAT THOSE WERE. 5288 03:52:25,842 --> 03:52:29,313 A WEEK LATER, WE HAD OUR ANNUAL 5289 03:52:29,313 --> 03:52:30,981 PANEL RETREATS WHICH WAS HELD 5290 03:52:30,981 --> 03:52:32,182 IN WASHINGTON DC AND I'LL LET 5291 03:52:32,182 --> 03:52:34,051 YOU KNOW WHAT WE DISCUSSED. 5292 03:52:34,051 --> 03:52:37,287 AND IT SAYS SOON TO GO TO BE 5293 03:52:37,287 --> 03:52:39,389 RELEASED BUT IT HAS NOW BEEN 5294 03:52:39,389 --> 03:52:42,092 RELEASED WE HAVE UPDATED AND 5295 03:52:42,092 --> 03:52:43,860 RERELEASED CARING FOR PEOPLE 5296 03:52:43,860 --> 03:52:45,462 WITH HIV DISPLACEDS BY NATURAL 5297 03:52:45,462 --> 03:52:48,999 DISASTER AND THIS CAME OUT ON 5298 03:52:48,999 --> 03:52:51,268 OCTOBER 11, RIGHT BEFORE THE 5299 03:52:51,268 --> 03:52:53,737 RESENT TWO HURRICANES THAT HIT 5300 03:52:53,737 --> 03:52:55,605 THE SOUTHEASTERN UNITED STATES, 5301 03:52:55,605 --> 03:52:59,743 SO IT WAS A TIMELY UPDATE THERE. 5302 03:52:59,743 --> 03:53:03,914 NEXT, SO THE USE OF STATINS IN 5303 03:53:03,914 --> 03:53:14,324 HIV WAS AN IMPORTANT TOPIC. 5304 03:53:14,324 --> 03:53:17,060 IN REDUCING MIs AND STROKES AND 5305 03:53:17,060 --> 03:53:21,164 OTHER CARDIO VASCULAR 5306 03:53:21,164 --> 03:53:24,301 COMPLICATIONS TO CONTROL THEIR 5307 03:53:24,301 --> 03:53:25,702 LIPIDS. 5308 03:53:25,702 --> 03:53:28,905 AND WE ACTED VERY QUICKLY, WE 5309 03:53:28,905 --> 03:53:31,241 APPOINTED A LEADER JASON BAKER 5310 03:53:31,241 --> 03:53:32,843 FROM MINNESOTA, INCLUDED SOME 5311 03:53:32,843 --> 03:53:35,145 OF OUR MEMBERS AND THEN REACHED 5312 03:53:35,145 --> 03:53:40,450 OUT TO SEVERAL CARDIOVASCULAR 5313 03:53:40,450 --> 03:53:44,488 SOCIETIES, A.C. C AND A H A, 5314 03:53:44,488 --> 03:53:46,089 THE AMERICAN HEART ASSOCIATION 5315 03:53:46,089 --> 03:53:49,926 AS WELL AS ID S A ASKED PEOPLE 5316 03:53:49,926 --> 03:53:53,597 TO FORM A PANEL TO MAKE FORMAL 5317 03:53:53,597 --> 03:53:56,166 RECOMMENDATIONS FOR WITH HIV TO 5318 03:53:56,166 --> 03:53:57,167 TRY TO INCORPORATE THESE 5319 03:53:57,167 --> 03:53:57,768 RESULTS. 5320 03:53:57,768 --> 03:54:00,370 AND THESE DID COME OUT KIND OF 5321 03:54:00,370 --> 03:54:01,905 RECORD TIME, WE WERE VERY PROUD 5322 03:54:01,905 --> 03:54:04,875 OF THAT TO MAKE FORMAL 5323 03:54:04,875 --> 03:54:05,308 RECOMMENDATIONS TO 5324 03:54:05,308 --> 03:54:07,911 PRACTITIONERS AS TO WHAT TO DO 5325 03:54:07,911 --> 03:54:10,947 WITH STATINS AND AS YOU MAY 5326 03:54:10,947 --> 03:54:14,551 EXPECT, WE DID ENDORSE 5327 03:54:14,551 --> 03:54:15,685 STATINTHERAPY FOR PEOPLE WITH 5328 03:54:15,685 --> 03:54:16,386 HIV 5329 03:54:16,386 --> 03:54:19,122 WE ARE NOW GOING TO INCORPORATE 5330 03:54:19,122 --> 03:54:22,526 THIS INTO A MANUSCRIPT AND HOPE 5331 03:54:22,526 --> 03:54:25,262 TO SUBMIT THAT TO ANNUALS OF 5332 03:54:25,262 --> 03:54:25,962 MEDICINE. 5333 03:54:25,962 --> 03:54:28,565 AND THAT WAS ENDORSED BY ALL OF 5334 03:54:28,565 --> 03:54:29,199 THESE DIFFERENT GROUPS. 5335 03:54:29,199 --> 03:54:32,436 NEXT. 5336 03:54:32,436 --> 03:54:33,603 AS MENTIONED IN SEPTEMBER WE 5337 03:54:33,603 --> 03:54:40,210 CAME OUT WITH A MAJOR UPDATE TO 5338 03:54:40,210 --> 03:54:42,779 THE ANTI VIRAL GUIDELINES AND 5339 03:54:42,779 --> 03:54:43,713 GO THROUGH SOME UPDATES. 5340 03:54:43,713 --> 03:54:45,115 NEXT. 5341 03:54:45,115 --> 03:54:46,850 ONE BIG THING WAS TO ADD A BIG 5342 03:54:46,850 --> 03:54:47,884 SECTION. 5343 03:54:47,884 --> 03:54:50,387 WE HAD NEVER CONSIDERED ORGAN 5344 03:54:50,387 --> 03:54:54,958 TRANSPARENT IN HIV THAT IS 5345 03:54:54,958 --> 03:54:56,092 BECOMING INCREASINGLY COMMON 5346 03:54:56,092 --> 03:54:57,961 WEX LENT RESULTS. 5347 03:54:57,961 --> 03:55:00,730 WE COMMISSIONED ARTHUR KIM WHO 5348 03:55:00,730 --> 03:55:03,266 IS A PANEL MEMBERS AND 5349 03:55:03,266 --> 03:55:07,471 TRANSPLANT AND EXPERT DISEASE 5350 03:55:07,471 --> 03:55:11,441 PHYSICIAN, CHRISTINE WITH 5351 03:55:11,441 --> 03:55:14,110 EXTENSIVE EXPERIENCE IN HIV AND 5352 03:55:14,110 --> 03:55:14,878 TRANSPLANTATION. 5353 03:55:14,878 --> 03:55:17,414 AND WHAT THIS NEW SECTION DOES 5354 03:55:17,414 --> 03:55:22,953 IT TO PROVIDE GUIDANCE FOR ART 5355 03:55:22,953 --> 03:55:26,623 MANAGEMENT FOR CELL TRANSPLANT 5356 03:55:26,623 --> 03:55:30,060 BOTH CANDIDATES AND RECIPIENTS 5357 03:55:30,060 --> 03:55:32,529 EMPHASIZE THE IMPORTANCE OF 5358 03:55:32,529 --> 03:55:35,065 VIRAL SUPPRESSION AND EMPHASIZE 5359 03:55:35,065 --> 03:55:38,068 THE NEED FOR DISCIPLINARY TEAM 5360 03:55:38,068 --> 03:55:41,538 TO MANAGE THE COMPLEXITY OF 5361 03:55:41,538 --> 03:55:44,941 MULTIPLE MEDICATIONS POST 5362 03:55:44,941 --> 03:55:47,677 TRANSPLANT INCLUDING DRUG 5363 03:55:47,677 --> 03:55:54,518 INTERACTIONS OF ANTI VIRALS AND 5364 03:55:54,518 --> 03:55:56,119 OVERLAPPING TOXITIES AND IMPACT 5365 03:55:56,119 --> 03:55:58,188 ON ORGAN FUNCTION AND WE ALSO 5366 03:55:58,188 --> 03:55:59,389 DISCUSSED SPECIFICALLY ABOUT 5367 03:55:59,389 --> 03:56:01,925 DONOR WITH HELP SITES B, 5368 03:56:01,925 --> 03:56:03,994 HEPATITIS-C OR HIV, SO I THINK 5369 03:56:03,994 --> 03:56:05,962 IT'S A VALUABLE DECISION TO THE 5370 03:56:05,962 --> 03:56:06,730 GUIDELINES. 5371 03:56:06,730 --> 03:56:08,999 NEXT. 5372 03:56:08,999 --> 03:56:11,501 WE CHANGED OUR WHAT TO START 5373 03:56:11,501 --> 03:56:14,004 UPDATES IN A MAJOR WAY AND I'LL 5374 03:56:14,004 --> 03:56:16,106 DETAIL WHAT THOSE WERE, THE 5375 03:56:16,106 --> 03:56:24,581 FIRST IS VAC VEER NOW NOT 5376 03:56:24,581 --> 03:56:25,949 CONSIDERED AMONG THE MEMBERED 5377 03:56:25,949 --> 03:56:28,251 THERAPY AND THAT'S BECAUSE OF A 5378 03:56:28,251 --> 03:56:29,853 HOST OF FINDINGS INCLUDING THE 5379 03:56:29,853 --> 03:56:34,024 NEED FOR US A SPECIFIC GENETIC 5380 03:56:34,024 --> 03:56:37,460 TO RULE OUT THE HYPER SENSE 5381 03:56:37,460 --> 03:56:40,664 ITIVITY REACTION BUT ALSO 5382 03:56:40,664 --> 03:56:48,605 ASSOCIATE A VACAVIR AND THAT 5383 03:56:48,605 --> 03:56:49,839 NOW FEATURE IT AS AN 5384 03:56:49,839 --> 03:56:51,107 ALTERNATIVE. 5385 03:56:51,107 --> 03:56:57,681 SMFT OTHER REGIMENS HAVE BEEN 5386 03:56:57,681 --> 03:56:58,214 REMOVED. 5387 03:56:58,214 --> 03:57:05,989 SO WE NOW HAVE REMOVED BOTH AV 5388 03:57:05,989 --> 03:57:12,629 VIE, AND RAL TAGRE VIR SO 5389 03:57:12,629 --> 03:57:15,332 ESSENTIALLY LEAVING VICTIM, AND 5390 03:57:15,332 --> 03:57:20,103 TAG AND INJECTABLE BUT REMOVING 5391 03:57:20,103 --> 03:57:21,037 THOSE REMOVING, ADDUNSANVIR 5392 03:57:21,037 --> 03:57:27,243 FROM A LIST OF AND NOW THE ONLY 5393 03:57:27,243 --> 03:57:31,615 RECOMMENDED IS RESVIR AND ONLY 5394 03:57:31,615 --> 03:57:34,584 NNRTIs RECOMMENDED OUR DOVAVI 5395 03:57:34,584 --> 03:57:36,886 N*E AND REAL AND REMOVING THE 5396 03:57:36,886 --> 03:57:41,391 OLDER FORMULATION OF TENAFA DIR 5397 03:57:41,391 --> 03:57:46,463 T.D. F IN THE TRIPLE 5398 03:57:46,463 --> 03:57:47,731 COMBINATION COFORMULATION. 5399 03:57:47,731 --> 03:57:49,566 IN ADDITION, WE EXPANDED OUR 5400 03:57:49,566 --> 03:57:50,967 DISCUSSIONS WITH TREATING 5401 03:57:50,967 --> 03:57:55,772 PEOPLE WITH HIV WHO USED AN 5402 03:57:55,772 --> 03:58:00,777 INTER GRACE INHIBITOR EITHER 5403 03:58:00,777 --> 03:58:01,911 FOR PREP. 5404 03:58:01,911 --> 03:58:05,849 SO ESSENTIALLY STREAMLINING AND 5405 03:58:05,849 --> 03:58:08,184 EMPHASIZING THE MORE AFFECTIVE 5406 03:58:08,184 --> 03:58:12,555 CHOICES FOR BOTH PREFERRED AND 5407 03:58:12,555 --> 03:58:13,757 ALTERNATIVE REGIMEN BASED ON 5408 03:58:13,757 --> 03:58:14,157 DATA DRIVEN. 5409 03:58:14,157 --> 03:58:17,594 NEXT. 5410 03:58:17,594 --> 03:58:23,233 WE EXPANDED SECTIONS ON LONG 5411 03:58:23,233 --> 03:58:26,636 ACTING AND ADDRESSED OPTIMIZING 5412 03:58:26,636 --> 03:58:32,542 ART WHAT TO DO IN THE IN THE 5413 03:58:32,542 --> 03:58:37,981 BIOLOGIC FAILURE OR ADHERENCE. 5414 03:58:37,981 --> 03:58:44,087 AS YOU'RE AWARE, V EMERGING 5415 03:58:44,087 --> 03:58:47,323 DATA YOU GO SUGGESTING ITS USE 5416 03:58:47,323 --> 03:58:50,026 IN OTHER POPULATIONS WHERE IT 5417 03:58:50,026 --> 03:58:54,230 MIGHT BE HELPFUL INCLUDING 5418 03:58:54,230 --> 03:58:56,332 VIREMIC PATIENTS, SO THEY'RE 5419 03:58:56,332 --> 03:58:58,601 EMERGING DATA ON THAT GROUP SO. 5420 03:58:58,601 --> 03:59:01,371 WHAT WE WROTE FOR THAT A GROUP 5421 03:59:01,371 --> 03:59:04,174 IS BASED ON VERY LIMITED DATA, 5422 03:59:04,174 --> 03:59:07,377 THE PANEL RECOMMENDS THE USE OF 5423 03:59:07,377 --> 03:59:12,615 LUNG ACTING CAB ON A CASE BY 5424 03:59:12,615 --> 03:59:15,285 CASE BASIS. 5425 03:59:15,285 --> 03:59:20,757 AND SHARED DECISION MAKING--WHO 5426 03:59:20,757 --> 03:59:23,960 HAVE NO EVIDENCE RESISTANCE TO 5427 03:59:23,960 --> 03:59:26,596 CAB AND SHARED DECISION MAKING 5428 03:59:26,596 --> 03:59:30,233 BETWEEN PROVIDERS AND PEOPLE 5429 03:59:30,233 --> 03:59:32,969 WITH HIV, STI IS AN OPTIONAL 5430 03:59:32,969 --> 03:59:34,370 AND 3 THE LOWEST QUALITY OF 5431 03:59:34,370 --> 03:59:37,774 EVIDENCE THAT IS EXPERT OPINION. 5432 03:59:37,774 --> 03:59:41,478 BUT WE REALLY WANTED TO LEAVE 5433 03:59:41,478 --> 03:59:43,813 THIS OPEN FOR PEOPLE IN THIS 5434 03:59:43,813 --> 03:59:45,181 SCENARIO AND LOOK FORWARD TO 5435 03:59:45,181 --> 03:59:46,850 MORE STUDIES TO PLAYBOYING IT 5436 03:59:46,850 --> 03:59:47,283 MORE EVIDENCE BASE. 5437 03:59:47,283 --> 03:59:51,788 NEXT. 5438 03:59:51,788 --> 03:59:53,256 WE UPDATED A NUMBER OF OTHER 5439 03:59:53,256 --> 03:59:56,126 SECTIONS, AS YOU CAN SEE HERE. 5440 03:59:56,126 --> 03:59:59,596 SUBSTANCE USE DISORDER, 5441 03:59:59,596 --> 04:00:02,132 TRANSGENDER PEOPLE, ADHERENCE, 5442 04:00:02,132 --> 04:00:04,934 HEPATITIS B, TB COINFECTION, 5443 04:00:04,934 --> 04:00:07,670 DRUG RESIST NOTS TESTING AND 5444 04:00:07,670 --> 04:00:10,173 EARLY HIV INFECTION, WOMEN COST 5445 04:00:10,173 --> 04:00:10,874 CONSIDERATION, DRUG 5446 04:00:10,874 --> 04:00:13,576 INTERACTIONS AND WE UPDATED OUR 5447 04:00:13,576 --> 04:00:19,382 VOLUNTARY LUM NOUS ABLES AS 5448 04:00:19,382 --> 04:00:20,850 WELL. 5449 04:00:20,850 --> 04:00:23,653 THIS WAS THE RETREAT THAT WE 5450 04:00:23,653 --> 04:00:26,422 HAD SEPTEMBER 20, 2024 WAS HELD 5451 04:00:26,422 --> 04:00:27,590 IN THE DC AREA. 5452 04:00:27,590 --> 04:00:30,326 AND YOU CAN SEE WE HAD GREAT 5453 04:00:30,326 --> 04:00:35,398 ATTENDANCE, A LARGE GROUP OF 5454 04:00:35,398 --> 04:00:37,133 OUR FOLKS. 5455 04:00:37,133 --> 04:00:40,336 CAN WE ACKNOWLEDGE WE HAD FIVE 5456 04:00:40,336 --> 04:00:43,373 OUTGOING MEMBERS, DR., BROOKS, 5457 04:00:43,373 --> 04:00:46,843 SWINDLE AND THOMPSON AND 5458 04:00:46,843 --> 04:00:47,277 ACKNOWLEDGED THEIR 5459 04:00:47,277 --> 04:00:48,878 CONTRIBUTIONS. 5460 04:00:48,878 --> 04:00:50,713 NEXT, WE ALSO WELCOMED NEW 5461 04:00:50,713 --> 04:00:53,283 MEMBERS TO THE PANEL AS YOU CAN 5462 04:00:53,283 --> 04:01:03,459 SEE HERE. 5463 04:01:03,893 --> 04:01:05,261 DR. KNEEL--NEILAN WHO IS ON THE 5464 04:01:05,261 --> 04:01:05,695 CALL TODAY. 5465 04:01:05,695 --> 04:01:08,898 AND YOU CAN SEE THE AREA OF 5466 04:01:08,898 --> 04:01:10,066 EXPERTISE REALLY HELPING FILL 5467 04:01:10,066 --> 04:01:11,801 OUT EXPERTISE ON THE PANEL 5468 04:01:11,801 --> 04:01:12,202 RIGHT NOW. 5469 04:01:12,202 --> 04:01:16,439 NEXT. 5470 04:01:16,439 --> 04:01:20,310 WHAT ELSE DO WE CONSIDER AT THE 5471 04:01:20,310 --> 04:01:22,612 RETREAT, WE DID A REVIEW OF THE 5472 04:01:22,612 --> 04:01:24,480 GUIDELINES, WE LIKE TO SEE HOW 5473 04:01:24,480 --> 04:01:26,716 OUR GUIDELINES FIT IN WITH OR 5474 04:01:26,716 --> 04:01:28,084 WITHOUT WHAT PEOPLE ARE DOING. 5475 04:01:28,084 --> 04:01:30,887 WE HAD A VERY SPIRITED DEBATE 5476 04:01:30,887 --> 04:01:33,423 ABOUT WHETHER WE SHOULD DO 5477 04:01:33,423 --> 04:01:34,357 INTER GRACE RESISTANCE TESTING 5478 04:01:34,357 --> 04:01:37,393 IN ALL PEOPLE WITH HIV PRIOR TO 5479 04:01:37,393 --> 04:01:41,197 STARTING ART. 5480 04:01:41,197 --> 04:01:43,233 MELODY THOMPSON REVIEWED NEW 5481 04:01:43,233 --> 04:01:45,501 DRUG IN THE PIPELINE WHERE 5482 04:01:45,501 --> 04:01:48,204 THERE ARE MANY AND DISCUSSION 5483 04:01:48,204 --> 04:01:50,506 ON RESEARCH GAPS, WE ASKED ALL 5484 04:01:50,506 --> 04:01:54,444 THE PANEL MEMBERS WHAT DATA ARE 5485 04:01:54,444 --> 04:01:56,112 WE MISSING, AND I'LL SHARE THE 5486 04:01:56,112 --> 04:01:58,348 TOP FIVE ON THE NEXT SLIDE. 5487 04:01:58,348 --> 04:01:59,916 AND THEN FINALLY, WE DEVELOPED 5488 04:01:59,916 --> 04:02:01,551 A REVISION PLAN FOR THE NEXT 5489 04:02:01,551 --> 04:02:02,719 YEAR MOVING FORWARD. 5490 04:02:02,719 --> 04:02:03,620 NEXT. 5491 04:02:03,620 --> 04:02:05,121 SO WE THOUGHT IT WOULD BE 5492 04:02:05,121 --> 04:02:06,890 INTERESTING FOR YOU ALL TO SAY, 5493 04:02:06,890 --> 04:02:10,627 WELL WHAT ARE THE RESEARCH GAPS 5494 04:02:10,627 --> 04:02:10,860 IN ART? 5495 04:02:10,860 --> 04:02:18,234 WHAT DATA DO WE NEED TO BETTER 5496 04:02:18,234 --> 04:02:21,137 INFORM THE GUIDELINES, THESE 5497 04:02:21,137 --> 04:02:23,673 ARE THE TOP FIVE. 5498 04:02:23,673 --> 04:02:27,610 NOT A LOT OF DATA THERE, RESIST. 5499 04:02:27,610 --> 04:02:31,281 HOW DO WE BEST USE LONG ACTING 5500 04:02:31,281 --> 04:02:38,321 ART ON NON VIROLOGYCAL SUPPRESS 5501 04:02:38,321 --> 04:02:39,322 THED POPULATIONS. 5502 04:02:39,322 --> 04:02:47,897 WHAT IS THE ROLE OF GLP-1 5503 04:02:47,897 --> 04:02:49,766 AGONIST FOR WEIGHT LOSS AND 5504 04:02:49,766 --> 04:02:57,240 SUBSTANCE USE DISORDER. 5505 04:02:57,240 --> 04:02:59,342 AND HOW ABOUT DRUG-DRUG 5506 04:02:59,342 --> 04:02:59,776 INTERACTIONS. 5507 04:02:59,776 --> 04:03:02,045 AND LAST BUT NOT LEAST, WHAT 5508 04:03:02,045 --> 04:03:05,481 ARE THE LONG TERM OUTCOMES IN 5509 04:03:05,481 --> 04:03:11,854 SPECIAL POPULATIONS ARE HIV 5510 04:03:11,854 --> 04:03:16,392 INCLUDING THE PARANATAL AND 5511 04:03:16,392 --> 04:03:17,660 TRANSGENDER. 5512 04:03:17,660 --> 04:03:20,229 THIS IS MY LAST SLIDE, UPDATE 5513 04:03:20,229 --> 04:03:22,732 FOR CARING FOR PEOPLE DISPLACED 5514 04:03:22,732 --> 04:03:26,035 BY NATURAL DISASTERS ON OCTOBER 5515 04:03:26,035 --> 04:03:29,639 11, WE ARE WORKING ON A NEW 5516 04:03:29,639 --> 04:03:32,842 SECTION ON METABOLIC IN PEOPLE 5517 04:03:32,842 --> 04:03:35,578 WITH HIV FOLLOWING THE REPRIEVE 5518 04:03:35,578 --> 04:03:37,213 STUDY AND WE EARMARKED A NUMBER 5519 04:03:37,213 --> 04:03:39,315 OF SECTION THAT'S WE WANT TO 5520 04:03:39,315 --> 04:03:41,384 UPDATE AND REVISE INCLUDING 5521 04:03:41,384 --> 04:03:43,920 LAND MONITORING, WHEN TO START, 5522 04:03:43,920 --> 04:03:47,590 TREATMENT AS PREVENTION, POOR 5523 04:03:47,590 --> 04:03:51,894 CD4 RECOVERY AND PERSISTENT 5524 04:03:51,894 --> 04:03:55,565 INFLAMMATION, SO-CALLED IMMUNO 5525 04:03:55,565 --> 04:04:02,038 LOGIC FAILURE, ADOLESCENT AND A 5526 04:04:02,038 --> 04:04:03,106 ADVERSE AFFECTS. 5527 04:04:03,106 --> 04:04:04,340 WE HAVE A BUSY YEAR. 5528 04:04:04,340 --> 04:04:07,143 I THINK THAT'S MY LAST SLIDE. 5529 04:04:07,143 --> 04:04:08,778 >> THANK YOU, DOCTOR. 5530 04:04:08,778 --> 04:04:11,514 THE FINAL UPDATE WILL BE FROM 5531 04:04:11,514 --> 04:04:13,149 DR. FRANKLIN YATES WHO WILL 5532 04:04:13,149 --> 04:04:18,087 PROVIDE AN UPDATE ON PEDIATRIC 5533 04:04:18,087 --> 04:04:20,656 INFECTION GUIDELINES. 5534 04:04:20,656 --> 04:04:22,759 DR. YATES, YOU MAY BEGIN. 5535 04:04:22,759 --> 04:04:25,995 >> HI, EVERYBODY I'M PLEASED TO 5536 04:04:25,995 --> 04:04:31,034 BE HERE AND AND PRESENT OUR 5537 04:04:31,034 --> 04:04:32,902 BRIEF HIV GUIDELINES AND I'M 5538 04:04:32,902 --> 04:04:38,408 ALSO PLEASED TO DO IT WITH DR. 5539 04:04:38,408 --> 04:04:42,845 DONENBERG WHO IN KNOW WELL FROM 5540 04:04:42,845 --> 04:04:44,347 OTHER CAPACITIES. 5541 04:04:44,347 --> 04:04:46,649 NEXT SLIDE, SO THIS CHART 5542 04:04:46,649 --> 04:04:47,817 DEMONSTRATES THE CONTINUING 5543 04:04:47,817 --> 04:04:50,753 HIGH RATE OF PAGE VIEWS OF 5544 04:04:50,753 --> 04:04:56,893 THESE GUIDELINES, THE PEDS ARE 5545 04:04:56,893 --> 04:04:58,761 SMALLER BUT THE STABILITY OF 5546 04:04:58,761 --> 04:05:00,263 THESE NUMBERS SHOW HOW THESE 5547 04:05:00,263 --> 04:05:01,798 GUIDELINES CONTINUE TO BE 5548 04:05:01,798 --> 04:05:04,233 RELEVANT AND USEFUL RESOURCE 5549 04:05:04,233 --> 04:05:10,173 FOR PRACTITIONERS. 5550 04:05:10,173 --> 04:05:12,008 THIS CALENDAR YEAR REEMBARKED 5551 04:05:12,008 --> 04:05:15,978 ON OF RESTRUCTURING AND 5552 04:05:15,978 --> 04:05:16,846 REVISION PROCESS. 5553 04:05:16,846 --> 04:05:19,615 I THINK NEXT, SLIDE, PLEASE. 5554 04:05:19,615 --> 04:05:19,849 YES. 5555 04:05:19,849 --> 04:05:22,385 THANKS. 5556 04:05:22,385 --> 04:05:24,720 WE HAVE DONE AN ANALYSIS ON THE 5557 04:05:24,720 --> 04:05:26,522 TIMELINE OF OUR REVISIONS 5558 04:05:26,522 --> 04:05:28,658 PROCESS OVER THE PAST TWO 5559 04:05:28,658 --> 04:05:30,693 YEARS, AND FOUND THAT IT IS 5560 04:05:30,693 --> 04:05:35,098 BEEN TAKING TOO LONG UPWARDS OF 5561 04:05:35,098 --> 04:05:41,704 A YEAR TO REVISE AND FURTHER A 5562 04:05:41,704 --> 04:05:43,739 SECTION WE DID FURTHER ANALYSIS 5563 04:05:43,739 --> 04:05:48,344 ON THE NEED FOR PHARMACOLOGY AS 5564 04:05:48,344 --> 04:05:52,281 WELL AS EVALUATION OF OUR 5565 04:05:52,281 --> 04:05:56,052 SECTION FORMATTING WITH AN EYE 5566 04:05:56,052 --> 04:05:57,687 TO ENSURING CONSISTENCY BETWEEN 5567 04:05:57,687 --> 04:06:02,525 OUR OWN SECTIONS AND THOSE OF 5568 04:06:02,525 --> 04:06:05,661 ADULT GUIDELINES AS WELL AS 5569 04:06:05,661 --> 04:06:06,429 SOME EXTERNAL SOCIETY 5570 04:06:06,429 --> 04:06:07,296 GUIDELINES. 5571 04:06:07,296 --> 04:06:09,332 SO THINGS THAT WE'VE DONE IN 5572 04:06:09,332 --> 04:06:13,002 THE PAST YEAR, WE MAINTAINED A 5573 04:06:13,002 --> 04:06:16,272 RELATIONSHIP WITH OUR CDD 5574 04:06:16,272 --> 04:06:20,176 LIASON SO ENSURE THAT WE HAVE 5575 04:06:20,176 --> 04:06:22,245 CDC SUBJECT MATTER EXPERT 5576 04:06:22,245 --> 04:06:23,546 CONTRIBUTIONS TO SECTIONS 5577 04:06:23,546 --> 04:06:25,214 MOVING FORWARD. 5578 04:06:25,214 --> 04:06:27,083 WE HAVE A RECURRENTLY IN THE 5579 04:06:27,083 --> 04:06:37,627 PROCESS OF EXPANDING OUR PEDS 5580 04:06:37,627 --> 04:06:41,464 PANEL WHO ONLY HAS TWO 5581 04:06:41,464 --> 04:06:45,334 PHARMACOLOGIST TO ALLOW FOR 5582 04:06:45,334 --> 04:06:47,637 FOUR FORMAL FORM LOGICAL REVIEW 5583 04:06:47,637 --> 04:06:50,439 OF EACH SECTION AND WE HAVE 5584 04:06:50,439 --> 04:06:54,043 CREATED A NEW GUIDE FOR 5585 04:06:54,043 --> 04:06:59,048 ENSURING THAT THERE WILL BE 5586 04:06:59,048 --> 04:07:02,451 FORMATTING CONSISTENCY BETWEEN 5587 04:07:02,451 --> 04:07:04,620 OUR PEDS GUIDELINES AND ADULT 5588 04:07:04,620 --> 04:07:06,956 GUIDELINES AND IN SOME CASES, 5589 04:07:06,956 --> 04:07:10,993 GUIDELINES OF OTHER SOCIETY 5590 04:07:10,993 --> 04:07:12,428 EXTERNAL SOCIETIES. 5591 04:07:12,428 --> 04:07:13,863 NEXT SLIDE, PLEASE. 5592 04:07:13,863 --> 04:07:16,866 SO OUR MOST RESENT SECTION 5593 04:07:16,866 --> 04:07:21,003 UPDATE IS A BRAND NEW SECTION 5594 04:07:21,003 --> 04:07:22,638 FOR US COVID-19 SECTION, IT 5595 04:07:22,638 --> 04:07:24,407 DESCRIBES THE APPROACH TO 5596 04:07:24,407 --> 04:07:26,709 PREVENTION AND MANAGEMENT OF 5597 04:07:26,709 --> 04:07:30,479 COVID-19 AND CHILDREN EXPOSED 5598 04:07:30,479 --> 04:07:36,953 TO HIV 5599 04:07:36,953 --> 04:07:38,521 INCLUDES COVID-19 VACCINATION 5600 04:07:38,521 --> 04:07:39,889 IN CHILDREN. 5601 04:07:39,889 --> 04:07:41,490 AND ALSO HAS RECOMMENDATIONS 5602 04:07:41,490 --> 04:07:50,132 FOR THE TREATMENT OF COVID-19 5603 04:07:50,132 --> 04:07:58,507 FOR EN DES--R*E MDESVIR. 5604 04:07:58,507 --> 04:07:59,308 NEXT SLIDE PLEASE. 5605 04:07:59,308 --> 04:08:02,678 WE HAVE A NUMBER OF SECTIONS 5606 04:08:02,678 --> 04:08:05,881 THAT ARE IN THE PIPELINE FOR 5607 04:08:05,881 --> 04:08:07,516 THIS YEAR AND WE THOUGHT THAT 5608 04:08:07,516 --> 04:08:09,585 THEY MAY BE PUBLISHED BY THIS 5609 04:08:09,585 --> 04:08:11,921 MONTH BUT THEY'RE ACTUALLY DUE 5610 04:08:11,921 --> 04:08:13,889 TO BE PUBLISHED IN NOVEMBER AND 5611 04:08:13,889 --> 04:08:16,125 DECEMBER, SO IF I SHOULD HAVE 5612 04:08:16,125 --> 04:08:18,194 MORE DETAILS BY NEXT GO-AROUND 5613 04:08:18,194 --> 04:08:20,263 OF THIS MEETING. 5614 04:08:20,263 --> 04:08:23,232 BUT, IN NOVEMBER, WE DO 5615 04:08:23,232 --> 04:08:27,370 ANTICIPATE HEPATITIS-C, 5616 04:08:27,370 --> 04:08:29,438 BACTERIAL INFECTIONS AS WELL AS 5617 04:08:29,438 --> 04:08:32,441 IMPORTANT AND IN DECEMBER, WE 5618 04:08:32,441 --> 04:08:34,944 ANTICIPATE THE PUBLICATION OF 5619 04:08:34,944 --> 04:08:36,612 OUR VACCINE PREVENTABLE 5620 04:08:36,612 --> 04:08:42,385 DISEASES SECTION, HEPATITIS B 5621 04:08:42,385 --> 04:08:47,890 AND OUR IMPORTANT TABLES 4 AND 5622 04:08:47,890 --> 04:08:49,458 5 PHARMACOLOGY THOSE THAT HAVE 5623 04:08:49,458 --> 04:08:51,994 TO DO WITH DRUG INTERACTIONS 5624 04:08:51,994 --> 04:08:52,695 AND ADVERSE AFFECT. 5625 04:08:52,695 --> 04:08:56,666 NEXT SLIDE. 5626 04:08:56,666 --> 04:08:59,635 SO I BELIEVE THAT IS IT FOR MY 5627 04:08:59,635 --> 04:09:01,003 BRIEF UPDATE AND THANK YOU FOR 5628 04:09:01,003 --> 04:09:05,074 THE OPPORTUNITY TO PRESENT. 5629 04:09:05,074 --> 04:09:12,481 >> THANK YOU, DR. YATES. 5630 04:09:12,481 --> 04:09:14,250 I WANT TO CHECK IN WITH 5631 04:09:14,250 --> 04:09:15,951 GLENSHAW AT THIS TIME, DO WE 5632 04:09:15,951 --> 04:09:17,687 HAVE TIME FOR AT LEAST ONE OR 5633 04:09:17,687 --> 04:09:19,322 TWO QUESTIONS. 5634 04:09:19,322 --> 04:09:20,489 >> ABSOLUTELY, WE HAVE ABOUT 15 5635 04:09:20,489 --> 04:09:21,457 MINUTES. 5636 04:09:21,457 --> 04:09:22,692 >> OKAY, GREAT. 5637 04:09:22,692 --> 04:09:23,693 ANYBODY HAVE ANY QUESTIONS, 5638 04:09:23,693 --> 04:09:31,500 COMMENTS? 5639 04:09:31,500 --> 04:09:32,668 YES, DR. FLETCHER. 5640 04:09:32,668 --> 04:09:34,503 >> HI, I WANT TO THANK EVERY 5641 04:09:34,503 --> 04:09:37,506 ONE FOR THE VERY NICE UPDATE. 5642 04:09:37,506 --> 04:09:45,581 MY QUICK QUESTION WOULD BE FOR 5643 04:09:45,581 --> 04:09:48,351 DR. DHONEREDDY, I GUESS IT CAME 5644 04:09:48,351 --> 04:09:53,556 TO A SURPRISE THAT THE CDC DID 5645 04:09:53,556 --> 04:09:58,861 NOT APPOINT A DIRECTOR. 5646 04:09:58,861 --> 04:10:00,062 DOES THAT CREATE--. 5647 04:10:00,062 --> 04:10:02,098 >> SIMILAR TO THE PEDIATRIC 5648 04:10:02,098 --> 04:10:04,400 GUIDELINES, WE'LL STILL 5649 04:10:04,400 --> 04:10:05,768 CONTINUE TO HAVE GROUP MEMBERS 5650 04:10:05,768 --> 04:10:08,971 IN OUR SECTIONS THAT ARE FROM 5651 04:10:08,971 --> 04:10:13,075 THIS CDC WHAT IS ELIMINATED IS 5652 04:10:13,075 --> 04:10:14,710 THE CLEARANCE PROCESS BY HAVING 5653 04:10:14,710 --> 04:10:17,279 THE CO-CHAIR AND HAVE THE 5654 04:10:17,279 --> 04:10:19,248 GUIDELINES BE PART OF THE CDC 5655 04:10:19,248 --> 04:10:23,419 GUIDE GUELINES. 5656 04:10:23,419 --> 04:10:27,189 THAT PROCESS TAKES A LONG TIME 5657 04:10:27,189 --> 04:10:28,357 WITH ADDITIONAL TIMELY UPDATES 5658 04:10:28,357 --> 04:10:31,327 IN THE GUIDELINES AND I'M SURE 5659 04:10:31,327 --> 04:10:32,695 MY PEDIATRIC COLLEAGUES WOULD 5660 04:10:32,695 --> 04:10:33,396 AGREE WITH THAT. 5661 04:10:33,396 --> 04:10:35,464 SO I THINK THIS ACTUALLY, WE'LL 5662 04:10:35,464 --> 04:10:37,533 CONTINUE TO HAVE THE SAME 5663 04:10:37,533 --> 04:10:39,835 SUBJECT MATTER EXPERTS BUT LESS 5664 04:10:39,835 --> 04:10:41,470 OF THE BUREAUCRATIC CLEARANCE 5665 04:10:41,470 --> 04:10:42,238 PART OF THE PROCESS. 5666 04:10:42,238 --> 04:10:49,445 >> GREAT, THANK YOU. 5667 04:10:49,445 --> 04:10:59,855 >> ANYONE ELSE? 5668 04:10:59,855 --> 04:11:00,489 DR. MONT ANER. 5669 04:11:00,489 --> 04:11:02,558 >> YES, THANK YOU JUST A POINT 5670 04:11:02,558 --> 04:11:11,200 OF DISCUSSION FOR DR.--THANK 5671 04:11:11,200 --> 04:11:12,768 YOU FOR THE PROCESS. 5672 04:11:12,768 --> 04:11:14,870 IT'S SUCH AN IMPORTANT PIECE OF 5673 04:11:14,870 --> 04:11:17,373 THE NIH PORTFOLIO, THANK YOU 5674 04:11:17,373 --> 04:11:19,208 FOR THE LEADERSHIP AND 5675 04:11:19,208 --> 04:11:21,677 CONTRIBUTION OF EVERY ONE. 5676 04:11:21,677 --> 04:11:25,614 KIND OF LIKE I SIT IN THE 5677 04:11:25,614 --> 04:11:28,150 FEDERAL CLINIC BOARDS HERE IN 5678 04:11:28,150 --> 04:11:29,952 PHILADELPHIA AND ALSO 5679 04:11:29,952 --> 04:11:31,554 PARTICIPATE IN SEVERAL 5680 04:11:31,554 --> 04:11:33,422 INITIATIVES AND CENTER MINORITY 5681 04:11:33,422 --> 04:11:35,024 INSTITUTIONS AND THEIR YEARLY 5682 04:11:35,024 --> 04:11:35,925 MEETINGS. 5683 04:11:35,925 --> 04:11:37,293 AND THROUGH THESE TYPES OF 5684 04:11:37,293 --> 04:11:40,596 EXPERIENCES, I KIND OF LIKE 5685 04:11:40,596 --> 04:11:42,898 ALWAYS HAD A KIND OF DESIRE 5686 04:11:42,898 --> 04:11:45,534 THAT THERE WOULD BE MORE KIND 5687 04:11:45,534 --> 04:11:47,837 OF BRIDGES BETWEEN THE EXISTING 5688 04:11:47,837 --> 04:11:50,039 NETWORKS AND THESE TYPES OF 5689 04:11:50,039 --> 04:11:52,107 ORGANIZATIONS BECAUSE OF THEIR 5690 04:11:52,107 --> 04:11:54,310 OBVIOUS CONSTITUENCY THAT DEALS 5691 04:11:54,310 --> 04:11:56,178 WITH A LOT OF PEOPLE LIVING 5692 04:11:56,178 --> 04:11:56,979 WITH HIV 5693 04:11:56,979 --> 04:12:00,216 SO I'M JUST SORT OF APPOINT OF 5694 04:12:00,216 --> 04:12:01,851 OBSERVATION THAT IF THERE WOULD 5695 04:12:01,851 --> 04:12:07,022 BE ANY CONSIDERATIONS TO CREATE 5696 04:12:07,022 --> 04:12:10,392 THEIR INTENTIONAL INITIATIVE TO 5697 04:12:10,392 --> 04:12:13,329 TRIAL WHETHER IT BE 5698 04:12:13,329 --> 04:12:14,997 INCENTIVIZING TO HAVE 5699 04:12:14,997 --> 04:12:17,233 TMENT IN THESE SITES OR 5700 04:12:17,233 --> 04:12:18,167 INCORPORATE INVESTIGATORS INTO 5701 04:12:18,167 --> 04:12:20,035 THEIR TEAMS OR ANY SORT OF 5702 04:12:20,035 --> 04:12:22,438 ACTIVE OUT REACH INITIATIVE TO 5703 04:12:22,438 --> 04:12:24,273 CREATE MORE BRIDGES SO PEOPLE 5704 04:12:24,273 --> 04:12:26,742 CAN TALK AND INTERACT. 5705 04:12:26,742 --> 04:12:28,344 YOU HAVE SUCH A UNIQUE 5706 04:12:28,344 --> 04:12:29,378 OPPORTUNITY THAT YOU'RE SETTING 5707 04:12:29,378 --> 04:12:31,747 THE AGENDA FOR THE NEXT SEVEN 5708 04:12:31,747 --> 04:12:35,918 YEARS IN RELATION TO HOW THESE 5709 04:12:35,918 --> 04:12:37,186 NETWORKS OPERATE. 5710 04:12:37,186 --> 04:12:40,823 I REBT TIME WHEN THERE WERE THE 5711 04:12:40,823 --> 04:12:43,559 NETWORKS AND THE, THESE 5712 04:12:43,559 --> 04:12:46,128 INITIATIVES WERE REALLY 5713 04:12:46,128 --> 04:12:46,829 SUCCESSFUL IN PENETRATING 5714 04:12:46,829 --> 04:12:48,497 COMMUNITIES AND IT SEEMS SINCE 5715 04:12:48,497 --> 04:12:51,500 THAT STOPPED AND WE WENT TO THE 5716 04:12:51,500 --> 04:12:53,903 SCBG SITES NOW WITH THE FEDERAL 5717 04:12:53,903 --> 04:12:55,271 CLINICS PERHAPS THERE IS 5718 04:12:55,271 --> 04:12:57,573 ANOTHER OPPORTUNITY TO LOOK FOR 5719 04:12:57,573 --> 04:12:58,908 SOME OTHER WAYS. 5720 04:12:58,908 --> 04:13:00,910 I DON'T HAVE THE ANSWERS BUT I 5721 04:13:00,910 --> 04:13:05,748 HAVE SUCH AN OBSERVATION IF 5722 04:13:05,748 --> 04:13:08,117 THERE WAS AN OPPORTUNITY TO 5723 04:13:08,117 --> 04:13:09,885 THINK ABOUTHWHAT WE COULD TRY 5724 04:13:09,885 --> 04:13:11,487 TO BRIDGE, THIS WOULD BE IT. 5725 04:13:11,487 --> 04:13:14,256 >> YOU RAISE A VERY IMPORTANT 5726 04:13:14,256 --> 04:13:14,990 POINT, LUIS, I APPRECIATE THAT 5727 04:13:14,990 --> 04:13:15,691 A LOT. 5728 04:13:15,691 --> 04:13:16,959 THIS IS AN AREA OF ACTIVE 5729 04:13:16,959 --> 04:13:18,627 DISCUSSION. 5730 04:13:18,627 --> 04:13:21,363 AND THERE IS, THERE IS A LOT OF 5731 04:13:21,363 --> 04:13:24,366 PRESSURE ON THE CLINICAL TRIAL 5732 04:13:24,366 --> 04:13:26,435 UNITS AND CLINICAL TRIAL SITES. 5733 04:13:26,435 --> 04:13:30,105 IF THEY'RE ENGAGED IN IND LEVEL 5734 04:13:30,105 --> 04:13:32,608 RESEARCH THAT REQUIRES THE 5735 04:13:32,608 --> 04:13:35,778 INPUT OF DATA INTO TRIAL MASTER 5736 04:13:35,778 --> 04:13:45,220 FILE AND IT'S HEADED TOWARDS A 5737 04:13:45,220 --> 04:13:46,121 REGULARATRY COMPLIANCE. 5738 04:13:46,121 --> 04:13:50,092 IT REQUIRES A SITE TO HAVE AN 5739 04:13:50,092 --> 04:13:51,694 EXTENSIVE AMOUNT OF EXPERIENCE.U 5740 04:13:51,694 --> 04:13:57,299 SO YOU JUST CAN'T ARM ONE OF 5741 04:13:57,299 --> 04:13:59,401 THOSE--[INDISCERNIBLE] 5742 04:13:59,401 --> 04:14:01,704 A CLINICAL PROGRAM THAT PROVIDE 5743 04:14:01,704 --> 04:14:03,372 CARE DOES NOT MEET THAT 5744 04:14:03,372 --> 04:14:04,073 STANDARD AT ANY LEVEL. 5745 04:14:04,073 --> 04:14:05,908 SO WHEN I TALKED ABOUT THE 5746 04:14:05,908 --> 04:14:10,312 OTHER WAYS OF ADDING SITES, THE 5747 04:14:10,312 --> 04:14:11,313 THE SPECIFIC SITES, THAT IS THE 5748 04:14:11,313 --> 04:14:13,315 WAY IN. 5749 04:14:13,315 --> 04:14:20,789 IS THAT PROTOCOLS THAT HAVE ARE 5750 04:14:20,789 --> 04:14:22,224 IMPORTANT BUT NEED POPULATIONS 5751 04:14:22,224 --> 04:14:25,327 OR THERE IS A DEMONSTRATED 5752 04:14:25,327 --> 04:14:35,871 ABILITY FOR THOSE KINDS OF SITES 5753 04:14:39,475 --> 04:14:41,677 THE QUESTION IS HOW DO WE 5754 04:14:41,677 --> 04:14:42,845 CAPTURE THE ABILITY OR 5755 04:14:42,845 --> 04:14:45,347 EXPERIENCE OF SITES? 5756 04:14:45,347 --> 04:14:46,448 WITHOUT OVERLOADING THE REVIEW 5757 04:14:46,448 --> 04:14:56,592 PROCESS? 5758 04:15:00,996 --> 04:15:03,298 THEY DON'T HAVE THE ARTS THAT 5759 04:15:03,298 --> 04:15:04,133 PEOPLE NEED. 5760 04:15:04,133 --> 04:15:14,543 SO THAT, YOU THINK THE 5761 04:15:16,445 --> 04:15:17,546 ABILITY TO BRIDGE IN THE HEALTH 5762 04:15:17,546 --> 04:15:18,814 CENTERS WOULD BE A GREAT PLACE 5763 04:15:18,814 --> 04:15:19,381 TO START. 5764 04:15:19,381 --> 04:15:25,621 I THINK THE OTHER ISSUE ARE 5765 04:15:25,621 --> 04:15:27,856 THE, THE H U MEDICAL 5766 04:15:27,856 --> 04:15:29,391 SCHOOLS IS ANOTHER OPTION 5767 04:15:29,391 --> 04:15:31,226 THROUGH THE PROGRAM. 5768 04:15:31,226 --> 04:15:33,729 WE'VE BUILT REALLY OUTSTANDING 5769 04:15:33,729 --> 04:15:35,698 BRIDGE WITH H B.C. MEDICAL 5770 04:15:35,698 --> 04:15:36,965 SCHOOL AND I THINK THAT WOULD 5771 04:15:36,965 --> 04:15:39,968 BE ANOTHER PLACE THAT WE'RE, 5772 04:15:39,968 --> 04:15:41,637 ACTIVELY TALKING ABOUT HOW 5773 04:15:41,637 --> 04:15:45,240 THOSE BRIDGES COULD BE EXPANDED. 5774 04:15:45,240 --> 04:15:48,510 YOU KNOW, HOW IT'S A MA'SAYER I 5775 04:15:48,510 --> 04:15:50,012 LIKE THAT. 5776 04:15:50,012 --> 04:15:51,847 SO IT'S AN IMPORTANT QUESTION. 5777 04:15:51,847 --> 04:15:53,515 IT'S ONE THAT WE'RE ACTIVELY 5778 04:15:53,515 --> 04:15:54,283 TALKING ABOUT. 5779 04:15:54,283 --> 04:15:55,584 SO THANK YOU FOR RAISING IT. 5780 04:15:55,584 --> 04:16:00,556 >> YES. 5781 04:16:00,556 --> 04:16:04,093 >> ANY FINAL QUESTION>> 5782 04:16:04,093 --> 04:16:06,295 OKAY. 5783 04:16:06,295 --> 04:16:09,898 SEEING NO HANDS RAISED, AS WE 5784 04:16:09,898 --> 04:16:12,634 BEGIN TO CLOSE TODAY'S MEETING, 5785 04:16:12,634 --> 04:16:18,373 THIS IS THIS TIME HAS BEEN 5786 04:16:18,373 --> 04:16:19,742 LO--THIS TIME HAS BEEN 5787 04:16:19,742 --> 04:16:23,879 ALLOCATED FOR PUBLIC COMMENT. 5788 04:16:23,879 --> 04:16:24,813 DOCTOR GLENSHAW, HAVE YOU 5789 04:16:24,813 --> 04:16:26,281 RECEIVED ANY PUBLIC COMMENT FOR 5790 04:16:26,281 --> 04:16:27,149 TODAY'S MEETING. 5791 04:16:27,149 --> 04:16:28,050 >> NO, NOT TODAY. 5792 04:16:28,050 --> 04:16:29,218 >> OKAY. 5793 04:16:29,218 --> 04:16:31,320 >> I WOULD LIKE TO TAKE THIS 5794 04:16:31,320 --> 04:16:34,289 OPPORTUNITY TO THANK EVERY ONE 5795 04:16:34,289 --> 04:16:37,760 AND AGAIN TO THANK OUR TASK 5796 04:16:37,760 --> 04:16:39,762 FORCE CHAIRS EXECUTIVES AND 5797 04:16:39,762 --> 04:16:42,498 MEMBERS FOR ALL THEIR WORK. 5798 04:16:42,498 --> 04:16:45,234 AND FOR OUR OARAC MEMBERS 5799 04:16:45,234 --> 04:16:46,869 YOU'LL RECEIVE A CONFLICT OF 5800 04:16:46,869 --> 04:16:48,237 INTEREST FORM AT THE CLOSE OF 5801 04:16:48,237 --> 04:16:51,173 THE MEETING IN A FEW MINUTES 5802 04:16:51,173 --> 04:16:54,610 AND PLEASE SIGN AND RETURN THAT 5803 04:16:54,610 --> 04:16:58,247 AT YOUR EARLIEST CONVENIENCE. 5804 04:16:58,247 --> 04:17:04,153 PLEASE NOTE OUR NEXT MEETING IS 5805 04:17:04,153 --> 04:17:06,588 FEBRUARY 20. 5806 04:17:06,588 --> 04:17:07,322 OVER TO YOU. 5807 04:17:07,322 --> 04:17:09,591 >> THANK YOU, I'M SO GRATEFUL 5808 04:17:09,591 --> 04:17:11,527 FOR EVERY ONE WHO TOOK THE TIME 5809 04:17:11,527 --> 04:17:13,228 TO BE HERE TODAY. 5810 04:17:13,228 --> 04:17:14,897 AGAIN THANKS FOR EVERY ONE'S 5811 04:17:14,897 --> 04:17:18,767 HARD WORK AND PURSUITHIS 5812 04:17:18,767 --> 04:17:23,472 AND I WILL LEAD THAT 5813 04:17:23,472 --> 04:17:24,406 LEAVE IT THERE. 5814 04:17:24,406 --> 04:17:27,342 SO HAVE A VERY NICE REST OF 5815 04:17:27,342 --> 04:17:32,981 YOUR DAY AND YOUR WEEKEND. 5816 04:17:32,981 --> 04:17:37,886 >> AND THANK YOU, EVERY ERONE F 5817 04:17:37,886 --> 04:17:38,821 ENGAGING IN THIS FABULOUS 5818 04:17:38,821 --> 04:17:39,955 MEETING. 5819 04:17:39,955 --> 04:17:44,793 AND ONCE AGAIN, I WOULD LIKE TO 5820 04:17:44,793 --> 04:17:48,497 WELCOME DR. DONENBERG, 5821 04:17:48,497 --> 04:17:52,768 FLETCHER, FLORES AND MA SANTA 5822 04:17:52,768 --> 04:17:54,236 MARIA. 5823 04:17:54,236 --> 04:17:56,004 TODAY'S MEETING IS NOW 5824 04:17:56,004 --> 04:17:56,338 ADJOURNED. 5825 04:17:56,338 --> 04:17:56,972 >> THANK YOU. 5826 04:17:56,972 --> 04:17:57,906 >> THANK YOU. 5827 04:17:57,906 --> 04:17:58,841 >> THANK YOU. 5828 04:17:58,841 --> 04:18:00,976 >> THANK YOU, BYE BYE. 5829 04:18:00,976 --> 04:18:11,220 >> THANK YOU.